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Abstract
The design and synthesis o f  potent chemotherapeutics offers one o f the most 
successful routes for the treatment o f  disease. A  series o f amino acid, dipeptidyl and stilbenyl 
derivatives have been synthesised and evaluated as potential therapeutic agents. These 
compounds were fully characterised by a range o f spectroscopic techniques including; IR, IH, 
13C, 19F, 3 IP, DEPT 135 and HMQC NM R in addition to ESIMS. X-ray crystal structures 
were also obtained in certain cases.
M ultidrug resistance (MDR) is used to define resistance whereby cells become 
resistant to different drugs with no obvious structural resemblance and with different cellular 
targets. The preparation o f TV-fluorobenzoyl amino acid derivatives has resulted in the 
synthesis o f multidrug resistance modulators. TV-pentafluorobenzoyl-L-alanine methyl ester 
81 was the most potent derivative. This compound although relatively non-toxic was shown 
to increase the potency o f the anticancer drug epirubicin by 65%.
Fasciolosis is not only an important human disease but also affects cattle and sheep 
worldwide causing economic losses o f approx 2 billion dollars. Potent inhibitors o f Fasciola 
hepatica cathepsin L endoproteases have been developed. These dipeptidyl derivatives were 
synthesised by using the standard 1,3-dicyclohexylcarbodiimide (DCC) or l-ethyl-3-(3- 
dimethylaminopropyl)carbodiimide (EDC), 1-hydroxybenzotriazole (HOBt) protocol. N -4- 
fluorobenzoyl-L-leucine-glycine nitrile 151 was shown to be the most active compound with 
an IC 50 value o f 2.78 |j.M recorded.
a-Chymotrypsin has served as a prototypical enzyme for the serine proteases and has 
been very useful as a model target enzyme for the development o f compounds o f 
pharmacological interest. A series o f dipeptidyl phosphonate esters were prepared by 
standard EDC/HOBt protocol. jV-4 -fluorobenzenesulphonyl-glycine-phenylalaninep-(OPh ) 2  
165 was the m ost potent derivative with an IC 50 value o f  16.15 jiM against a-chymotrypsin.
Resveratrol found in grapes is a naturally occurring phytoalexin formed in response to 
fungal infections. It has been shown to exhibit various biological properties including 
antifungal, anticancer, estrogenic and heart protecting activities. The synthesis o f fluorinated 
analogues o f this bioactive compound were carried out using a decarbonylative Heck reaction 
with preliminary biological results indicating that (£)-l-(4-acetoxystyryl)-3,5- 
difluorobenzene 192 was a potent growth inhibitor o f  breast, lung and central nervous system 
cancer lines. A t a concentration o f 100 (.iM the growth o f  central nervous system cancer was 
limited by 99%.
Table of Contents
Title Page i
Dedication ii
Declaration iii
Acknowledgements iv
Abstract v
Chapter 1. Literature Review
1.1 Proteases and their inhibition
1.1.1 Introduction 1
1.1.2 Protease mechanism 2
1.1.3 Protease inhibitors 5
1.1.4 Categories o f  protease inhibitor 7
1.1.5 Non-specific protease inhibitors 8
1.1.6 S erine protease inhibitors 10
1.1.7 Cysteine protease inhibitors 14
1.1.8 Aspartic protease inhibitors 19
1.1.9 M etalloprotease inhibitors 24
1.1.10 Fluorine containing protease inhibitors 28
1.1.11 Conclusion 3 2
1.2 Cancer and cancer resistance
1.2.1 Introduction 3 3
1.2.2 M odulators o f  P-glycoprotein associated cancer resistance 34
1.2.3 Synthetic inhibitors o f  M R P-1 associated cancer resistance 38
1.2.4 Glutathione S-transferase associated cancer resistance 38
1.2.5 Cancer resistance related to the topoisomerases 40
1.2.6 Conclusion 42
1.3 References 43
Chapter 2. Synthesis, characterisation and biological activity of novel modified amino 
acid derivatives
2.1 Introduction 50
2.2 Synthesis o f  7V-fluorobenzoyl amino acid esters 52
2.2.1 Synthesis o f  TV-fluorobenzoyl-L-alanine methyl esters 54
2.2.2 ^  NM R studies o f the iV-fluorobenzoyl-L-alanine methyl esters 55
2.2.3 Synthesis o f ALfluorobenzoyl-L-phenylalanine methyl esters 57
2.2.4 Electrospray ionisation mass spectrometry studies o f the N-
fluorobenzoyl-L-phenylalanine methyl esters 58
2.2.5 13C N M R studies o f the JV-fluorobenzoyl-L-phenylalanine
derivatives 59
2.2.6 Synthesis o f  iV-fluorobenzoyl-glycine ethyl esters 60
2.2.7 Infrared study o f the iV-fluorobenzoyl-glycine derivatives 61
2.2.8 19F N M R study o f  the iV-fluorobenzoyl-glycine derivatives 63
2.2.9 Synthesis o f iV-fluorobenzoyl-L-leucine methyl esters 63
2.2.10 HMQC study o f  7V-3-fluorobenzoyl-L-leucine methyl ester 64
2.3 Structural study o f  the 7V-fluorobenzoyl amino acid esters 67
2.4 N-Eluorobenzoyl amino acid derivatives as potential multidrug resistance
inhibitors
2.4.1 Introduction 76
2.4.2 Cytotoxicity o f  the /V-fluorobenzoyl amino acid derivatives 77
2.4.3 Combination toxicity o f  iV-fluorobenzoyl amino acid derivatives
and epirubicin 79
2.5 Conclusion 81
2.6 Experimental 82
2.7 References 107
Chapter 3. Fluorobenzoyl dipeptidyl derivatives as inhibitors of the Fasciola hepatica 
cathepsin L endoproteases
3.1 Introduction 110
3.2 Synthesis o f dipeptidyl derivatives 111
3.2.1 Synthesis and characterisation o f TV-fluorobenzoyl dipeptidyl
benzyl esters 113
3.2.2 ]H N M R  Study o f  the iV-fluorobenzoyl dipeptidyl benzyl esters 114
3.2.3 Synthesis and characterisation o f  TV-pentafluorobenzoyl dipeptidyl
methyl esters 116
3.2.4 13C N M R study o f  the jV-pentafluorobenzoyl-L-alanine dipeptidyl
methyl esters 119
3.2.5 Synthesis and characterisation o f  jV-fluorobenzoyl dipeptidyl
nitrile derivatives 120
3.2.6 HMQC study o f  4-fluorobenzoyl-L-leucine-glycine nitrile 122
3.3 Protease inhibitory activity o f jV-fluorobenzoyl dipeptidyl derivatives
against the Fasciola hepatica cysteine cathepsin L endoproteases
3.3.1 Introduction 124
3.3.2 Fluorescent assay to determine the inhibitory potency of
dipeptidyl derivatives 124
3.3.3 Protease inhibition o f  the TV-fluorobenzoyl dipeptidyl benzyl ester
derivatives 125
3.3.4 Protease inhibition o f  the jV-pentafluorobenzoyl dipeptidyl methyl
ester derivatives 127
3.3.5 Protease inhibition o f  the iV-fluorobenzoyl dipeptidyl nitrile
derivatives 128
3.3.6 True inhibitory activity o f  the most potent protease inhibitors 129
3.4 Conclusion 130
3.5 Experimental 132
3.6 References 152
Chapter 4. Dipeptidyl phosphonate diphenyl esters as inhibitors of the serine protease 
bovine pancrease a-chymotrypsin
4.1 Introduction 154
4.2 Synthesis and structural characterisation o f  diphenyl-a-amino
phosphonates 157
4.3 Dipeptidyl phosphonate diphenyl esters
4.3.1 Synthesis and structural characterisation o f  N- 4-
fluorobenzenesulphonyl dipeptidyl phosphonate diphenyl esters 159
4.3.2 ' l l  N M R study o f  AM-fluorobenzenesulphonyl dipeptidyl
phosphonate esters 161
4.3.3 Synthesis and structural characterisation o f N -cinnamoyl
dipeptidyl phosphonate diphenyl esters 162
4.3.4 13C N M R study o f TV-cinnamoyl dipeptidyl phosphonate esters 164
4.3.5 Synthesis and structural characterisation o f  TV-trifluoroacetyl 
dipeptidyl phosphonate diphenyl esters
HMQC Study o f iV-trifluoroacetyl dipeptidyl phosphonate esters4.3.6
4.4 Structural study o f  the dipeptidyl phosphonate esters
166
167
169
4.5 Protease inhibitory activity o f  dipeptidyl phosphonate esters
4.5.1 Introduction 179
4.5.2 Assay to determine the inhibitory potency o f  dipeptidyl
phosphonate esters on bovine pancrease a-chymotrypsin serine
pro tease 179
4.5.3 Protease inhibition o f  the AM-fluorobenzenesulphonyl dipeptidyl
phosphonate ester derivatives 180
4.5.4 Protease inhibition o f  the 7V-cinnamoyl dipeptidyl phosphonate
ester derivatives 181
4.5.5 Protease inhibition o f  the 7V-trifluoroacetyl dipeptidyl phosphonate
ester derivatives 183
4.6 Conclusion 184
4.7 Experimental 186
4.8 References 202
Chapter 5. Fluorinated analogues of resveratrol as potential anticancer agents
5.1 Introduction 205
5.2 Biosynthetic pathway o f resveratrol 206
5.3 Syntheses o f  resveratrol 207
5.4 Synthesis and structural characterisation o f fluorinated analogues o f
resveratrol 211
5.4.1 *H N M R  study o f  the fluorinated resveratrol analogues 216
5.4.2 13C N M R study o f the fluorinated resveratrol analogues 217
5.5 Biological activity o f  the fluorinated resveratrol analogues
5.5.1 Introduction 219
5.5.2 Anticancer potential o f  fluorinated resveratrol analogues 220
5.6 Synthesis and characterisation o f  3,5-difluorophenyl resveratrol analogues 221
5.6.1 HM QC study o f (E)-4-(3,5-
difluorostyryl)phenylmethanesulphonate 224
5.7 Conclusion 226
5.8 Experimental 227
5.9 References 235
Appendix I-List of abbreviations 238
ix
Chapter 1
Literature Review
1.1 Proteases and their inhibition
1.1.1 Introduction
A proteinase or protease as it is commonly known, catalyses the cleavage of peptide 
bonds. Proteolytic cleavage o f peptide bonds is one o f the most common and important 
enzymatic modifications o f proteins. Proteases only catalyse the hydrolysis o f a peptide bond but 
their diversity o f function make them one o f the most fascinating group o f enzymes. Their 
control over protein synthesis enables them to regulate physiological processes such as 
fertilization, growth and differentiation. The inhibition o f such proteases has led to the treatment 
o f  conditions such as cancer and HIV.1
Figure 1.1 Classes o f  peptidases.
Investigations into kinetics, inhibition and single crystal X-ray structures o f proteases 
have led to the identification o f their active sites. Proteases can be divided into certain groups, 
w ith members o f each group having similar structures and analogous mechanisms o f action. 
Proteolytic enzymes are members o f the peptidase family indicating that they hydrolyse peptide 
bonds. Enzymes that require the presence o f an unsubstituted N- or C- terminus in the substrate 
are termed exopeptidases and those that do not are known as endopeptidases. The secondary and 
tertiary structure o f protein substrates usually prevents attack by the exopeptidases. The presence 
o f  a free N- or C- terminus is usually not favoured by endopeptidases. Exopeptidases remove a
1
single amino acid, dipeptide or tripeptide from the N- or C- terminus, actions that determine its 
classification.
Four mechanistic classes of endopeptidases are recognised by the International Union o f 
Biochemistry, namely serine, cysteine, aspartic and metalloproteases.2 Each class o f protease is 
characterised by a distinct set o f functional amino acid residues arranged in a particular order to
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F igure 1.2 Substrate-Enzyme binding sites
form the active site. The nomenclature to describe the interaction o f a substrate with a protease 
has been described.3 The amino acids o f the polypeptide chain bind with the subsites in the 
enzyme active site. The subsite is referred to as S and the substrate amino acids P. The amino 
acids adjacent to the scissile site on the /V-terminus are labeled P I, P2, P3 etc and on the C- 
terminus P I ’, P2’, P3’ etc with the P I /P I ’ being closest to the cleavage site. The complementary 
sites on the enzyme are labeled SI, S2, S I ’, S2’ etc. The specificity o f different proteases is due 
to differing amino acid residue substitution in the primary substrate binding site P I /P I ’ and 
minor differences in the secondary binding sites (P2-P8/P2’-P8’). A prime example is the serine 
protease a-chymotrypsin. It prefers an aromatic side chain on the substrate at P I ’.4 This is 
because the bulky aromatic group can fit snugly into a slit-like hydrophobic pocket near the 
active site.
1.1.2 P ro tease M echanism .
The general mechanism for the four classes o f proteolytic enzyme, differ, only in a minor 
manner with the overall process, i.e. hydrolysis o f  the peptide bond, similar in all cases. Serine 
proteases have been the most studied group o f enzymes in the protease field with trypsin, a- 
chymotrypsin, tryptase, elastase and thrombin implicated in a variety o f conditions. Their mode 
o f  action involves the substrate binding in the active site to form a Michaelis complex.
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Figure 1.3 Tetrahedral intermediate formed by attack o f a serine hydroxyl at amide bond.
The trigonal carbonyl group o f the scissile amide bond is exposed to nucleophilic attack 
by the active site serine hydroxyl. The imidazole side chain o f His57 activates this hydroxyl 
group. The resulting tetrahedral intermediate is stabilized by hydrogen bonding to the N-H 
backbone o f  Ser195 and Gly193, hence forming the oxyanion hole.
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Figure 1.4 Deacylation o f acyl enzyme intermediate facilitated by attack o f a water molecule.
Proton transfer from the His57 residue to the amine o f the tetrahedral intermediate 
eliminates the C-terminal fragment as a leaving group. The covalent acyl-enzyme complex is 
attacked by a water molecule activated by the imidazole side chain o f histidine57, with formation 
o f a new tetrahedral intermediate. This intermediate subsequently breaks down via acid catalysis 
to form the carboxy fragment o f the cleaved substrate and regeneration o f the Ser195 residue o f 
the active site.
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Figure 1.5 Peptide cleavage and regeneration o f the serine195 residue.
Cysteine proteases are believed to act in an analogous manner to the serine proteases. In 
their case it is the sulphur atom of a cysteine residue that is believed to act as the nucleophile. 
Resembling the mechanisrh o f serine proteases, a histidine side chain is thought to be involved in 
hydrogen bonding to the oxygen anion formed from the attack o f the nucleophile on the 
carbonyl. However it is still debatable whether the catalytic pair o f Cys25 and H is159 involved is 
sufficient for full catalytic activity.5
Aspartic proteases are understood to catalyse the cleavage o f peptide bonds without the 
use o f nucleophilic attack but by a functional group o f the enzyme. Therefore, there is no 
tetrahedral intermediate formed between the enzyme and the substrate. Catalysis involves the 
involvement o f two aspartic acid side chains. Nucleophilic attack is not involved, as the carboxyl 
group is not renowned as an effective nucleophile. The low pH optimum o f this group of 
enzymes further strengthens the belief that the carboxyl groups are involved in the catalysis.
Metalloproteases like aspartic proteases do not form covalent intermediates. As an 
alternative o f  using hydrogen bonding via an ‘oxyanion’ hole to exert a catalytic effect on the 
carbonyl group, the metalloproteases are believed to use co-ordination to a metal ion to exert this 
effect. The metal involved is usually zinc. It provides a strong electrophilic interaction to assist 
the attack o f  a water molecule that is co-ordinated to the fourth tetrahedral site. The water 
molecule can be displaced during co-ordination o f the substrate carbonyl to the metal atom but it 
is believed to remain at the active site. The water molecule is also hydrogen bonded to a glutamic 
acid. The carboxyl group acts as a base to remove a proton and assist the attack o f the same 
water molecule on the peptide carbonyl. A proton must be transferred to the leaving nitrogen 
atom and perhaps this could be derived from glutamic acid.
4
Figure 1.6 Zinc protease, a metalloprotease from the microorganism Streptomyces caespitosus. 
It is the smallest protease found to date. It consists o f 132 amino acid residues.6
1.1.3 Protease Inhibitors.
Protease inhibitors are compounds that decrease the rate o f hydrolysis o f a given 
substrate with the kinetics o f such a reaction fundamental to the degree o f  inhibition achieved. 
The kinetics o f the reaction between a protease and its potential inhibitor determine the inhibitors 
effectiveness. The suppression o f protease activity is regulated by the kinetic constants o f the 
reaction between the protease and the inhibitor. The calculation o f  such parameters allows 
determination o f both the quantity and the duration required to achieve efficient inhibition. Most 
protease inhibitors are defined as ‘active site directed’, i.e. they combine with the catalytic and 
substrate binding sites o f  the proteinase to form a tight and stable complex.2 These inhibitors, 
natural or synthetic mimic a substrate.
Many protease inhibitors form irreversible covalent complexes with proteases. 
Irreversible or tight binding inhibitors (reversible inhibitors that bind to the enzyme with high 
affinity) decrease the number o f active sites available for substrate. Protease inhibition can be 
described as a bimolecular reaction between protease (E) and inhibitor (I) that results in the 
formation o f a stable complex (E-I) via an intermediate analogous to substrate binding (El).2 The
E + 1 El ------► E-I Equation 1
k-i
rates o f the reactions are described by the rate constants k], k.] and k2 (Equation 1). This equation 
describes an irreversible reaction. Irreversible inhibitors form covalent bonds with the enzyme 
and often these bonds remain when the enzyme is denatured. The parameters that govern the 
reaction o f a protease with an irreversible inhibitor are the three rate constants. The most 
important quantity in this type o f  inhibition is the apparent rate o f inhibition (or association) 
called kass (Equation 2). For inhibitors following the above mechanism, kaSS is defined as
kass= ki .k2/k_i Equation 2
Under appropriate conditions all three rate constants can be measured, however for practical 
purposes kass is sufficient to describe the reaction rate o f irreversible inhibitors.
Reversible inhibitors are bound to the enzyme through a combination o f van der Waals, 
electrostatic, hydrogen bonding and hydrophobic forces. An equilibrium between the complexed 
form o f an enzyme and free enzyme characterizes reversible inhibitors.
ki
E + 1 =^== El Equation 3
k-i
The equilibrium constant for the reaction, K; is given by
Kj = [E][I]/[EI] = k-i/k. Equation 4
The practical use o f  these kinetic constants is the estimation o f efficiency o f the inhibitor. K; and 
kass are constant for a particular enzyme-inhibitor reaction. It is from these values that parameters 
such as IC50 or ti /2 can be calculated. The IC50 is the inhibitor concentration required to half the 
enzyme activity. It depends on substrate concentration (S) and km and is given by
IC50 = Kj (1+ S/km) Equation 5
where km is the Michaelis constant. IC50 values represent one o f the most common methods of 
comparing protease inhibitors.
For protease inhibitors to be effective as biological tools it is vital that not only are they 
very potent but also highly selective in binding to a particular protease. A key mechanistic 
feature o f many protease inhibitors is the presence o f a transition state isostere that simulates the
6
transition state o f amide bond hydrolysis. The incorporation o f such amide bond surrogates has
. . . .  1
proven to be a very successful strategy for rapidly converting protease substrates into inhibitors. 
Inhibitor composition has also been an important feature o f  protease inhibitor design to date. As 
drugs, protease inhibitors need on one hand to be designed to adopt an extended conformation 
and make hydrogen bonds to, and interact through hydrophobic effects with specific proteases, 
they also need to avoid degradation en route to the desired protease interactions with numerous 
other proteases in the digestive tract, in plasma and inside cells. This problem is compounded by 
the fact that natural peptide substrates for proteases are very susceptible to such degradation. 
Protease inhibitors also suffer from other major delivery problems such as low membrane 
permeability, high first pass metabolism and very low bioavailability. The most successful drugs 
based on protease inhibition to date have tended to be small organic molecules with few or no 
peptide bonds, significant lipophilicity and high selectivity for both the specific protease and the 
clinical objective being targeted.
1.1.4 Categories of protease inhibitor
Protease inhibitors can be split into two general classes, the natural product derived 
inhibitors and the low molecular weight synthetic inhibitors. Over one hundred natural peptide 
based protease inhibitors have been isolated from plant, animal and bacterial sources. They 
behave as tight binding reversible or pseudo-irreversible inhibitors o f proteases preventing 
substrate access to the active site through steric hindrance. As such they are usually large protein
chains but are extremely variable in size from fifty residues (Bovine Pancreatic Trypsin
■ • ■ 2Inhibitor) to over four hundred residues (a -1-proteinase inhibitor).
The low molecular weight inhibitors can be either synthetic or o f bacterial and fungal 
origin and irreversibly modify an amino acid residue o f the protease active site. The huge 
diversity o f protease inhibitors means that they are often grouped according to their reaction 
mechanism, origin or structural similarity. However, the most efficient method o f separating 
different classes o f inhibitors is by their specificity. As such they can be ordered according to 
which family o f proteases they inhibit although some inhibitors are potent against multiple 
enzymes. Presently, the majority o f  research in the area o f protease inhibition is concentrated on 
the design and synthesis o f low molecular weight synthetic inhibitors with high specificity for 
individual proteolytic enzymes.
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1.1.5 Non-specific protease inhibitors
a-Macroglobulins are a large group o f natural protein protease inhibitors and for the most 
part extremely class specific. However, the human-plasma protein a 2 -macroglobin fails to 
discriminate between the proteinase classes. It is a glycoprotein composed o f four identical 
subunits. The inhibitory ability arises from a conformational change during the reaction that traps 
the enzyme allowing only small substrate molecules to enter and to be cleaved by the entrapped 
protease.8 This binding is irreversible and is mechanistically different to other inhibitors that tend 
to concentrate on active site deactivation. The a-macroglobulins are the only natural inhibitors 
that fail to discriminate among protease classes.
Peptide aldehydes are di-, tri- or tetrapeptides containing an aldehyde moiety in place of 
the usual carboxylate group. They are reversible inhibitors that are often referred to as ‘transition 
state analogues’ because they act by mimicking the tetrahedral intermediate formed during 
peptide bond hydrolysis. The most notable example is leupeptin 1. Leupeptin inhibits serine 
(trypsin), plasmin (kallikrein) and cysteine proteases (papain).2 The structure o f leupeptin is 
acetyl-leucyl-leucyl-arginal. A number o f peptidyl aldehyde derivatives have been synthesized in 
attempts to improve specificity.9 Two major drawbacks limit their usefulness as selective or 
specific inhibitors. Firstly, the lack o f selectivity allows for the inhibition o f proteases other than 
those under investigation. Secondly, in aqueous solution most aldehydes exist primarily as 
inactive hydrates. Accordingly the rate limiting step for inhibition can be the formation o f the 
aldehyde rather than the encounter with a suitable target enzyme.
o
1
Peptidyl chloromethyl ketones are irreversible inhibitors that represented one o f the first 
approaches in the study o f active site directed protease modification.10 The two best known 
members are tosyl-L-lysine chloromethyl ketone (TLCK) 2 and tosylamido-L- 
phenylethylchloromethyl ketone (TPCK) 3.
8
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The mechanism o f inactivation o f serine proteases shows that inhibition results from the
protease binding the inhibitor in a substrate like manner followed by alkylation o f the active site 
histidine by the chloromethyl moiety. It has been shown that halomethyl ketone inhibitors form 
an irreversible tetrahedral covalent adduct with the active site histidine residue o f serine
proteases. 11
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Figure 1.7 Proposed mechanism o f inhibition o f serine proteases by peptidyl chloromethyl 
ketones.
Unfortunately chloromethyl ketones also have the ability to inactivate cysteine proteases, 
by a similar mechanism to serine proteases. Considerable specificity for individual serine and 
cysteine proteases can be obtained by altering the peptide sequence o f  the inhibitor. It should be 
noted that many researchers claim specific inhibitors without actually demonstrating that the 
inhibitor does not react with the other potential target proteases. The use o f chloromethyl 
ketones in cell culture and animal studies is limited by toxicity resulting from alkylation of 
cellular components.
9
1.1.6 Serine protease inhibitors
Serine proteases are classified by their substrate specificity with particular emphasis 
placed on the nature o f the residue present at PI. The most common examples are trypsin like 
(positively charged residues Lys/Arg preferred at PI), elastase like (small hydrophobic residues 
Ala/Val at P I) and chymotrypsin like (large hydrophobic residues Phe/Tyr/Leu/Trp at PI). X-ray 
crystal structural data for the interactions o f serine proteases and inhibitors is available for 
trypsin, a-chymotrypsin, y-chymotrypsin, thrombin and human cathepsin G . 6 The main goal of 
inhibitor design is to synthesise potent inhibitors that maximise selectivity for closely related 
proteases. Therefore the inhibitor should have the ability to inhibit only one protease in a mixture 
and such inhibitors should have an inhibition rate constant for the protease o f one thousand fold 
less than for any other protease in the mixture.
Thrombin is a trypsin like serine protease that plays a central role in haemostasis and 
blood coagulation . 12 Thrombin hydrolyses the blood factors V, VII, XII and fibrinogen that 
generate fibrin . 13 The polymerisation o f fibrin produces the core o f a blood clot. Thrombin 
essentially protects us from bleeding to death but an excess o f this protease can lead to undesired 
thrombosis often causing death from stroke. The substrate pocket SI o f thrombin is optimised to 
recognise an arginine side chain. Argatroban 4 is a potent arginine derivative that inhibits platelet 
aggregation by clot-associated thrombin . 14 It is a 64:36 mixture o f 21-(i?) and 2l-(S)  
diastereomers with the latter being twice as potent as the former in an in vitro assay but also less 
soluble in aqueous buffer. It has been approved for treating peripheral arterial occlusive disease
in Japan. Bristol-Myers Squibb have more recently developed a potent inhibitor o f thrombin 
(BMS 189090) 5 . 15 This was shown to have an IC50 value o f 16 nM when assayed against the 
chromogenic substrate S-2238. The crystal structure o f thrombin complexed with 5 is shown in
1 0
Figure 1.8. It can be seen that the inhibitor binds in an antiparallel fashion to thrombin. BMS 
189090 has also been shown to be an effective inhibitor in protecting mice from thrombin- 
induced lethality and in inhibiting arterial and venous thrombosis in rats. The administration o f a
0.5 mg/kg dose resulted in almost complete inhibition o f venous thrombosis.
F igure 1.8 Three dimensional structure o f thrombin complexed with compound 5 showing the 
bound confirmation o f the inhibitor, the active site residues and solvent molecules in the active 
site.16
' i 7A potent orally active inhibitor o f thrombin has been recently developed by Lee et al. ‘ 
This highly potent diphenylalanine derivative 7 (K\ = 0.015 nM) is based on an optimised highly 
efficient thrombin inhibitor 6. Although this gave potent inhibition with a K, value o f 3 pM in 
vitro, clinical trials revealed a short duration o f action and poor bioavailability. Optimisation o f 
this derivative resulted in potent inhibition being achieved by the incorporation o f a 
thiophenamidine in the PI position. Although the inhibitory potency o f 7 was slightly less than 6 
the bioavailability o f 7 was significantly superior with a maximum concentration o f 3.8 (xg/ml 
recorded after oral dosage. 7 was also shown to be highly selective when assayed against other
11
serine proteases such as factor Xa, trypsin, and plasmin. Compound 7 has been recently selected 
for preclinical and clinical development.
Nil
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• • • **18 Elastase is a serine protease implicated in cystic fibrosis and chronic bronchitis.
Endogenous inhibitors such as the secretory leukocyte protease inhibitors tightly regulate
elastase activity but an imbalance between proteases and antiproteases can lead to the
degradation o f  healthy tissue and disease development. The inhibition o f  elastase has led to the
development o f  numerous therapeutic agents. The cyclic thiol M R 889 8 is in clinical evaluation
for the treatment o f chronic obstructure pulmonary disease (COPD).19 It is a reversible, slow
binding inhibitor with specific activity towards neutrophil elastase (K{ = 1 .3 8  (xM) and may be
given to COPD patients safely for a period o f  four weeks without any major side effects.
Gerard and co-workers have synthesised the (3-lactam 9. This has been been shown to
promote suicide inhibition o f porcine pancreatic elastase. It is a potent reversible inhibitor (IQ =
10 |iM ) and only one in a series o f (3-lactams that have been developed as potential protease
inhibitors.20 Baylac et al have recently reported that the natural fragrant extracts o f aromatic
plants have the ability to successfully inhibit human leukocyte elastase.21 The most potent
fragrant was shown to be the spice known as turmeric that was once used in the treatment o f 
jaundice.22 This novel method o f inhibition offers an alternative therapeutic route to the 
treatment o f various diseases.
Tryptase is a trypsin like serine protease that has been implicated as a mediator in various 
inflammatory and allergic conditions such as conjuctivitis and asthma.23 It is estimated that over
1 2
100 million people will suffer from asthma by the end o f this decade. To lessen the severity of 
asthma, therapeutics attacking the underlying inflammatory processes are being investigated.24 
Tryptase is produced by mast cells and accounts for 20-25% o f the total lung and skin mast cell 
protein. The SI pocket o f tryptase is large enough to accommodate a range o f simple PI nitrogen 
bases. The crystal structure o f  the enzyme has indicated preference for simple aromatic and 
aliphatic nitrogen bases at-PI.25 A piperazine based derivative 10 is a very selective and potent 
inhibitor o f  tryptase.26 Compound 10 has a K\ value o f 70 pM  against tryptase and selectivity 
over trypsin and thrombin close to 105 fold. These dibasic inhibitors are C2 symmetric with one 
end o f the molecule fitting the SI pocket with the other end o f the molecule potentially docking 
into another SI pocket of an adjacent tryptase monomer.
More recently Johnson and Johnson have developed potent selective inhibitors o f human 
mast cell tryptase. The benzothiazole ketone derivative 11 has been reported to have a K\ value 
o f  10 nM against tryptase and 8.1 nM against trypsin.27 Although this compound potently 
inhibits trypsin it is highly selective against other serine proteases such as kallikrein, plasmin and 
thrombin. The benzothiazole derivatives were shown to be up to eight times more potent than 
their thiazole analogues. The success o f aerosol administration o f 11 into the sheep model of
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asthma has led to the advancement o f this compound into clinical trials. Bristol Myers Squibb
• ■ • . . .  2 8  have developed the piperidine derivative 12 as a potent and selective inhibitor o f tryptase. It
has an IC50 value o f 1 nM against tryptase and 440 nM against trypsin. Although the presence of
aromatic rings adjacent to the amide bond failed to improve the activity o f 12 it managed to
increase selectivity substantially.
Serine protease inhibitors frequently have 3-5 amino acid residues and thus interact with 
only a small region o f the enzyme. This leads to the increased problem o f selectivity. For the 
development o f  therapeutically useful serine protease inhibitors, it has generally been accepted 
that reversible inhibitors are preferred over irreversible ones. Irreversible inhibitors would be 
expected to covalently bind with nucleophiles en route to the intended target most likely 
resulting in toxic side effects. Reversible transition state analogues usually possess an 
electrophilic isostere located at the C-terminus o f PI residues. Examples include aldehydes, 
boronic acids and activated ketones. The presence o f a reactive electrophilic site in many 
reversible inhibitors will undoubtedly lead to pharmacological problems when administered to 
humans. For example, peptidyl aldehydes are easily oxidised to carboxylic acids and are prone to 
racemisation in the presence o f acid or base if  a chiral centre is present in the molecule.
1.1.7 Cysteine protease inhibitors.
Cysteine proteases exist in three structurally distinct classes that are either papain like (eg 
cathepsins), ICE (interleukin-1 converting enzyme) like (caspases) or picoma-viral (similar to 
serine proteases with cysteine replacing serine). Cathepsins have historically been the most 
studied cysteine proteases. Cysteine proteases hydrolyse amide bonds in much the same manner 
as serine proteases except for the fact that the thiol moiety o f a cysteine residue is involved in 
catalysis compared to the hydroxy nucleophile o f a serine residue in serine pro teases. The 
biggest problem encountered in the design o f cysteine protease inhibitors is the similarity in their 
substrate affinities and proteolytic mechanisms with serine proteases.
The term “cathepsin” was introduced by Willstatter and Bamann in 1929 to describe a 
protease that is active at acidic pH but can be differentiated from pepsin . 5 Cathepsin A, B and C
• • • 2 9have been suggested as the intracellular counterparts o f pepsin, trypsin and a-chymotrypsin. 
Cathepsin inhibitors are promising therapeutics for the treatment o f  diseases characterized by 
excessive bone loss such as osteoporosis and inflammatory and traumatic processes such as
14
rheumatoid arthritis and cancer metastasis . 30 Among the earliest reported inhibitors were peptidyl 
diazomethyl ketones and aldehydes.
CHN,
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Diazomethyl ketones inactivate cathepsin B by alkylation o f the active site cysteine 
residue. The most effective example is 13. It has been reported to inactivate cathepsin B and C 
effectively . 31 More recently, Zhou et al have synthesised a series o f 6 -substituted amino-4-oxa-l- 
azabicyclo[3,2,0]heptan-7-one derivatives 14 as cathepsin B protease inhibitors . 32 Compound 14 
was found to have an IC 50 value o f 1.76 (xM against cathepsin B protease. Molecular modelling 
studies carried out suggested that the 1-N atom in 14 can be involved in hydrogen bonding to the 
protonated histidine in the active site o f cysteine proteases therefore acting as an effective 
inhibitor. Unfortunately 14 was also found to be extremely potent against cathepsin L, K  and S 
with nanomolar inhibition often occurring.
Cathepsin K is a cysteine protease abundant in osteoclasts and is involved in the 
degradation o f  various bone proteins . 33 The peptidyl nitrile 15 is a potent inhibitor o f cathepsin K 
and significantly reduces bone loss .34 The leucine glycine nitrile scaffold o f this inhibitor has 
previously been a successful design feature o f potent cysteine protease inhibitors. Compound 15
has an IC 50 value o f 0.2 nM against human cathepsin K and is shown to substantially reduce 
bone resorption at a concentration o f 10 nM. GlaxoSmithKline have recently developed a series 
o f  highly potent ketoamide based inhibitors o f cathepsin K .35 Compound 16 was the most potent 
derivative with an IC50 value o f 1. 6  nM. Unfortunately this compound is not very selective with
15
cathepsin S also undergoing inhibition with an IC50 value o f 2.56 nM. The key step in the 
synthesis o f this derivative is the preparation o f the a-ketoamide from the oxidation o f a 
phosphorus ylide using ozone followed by loss o f the nitrile moiety using the Wasserman 
procedure.
Ozone
Figure 1.9 Key synthetic step in the synthesis o f the GlaxoSmithKline cathepsin K  inhibitor 16
Cathepsin L has been implicated in tumor metastasis with the presence o f metastatic 
human melanoma cells associated with the secretion o f a cathepsin L protease. E-64 17 is a 
naturally occurring cysteine protease inhibitor with high potency against cathepsin B, F, K and L 
proteases.38 Treatment with the epoxide E-64 inhibits cathepsin L protease in the nanomolar 
range and offers a potential treatment for metastasis. Lately, the azepanone scaffold has been 
used in the preparation o f  cathepsin L inhibitors. The potent inhibitor 18 is shown to be 
impressively selective over cathepsin K  for cathepsin L with 50,000-fold selectivity.39 It has a K\ 
value o f 9.9 pM against human cathepsin K compared to a K, value o f  503 nM for human 
cathepsin K.
Caspase is a new term given to cysteine endoproteases with absolute specificity for 
aspartic acid at PI in their substrates. They also have specificity for the four amino acids to the 
amino terminal side o f the cleavage site. Caspases have become promising therapeutic 
candidates for the treatment o f  inflammatory and degenerative diseases such as rheumatoid 
arthritis, Alzheimer’s disease and Parkinson’s disease.40 The first demonstration o f an effective 
inhibitor in a chronic disease was the prodrug V E-13045 19.41 The aspartyl side chain ester in the
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compound is rapidly hydrolysed in vivo, yielding a bioactive molecule based on the Cbz-Val- 
Ala-Asp template. The tripeptidyl derivative 19 was shown to reduce inflammation and 
progression o f arthritis when administered to mice with established disease. Pfizer have recently
developed a potent caspase-1 inhibitor based on an alanyl-aspartyl sulphonamide scaffold.42 This 
derivative 20 has an IC5o value o f  3.4 nM  against caspase-1 and the presence o f an aspartic acid 
residue at the PI position along with the sulphonamide moiety is crucial for potent inhibition.
Caspase-3 is believed to be a key component in apoptosis and is involved in 
neurodegenerative diseases such as Alzheimer's, Parkinson's and Huntingdon's disease.43 It has 
been well publicised that an aspartyl residue in the P4 position is crucial for caspase-3 inhibition. 
The potent caspase-3 inhibitor 21 has an IC50 value o f 18 nM against caspase-3.44 This 
conformationally constrained bicyclic caspase inhibitor is a potent caspase-3 inhibitor due to the 
aspartic acid residue present at P4. It has selectivity in the region o f 577 fold relative to caspase-
1. Researchers at Wayne State University, Detroit have recently reported structure-based design 
o f  irreversible, non-peptidyl inhibitors o f  caspase 3. The iV-nitroso aniline 22 was designed as a
0  /  
HO,C
Ac-Asp-Val-Ala-Asp -
NO
I
-N
OH
22
17
novel irreversible inhibitor.45 Inhibition takes place by S-nitrosylation o f the active site cysteine 
thiol moiety. The nitroso aniline moiety had very weak inhibitory activity by itself. Incorporation 
o f a peptide analogue to a substrate of caspase-3 furnished a more potent inhibitor. Although the 
inhibition o f caspase-3 was not remarkable these nitric oxide (NO) donating compounds provide 
a novel scaffold for the design o f inhibitors to specifically deliver NO to the enzyme.
The rhinovirus 3C,protease is a member o f the picomaviral cysteine proteases. Human 
rhinoviruses (HRV) are the viruses that are responsible for the common cold. Since they occur in 
over one hundred different variants, the development o f  a vaccine seems unlikely, whereas the 
inhibition o f their component cysteine proteases 2A and 3C that are essential for replication 
represents a possible strategy against the common cold. Rhinovirus 3C protease is a 20 kDa 
picomaviral protease that selectively catalyses the hydrolysis o f glutamine-glycine peptide 
bonds. Glutaminal based inhibitors have limitations due to the fact that they exist predominantly 
in the cyclic hemiaminal form. The design and synthesis o f isosteres o f the glutamine side chain 
are a possible method o f potent inhibition. Compound 23 has been reported to inhibit the 
replication o f  several different HRV serotypes.46 23 has a K\ value o f 6 nM against HRV 3C 
protease. This compound was able to reduce the levels o f infectious virus even when 
administered late in the HRV life cycle. More recently Eli Lilly have described the synthesis and 
inhibitory potency o f a series o f tripeptidyl a-ketoamide derivatives.47 Compound 24 was the 
most potent derivative with an IC50 value o f 170 nM against H RV -14. This noncytotoxic 
compound also exhibits potent antiviral activity with an EC50 o f 0.85 p,M against HRV-14.
V a V t  M W . -o
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To date there are few electrophilic isosteres appropriate for developing selective,
reversible inhibitors o f cysteine proteases. This may explain why very few cysteine protease 
inhibitors have advanced to clinical trials. C-terminal aldehydes and ketones, which react with 
the active site cysteine to form reversible thioacetal transition state analogues, are the most used 
isosteres for developing reversible cysteine protease inhibitors. The main problem with aldehyde
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isosteres is the fact that they are not very selective inhibitors. In contrast to this there have been 
many functional groups capable o f irreversibly alkylating the active site cysteine incorporated 
into peptides including epoxides, nitriles and diazomethyl ketones. These functional groups are 
activated electrophiles that are generally quite selective for cysteine versus serine proteases. To 
date the majority o f  these compounds are still too reactive to various nucleophiles in the body. 
These concerns have severely limited the development o f such irreversible inhibitors as 
therapeutic agents. It remains to be seen whether electrophilic analogues will provide irreversible 
cysteine inhibitors with the pharmokinetic and pharmacological profiles required o f  therapeutic 
agents in the future.
1.1.8 Aspartic acid pro tease inhibitors.
Aspartic proteases generally bind 6-10 amino acid residues o f their polypeptide substrates 
and are typically processed with the aid o f two catalytic aspartic acid residues in the active site. 
There is usually considerable scope for building efficient inhibitors for a particular aspartic 
protease by taking advantage o f  the numerous interactions on both sides o f its scissile amide 
bond. Various aspartic proteases also contain one or more flaps that close down on top o f the 
inhibitor further adding to inhibitor-protease interactions and increasing the basis for selectivity. 
The general acid-base mechanism that is considered most likely for peptide hydrolysis catalysed 
by aspartic proteases involves the scissile amide bond undergoing nucleophilic attack by a water 
molecule which is itself activated by a deprotonated aspartic acid residue.
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The number o f people living with HIV/AIDS is estimated at 38 million and 
approximately 3 million AIDS deaths were recorded in 2003.48 The virally encoded protease of 
the human immunodeficiency virus (HIV-1 protease) has proved to be an attractive drug target 
due to its essential role in the replicative cycle o f HIV and its inactivation has led to the 
formation o f immature and non-infectious viral serotypes.49 Several low molecular weight 
inhibitors o f HIV-1 protease are now administered clinically including saquinavir 25 and
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ritonavir 26.50 These are among the first successful examples o f receptor-structure based 
designer drugs and were developed using structures o f compounds bound in the active site of 
HIV-1 protease and with the knowledge o f inhibitors o f other aspartic acid proteases e.g. renin. 
All HIV-1 protease inhibitors developed so far target the active site substrate binding groove of 
the homodimeric enzyme, a long cylindrical cavity that binds 6-7 amino acids via ionic, van der 
Waals or hydrogen bonding interactions.51 Two catalytic aspartic acid residues present at the 
centre o f this cavity promote amide bond hydrolysis.
Saquinavir became the first HIV protease inhibitor to be approved for human use in 1996 
despite low oral bioavailability due to poor adsorption and extensive first pass degradation by 
cytochrome P450.50 It is generally administered in combination with nucleoside analogues for 
the treatment o f  advanced HIV infection and is active in cell culture against both HIV-1 and
HIV-2 viruses. The most common side effects experienced with 25 are gastrointestinal including 
diarrhoea and nausea. Ritonavir was approved in February 1996 for use in combination with 
nucleosides or as monotherapy for the treatment o f HIV infection. 26 is metabolised primarily 
through cytochrome P4503A and is considered both as a potent inhibitor and an inducer o f the 
cytochrome P450 metabolic pathway.50 The most frequently reported adverse effects in 1,140 
patients who received ritonavir included nausea and vomiting. The addition o f ritonavir to a 
saquinavir course o f  therapy boosts levels o f  saquinavir by 20 fold based on ritonavir's potent 
inhibition o f P4503A. Doses o f both drugs can be reduced thereby potentially decreasing the side 
effects o f both inhibitors.
Viral resistance to monotherapy with any o f these drugs is a significant problem. Serial 
passages o f H IV -1 in vitro in the presence o f  increasing concentrations o f a protease inhibitor 
cause rapid emergence o f drug resistant viral strains o f HIV-1. Resistance is due to amino acid 
substitutions in the protease. However, cross resistance is not always observed for inhibitor
2 0
cocktails so HIV patients who experience clinical failure with one protease inhibitor may still 
benefit from another protease inhibitor.
The HIV inhibitor Lopanavir 27 is the antiviral component o f Kaletra™ (approved by the 
FDA in September 2000) that has been approved as a HIV protease inhibitor for the treatment o f 
HIV infection.52 27 possesses high potency against wild type and mutant HIV proteases with K\ 
values ranging from 1.3-28 pM .53 Lopanavir also exhibits potent antiviral activity with an EC5o 
value o f 100 nM recorded. The core unit o f 27 is identical to that o f ritonavir. The two benzyl 
groups at PI and P I ’ are believed to be essential for efficient inhibition. GlaxoSmithKline have 
recently developed a series o f pyrrolidone based derivatives as potent inhibitors o f HIV-1 
protease.54 The inhibitors incorporate the P l'-P 2 ' scaffold o f the approved HIV drug Indinavir 
28. The phenolic derivative 29 was reported to have a Ki value o f 0.05 nM against the HIV-1 
protease compared to 0.07 nM for Indinavir. It also has increased water solubility due to the 
presence o f the hydroxy group at the meta position. The majority o f HIV protease inhibitors to 
date are based on the replacement o f the scissile bond with non-hydrolysable isosteres. The 
peptidic nature o f these derivatives limits their oral bioavailability and a short plasma half-life is 
often observed. Despite the success o f the available inhibitors, viral resistance and cost o f 
synthesis remains the main problems facing the inhibition o f this fatal disease.
The aspartic acid protease renin is involved in the rate limiting first step o f the renin- 
angiotensin system. Due to their specificity, renin inhibitors are antihypertensive agents similar 
in action to ACE (Angiotensin Converting Enzyme) inhibitors but free o f some side effects 
associated with ACE administration. Zankiren 30 was the first peptidic renin inhibitor with 53% 
oral absorption.55 It is also a potent inhibitor o f human plasma renin at pH 7.4. A 10 mg/Kg 
intraduodenal dose in sodium depleted monkey’s reduced mean arterial blood pressure by 37%
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for 2 hours. Zankiren 30 has also been shown to reduce the incidence o f dry cough associated 
with ACE treatment. Renin inhibitors have mainly been developed by modifying substrate 
fragments from the angiotensinogen cleavage site but their clinical progress has been hampered 
by  their peptidic character that confers low stability and poor oral availability in humans. 
Another hurdle has been the high cost o f production compared with antihypertensives such as 
ACE inhibitors. Renin inhibitors generally need to interact with 5 subsites (S4-S1’) o f the 
enzyme to bind tightly and selectively compared with only 3 for ACE inhibitors. Consequently, 
renin inhibitors tend to have a higher molecular weight, have more stereocentres and are thus 
more expensive to manufacture. Several renin inhibitors with low molecular weight, less peptidic 
character and improved oral bioavailability have emerged.
Aliskiren 31, an orally active renin inhibitor has been shown to inhibit the production of 
angiotensin I and II . 56 It decreases blood pressure in hypertensive patients at daily doses o f 75 
and 150 mg. Exploratory studies testing the efficiency and safety o f this renin inhibitor in 
patients with renal disease and congestive heart failure are currently underway. Pfizer have 
recently reported the synthesis o f a series o f non-peptidic cw-disubstituted amino-aryl-piperidine 
based renin inhibitors . 57 The racemic mixture 32 has IC50 value o f 61 nM against human renin.
31
This compound is characterised by the cis orientation o f the two stereocenters on the amino-aryl- 
piperidine template. It was also shown to have in vivo antihypertensive activity after oral dosage 
to mice (30 mg/kg) gave peak antihypertensive activity one and a half hours post dose.
2 2
Unfortunately this compound suffers from submicromolar interactions with cytochrome P 450 
isoenzymes. This limits its potential for further development although these compounds can be 
used as a starting point for'second generation renin inhibitors.
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Pepstatin 33 is a naturally occurring inhibitor isolated by Umezawa et al, and provides a 
good example o f the information that can be gained from the detailed study o f a naturally 
occurring inhibitor by a variety o f physical methods.58 Pepstatin (Iva-Val-Val-Sta-Ala-Sta) 
which contains the novel amino acid statine 34 [(3S,4S)-4-amino-3-hydroxy-6-methyl heptanoic 
acid] inhibits most aspartic proteases except for renin. Existing data indicates that the (35)- 
hydroxyl group is needed for maximal inhibition. Thus pepstatin analogues lacking a pro-(S) C-3
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hydroxyl group are much weaker inhibitors o f aspartic proteases than inhibitors containing the 
pro-(iS) C-3 hydroxyl group found in natural statine.59 The structure o f statine provides an 
isosteric replacement for a dipeptidic unit. The structures o f statine and the tetrahedral 
intermediate for amide hydrolysis illustrates that statine can be isosteric with the tetrahedral 
intermediate only from C3 through C7. Statine is either 2 atoms too long to be isosteric with a 
normal a-amino acid or one atom short to be isosteric with a dipeptide.
The majority o f aspartic protease inhibitors developed to date bind to their target enzyme 
through non-covalent interactions. These compounds are therefore reversible inhibitors of 
proteases and inhibition relies on the enzyme having very much higher affinity for the inhibitor
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than its natural substrate. High affinity for any particular aspartic acid protease has been 
achieved by trying to maximise the number o f non-covalent interactions that the inhibitor makes 
with the enzyme. One approach that has proved successful is the introduction o f a transition state 
isostere that can mimic the tetrahedral transition state o f amide bond hydrolysis. It has been 
suggested that stable structures which can resemble the transition state for an enzyme reaction, 
will be bound more tightly than the substrate for the enzyme catalysed reaction. Studies carried 
out with pepstatin showed that increased affinity due to an isostere can be as great as 104 fold 
and is not only due to mimicry o f the transition state o f amide hydrolysis but also due to the 
displacement o f the catalytic water molecule hydrogen bonded to the catalytic aspartic acid 
residues.
1.1.9 Metalloprotease inhibitors.
Metalloproteases like the aspartic acid proteases do not form covalent intermediates but 
instead utilize coordination to a metal center to achieve their catalytic effect o f hydrolyzing 
peptide bonds.2 All known metalloproteases to date use a zinc atom to effect amide bond 
hydrolysis but theoretically the use o f metals such as nickel and copper could be feasible. The 
currently accepted catalytic mechanism involves a Zn2+ ion tetrahedrally coordinated to three 
donor groups from the enzyme and a water molecule. This water molecule is also hydrogen 
bonded to the carboxylic side chain o f a glutamic acid and is therefore activated for nucleophilic 
attack as shown in Figure 1.10a. The coordination o f the carbonyl moiety o f the scissile amide 
bond to zinc is followed by nucleophilic attack by the water molecule with a proton transfer to 
the carboxylate giving a tetrahedral zinc intermediate (Figure 1.10b). The transfer o f a proton 
from glutamic acid to the amide nitrogen is followed by collapse o f the tetrahedral intermediate 
with the generation o f a salt bridge between glutamic acid and the free amine o f the cleaved 
substrate as shown in Figure 1.10c. The design o f inhibitors has focused on attempts to bind the 
catalytic zinc atom. Synthetic inhibitors generally contain a moiety such as a thiol, carboxylic 
acid or hydroxamic acid moiety as the warhead, capable o f coordinating to a zinc atom attached 
to a series o f other groups that are designed to fit the specificity pockets o f a particular 
protease.60 This hypothesis o f inhibition has turned out to be very successful with numerous 
potent and selective inhibitors o f metalloproteases being approved for clinical administration.
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Figure 1.10 Proposed catalytic mechanism for the matrix metalloproteases.
Angiotensin converting enzyme (ACE) is a zinc metalloprotease that is expressed in 
many tissues including the heart, the lungs and several regions o f the brain. ACE has received 
considerable attention due to its pivotal role in blood regulation by catalyzing the proteolysis o f 
angiotensin I to the vasopressor angiotensin II.61 The inhibition o f ACE decreases levels of 
angiotensin II in the body leading to a decrease in blood pressure.62 Angiotensin converting 
enzyme is one o f the most studied drug design targets and inhibitor development has been 
extensively documented. Many ACE inhibitors have been approved for therapeutic use including
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captopril 35 and enalapril 36.63 These inhibitors are not only useful for the treatment of 
hypertension but also for congestal heart failure and renal protection. These compounds are 
small, low molecular weight derivatives that generally only occupy the SI, S I ’ and S2’ subsites 
o f  ACE. They all employ a chelating group that binds to the active site zinc resulting in high 
inhibitory potency and selectivity. ACE is a nonspecific enzyme that cleaves not only 
angiotensin converting enzyme I but also bradykinin and other peptide hormones. The inhibition 
o f  ACE leads to side effects such as cough and skin rash. These side effects are believed to be 
associated with a buildup o f bradykinin caused by its inhibition by ACE.64 In recent times, low 
molecular weight, lipophilic inhibitors o f ACE have been developed that are devoid o f side
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effects. A prime example is that o f losartan 37.65 Losartan is a nonpeptidyl angiotensin II 
receptor antagonist and differs from ACE inhibitors by producing direct antagonism o f the 
angiotensin II receptor. It is beneficially devoid o f side effects such as cough associated with 
other ACE inhibitors. This derivative may have the potential to compete effectively with ACE 
inhibitors as drugs o f choice for the treatment o f  hypertension in the market place.
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Kim et a l have recently described the synthesis o f silanediol peptidomimetics as ACE
inhibitors.66 These non-hydrolysable mimics act as transition state analogues replacing the 
scissile amide carbonyl o f the protease substrate. The most potent derivative 38 was shown to 
have an IC 50 value o f 72 nM against angiotensin converting enzyme from rabbit lung. This was 
almost fifty times more potent than the carboxy analogue.
Matrix metalloproteases (MMP) are a family o f proteases that were first described in 
1962 when Gross and Lapiere identified an enzyme from a tadpole tail with proteolytic action 
capable o f attacking collagen.67 M M P's were initially characterized by their ability to degrade 
components o f the extracellular matrix. These enzymes require a zinc ion at their active site and 
are inhibited by zinc and calcium chelating agents. Although matrix metalloproteases are 
inhibited naturally by locally produced tissue inhibitors o f metalloproteases (TIMP), an 
imbalance caused by overexpression and activation o f matrix metalloproteases results in tissue 
degradation. It is thought that matrix metalloproteases are important in the growth and spread o f
26
■ d-°
malignant tumors and development o f chronic diseases such as multiple sclerosis and arthritis.''" 
For these reasons matrix metalloproteases are considered to be attractive targets for inhibitor 
development and the treatment of these disorders.
Various matrix metalloprotease inhibitors are undergoing evaluation in clinical trials for 
the treatment o f  cancer, arthritis and multiple sclerosis. Marimastat 39 is the most notably 
advanced and is a broad spectrum metalloprotease inhibitor having a low nanomolar activity 
against MMP-1 with an IC 50 value o f 10 nM  recorded .69 This peptidomimetic is the end result of 
years o f substrate based inhibitor design based on the Gly-Ile and Gly-Leu collagenase (MMP-1) 
cleavage sites. The most important feature o f these inhibitors is the zinc binding component, a 
terminal hydroxymate proving to be the most effective ligand for enhancing the potency. One o f 
the main side effects o f 39 is the onset o f joint toxicity occurring predominantly in the upper 
limbs.
As a means o f avoiding these side effects, Wada et al have recently synthesised a series 
o f  highly selective MMP inhibitors as antitumor agents . 70 Compound 40 has been shown to be 
the most potent o f these inhibitors with an IC50 value o f 0.50 nM recorded against MMP-9. It 
possesses greater selectivity than marimistat and has pharmokinetics consistent with once a day 
dosage. Compound 40 exhibits significant inhibition o f tumour growth in animal cancer models 
and to date is shown to have considerably less side effects than 39. It is currently undergoing 
phase I clinical trials in cancer patients. More recently Moriyama et al have reported the 
synthesis o f azasugar based MMP inhibitors as antipsoriatic agents.7’ Psoriasis is a complex 
inflammatory skin disease that affects 2% o f the population. Compound 41 gave a K\ value o f 5.3 
nM  against MMP-1. I t ' was shown to suppress psoriasis in vivo on a mouse (12-0- 
tetradecanoylphorbol-13-acetate) TPA induced epidermal hyperplasia model at doses between 1 
and 1 0 0  (xg.
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MMP inhibition offers a promising opportunity to develop novel and innovative therapies 
for many chronic diseases that currently lack effective treatment. Despite the strong strategic
S I, S I ’ and S2’ subsites o f the enzyme. Oral bioavailability has been the greatest stumbling 
block for these substrate based inhibitors. Second generation compounds with improved 
bioavailability and selectivity should accelerate the development o f this class o f inhibitors.
1.1.10 Fluorine containing protease inhibitors.
The incorporation o f a fluorine atom into a drug molecule has been fundamental in the 
improvement o f biological activity. The importance o f fluorine substitution in pharmaceutical 
development is evident in the large number o f fluorinated derivatives approved by the FDA for 
use as anticancer, antiviral, antidepressant and anesthetic agents. There are generally two 
consequences o f introducing fluorine into a drug molecule. Firstly there are the physiochemical 
properties. Fluorine has the ability to simultaneously modulate electronic, lipophilic and steric 
parameters that can critically influence the pharmacological properties o f  a drug molecule. The 
introduction o f  a fluorine atom will generally increase lipophilicity, decrease basicity and alter 
the hydrogen bonding interactions o f a molecule. Secondly, there is the influence o f fluorine 
substitution on the biological stability o f a drug molecule, e.g., through altering susceptibility to 
metabolism (Figure 1.11).72 Fluorine has been used as a means to developing safer and more 
reactive pharmaceuticals due to the strength o f the carbon-fluorine bond that is very difficult to 
metabolize so harmful and unproductive side reactions are unlikely to occur.
position o f this class o f compounds, only a few MMP inhibitors have entered clinical trials. In 
general the greatest potency has been obtained by designing inhibitors to interact with at least the
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Figure 1.11 Prevention o f metabolic deactivation
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The lipid lowering agent 43 has been developed as a means o f treating hyperlipidemia. Its half 
live o f 22 hours is in part due to the presence o f the fluorine atoms that block unfavourable 
metabolic processes. It is approved by the FDA for combination therapy with statin derivatives 
for the treatment o f hypercholesterolemia.
The Van der Waals radius o f the fluorine atom is 1.47 A .  This value is positioned 
between the values o f hydrogen (1.20 A )  and oxygen (1.52 A )  allowing it to mimic a hydroxyl 
group and to participate in hydrogen bonding interactions. The concept o f  replacing the hydroxyl 
moiety o f a bioactive molecule with a fluorine atom has been a prevalent method for the 
enhancement o f  biological activity. Medicinal chemists have recognised for some time that 
fluorine and hydroxyl groups are chemical isosteres.73 The introduction o f a fluorine atom into a 
bioactive molecule also provides a marker for 19F NMR studies where drug-protein interactions 
can be assessed in vitro and in vivo due to the absence o f fluorine in living tissue.
Phosphonyl and sulphonyl fluorides were the first reported fluorine containing protease 
inhibitors and were developed more than eighty years ago. The inhibitors 
diisopropylfluorophosphate (DFP) 44 and phenylmethylsulphonyl fluoride (PMSF) 45 are two of 
the most effective examples o f protease inhibitors and are generally associated with serine 
inhibition.74 These inhibitors phosphorylate or sulphonylate the active site serine hydroxy group 
due to the electrophilicity o f the phosphorus or sulphur atom induced by the adjacent fluorine 
atom. Unfortunately these inhibitors are extremely toxic and suffer poor selectivity with both 
serine and cysteine proteases. Bartlett et al have synthesized increasingly selective phosphonyl 
fluorides. Compound 46 incorporates peptidyl character as a means o f  improving the selectivity 
o f a potent phosphonyl fluoride. It is a potent inhibitor o f elastase with 6-fold selectivity for 
elastase over a-chymotrypsin.75
The incorporation o f  fluoromethyl ketone moieties into protease inhibitors has led to the 
development o f potent transition state inhibitors for a variety o f proteases including porcine 
pancreatic elastase and cathepsin B.76 The introduction o f a fluorine atom into a methyl ketone
29
creates a highly reactive carbon center that readily undergoes nucleophilic attack. Peptidyl 
derivatives containing fluoroketones have the ability to be potent inhibitors o f proteases due to 
the vastly increased electrophilic nature o f  this carbon center. Both di- and trifluoromethyl 
ketones exist in water almost entirely in the hydrated form and thus it seems likely that fluoro 
ketones would form a hemiketal at the active site o f a serine protease or as it hydrates, bind 
tightly to both metallo and aspartyl proteases . 77 In contrast to chloromethyl ketones, the C-F 
bond in fluoromethyl ketones is much stronger than the C-Cl bond in the chloro analogues. This 
suggests that fluoromethyl ketones should be much poorer alkylating agents than chloromethyl 
ketones. This property should reduce the side effects associated with the use o f  chloromethyl 
ketones.
Akahoshi et al have developed a series o f protease inhibitors incorporating a 
difluoromethylene ketone . 78 These derivatives were potent human chymase inhibitors with high 
enzymatic selectivity and satisfactory metabolic stability. It has previously been reported that the 
inclusion o f a difluoromethyl ketone moiety increased affinity and selectivity for human 
chymase compared to other chymotrypsin like serine proteases . 79 The most potent derivative 47 
has a K\ value o f  2.62 nM against the serine protease human heart chymase and is 1600-fold 
more selective for this serotype o f chymase than rat peritoneal chymase. In vivo analysis carried 
out showed that 47 had satisfactory pharmokinetics with oral bioavailability o f 32% in dogs and 
17% in rats. Due to its biological and pharmokinetic profile this compound is currently being 
evaluated for its therapeutic potential against chymase induced diseases such as asthma.
More recently Cai et al have described a series o f dipeptidyl aspartyl fluoromethyl ketone 
derivatives as broad spectrum inhibitors o f the caspases . 80 Compound 48 was the most potent 
derivative with an IC50 value o f 17 nM against human caspase-3 protease. This compound was 
also shown to provide 50% cell protection against apoptosis induced by tumour necrosis factor-a
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(TNF-a) at a concentration o f 0.2 |xM. Unfortunately it was also shown to inhibit caspases 1, 3, 
6 , 7, 8  and 9 with IC 50 values between 11 and 50 nM. However, this compound was selective
The intravenous administration o f 48 at a dosage o f  10 mg/kg showed that there was 83% 
increase in the number o f  mice surviving after 3 days.
Perhaps the most successful example o f a fluorinated protease inhibitor is the tripeptidyl
proteases occurring at a concentration o f 10 nM and was shown to be stable in human plasma, 
dog plasma and a-chymotrypsin with half lives o f greater than 60 minutes recorded. This drug is
currently in phase three clinical trials for intranasal delivery and was one o f the first drugs
81utilised as a potential inhibitor o f the SARS outbreak in 2003.
The incorporation o f a fluorine atom has been shown to improve bioactivity and has led 
to development o f some o f the most successful pharmaceuticals to date. Despite this there are 
still very few examples o f  fluorinated protease inhibitors approved for clinical use. The most 
potent series o f  derivatives have been based on a fluoromethyl ketone scaffold. Examples o f such 
derivatives have shown potent inhibition o f serine and cysteine proteases. They are considerably 
more stable than their chlorine analogues although their alkylating ability often induces toxic 
side effects. The introduction o f a trifluoromethyl moiety may be a more successful route for the 
inhibition o f nucleophilic proteases given that the steric size o f the trifluoromethyl moiety is 
similar to a chlorine atom and also it has the ability to induce an electrophilic center. The 
development o f potent selective inhibitors such as 49 furnishes optimism for the development o f 
further fluorinated protease inhibitors.
against non-caspase proteolytic enzymes with 105 selectivity over cathepsin B, calpain-1 and 
Factor Xa recorded. Compound 48 was also found to be active in a mouse liver apoptosis model.
Michael acceptor containing human rhinovirus (HRV) inhibitor Rupintrivir™ 49. Rupintrivir™ 
is a potent irreversible inhibitor o f HRV 3C protease with an EC50 value o f 5 nM recorded. This 
compound was a selective inhibitor o f HRV 3C protease with no inhibition o f serine or cathepsin
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1.1.11 Conclusion
The design and synthesis o f protease inhibitors offers the potential for potent and 
selective chemotherapeutic agents. Historically, the design o f  protease inhibitors has 
incorporated highly reactive electrophilic warheads that alkylate, acylate, phosphonylate or 
sulphonylate the active site residues o f serine and cysteine proteases. These first generation 
inhibitors although very potent were shown to suffer from severe side effects due to their 
reactivity and poor selectivity due to their lack o f peptide character. The design o f  aspartic acid 
protease inhibitors has concentrated on the incorporation o f transition state isosteres that mimic 
the tetrahedral transition state o f amide bond hydrolysis. This is due to the fact that aspartic acid 
protease inhibitors bind to their target enzyme through non-covalent interactions. This method of 
design has been particularly successful with inhibitors o f the HIV-1 protease. The replacement of 
the peptide backbone o f peptide inhibitors with peptidomimetrics has been successful in 
improving the bioavailability and stability o f aspartic acid protease inhibitors in biological 
systems. Finally, metalloproteases have been most effectively inhibited by the incorporation of 
moieties such as thiols and hydroxymates capable o f binding to the Zn2+ ion. Although potent 
and selective inhibitors have been developed the majority o f these derivatives have suffered from 
very poor bioavailability. More recently inhibition design has began to utilise molecular 
modelling in tandem with the crystal structures o f  enzyme-inhibitor complexes. These complexes 
offer a clear picture o f  how the conformation o f  the inhibitor is related to the active site o f the 
enzyme and guides the design o f future inhibitors. This mechanism o f design has been particular 
fruitful when used in combination with library screening.
The inhibition o f proteases offers great potential for the treatment o f  various diseases. 
Unfortunately there are very few inhibitors that have reached the market as drugs. The main 
problems that are encountered by inhibitors are their lack o f selectivity, poor bioavailability and 
toxicity. The active sites o f serine and cysteine proteases are very similar and often a potent 
inhibitor o f a serine protease will also effectively inhibit similar cysteine proteases. The peptide 
nature o f inhibitors limits their bioavailability and toxicity due to reactive warheads incorporated 
into design is observed. Alternatively, protease inhibition has been extremely successful in the 
treatment o f hypertension,,HIV and parasitic diseases. HIV protease inhibitors such as saquinavir 
and lopanavir have not only revolutionised the treatment o f this horrendous disease but have also 
increased the expectation that potent inhibitors o f other proteases will be developed as drugs.
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1.2 Cancer and cancer resistance
1.2.1 Introduction
Cancer is a set o f diseases characterized by unregulated cell growth leading to invasion of 
surrounding tissues and metastasis. It is an ancient condition and was known to the early 
Egyptians. Cancer is a major cause o f premature death in the western world second only to heart 
disease.82 It is caused by a variety o f factors including smoking, pollution, diet and lifestyle. The 
best form o f treatment is prevention with initiatives such as smoking control and dietary 
awareness becoming more prevalent. The next best approach is early detection. The smaller the 
number and less malignant the nature o f the cancer cells the greater the probability o f  finding a 
cure. Screening programmes are now in place for the early detection o f cervical, breast, prostate 
and colon cancers.
Chemotherapy is the most effective treatment for metastatic tumors. It is the treatment o f 
choice for patients who have cancers that do not respond to surgery or radiation. The appearance 
o f  tumor cells resistant to a range o f cytotoxic drugs is a serious problem in cancer 
chemotherapy. Clinical drug resistance is a major barrier to overcome before chemotherapy can 
become curative for patients presenting with metastatic cancer. There are two main types of 
cancer resistance. Intrinsic drug resistance is present at the time o f diagnosis, in tumors that fail 
to respond to first line chemotherapy while acquired drug resistance occurs in tumors that are 
initially often highly responsive to initial treatment but on tumor recurrence appear to be strongly 
resistant to the original treatment.83 They become resistant to both previously used drugs and 
new agents with different structures and modes o f action. A number o f specific resistance 
mechanisms that occur at a molecular level have been described in vivo and in vitro. The three 
main proposed mechanisms include the reduction o f the intracellular accumulation o f anticancer 
drugs by increased drug efflux (MDR), alterations in drug targets (topoisomerase II) or activation 
o f  detoxifying systems (gluthathione-S-transferases). The absence o f  a structural relationship 
between the various types o f cancer resistance modulators increases the difficulty in eradicating 
resistance to chemotherapeutics. Compounds as diverse as non-steroidal anti-inflammatory’s, 
calcium channel blockers and protease inhibitors have all been used successfully to treat cancer 
resistance.
The broad spectrum resistance to structurally and mechanistically diverse anticancer 
agents is known as multidrug resistance (MDR). It results from the over expression o f adenosine
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triphosphate (ATP) binding cassette (ABC) transporters.84 The ABC transporters are a large 
family o f transmembrane proteins that use the energy o f ATP hydrolysis to transport their 
substrates across biological membranes. They function as a mechanism o f eliminating harmful 
substances from the body. The two most studied ABC transporters are P-glycoprotein (Pgp) and 
multidrug resistance associated protein (MRP-1). Pgp and MRP-1 are drug efflux pumps 
typically coexpressed with other ABC transporters such as breast cancer resistance protein 
(BCRP) and lung cancer resistance protein (LRP).84 Although Pgp and MRP-1 belong to the 
same family o f transporters there are some distinct differences between them. Pgp is expressed 
by secretory cells such as capillary endothelial cells in the brain and testis and at sites within the
oc
pancreas, kidney and liver whereas MRP-1 has been observed in virtually every type o f tissue. 
An additional difference relates to their expression in human tumors. The levels o f Pgp are often 
increased in tumor cells from patients undergoing chemotherapy. In contrast, although MRP-1 is 
expressed in a high percentage o f tumors, its over expression is not consistently found in tumors. 
For example MRP-1 levels in lung tumors were found to be lower than those in normal lung 
tissue.85 Therefore it seems that over expression o f Pgp activity is clinically more significant than 
the elevation o f M RP-1 levels.
1.2.2 Modulators of P-glycoprotein associated cancer resistance
P-glycoprotein was the first protein implicated in multidrug resistance and confers 
resistance by pumping drugs out o f the cell. Inhibition o f Pgp has been employed to improve the 
effectiveness o f chemotherapy. The inactivation o f Pgp should have no side effects as studies on
« ■ *mice have concluded that the protein is not essential for their survival. Chemosensitizers is the 
term now used to describe drugs that act by blocking Pgp. Verapamil 50 was the first compound
reported to overcome vincristine 52 resistance in P388 leukemia in vivo and in vitro?1 Structural 
studies showed that 50 directly interacts with Pgp and inhibits the binding o f Pgp transported 
agents to the pump, thus blocking drug efflux. This calcium channel antagonist is a potent
34
inhibitor o f Pgp in vitro but the plasma concentrations o f 50 required to efficiently block Pgp 
transport are rarely achieved clinically despite the administration o f sufficient verapamil 50 to
QQ
induce cardiotoxicity.
Teodori et al have synthesized a series o f verapamil analogues with additional aromatic 
rings adjacent to the amino moiety.88 Previous research has shown that besides the overall 
lipophilicity o f the molecule, weak polar interactions such as those produced by the overlapping 
o f  n orbitals o f aromatic rings can play an important role in stabilizing the binding of MDR 
reversing agents to Pgp.89 The transmembrane segments o f Pgp are believed to be rich in 
aromatic amino acid residues. The phenanthrene derivative 51 was shown to be a nanomolar 
MDR reverter with a dosage o f 50 nM increasing the nuclear concentration o f pirarubicin 54 in 
resistant erythroleukemia JC 562 cells by 50%. This compound was more than 30-fold more 
potent than verapamil in reversing MDR. Its inactivity as a vasodilator limits its potential 
cardiotoxicity. 51 also presents a pharmacological profile that makes it a promising drug 
candidate to treat MDR.
R = CHO 52 54
R = CH3 53
A series o f novel taxane based multidrug resistant reversal agents have been described.90 
The synthesis o f  these compounds is based on the fact that natural taxanes from the Japanese 
yew tree, Taxus cuspidate increase the cellular accumulation o f vincristine in MDR tumor cells 
as much as verapamil.91 The incorporation o f a hydrophobic conjugated ring has been shown to 
be a common theme in previous structure-activity relationship studies o f structurally different 
classes o f MDR reversal agents. The noncytotoxic compound 55 with a hydrophobic benzoyl-
COOCHj
HO COOCH,
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cinnamoyl moiety reached 99.8% recovery o f the original antitumor activity o f paclitaxel 56 
against the resistant breast tumor cell line MCF7-R when administered at a 1 (iM level. The Pgp 
transporter is known for its ability to non-selectively eliminate hydrophobic agents from cells but 
this study suggests that the presence o f a hydrophobic moiety bonded to a taxane based 
derivative furnishes effective reversal agents. The taxol derivative 55 was confirmed as a 
modulator against P-glycoprotein overexpression in drug resistant cell lines, it was also shown to 
inhibit efflux pumps mediated by the ABC transporters MRP-1 and BCRP and offers a lead 
compound for the revitalization o f well studied anticancer agents.
The naturally occurring steroid hormone progesterone 57 has been described as a potent 
modulator o f Pgp.92 Clarke et al have recently designed and synthesized a series o f Pgp 
inhibitors based on the progesterone skeleton.93 Their hypothesis involved substitution at the C-7 
position with an aromatic moiety would exhibit reduced Pgp affinity, increased anti-Pgp activity 
and reduced affinity for progesterone receptors. This is one o f the first examples o f the rational 
design o f Pgp inhibitors. To date the majority o f Pgp inhibitors have not been designed as MDR 
reverters thus side effects related to the normal function o f these agents may be induced at 
concentrations required to affect Pgp function. These inhibitors have been evaluated for their Pgp 
modulating activity with breast cancer models that have Pgp expression as the only mechanism 
present to produce MDR.
The methylbenzyl amine derivative 60 was shown to be the most potent Pgp inhibitor. 
This compound was synthesized by firstly preparing 6-dehydroprogesterone 58 from the reaction 
o f  57 with the oxidizing agent 2,3-dichloro-5,6-dicyano-l,4-benzoquinone (DDQ) and p- 
toluenesulphonic acid. This was then reacted with 4-aminothiophenol and sodium hydroxide to
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furnish a substituted aminothiophenol derivative 59. Reaction o f this compound with a- 
methylbenzylisocyanate iii the presence o f dichloromethane yielded 60. This noncytotoxic 
compound has an IC5o value greater than 20 (iM against breast cancer cells independent o f 
progesterone receptors. Because Pgp is an efflux pump the ability o f 60 to influence the 
intracellular accumulation o f  the cytotoxic drug vinblastine 53 was measured. Vinblastine 
content in Pgp positive cells exposed to media containing 53 was approx. 6-fold lower than in 
Pgp negative cells. At a concentration o f 0.7 |xM 60 was shown to decrease the difference in 
accumulation o f vinblastine in Pgp positive and Pgp negative cells by 50%. This was 28-fold 
more potent than 57 and more than four times more potent than verapamil. It was also shown not 
to bind to its predicted cellular target, progesterone receptors at concentrations that inhibit Pgp 
activity. This progesterone analogue significantly increased anti-Pgp activity when compared 
with progesterone and verapamil, lost its ability to activate progesterone receptors and is 
predicted to exhibit relatively low intrinsic toxicity in vivo.
DDQ/p-TsOH
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Figure 1.12 Synthesis o f  the progesterone based P-glycoprotein inhibitor 60
37
1.2.3 Synthetic inhibitors o f M RP-1 associated cancer resistance
The drug efflux pump MRP-1, a member o f the ABC transporters, is a 190 Kda protein 
localized mainly in the plasma membrane.94 Resistance associated with MRP-1 is different than 
Pgp mediated resistance although many anticancer drugs are affected by both mechanisms. The 
overexpression o f M RP-1 in tumor cells confers resistance to anthracyclines and vinca alkaloids 
but in contrast to Pgp taxanes are poor substrates for MRP-1.95 Although various inhibitors of 
Pgp have entered clinical trials the development o f selective MRP-1 inhibitors is in its infancy. 
Scientists at Xenova Ltd. have recently described potent, selective inhibitors o f MRP-1.95 The 
pyrrolopyrimidine derivative 61 was shown to have an IC50 value o f 138 nM against the MRP-1 
expressing cell line CORL23/R. This compound was more than 362-fold more selective for 
MRP-1 than Pgp. Cytochrome P450's (CYP) are a major class o f oxidative enzymes involved in 
drug metabolism. Potential MRP-1 modulators will be administered with cytotoxic agents and it 
is essential that these modulators will not inhibit CYP. Compound 61 exhibited minor inhibition 
against CYP with an IC50 value o f  45.8 ^M  recorded. It was also shown to have bioavailability o f 
71.6% when administered orally at 50 mg/kg in mice. More importantly the plasma 
concentrations o f this compound were 10-fold greater than their IC50 value for several hours after 
dosing. Finally, the in vivo efficacy o f 61 was assessed with mice bearing CORL23/R tumors. 
The antitumor activity o f vincristine was improved by 35 %. In contrast, both vincristine and 57 
alone had no effect on tumor growth in this MRP-1 resistant tumor model.
1.2.4 Glutathione 5-transferase associated cancer resistance
The overexpression o f  glutathione ^-transferase (GST) particularly the GST-71 isozyme 
has been proposed to be one o f the biochemical mechanisms responsible for drug resistance in 
cancer chemotherapy and offers a therapeutic target for the inhibition o f GST mediated drug 
resistance.96 The glutathione S-transferases are a family o f enzymes that catalyze the addition o f
38
Q7
the tripeptide glutathione 62 to endogenous substrates that have electrophilic functional groups. 
The glutathione 62 adducts produced have increased solubility in water and are subsequently 
enzymatically degraded to mercapturates and excreted. GST has been shown to deactivate a
• QO
number o f chemotherapeutic drugs including the alkylating agent melphalan 63. u The over­
expression o f three GST isozymes (a, |j. and n) have been found in cultured tumor cells resistant 
to cancer chemotherapy with the human GST-7t isozyme being overexpressed in carcinoma of 
the colon, lung, kidney and pancreas." GST-tc inactivates chemotherapeutic substances by 
conjugating them to glutathione 62 and their inhibition offers a potential method for cancer 
resistance.
Zheng et al have reported the synthesis o f a series o f haloenol lactones as potent 
inhibitors o f human GST-71 isoenzym e." The bromoolefin 64 was the most potent inhibitor with 
GST activity reducing by 0.1504% m in '1 over a twelve minute duration. The method of 
inhibition was proposed to involve the enzymatic hydrolysis o f the haloenol lactone by the Cys47 
residue o f the GST-7: active site. This proposal was confirmed by electrospray ionisation mass 
spectrometry (ESIMS) o f proteolytic fragments from haloenol lactone modified GST-tt indicated 
that the haloenol lactone is covalently bonded to the protein at Cys47.
OH
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Cisplatin 65 has been one o f the most successful examples o f a chemotherapeutic agent 
and is used in approx. 70% o f all cancer treatments. Despite this success, drug resistance to 
cisplatin remains a serious problem. GST is known to catalyze the conjugation o f  glutathione 
with cisplatin in vitro that leads to elimination o f toxic compounds.100 Ethacrynic acid 66, a 
diuretic in clinical use has been shown to be a potent inhibitor o f GST enzymes. Satraplatin 67 is 
a Pt(IV) anticancer drug currently undergoing Phase 3 clinical trials for combination therapy in 
patients with prostate cancer. It functions as a prodrug releasing its cytotoxic Pt(II) payload after 
losing its axial aceto-ligands by reduction in vivo. It has been shown to be suitable for oral 
administration. Dyson et al have recently synthesized a Pt(IV) prodrug 68 incorporating two 
molecules o f 66 as ligands.100 This compound will be reduced in vivo in analogous manner to 67
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but releasing the ethacrynic acid moiety as well as a cytotoxic Pt(II) center thus reversing 
cisplatin associated drug resistance. Compound 6 8  was shown to be a more potent inhibitor of 
GST than cisplatin or ethacrynic acid when assayed directly against the GST-a-isoenzymes 
GSTP1-1 and GSTA1-1, and was capable o f reducing the activity o f both enzymes to less than 
10%. Mass spectrometric analysis indicated that a GST induced cleavage o f the platinum- 
ethacrynic acid carboxylate bond could be responsible for inhibition although the mechanism of 
carboxylate bond cleavage may not be the same as GST conjugation. Compound 6 8  was also 
shown to have broad spectrum anticancer activity and significantly more cytotoxic than cisplatin 
against the cisplatin resistant breast tumor cell line MCF-7. 6 8  was shown to have an IC50 value 
o f 31.85 |xM compared to > 80 (oM for 65 24 hours after exposure.
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1.2.5 Cancer resistance related to the topoisomerases
Topoisomerases are a series o f enzymes that catalyze topological changes in DNA and 
are essential for cell division and replication.101 There are three types o f mammalian 
topoisomerases with type II existing in a  and p isoforms.102 Topoisomerase II is a major target 
for chemotherapeutic agents used in the treatment o f  cancer. Topoisomerase II directed agents 
are able to stabilize the covalent DNA-topoisomerase II complex and are traditionally known as 
topoisomerase poisons.103 Rather than inhibiting the overall catalytic activity o f the enzyme, 
poisons act by stabilizing covalent DNA-topoisomerase II complexes that eventually results in 
the generation o f  lethal DNA double strand breaks in treated cells. These poisons convert 
essential enzymes into potent cellular toxins that facilitate apoptosis.
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The most successful example o f a topoisomerase poison is the epipodophyllotoxin 
etoposide 69 that is used extensively in the treatment o f small cell lung cancer and testicular 
carcinoma . 104 Although 69 is used extensively in therapy the development o f resistance is a 
major stumbling block. Etoposide is affected by a distinct resistance phenotype that differs to 
any previously discussed mechanisms. It was first observed when leukemic cells resistant to 
anthracyclines and epipodophyllotoxins showed no reduction o f drug accumulation. This type of 
atypical multidrug resistance has shown some distinctive characteristics. Topoisomerase II is 
often down regulated, decreased in stability or mutated in the active site. More recently it has 
been hypothesized that resistance to topoisomerase II targeted anticancer agents also results from 
a decreased drug-enzyme binding affinity . 105 Presently the relationship between topoisomerase II 
and resistance is not as clearly understood as other resistance phenotypes such as Pgp, MRP-1 or 
GST. This limits the development o f chemotherapeutics to eradicate this atypical resistance. 
Presently the development o f more potent topoisomerase II inhibitors without consideration of 
resistance properties has been the main direction o f research for more successful anticancer 
agents.
Monneret et al have recently synthesized a series o f etoposide analogues as potent 
topoisomerase inhibitors and antitumor drugs . 104 At a concentration o f 20 (iM, the diamino 
etoposide derivative 70 was shown to inhibit 64% of topoisomerase compared to only 50% for 
69. It was also shown to be 10-fold more cytotoxic with an IC50 value o f 8 8  nM against the 
leukemia cell line L1210. This compound is a promising anticancer agent but it will not be until 
the concepts o f topoisomerase II related resistance are entirely understood that such potent 
derivatives can be administered as antitumor agents.
OH
69 70
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1.2.6 Conclusion
Clinical drug resistance is a multi-facet problem with often more than one drug resistance 
phenotype prevailing in the cell. The quantity and complexity o f these drug resistant mechanisms 
renders their modulation challenging. To date there is still a distinct lack o f understanding 
relating to many o f these phenotypes and this has led to the majority o f modulators being 
developed serendipitously. Although some potent inhibitors have been developed their extreme 
side effects often limits their employment. The design o f specific drug resistance modulators has 
been limited. The use o f traditional drug discovery tools such as SAR and QSAR have not 
produced many potent inhibitors o f drug resistance due to the unrelated structures o f many 
common inhibitors. Genome studies correlating drug response with DNA microarray datasets 
have identified many o f the genes and proteins involved in drug resistance. The identification o f 
specific biomarkers offers the potential for the selection o f optimal treatment for individual 
patients and the most promising solution for the eradication o f drug resistance.
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Chapter 2
Synthesis, characterization and biological activity of novel 
modified amino acid derivatives
2.1 Introduction
vV-benzoyl peptides have been shown to have a wide range o f biological activity varying 
from the treatment o f diabetes and rheumatoid arthritis to the improved drug delivery o f certain 
potential pharmaceuticals.1 The benzoylation o f a TV-terminal amino acid increases the 
lipophilicity o f the amino acid and substitution on such a group is often crucial for its biological 
activity. Alrestatin 71, a benzoylglycine derivative is an effective aldose reductase inhibitor. It 
has been used to delay the development o f long-term diabetes complications such as cataract and 
neuropathy.2 The planar structure in addition to a carboxylic or another acidic proton is believed 
to be essential for the inhibitory effect.
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A series o f TV-fluorobenzoyl glycine methyl esters have been previously described.3 These 
derivatives have been used to probe the structure o f substrate-enzyme complexes using 
resonance Raman spectroscopy. From this study it was shown that enzyme-substrate contacts 
between papain and the TV-fluorobenzoyl glycine methyl esters involve fluorine atoms at both the 
meta and ortho positions in the phenyl ring. The introduction o f a fluorine atom onto the phenyl 
ring has been shown to enhance biological activity.4 There are generally two consequences o f 
introducing fluorine into a drug molecule. Firstly there are the physiochemical properties, i.e. 
increased lipophilicity, increased acidity, decreased basicicity and a change in hydrogen bonding 
properties. Lipophilicity is an important consideration in the design o f biologically active 
compounds since it often controls absorption, transport or receptor binding.5 Secondly, there is 
the influence o f fluorine substitution on the biological stability o f a drug molecule. Fluorine 
substitution at different positions around the aromatic ring has led to improvements in selectivity 
and affinity along with a reduction in oxidative metabolism.6 Although heavier halogens and
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electron withdrawing groups are often more successful methods o f reducing oxidative 
metabolism, these moieties are often limited by factors such as potency, selectivity and 
solubility.
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Figure  2.1 7V-fluorobenzoyl amino acid esters as bioactive building blocks.
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The introduction o f fluorine into the bioactive molecules as markers also provide a 
valuable tool for 19F NMR studies by taking advantage o f the fact that fluorine is virtually absent 
in living tissue. iV-fluorobenzoylamino acid esters also can be very useful chiral building blocks 
for organic synthesis (Figure 2.1). A number o f one step reactions can readily turn the amino 
acid esters into very interesting bioactive molecules such as thiazoles, hydrazides and lactones. 
For example the reaction o f AM-fluorobenzoyl-L-Ala-OMe with phosphorus oxychloride can 
furnish the corresponding oxazole derivative. The benzoyl derivatives o f such compounds have 
been prepared but to date very little work has taken place on their fluoro analogues. Besides the 
utility o f fluorobenzoyl amino acid esters as versatile synthetic intermediates they may have 
intrinsic importance as a pharmacophore o f various therapeutic agents since the benzoyl amino 
acid skeleton is found in numerous pharmacologically active molecules possessing antihepatitis, 
anticonvulsant and anti-HIV activities.7 Herein the synthesis and structural characterization o f a 
series o f fluorobenzoyl amino acid esters is presented.
2.2 Synthesis o f A-fluorobenzoyl amino acid esters
There are potentially three alternative procedures for the synthesis o f jV-fluorobenzoyl 
amino acid esters (Figure 2.2). The first route involves fluorination o f iV-aminobenzoyl amino 
acid esters using diazotisation and sodium tetrafluoroborate that furnish fluorobenzoyl amino 
acid esters although such reactions have shown poor yields.5 The introduction o f a fluorine atom 
onto the phenyl ring can be achieved by a number o f ways. Historically fluorination was carried 
out by selectively chlorinating the aromatic ring using FeCl3 and CI2 gas followed by halogen 
exchange using metal fluorides, HF or antimony halide/HF as fluorinating agents. Halex 
(halogen exchange) methodology involves the displacement o f a heavier halogen from a ring 
carbon by a fluorine atom in the form o f a fluoride ion. The reaction does not proceed at an 
acceptable rate unless the leaving group is activated. Activation can be achieved by introducing 
electron withdrawing groups at the ortho or para  positions to the halogen being exchanged.8 
Alternative methodologies include the use o f organometallic, radical and electrophilic reagents 
but all o f these suffer from environmental and safety issues.
Elemental fluorine F2 has also been used successfully to halogenate phenyl rings. 
However its use has been quite limited due to the uncontrollable nature o f  the reaction that leads 
to decomposition products. Furthermore it has been shown that /jora-disubstituted benzene with
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two ortho/para directing groups can be fluorinated with high selectivity.9 Elemental fluorine is 
therefore o f use as a fluorinating agent for aromatic molecules when the directing effects o f the 
groups on the ring are complimentary. Deaminative fluorination is by far the most effective 
method o f introducing fluorine into an aromatic ring. The first step o f this procedure is 
diazotisation with nitrous acid and sodium tetrafluoroborate to produce arenediazonium 
tetrafluoroborates (Arl^BR}) followed by fluorinative decomposition to furnish fluoroarene 
derivatives. The Balz-Schiemann reaction as it is known is the most convenient and practical 
method for the regiospecific introduction o f fluorine onto aromatic rings.10 However many 
difficulties arise with isolation o f some ArN2BF4  and yields are often low. The use o f HF for the 
diazotization o f aminoarenes greatly simplified the transformation o f ArNH2 to A rF.11 This 
procedure offers the advantage o f a one pot deaminative fluorination o f ArNH2 due to the fact 
that the diazonium salts do not have to be isolated. More recently Olah and his group have 
recorded yields o f up to 90% by the diazotisation o f ArNH2 using a pyridinium polyhydrogen 
fluoride (Py.9HF) solution.12 The only disadvantage to this procedure is the extreme corrosive 
nature o f  the reagent used.
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Figure 2.2 Alternative syntheses o f  /V-fluorobenzoyl amino acid esters.
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Alternatively peptide coupling using 1,3-dicyclohexylcarbodiimide (DCC) and 1- 
hydroxybenzotriazole (HOBt) is another useful method. The main disadvantage to this process is 
the formation o f the jV-acylurea byproduct that reduces the total yield to less than 50% in certain 
cases. The third procedure for the synthesis o f fluorobenzoyl amino acid esters involves the 
preparation o f  the acid derivatives followed by esterfication o f the free acid group by 
diazomethane or thionyl chloride/methanol yielding the esters in good yields. The synthesis of 
the acid derivatives usually results in the formation o f the fluorobenzoic acid by-product. 
Isolation o f the TV-fluorobenzoyl amino acids can often be difficult. The logic behind the 
selection o f our synthetic route was increased yields and ease o f purification by recrystallisation.
A series o f novel TV-fluorobenzoyl amino acid esters have been synthesized using the 
amino acids L-alanine, L-phenylalanine, glycine and L-leucine as starting materials. A series of 
mono-, di- and pentafluoro compounds have been synthesized. The first step o f the synthesis 
involves the preparation o f  the appropriate fluorobenzoyl chloride. This is formed from the 
reaction o f  the benzoic acid derivative and the chlorinating agent thionyl chloride. Excess thionyl 
chloride is distilled off to give the acid chloride in almost quantitative yield. The acid chloride 
thus formed is then reacted with an equimolar amount o f an amino acid ester and an excess o f 
triethylamine in dichloromethane to form the N-fluorobenzoyl amino acid derivatives. The 
reaction is shown in Scheme 2.1. This reaction is analogous to the Schotten-Baumann reaction.10
(ii)
(i) SOCl2 R, =  H, CH3, CH2C6H5 and 'C4H9
(ii) NEt3, CH2C12 and amino acid ester R2 = CH3 or C2H5
Scheme 2.1 Synthesis o f N -fluorobenzoyl amino acid esters.
2.2.1 Synthesis o f /Y-fluorobenzoyl-L-alanine methyl esters
A series o f ten 7V-fluorobenzoyl-L-alanine methyl esters were prepared. The compounds 
are presented in Table 2.1. Compound 72 has been previously reported as a root growth 
promoting agent.13 Compound 74 furnishes the highest yield with a value o f 78%. The superior 
yields o f the monofluoro derivatives are probably due to a solubility effect. The monofluoro
54
derivatives 72-74 were found to be soluble in most organic solvents. The lowest yield o f 41 % 
was recorded for 7V-pentafluorobenzoyl-L-alanine methyl ester 81. This compound was found to 
have poor solubility in both polar and non-polar organic solvents. The effect o f five fluorine 
atoms on the benzoyl ring may result in steric hindrance but if  this was the case a similar 
discrepancy in yield would be expected between the 2-fluoro and 4-fluoro analogues. The 
addition o f sodium hydroxide to the amino acid for the synthesis o f the jV-pentafluorobenzoyl 
amino acid derivative 82 furnished an increased value o f 73%.
Table 2.1 TV-fluorobenzoyl-L-alanine derivatives.
Compound R i r 2 % Yield
7V-2-fluorobenzoyl-L-Ala-OMe 72 2-F-C6H4CO- -c h 3 74
./V-3-fluorobenzoyl-L-Ala-OMe 73 3 -F-C6H4CO- -c h 3 69
AM-fluorobenzoyl-L-Ala-OMe 74 4-F-C6H4CO- -c h 3 78
jV-2,3-difluorobenzoyl-L-Ala-OMe 75 2,3-(F)2-C6H3CO- -c h 3 47
7V-2,4-difluorobenzoyl-L-Ala-OMe 76 2,4-(F)2-C6H3CO- -c h 3 53
7V-2,5-difluorobenzoyl-L-Ala-OMe 77 2,5-(F)2-C6H3CO- -c h 3 43
7V-2,6-difluorobenzoyl-L-Ala-OMe 78 2,6-(F)2-C6H3CO- -c h 3 62
N-3 ,4-difluorobenzoyl-L-Ala-OMe 79 3,4-(F)2-C6H3CO- -c h 3 58
N -3 ,5-difluorobenzoyl-L-Ala-OMe 80 3,5-(F)2-C6H3CO- -c h 3 53
iV-pentafluorobenzoyl-L-Ala-OMe 81 2,3,4,5,6-(F)5-C6CO- -c h 3 41
iV-pentafluorobenzoyl-L-Ala-OH 82 2,3,4,5,6-(F)5-C6CO- -H 73
2.2.2 'H NM R studies o f the A-fluorobenzoyl-L-alanine derivatives
One o f the most interesting results recorded is the effect o f I3C -19F and 'H -^ F  coupling
i  •> i q  n  i
on the NM R spectra. Presently it is impossible to decouple the C- F and C- H interactions 
simultaneously on the available NMR instrument. The effects o f this coupling have been shown 
to extend to a four-bond distance. Theoretical calculations o f the chemical shifts expected with 
fluoro substitution on the phenyl ring were very accurate and invaluable in assigning each carbon 
and hydrogen.14 The *H NMR spectrum o f 7V-2,4-difluorobenzoyl-L-alanine methyl ester 76 is 
shown in Figure 2.3. The' solvent used was deuterated dimethyl sulphoxide (DMSO-dg). The 
amide peak present at 8 ~8.73 is a doublet with a coupling constant o f 6.8 Hz due to coupling
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with the a  hydrogen. This chemical shift is attributed to a hydrogen bond interaction between the 
amide proton and the polar S= 0  bond in the sulphoxide group o f DMSO-d^. The characteristic 
splitting pattern for a 2,4-difluoro substituted benzene ring is seen as a multiplet centered at 8 
-7 .7 , a multiplet centered at 8 -7.35 and a multiplet centered at 8 -7 .18 each o f  which integrate 
for one proton each. The reason these all appear as multiplets is due to the effect o f ’H -19?  
coupling on the phenyl ring. The a-hydrogen integrating for one proton shows up as a multiplet 
centered at 8 -4 .48. This can be explained by its proximity to both the amide proton and the 
methyl side chain o f alanine. The alanine methyl group is coupled to the a-hydrogen and appears 
as a doublet at 8 -1 .38  with a coupling constant o f 7 Hz. The characteristic methyl ester signal 
appears as a singlet at 8 -3.67. The *H NMR spectrum o f 7V-2,4-difluorobenzoyl-L-alanine 
methyl ester 76 is shown in Figure 2.3.
F igure 2.3 *H NM R spectrum of 2,4-difluorobenzoyl-L-alanine methyl ester 76.
A measure o f  the electron withdrawing nature o f the fluorobenzoyl moiety is recorded by 
the chemical shift o f  the amide protons. The most electron withdrawing substituent 
pentafluorobenzoyl, shifts the amide proton chemical shift down to 8 9.42. A similar effect is 
seen with the 2,6-difluoro analogue with the amide proton appearing at 8 9.19. Therefore this 
indicates a fluorine atom present in the 2- and 6- positions have the greatest influence over the
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chemical shift of the amide proton. Selected chemical shift values for the jV-fluorobenzoyl-L-
alanine derivatives are present in Table 2.2.
Table 2.2 Selected 'H  NMR data (8) for the vV-fluorobenzoyl-L-alanine derivatives.
Compound No. NH a-H -o c h 3 -c h 3
72 8.75 4.45-4.52 3.67 1.39
74 8.84 4.47-4.54 3.65 1.41
76 8.73 4.46-4.50 3.67 1.38
78 9.19 4.47-4.51 3.67 1.35
81 9.42 4.47-4.55 3.68 1.37
2.2.3 Synthesis o f /V-fluorobenzoyl-L-phenylalanine methyl esters
Phenylalanine (Phe) is an essential amino acid used as a precursor for neurotransmitter 
biosynthesis.15 Phenylalanine has been shown to promote the division o f existing melanoma 
cells.16 The artificial sweetener Aspartame is comprised o f 50% L-phenylalanine. It is often 
crucially important in biologically active peptides to elicit bioactivity where the side chain
* * 17phenyl group often plays an essential role in the ligand-receptor interaction. The molecular 
mechanism o f  this hydrophobic interaction is believed to involve interaction o f phenylalanine 
with the alkyl side chains o f amino acids whereby the Phe-phenyl n system is believed to 
function as a hydrogen acceptor.
The phenylalanine derivatives prepared are shown in Table 2.3. jV-pentafluorobenzoyl-L- 
phenylalanine methyl ester 92 was prepared in the lowest yield o f 39% due to its poor solubility 
in organic solvents. A similar observation was made in the case o f the alanine derivatives. The 
introduction o f  sodium hydroxide gives compound 93 in the highest yield o f 78 %. The melting 
points o f  the L-phenylalanine derivatives substantially higher than the L-alanine derivatives with 
highest being the 158-159 °C o f  the acid 93.
83-93
Scheme 2.2 Synthesis o f  TV-fluorobenzoyl-L-phenylalanine derivatives
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Table 2.3 Af-fluorobenzoyl-L-phenylalanine derivatives.
Compound Ri R 2 % Yield
/V-2-fluorobenzoyl-L-Phe-OMe 83 2-F-C6H4CO- -c h 3 56
jV-3-fluorobenzoyl-L-Phe-OMe 84 3-F-C6H4CO- -c h 3 45
yV-4-fluorobenzoyl-L-Phe-OMe 85 4-F-C6H4CO- -c h 3 49
jV-2,3-difluorobenzoyl-L-Phe-OMe 86 2,3-(F)2-C6H3CO- -c h 3 56
7V-2,4-difluorobenzoyl-L-Phe-OMe 87 2,4-(F)2-C6H3CO- -c h 3 62
7V-2,5-difluorobenzoyl-L,-Phe-OMe 88 2,5-(F)2-C6H3CO- -c h 3 48
7V-2,6-difluorobenzoyl-L-Phe-OMe 89 2,6-(F)2-C6H3CO- -c h 3 42
N-3,4-difluorobenzoyl-L-Phe-OMe 90 3,4-(F)2-C6H3CO- -c h 3 44
N-3,5 -difluorobenzoyl-L-Phe-OMe 91 3,5-(F)2-C6H3CO- -c h 3 51
,/V-pentafluorobenzoyl-L-Phe-OMe 92 2,3,4,5,6-(F)5-C6CO- -c h 3 39
iV-pentafluorobenzoyl-L-Phe-OH 93 2,3,4,5,6-(F)5-C6CO- -H 78
2.2.4 Electrospray Ionization Mass Spectrometry (ESIMS) studies of the /V-fluorobenzoyl- 
L phenylalanine derivatives
Electrospray is the term that refers to the small flow o f liquid from a capillary needle 
when a potential difference is applied between the end o f the capillary and a cylindrical 
electrode,18 Under these conditions the samples leaving the capillary do not leave as liquids but 
as fine mists. These mists consist o f droplets that are highly charged and may be either positive 
or negative depending on the sign o f the voltage applied to the capillary. Upon evaporation of the 
solvent droplets, a molecular ion o f the sample is obtained in a desolvated state. These ions are 
then transported into the ion analyzer by an electric field. The evaporation process yields either 
[M+H]+ or [M-H]' adducts with their generation promoting desolvation, as repulsive Coloumbic 
forces become stronger than the cohesive forces o f the droplet. Electrospray ionization (ESI) is a 
particularly effective technique for the production o f  molecular ions from polar molecules. ESI 
mass spectrometry was carried out on compounds 83-86 on a Bruker Esquire 3000 series LC/MS.
The positive ion mode mass spectrum of 84 shows an intense peak at m/z 324 when a cone 
voltage o f 20 was applied. The appearance o f this peak confirms the molecular mass o f the 
compound and reveals the presence o f a [M+Na]+ adduct. Relatively intense peaks also appear at 
m/z 340 and 625 respectively. The presence of the peak at m/z 340 can be attributed to the [M+K]+
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adduct while the peak at m/z 625 is due to a [2M+Na]+ species. A weak peak is also present at m/z 
120 responsible for the phenylalanine side chain derivative as shown in Figure 2.4. When the cone 
voltage is increased to 40 volts there is the appearance o f one intense peak, the [M+Na]+ adduct. 
There is also the presence o f weak peaks at m/z 242 and m/z 123 that represent phenylalanine 
methyl ester and the fluorobenzoyl moiety that are present after fragmentation. The mass spectrum 
of 83 displays a similar pattern except a distinct weak peak appears at m/z 302 representing the 
[M+H]+ species.
m/z 123
Figure 2.4 Fragmentation o f TV-3-fluorobenzoyl-L-phenylalanine 84.
2.2.5 13C NMR Studies of the A-fluorobenzoyl-L-phenylalanine derivatives 83-93
A 1JC NMR and DEPT 135 study was carried out on all compounds synthesised. The 13C 
NM R o f iV-3,5-difluorobenzoyl-L-phenylalanine methyl ester 91 is shown in Figure 2.5. In the 
13C NMR spectrum, the amide carbonyl peak appears at 8 ~164 as a triplet due to the effect of 
13C -19F coupling and the ester carbonyl peak appears at 8 ~172. Each o f the carbon atoms on the 
fluorinated aromatic ring appear as doublets and triplets due to the affect o f  13C -19F on the ring.
220 200 100 160 140 120 100 BO 60 40 20 0 ppw
Figure 2.5 13C NMR spectrum o f jV-3,5-difluorobenzoyl-L-phenylalanine methyl ester 91.
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The carbon atoms to which fluorine is bonded appear at 8 —163 and 8 -161. The four other 
carbons on the ring appear at 8 -111, -110, -107  with the quaternary carbon appearing at 8 
-137.3. The phenylalanine phenyl ring shows peaks at 8 -137, -129, -128 and -126. The 
methyl ester peak appears downfield at 8 —52 due to the deshielding effect o f  the attached 
oxygen atom. The signal for the a-carbon appears at 8 -54. The methylene carbon o f L- 
phenylalanine group is present at 8 -36. This is confirmed by the 13C DEPT 135 spectra.
The fluorobenzoyl moiety has a distinct effect on the chemical shift o f the amide 
carbonyl. The compounds 92 and 93 with the most electron withdrawing substituent, the 
pentafluorobenzoyl moiety have a chemical shift o f 8 -157. This is in contrast to the 
monofluorobenzoyl derivatives 83 and 85 that have a chemical shift further downfield at 8 164.2 
and 8 165.7 respectively.
Table 2.4 Selected 13C NMR data (8) for the iV-fluorobenzoyl-L-phenylalanine derivatives.
Compound No. c-o Ester C = 0 Araide C-F a-C
83 172.1 164.2 159.6 54.5
85 172.5 165.8 164.3 54.7
87 172.0 163.3 163.9, 160.2 54.5
89 171.7 160.2 160.4, 158.0 54.4
92 171.4 157.1 144.6, 141.5, 142.1, 138.4, 136.0 54.5
Although each o f the compounds differ substantially in relation to the chemical shifts o f 
their aromatic carbon atoms, each compound has six distinct peaks representing the aromatic 
carbons even if  certain atoms would appear to be in the same chemical environment. This effect 
is due to 19F-13C coupling in the 13C NMR spectra.
2.2.6 Synthesis o f Af-fluorobenzoyl-glycine ethyl esters
A  series o f  TV-fluorobenzoyl-glycine derivatives are presented in Table 2.5. In contrast to 
the alanine and phenylalanine derivatives the highest yield 72% was obtained for the pentafluoro 
analogue 103. This is due to the increased solubility o f the glycine derivatives in organic solvents 
and also perhaps the fact that the lack o f a substantial side chain in glycine limits the amount of 
steric hindrance possible. This is reinforced by the fact that iV-pentafluorobenzoyl-glycine nitrile
104 has a yield o f  68% that is greater than the L-alanine or L-phenylalanine pentafluorobenzoyl 
analogues.
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Table 2.5 TV-fluorobenzoyl-glycine derivatives.
Compound Ri Rz m.p. °C % Yield
iV-2-fluorobenzoyl-Gly-OEt 94 2-F-C6H4CO- -COOEt oil 58
jV-3-fluorobenzoyl-Gly-OEt 95 3-F-C6H4CO- -COOEt 60-62 52
AM-fluorobenzoyl-Gly-OEt 96 4-F-C6H 4CO- -COOEt 101-103 63
7V-2,3-difluorobenzoyl-Gly-OEt 97 2,3-(F)2-C6H3CO- -COOEt 54-56 69
iV-2,4-difluorobenzoyl-Gly-OEt 98 2,4-(F)2-C6H3CO- -COOEt 77-79 61
7V-2,5-difluorobenzoyl-Gly-OEt 99 2,5-(F)2-C6H3CO- -COOEt 51-52 55
/V-2,6-difluorobenzoyl-Gly-OEt 100 2,6-(F)2-C6H3CO- -COOEt 67-68 66
7V-3,4-difluorobenzoyl-Gly-OEt 101 3,4-(F)2-C6H3CO- -COOEt 91-92 61
A^-3,5-difluorobenzoyl-Gly-OEt 102 3,5-(F)2-C6H3CO- -COOEt 80-81 52
TV-pentafluorobenzoyl-Gly-OEt 103 2,3,4,5,6-(F)5-C6CO- -COOEt 79-80 72
vV-pentafluorobenzoyl-GIv-CN 104 2,3,4,5,6-(F)5-C6CO- -CN 126-127 68
2.2.7 Infrared study of the /V-fluorobenzoyl-glycine derivatives
Infrared (IR) spectroscopy is a spectroscopic technique by which many functional groups 
can be identified. Compounds absorb IR radiation and various molecular vibrations are induced. 
The IR spectra o f these compounds typically show two bands between 3460 and 3400 cm '1 
(Amide I and II) as shown in Figure 2.6. These bands are representative o f secondary amide N-H 
groups, however, upon hydrogen bonding or if  the sample is in the solid state these N-H groups
O I
1 J
/ V  ii " "
I .
Amide I | Amide II
Figure 2.6 Configuration o f amides giving rise to two bands in the IR spectrum, 
will appear at a lower wavelength. The appearance o f two bands can be attributed to two types of 
amide absorptions.19 Hydrogen bonding lowers and broadens N-H stretching frequencies albeit 
to a lesser degree than is the case with O-H groups as the intensity o f the N-H absorption is
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usually less than that o f O-H absorptions. The amide carbonyl (Amide I) is observed stretching 
between 1695 and 1680 cm '1. At 1550 cm '1 the N-H (Amide II) bending occurs. The aromatic 
system o f these compounds produce bands between 1500 and 1600 cm '1. Further bands due to 
aromaticity are present in the fingerprint region but these are o f little diagnostic value.
The Infrared spectrum o f jV-3 ,4-difluorobenzoyl-glycine ethyl ester 101 is shown in 
Figure 2.7. The IR spectrum was obtained as a potassium bromide disk. The bands due to amide 
and ester carbonyls appear at 1646 and 1739 cm"1 respectively. Peaks at 1542 cm '1 can be 
attributed to N-H bending and C-N stretching o f the C-N-H group. A t 3306 cm '1 a peak due to 
N-H stretching is observed. Selected IR values for the iV-fluorobenzoyl-glycine derivatives are 
presented in Table 2.6.
T able 2.6 Selected IR values (c m 1) for the /V-fluorobenzoyl-glycine derivatives.
C om pound No. N-H C —O E s te r C = 0A m ide A ryl C-H
94 3309 1737 1645 701
96 3277 1748 1648 670
98 3411 1749 1656 772
100 3278 1734 1654 800
103 3271 1737 1658 786
3600 3 1 0 0 2600 2100 
W ave No
1600
Figure 2.7 Infrared spectrum o f 7V-3,4-difluorobenzoyl-glycine ethyl ester 101.
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2.2.8 19F NMR study o f A-fluorobenzoyl-glycine derivatives
The 19F NMR spectrum o f compound /V-2,5-difluorobenzoyl-glycine ethyl ester 99 is 
shown in Figure 2.8. There are two multiplets present, one centred at 5 —118.5 and the other 
centred at 8 —119.6. These peaks appear as multiplets due to ]H -19F and 19F-19F coupling 
between the fluorine atoms and the aromatic protons. These chemical shifts become 8 —42.8 
and 8 ~-43.8 when trifluoroacetic acid is used as an external standard. These two multiplets 
integrate for one fluorine atom each. The pentafluoro derivatives 103 and 104 show a distinctive 
pattern in the l9F NMR. The fluorine atom in the para  position appears as a triplet at 8 —77.7 
due to coupling with two fluorine atoms and integrates for one fluorine. The fluorine atoms in 
the ortho positions appear as a double doublet at 8—66.6. The fluorine atoms couple with the 
meta fluorine atoms to give a coupling constant o f -23 Hz and with each other giving an 
decreased coupling constant o f - 6  Hz. The integration o f this peak gives a value o f two. The 
fluorine atoms in the meta positions appear as a multiplet centred at 8—86.3. The fluorine atoms 
in these positions couple with each other, the ortho fluorine atoms and the para  fluorine atom. 
Finally the pattern for a 3,5-difluorosubstituted phenyl ring appears as a triplet with a coupling 
constant -  8 Hz. The fluorine atoms couple with protons in the ortho and para  positions. The 
results from the l9F NMR study shows that fluorine atom has the ability to couple with both the 
hydrogen and fluorine nuclei in NMR.
Figure 2.8 l9F NMR spectrum o f jV-2,5-difluorobenzoyl-glycine ethyl ester 99.
2.2.9 Synthesis of A-fluorobenzoyl-leucine methyl esters
The final class o f  fluorobenzoyl amino acid derivatives prepared were the L-leucine 
analogues. iV-fluorobenzoyl-L-leucine methyl esters 105-114 were prepared in the highest yields.
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However these derivatives turned out to be the least crystalline with a number o f  compounds 
oils. This may be due to the bulky hydrophobic nature o f the 'butyl side chain. The highest yield 
recorded was for compound 106 with a value o f 79 %. The TV-pentafluorobenzoyl derivative 
compound 114 was obtained in a yield o f 45 %. This yield is superior to the yields recorded for 
the alanine and phenylalanine analogues but it is still lower than the yields o f the mono- and 
difluorobenzoyl-L-leucine methyl esters. This decreased yield is related to the reduced solubility 
o f a pentafluorobenzoyl derivative in organic solvent.
r 2
R,
Table 2.7 iV-fluorobenzoyl-L-leucine derivatives.
Compound Ri r 2 % Yield
W-2-fluorobenzoyl-Leu-OMe 105 2-F-C6H4CO- -CH2CH(CH3)2 62
N-3 -fluorobenzoyl-L-Leu-OMe 106 3-F-C6H4CO- -CH2CH(CH3)2 79
JV-4-fluorobenzoyl-L-Leu-OMe 107 4-F-C6H4CO- -CH2CH(CH3)2 76
7V-2,3-difluorobenzoyl-L-Leu-OMe 108 2,3-(F)2-C6H3CO- -CH2CH(CH3)2 65
7V-2,4-difluorobenzoyl-L-Leu-OMe 109 2,4-(F)2-C6H3CO- -CH2CH(CH3)2 71
7V-2,5-difluorobenzoyl-L-Leu-OMe 110 2,5-(F)2-C6H3CO- -CH2CH(CH3)2 59
jV-2,6-difluorobenzoyl-L-Leu-OMe 111 2,6-(F)2-C6H3CO- -CH2CH(CH3)2 63
N-3 ,4-difluorobenzoyl-L-Leu-OMe 112 3,4-(F)2-C6H3CO- -CH2CH(CH3)2 51
N- 3,5-difluorobenzoyl-L-Leu-OMe 113 3,5-(F)2-C6H3CO- -CH2CH(CH3)2 73
7V-pentafluorobenzoyl-L-Leu-OMe 114 2,3,4,5,6-(F)5-C6CO- -CH2CH(CH3)2 45
2.2.10 HMQC study of jV-3-fluorobenzoyl-L-leucine methyl ester 106
The *H NMR spectra o f the 7V-fluorobenzoyl-L-leucine derivatives show the two methyl 
groups o f  the 'butyl side chain as two individual doublets even though they appear to reside in 
the same chemical environment. A similar result is observed in the 13C NMR where the two 
methyl groups appear at 5 ~21 and ô -23. The hydrogen atoms o f  the methine and methylene 
groups o f  the 'butyl side chain generally overlap with a multiplet appearing centred at 5 -1 .7 .
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HMQC (Heteronuclear multiple quantum correlation) is a 2D NMR spectroscopic technique 
which correlates the carbon and proton spectra and hence total structural elucidation can be 
achieved. HMQC is a C-H correlation method that is frequently used to resolve the overlapping 
proton signals in complex structures.19 This is o f great assistance when assigning both carbon 
and proton peaks and elucidating a structure. As quaternary carbons and carbonyls do not bear 
hydrogen, no representative peak appears in the HMQC spectrum. These spectra yield such 
useful information so as to remove many ambiguities regarding the structure o f the compound 
that is being characterised. Table 2.8 and Figure 2.9 shows the C-H correlation spectrum for JV-3- 
fluorobenzoyl-L-leucine methyl ester 106.
Table 2.8 C-H correlation o f JV-3-fluorobenzoyl-L-leucine methyl ester 106.
Site ‘H ,3C H M Q C
1 136.3
2 7.68-7.72 114.5
3 162.3
4 7.36-7.41 118.7
5 7.50-7.56 130.8
6 7.68-7.72 124.0
7 165.1
8 4.49-4.55 51.3
9 1.49-1.83 39.5
10 1.49-1.83 24.7
11 0.91 23.1
12 0.87 21.3
13 173.3
14 3.67 52.2
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Figure 2.9 HMQC Spectrum o f N-3 -fluorobenzoyl-L-leucine methyl ester 106.
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2.3 Structural study of the A'-fluorobenzoyl amino acid esters
Crystals suitable for single crystal x-ray crystallographic determinations o f  76, 81, 101 
and 114 were grown from hexane, yielding colourless block shaped crystals. All pertinent 
crystallographic information is summarized in Tables 2.9 and 2.11 and selected bond distances 
and angles o f non-hydrogen atoms are given in Tables 2.10 and 2.12. Figures 2.10 - 2.18 show 
perspective views o f each crystal structure with the atomic numbering scheme.
Compound 76 crystallizes in the monoclinic space group P2| (No. 4) with two 
independent molecules per asymmetric unit. The range o f the phenyl C-C bond distances is 
1.361(5) to 1.396(4) A  (mean 1.380(4) A ) .  The carbonyl C = 0 distance for molecule A is 
1.289(9) A  but molecule B has a carbonyl bond distance o f  1.228(10) A .  The F-C-C bond angles 
range from 117.2(3)° to 119.6(4)°. The amide C (0)-N  distances C(1A)-N(1A) 1.318(3) A  and 
C(1B)-N(1B) 1.447(3) A  exhibit a lot o f single bond character. The principle interactions in 76 
involve the amide N-H and carbonyl groups o f neighbouring residues interacting as N -H .. ,0=C  
and forming a one-dimensional chain (Figure 2.13).
Refinement has shown that there are two types o f disorder associated with 76. The amide 
carbonyl oxygen atom is disordered over two sites O IA /O IB  which differ in their orientation 
with respect to the amide moiety and with site occupancy factors subsequently fixed at 50% 
each. Secondly, the 2,4-difluorophenyl ring is disordered over two orientations with site 
occupancies o f 0.938(6) and 0.062(6) for the major and minor sites respectively. This was 
detected by analysis o f the difference maps.
Figure 2.10 PLATON drawing of the X-ray crystal structure of A'-pentafluorobenzoyl-L-alanine
methyl ester 76 depicting the intermolecular interactions.
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Compound 81 crystallizes in the orthorhombic space group P2i2i2t (N o.19) with four 
independent molecules per asymmetric unit. The range o f the phenyl C-C bond distances is 
1.373(4) to 1.396(3) A  (mean 1.382(4) A ) .  The carbonyl C = 0  distance for 81 is 1.221(3) A .  The 
F-C-C bond angles range from 117.9(2)° to 121.1(3)°. The torsion angle between the phenyl ring 
and the amide functionality is -53.6(3)°. This is in contrast to the values o f 76 which are 54.2(6)° 
for molecule A and 21.8(6)° for molecule B. The value o f 21.8(6)° for molecule B makes the 
three atom plane 0=C -N  almost co-planar with respect to the phenyl ring system. The principle 
interactions in 81 involve the amide N-H and carbonyl groups linked as one-dimensional chains 
(Figure 2.10).
Table 2.9 Crystal data and structure refinement for A^-2,4-difluorobenzoyl-L-alanine methyl ester
76 and /V-pentafluorobenzoyl-L-alanine methyl ester 81.
76 81
Empirical formula C iiH hN i0 3F2 C nH 8N i0 3F5
M r 243.21 297.18
Crystal color Colourless, block Colourless, block
Crystal System Monoclinic Orthorhombic
Space group P2,(#4) P2!2 i2 i(#19)
a/A 5.0014(8) 9.649(4)
b/A 18.571(2) 10.613(4)
c/A 6.2184(9) 11.879(5)
p/° 92.496(11) -
V/A3 577.02 1216.47(9)
z 2 4
Temperature/K 294 150
Dcaic/gcm'3 1.4 1.623
F(ooo) 252 600
p/m m '1 0.123 0.166
Crystal dimensions/mm 0.47 x 0.38 x 0.25 0 .4 2 x 0 .2 2 x 0 .1 2
Index ranges h, -6-6; k, -22-22; /, -7-7 A, -11-12; it, -13-13; /, -15-15
Max. and min. transmission 0.945 to 0.97 0.933 to 0.980
Refinement method Full matrix on F2 Full matrix on F2
Reflections collected/unique 2612/1177 4975/1574
Data/parameters 1094/174 1377/188
Goodness o f fit 1.04 1.07
Final R indices (I>2o(I)) 0.033(R0, 0.083(RW) 0.041 (Ri), 0.101(RW)
Density range in final diff. map/eA3 -0.12, +0.13 -0.25, +0.26
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Table 2.10 Selected bond distances ( A )  and angles (°) for 76 and 81 with estimated standard
deviations.
76 81
(a) Bond distances
C(12)-F(2) 1.353(3), 1.31(3) 1.339(3)
C(14)-F(4) 1.341(4) 1.335(3)
0(1)-C(1) 1.289(9), 1.228(10) 1.221(3)
N (l)-C (l) 1.318(3) 1.336(3)
C (l)-C (ll) 1.497(4) 1.510(3)
(b) Bond angles
0(1)-C (1)-C (11) 114.7(5), 123.4(5) 121.1(2)
F(2)-C(12)-C(l 1) 119.0(3) 120.4(2)
C (ll) -C (l)-N (l) 118.01(19) 114.8(2)
0(1)-C(1)-N(1) 117.3(5), 124.2(5) 124.1(2)
F 6 B
Figure 2.11 ORTEP view of the X-ray crystal structure of iV-2,4-difluorobenzoyl-L-alanine
methyl ester 76.
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F5
Figure 2.12 ORTEP view o f the X-ray crystal structure o f TV-pentafluorobenzoyl-L-alanine 
methyl ester 81.
Figure 2.13 PLATON drawing of the X-ray crystal structure of 7V-2,4-difluorobenzoyl-L-alanine
methyl ester 76 depicting the intermolecular interactions.
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Compound 101 crystallizes in the monoclinic space group P2]/c with four independent 
molecules per asymmetric unit. The range o f the phenyl C-C bond distances is 1.349(6) to 
1.388(4) A (mean 1.367(4) A). The phenyl C = 0  distance for this molecule is 1.244(4) A but the 
ester moiety has a carbonyl bond distance o f 1.175(5) A. The F-C-C bond angles range from 
117.9(6)° to 121.3(5)°. The amide C(0)-N  distance C (l)-N (l) 1.328(4) A exhibits a lot o f single 
bond character. The principle interactions in 101 involve the amide N-H and carbonyl groups of 
neighbouring residues interacting as N -H ...O =C and forming a one-dimensional chain. There is 
also a weak intermolecular hydrogen bond formed between the carbonyl o f  C (l) and C(12) o f the 
aromatic ring (Figure 2.14).
Table 2.11 Crystal data and structure refinement for 7V-3,4-difluorobenzoyl-glycine ethyl ester
101 and W-pentafluorobenzoyl-L-leucine methyl ester 114.
101 114
Empirical formula CUH 11N 1O3F2 C 14H 14N 1O3F5
Mr 243.21 339.26
Crystal color Colourless, needle Colourless, block
Crystal System Monoclinic Monoclinic
Space group P2i/c P2i
a/A 4.901(7) 11.878(2)
b/A 24.729(4) 8.765(18)
c/A 9.910(2) 15.568(3)
p/° 93.465(13) 106.91(3)
v/A3 1198.6(3) 1550.7(5)
z 4 4
Temperature/K 294 150
Dcalc/gcm'3 1.348 1.453
F(ooo) 504 696
jj/mm '1 0.118 0.140
Crystal dimensions/mm 0 .4 0 x 0 .4 0 x 0 .1 0 0 .2 0 x 0 .1 6 x 0 .1 0
Index ranges h, -6-1; k, -1-29; /, -11-11 h, -15-15; k, -11-9; /, -20-20
Max. and min. transmission 0.954 to 0.988 0.972 to 0.986
Refinement method Full matrix on F2 Full matrix on F2
Reflections collected/unique 3048/2121 13297/3791
Data/parameters 919/175 2549/422
Goodness o f fit 1.009 0.994
Final R indices (I>2o(I)) 0.065(Ri), 0.148(RW) 0.042(R0, 0 .091(RW)
Density range in final diff. map/e A ’ -0.15,+0.15 -0.18, +0.20
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Refinement has shown that there is disorder associated with 101. The ester carbonyl oxygen 
atom is disordered over two sites 0 1 A /O IB which differ in their orientation with respect to the 
ester moiety and with site occupancy factors subsequently fixed at 50% each.
Figure 2.14 PLATON drawing o f  the X-ray crystal structure o f iV-3,4-difluorobenzoyl-glycine 
ethyl ester 101 depicting the intermolecular interactions.
Compound 114 crystallizes in the monoclinic space group P2i with four independent molecules 
per asymmetric unit. The range o f the phenyl C-C bond distances is 1.361(5) to 1.391(4) À 
(mean 1.377(5) À). The carbonyl C = 0  distance for 114 is 1.237(4) À. The F-C-C bond angles 
range from 117.7(3)° to 121.0(3)°. The torsion angle between the phenyl ring and the amide 
functionality is 54.7(5)°. This value compares favorably with the value o f -53.6(3)° for 
compound 81. The principle interactions in 114 involve the amide N-H and carbonyl groups 
linked as one-dimensional .chains (Figure 2.17).
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Figure 2.15 ORTEP view o f the X-ray crystal structure o f 7V-3,4-difluorobenzoyl-glycine ethyl 
ester 3h.
F5R
C50 O
Figure 2.16 ORTEP view o f the X-ray crystal structure o f 7V-pentafluorobenzoyl-L-leucine
methyl ester 114
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Figure 2.17 PLATON drawing o f the X-ray crystal structure o f W-pentafluorobenzoyl-L-leucine 
methyl ester 114 depicting the intermolecular interactions.
Figure 2.18 PLATON drawing o f  the X-ray crystal structure o f 7V-pentafluorobenzoyl-L-leucine 
methyl ester 114 depicting the best fit between the two molecules in 114.
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Table 2.12 Selected bond distances ( A )  and angles (°) for 101 and 114 with estimated standard 
deviations.
101 114
(a) Bond distances
C(13)-F(3) 1.361(5) 1.3474(4)
C(14)-F(4) 1.353(4) 1.3477(4)
0(1)-C(1) 1.244(4) 1.236(4)
N (l)-C (l) 1.328(4) 1.329(4)
C (l) -C ( ll) 1.481(5) 1.492(5)
(b) Bond angles
0(1)-C (1)-C (11) 120.87(4) 121.19(3)
F(3)-C(13)-C(12) 121.3(5) 120.14(3)
F(4)-C(14)-C(13) 119.2(5) 120.75(3)
C(11)-C(1)-N(1) 119.81(3) 115.4(3)
0(1)-C(1)-N(1) 119.32(4) 123.4(3)
A t present there is only one example o f a TV-fluorobenzoyl amino acid derivative 
deposited with the Cambridge Crystallographic Data Center. This derivative 7Vr-4-fluorobenzoyl- 
L-valine 116 reported by Coates et al has many similarities with compounds 76, 81, 101 and 
114.20 The length o f the carbon-fluorine bond is 1.359 Á that compares favorably with 1.341 Á 
(76), 1.335 Á (81), 1.353 Á (101) and 1.347 Á (114). The bond distances o f compounds 81 and 
114 are slightly smaller due to the fact that these compounds are pentafluorobenzoyl derivatives 
and the selected bond lengths are the length o f  the carbon-fluorine bond in the para  position. 
According to the Cambridge Crystallographic Database April 2004 version the average length of 
an aromatic carbon-fluorine is 1.348 Á. The length o f the amide bond in these derivatives is very 
similar. Compound 116 has an amide bond length o f 1.319 Á compared to o f 1.318 Á compound 
76. Compound 101 has an amide bond angle (01)-(C1)-(N1) o f 119.32°. The TV-4-fluorobenzoyl- 
L-valine derivative 116 has a similar amide bond angle o f 122.37°. Finally the torsion angle 
between the phenyl ring and the amide shows compounds 76 and 116 to be comparable. 
Compound 76 has a torsion angle o f 21.8° whereas compound 116 has a torsion angle o f  26.3° 
between the phenyl plane and the amide bond.
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2.4 /V-fluorobenzoyl amino acid derivatives as potential multidrug resistance inhibitors
2.4.1 Introduction
Chemotherapy plays a significant role in the control o f metastatic cancers that cannot be 
cured by surgery due to their widespread diffusion within the body. The resistance o f cancer cells 
to cytotoxic drugs is a major cause o f  chemotherapy failure. The term multidrug resistance 
(MDR) is used to define resistance whereby cells become resistant to different drugs with no 
obvious structural resemblance and with different cellular targets. Multidrug resistance may be 
an inherent property o f the cells or acquired following exposure to one or more cytotoxic 
agents.21 The chemotherapeutic drugs to which the cells are resistant generally include the
anthracyclines, vinca alkaloids, peptide antibiotics and taxol but usually exclude nucleotide
* ■ • 22 analogues, metabolic inhibitors, alkylating agents and platinum analogues.
Multidrug resistance causes various changes in the biochemical and biophysical nature o f 
the cell. The most prevalent cellular alteration is associated with MDR is reduced drug 
accumulation and the associated over-expression o f a 170 Kda membrane associated energy 
dependent drug efflux pump termed P-glycoprotein (P-gp) which is coded for by the MDR 
gene.23 The over-expression o f a second 190 Kda drug efflux pump termed ‘Multi-drug 
Resistance related protein’ (MRP) is also capable o f attributing an MDR profile on cells.24 For 
some time after its discovery it was widely believed that P-gp was the exclusive cause o f 
multidrug resistance. However, over time it became clear that alternative forms o f drug 
resistance existed which were independent o f P-gp. Several cell lines were isolated that displayed 
multidrug resistant characteristics in the absence o f  detectable P-gp expression.
One such non P-gp multidrug resistant cell line is H69AR, which is derived from the 
parental NCI-H69 small cell lung cancer cell line by repeated transient exposure to the 
anthracycline doxorubicin 117 more commonly known as adriamycin®.25 H69AR cells displayed 
moderately high levels o f resistance to the vinca alkaloids and anthracyclines.
OMc o oh o 
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A gene named MRP-1 (Multidrug Resistance-associated Protein) with a molecular weight o f ~ 
190 Kda from H69AR cell line has been isolated.23 MRP-1 is a 1531 amino acid membrane 
phosphoprotein encoded by a 6.5 kilobase mRNA and is a member o f the ATP binding cassette
(ABC) family o f transmembrane transporters. MRP-1 has also been shown to play a crucial role
26in protecting tissues from toxin induced damage.
2.4.2 Cytotoxicity of the ¿Y-fluorobenzoyl amino acid derivatives
The toxicity o f compounds 72-115 was examined. Firstly an IC50 o f selected compounds 
was carried out. The IC50 is used to determine the concentration o f a drug at which 50% cell 
survival is seen and it is a good indication o f the toxicity o f a drug. This involved the use o f 
DLKP cells, a lung cancer derived cell line. Each drug was used at a variety o f concentrations 
ranging from 5|xM to 200pM. This involved the incubation o f the cells with the drugs for 
approximately one week, after which the plates were then read using an alkaline phosphatase 
assay. The results o f which were then graphed plotting concentration o f the drug in micromoles, 
against the percentage o f cell survival.
Table 2.13 IC 50 values o f the fluorobenzoyl amino acids against DLKP cells
Compound IC50 |iM
74 > 200
76 > 200
81 16
82 > 200
85 > 200
92 17
93 > 200
104 15
114 24
115 17
Compounds 74, 76, 82, 85 and 93 were shown to be relatively non-toxic. A very high percentage 
o f  cell survival was seen with all drug concentrations. Due to their non-toxic nature an IC 5 0  could 
not be determined. The remaining compounds tested showed mild toxicity. Compound 81 was
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found to be a relatively toxic compound with only 8 % cell survival seen at 200(iM. An IC50 of 
this compound was seen at about 16(xM. iV-pentafluorobenzoyl-glycine nitrile 104 was shown to 
be the most potent compound with an IC50 value o f 15|xM.
Cytotoxicity studies on the L-alanine derivatives showed that the pentafluorobenzoyl 
derivatives 81 and 82, were more cytotoxic than their difluoro 76 or monofluoro 74 analogues. 
This could be due to increased lipophilicity and increased acidity o f the pentafluoro derivatives. 
To a sse ss  what effect cellular hydrolysis might have on the toxicity o f the L-Ala derivatives, the 
pentafluorobenzoyl acid 82 was analysed. This compound should not undergo hydrolysis due to 
its lack o f an ester moiety and its toxicity was ultimately reduced by more than 12 fold. This 
shows that perhaps a cellular hydrolytic process or the increased lipophilicity of the ester 
derivatives is responsible for the cytotoxic nature o f the pentafluoro ester compounds. Analysis 
o f the L-phenylalanine derivatives gave similar results with the pentafluorobenzoyl derivative 92 
being far more cytotoxic than its monofluoro 85 or acid analogue 93. The L-leucine analogues 
also gave analogous results. The pentafluorobenzoyl derivative 114 was once again a cytotoxic 
agent but when the side chain was increased in size from an 'propyl to an indole group toxicity 
was increased by 30%. The increased activity o f compound 115 must be due to the hydrophobic 
side chain o f tryptophan. Compound 104 was also cytotoxic and this further indicated that a form 
o f hydrolysis was perhaps responsible for the cytotoxic nature o f these compounds as the nitrile
* 2 7group has been shown to be a target o f hydrolysis.
Figure 2.19 Line graph representing the % cell survival o f DLKP cells when treated with 
varying concentrations o f 7V-pentafluorobenzoyl-L-alanine methyl ester 81.
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2.4.3 Combination toxicity of A-fluorobenzoyl amino acid derivatives and epirubicin
Epirubicin 118 is a potent anthracycline antibiotic. It was first approved for clinical use in 
France in 1982.28 It is the 4 ’epimer o f doxorubicin with the hydroxy group in an equatorial 
position. It exerts its effects on cancer cells in three ways. Firstly it inhibits the activity o f the 
enzyme topoisomerase II that is crucial to DNA replication and transcription. It also intercalates 
between base pairs o f DNA and inhibits DNA dependent RNA synthesis. Finally it is known to 
generate free radicals that cause membrane damage and DNA strand breaks.29 It has broad 
spectrum anti cancer activity against Hodgkins disease, leukemia, prostate, lung and ovarian
h 2n
carcinomas.30 Epirubicin or Ellence® as it is commercially known is generally used in 
combination with other chemotherapy drugs to treat breast cancer that has spread to the lymph 
nodes under the arm following breast cancer surgery.31 Its metabolites are relatively non- 
cytotoxic although adverse effects such as nausea and congestive heart failure have been 
reported.32 It is generally administered as an intravenous infusion. Epirubicin has increased 
lipophilicity in comparison to doxorubicin and hence has increased cell penetration. Resistance 
to epirubicin is caused by two different processes, namely increased inactivation o f  free radicals 
caused by an increase in the levels o f glutathione dependent enzymes and also increased drug 
efflux caused by MRP-1 and P-gp.33
Compounds 81, 92, 104, 114 and 115 were found to be the only compounds exhibiting 
toxicity and these were combined with epirubicin, to further test their toxicity, and to examine 
their synergistic toxicity with epirubicin. To do so, a combination toxicity assay involving the 
fluorobenzoyl amino acid derivatives, compound 118, and DLKP cells, was carried out. 
Relatively non-toxic concentrations o f these fluorobenzoyl amino acids were combined with 
various concentrations o f  epirubicin. Combination toxicity assays involving the non-toxic amino 
acid derivatives 82 and 93 were also carried out but only after the potency o f the toxic analogues 
was assessed.
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Concentrations of drug used in micromoles
Compound 118; a = 0.01 ljiM , b = 0.013jiM, c = 0.019jiM.
Compound 81; a = 2jjM, b = 4.5pM, c = 16jiM.
Figure 2.20 Combination assay o f iV-pentafluorobenzoyl-L-alanine methyl ester 81 and 
epirubicin 118 with DLKP.
This combination assay confirmed the toxicity o f compound 81. Compound 81 showed 
synergistic toxicity with epirubicin. This gives a preliminary indication that this agent may be a 
substrate and/or inhibitor o f  the MRP-1 cancer resistance mechanism that is found in DLKP 
cells. Table 2.14 displays the concentration o f each agent used, the cell survival when 
administered alone and also the cell survival achieved when both agents are administered in 
combination.
Table 2.14 Synergistic toxicity o f  the fluorobenzoyl amino acid derivatives
Epirubicin (E) pM % Cell Survival Compound (C) % Cell Survival E+C % Cell Survival
19 40.61 8 1 - 2  jxM 97.02 31.64
6 54.61 8 2 - 2  (iM 98.64 51.29
4 94.07 9 2 - 1  |aM 100 88.13
6 55.20 9 3 - 2  (xM 100 51.17
7 66.37 104 - 2 nM 95.38 57.06
8 78.22 114 - 1 jjM 94.08 71.22
8 78.22 115 - 1 jjM 95.87 68.46
In terms o f cytotoxicity the three most potent compounds were 81, 104 and 115. They 
also showed the best synergistic results when combined with epirubicin. iV-pentafluorobenzoyl- 
L-alanine methyl ester 81 improved the cytotoxicity o f epirubicin by up to 8.4% Similar results 
were recorded for the L-tryptophan 115 and glycine 104 analogues with increased toxicity o f up 
to 10% with compound 115. Compounds 92 and 114 although not as toxic as compounds 81, 93 
or 104 showed synergistic toxicity, with the toxicity o f epirubicin increasing by up to 7%. These 
results indicate that the more cytotoxic the agent the greater the synergism. Two completely non­
toxic derivatives 82 and 93, were tested for any possible synergism when combined with 
epirubicin. These compounds showed minor synergistic toxicity when combined with epirubicin 
with the toxicity o f epirubicin increasing between 3-4%. From these results it can be said that the 
fluorobenzoyl amino acid m otif is a substrate and/or inhibitor o f the MRP-1 cancer resistance 
mechanism that is found in DLKP cells.
2.5 Conclusion
The synthesis, structural characterization and biological activity o f a series o f N- 
fluorobenzoyl amino acid derivatives has been carried out. TV-fluorobenzoyl amino acid 
derivatives have been shown to be inhibitors o f the MRP-1 cancer resistance mechanism. 
Further research will be focused on the development o f more cytotoxic benzoyl amino acid 
derivatives as it has been shown that increased cytotoxicity generally equals increased 
synergistic toxicity. This can be accomplished in three ways. Firstly alternative substitutions with 
hydroxy or nitro groups on the benzoyl ring that are relatively isosteric to the fluorine atom may 
increase the polar nature o f the compound. Variation in the size and polarity o f the amino acid 
side chain o f the amino acid must also be carried out. Finally, the introduction o f more 
electrophilic C-terminal substituents such as boronic acids or aldehydes may improve the toxicity 
o f  these compounds as the electrophilic nitrile moiety has shown to increase the cytotoxicity of 
the fluorobenzoyl amino acid esters. Electrophilic isosteres have been shown to be potent 
inhibitors o f the MRP-1 cancer resistance mechanism.34 These factors will be important in 
developing more cytotoxic agents. We have shown that the indole side chain o f L-Try has been 
shown to be the most effective group to date.
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2.6 Experimental
General Procedures.
All chemicals were purchased from Sigma/Aldrich and used as received. When necessary solvents 
were purified prior to use and stored under nitrogen. Dichloromethane was distilled from CaEk and 
triethylamine was distilled and stored over potassium hydroxide pellets. Commercial grade reagents 
were used without further purification. Riedel-de Haen silica gel was used for thin layer and column 
flash chromatography. Melting points were determined using a Griffin melting point apparatus and 
are uncorrected. Specific rotation [a]o studies were recorded on a Perkin Elmer 241 polarimeter. 
Infrared spectra were recorded on a Nicolet 405 FT-IR spectrometer and elemental analysis was 
carried out by the Microanalytical Laboratory at University College Dublin. Electrospray mass 
spectra were recorded on a Q-ToF Ultima equipped with a Waters 2790 LC system and a Bruker 
Esquire 3000 series LC/MS. NMR spectra were obtained on a Bruker AC 400 NMR spectrometer 
operating at 400 MHz for *H NMR, 376 MHz for 19F NMR and 100 MHz for 13C NMR. The *H 
and l3C NMR chemical shifts (ppm) are relative to tetramethylsilane and the 19F NMR chemical 
shifts (ppm) are relative to trifluoroacetic acid. All coupling constants (J) are in Hertz.
General procedure fo r  the synthesis o f  N-fluorobenzoyl-L-alanine m ethyl esters 72-81 
/V-2-fluorobenzoyl-L-alanine methyl ester 72
A solution o f 2-fluorobenzoyl chloride (2.00 g, 12.6 mmol) in dichloromethane (20 mis) was 
added dropwise to a solution o f  L-alanine methyl ester (1.76 g, 12.6 mmol) and triethylamine 
(2.55 g) in dichloromethane (20 mis). The solution was stirred for 8 hrs then washed with 5% 
NaHCC>3 , 5% HC1 and water. The organic extract was then dried over MgS0 4  and the solvent 
was removed in vacuo to yield a crude oil. Recrystallisation from hexane gave the title product
72 as white crystalline needles (2.11 g, 74%). 
m.p. 38-40 °C. [a]D25 = -6.2° (c, 1.32, EtOH).
Anal, calcd. for C i iH i2N ,0 3F 1: C, 58.66; H, 5.37; N, 6.21; F, 8.44.
Found C, 58.46; H, 5.35; N, 6.10; F, 8.75.
Mass Spectrum: [M+Na]+ found 248.1.
CuH ^N iO aFiN ai requires 248.2.
IR (KBr): u 3268, 3101, 1756, 1656, 1504, 1215, 994 cm '1.
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'H-NM R (400 MHz, DMSO): 5 8.75 (1H, d, J =  6.8 Hz, -NH-), 7.59-7.64 (1H, m, -A iH  6), 7.52­
7.58 (1H, m, -A iH  4), 7.26-7.31 (2H, m, -ArH  3 & 5), 4.45-4.52 (1H, m, a-H), 3.67 (3H, s, - 
OCHi), 1.39 (3H, d, J =  7.2 Hz, -C/ft).
13C-N M R(100 MHz, DMSO): 8 173.2 (-COOCH3), 164.1 (-ArCO-), 159.5 (d, -A rC2), 132.9 (d, 
-ArC 4), 130.4 (d, -ArC 6), 124.7 (d, -ArC 5), 123.8 (d, -ArC 1), 116.4 (d, -ArC 3), 52.3 (- 
OCH 3), 48.5 (a -Q , 17.0 (-CH3).
,9F-NMR (376 MHz, DMSO): 5 -38.9 - -38.6 (m).
iV-3-fluorobenzoyl-L-alanine methyl ester 73
3-Fluorobenzoyl chloride (2.00 g, 12.6 mmol) was used. Recrystallisation from hexane yielded
73 as a white powder (1.97 g, 69%).
m.p. 41-43 °C. [a]D25 = -14.2° (c, 4.0, EtOH).
Anal, calcd. for C n H 12N 10 3Fi: C, 58.66; H, 5.37; N, 6.21; F, 8.44.
Found C, 58.35; H, 5.30; N, 6.10; F, 8.84.
Mass Spectrum: [M+Na]+ found 248.1.
C nH [2N i0 3 FiNai requires 248.2.
IR (KBr): u 3322, 3072, 1748, 1641, 1542, 1227, 756 cm '1.
'H-NM R (400 MHz, DMSO): 5 8.91 (1H, d, J =  6.8 Hz, -NH-), 7.68-7.77 (2H, m, -A rH 2  & 6), 
7.51-7.57 (1H, m, -ArH  5), 7.38-7.43 (1H, m, -ArH  4), 4.45-4.52 (1H, m, a-H), 3.67 (3H, s, - 
O C / / 3 ) ,  1.41 (3H, d, J =  7.2 Hz, -CH3).
13C-NMR (100 MHz, DMSO): 5 173.4 (-COOCH3), 165.2 (d, -ArCO-), 163.3 (d, -ArC 3), 136.3 
(d, -ArC 1), 130.7 (d, -ArC 5), 123.9 (d, -ArC 6), 118.6 (d, -ArC 4), 114.5 (d, -ArC 2), 52.2 (- 
OCH 3), 48.7 (a -Q , 16.9 (-CH3).
19F-NMR (376 MHz, DMSO): 5 -37.3 - -37.2 (m).
7V-4-fluorobenzoyl-L-alanine methyl ester 74
4-Fluorobenzoyl chloride (2.00 g, 12.6 mmol) was used. Recrystallisation from hexane furnished
74 as white crystalline needles (2.22 g, 78%). 
m.p. 70-72 °C. [a]D25 = -10.2° (c, 3.4, EtOH).
Anal, calcd. for C nH i2N i03Fi: C, 58.66; H, 5.37; N, 6.21; F, 8.44.
Found C, 58.87; H, 5.40; N, 6.10; F, 8.82.
Mass Spectrum: [M+Na]+ found 248.1.
83
C iiH i2N i0 3 FiNai requires 248.2.
IR (KBr): u 3290, 3083, 1755, 1642, 1548, 1215, 846 cm '1.
•H-NMR (400 MHz, DMSO): 5 8.84 (1H, d, J =  6 . 8  Hz, -NH-), 7.97-8.00 (2H, m, -A iH 2  & 6 ), 
7.27-7.31 (2H, m, -ArH  3 & 5), 4.47-4.54 (1H, m, a -H), 3.65 (3H, s, -OCH3), 1.41 (3H, d, J  =
7.6 Hz, -CH3).
I3C-NMR (100 MHz, DMSO): 5 173.5 (-COOCH3), 165.6 (-ArCO-), 164.3 (d, -A rC 4), 130.5 (­
A rC 2), 130.45 (-ArC 1), 130.4 (-A rC 6 ), 115.5 (-A rC 3), 115.3 (-A rC 5), 52.1 (-OCH3), 48.7 (a­
C), 16.9 (-CH3).
19F-NMR (376 MHz, DMSO): 5 -33.8 - -33.6 (m).
A-2,3-difluorobenzoyl-L-alanine methyl ester 75
2.3-Difluorobenzoyl chloride (2.00 g, 11 mmol) and L-alanine methyl ester (1.54 g, 11 mmol) 
were used. Recrystallisation from hexane furnished 75 as a white powder (1.26 g, 47%).
m.p. 46-48 °C. [a ] D 25 = -10.7° (c, 7.2, EtOH).
Anal, calcd. for C n H n N ^ F z :  C, 54.32; H, 4.55; N, 5.75; F, 15.62.
Found C, 54.18; H, 4.47; N, 5.38; F, 15.39.
Mass Spectrum: [M+Na]+ found 266.1.
C iiH n N i0 3F2Nai requires 266.1.
IR (KBr): d 3303, 3059, 1760, 1643, 1536, 1482, 762 cm '1.
'H-NM R (400 MHz, DMSO): 5 8.92 (1H, d, 6 . 8  Hz, -NH-), 7.42-7.57 (1H, m, -ArH 6 ), 7.38­
7.42 (1H, m, -ArH  5), 7.27-7.32 (1H, m, -AxH  4), 4.46-4.53 (1H, m, a-H), 3.68 (3H, s, -OCH 3), 
1.39 (3H, d, J -  7.6 Hz, -CH3).
13C-NMR (100 MHz, DMSO): 5 172.9 (-COOCH3), 163.0 (d, -ArCO-), 148.6 (dd, -ArC 3),
147.5 (dd, -ArC 2), 126.2 (d, -ArC 1), 125.3 (t, -ArC 4), 125.2 (d, -ArC 5), 119.6 (d, -ArC 6 ),
52.2 (-OCH3), 48.5 (a-C), 16.9 (-CH3).
19F-NMR (376 MHz, DMSO): 5 -63.1 - -63.0 (m), -65.1 - -65.0 (m).
A -2,4-difluorobenzoyl-L-alanine methyl ester 76
2.4-Difluorobenzoyl chloride (2.00 g, 11 mmol) was used. Recrystallisation from hexane 
furnished 76 as colourless block shaped crystals (1.42 g, 53%) which were o f sufficient quality 
for an X-ray diffraction study.
m.p. 59-61 °C. [<x] D25 = -6.5° (c, 8.3, EtOH).
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Anal, calcd. for CnHnNiOsFz: C, 54.32; H, 4.55; N, 5.75; F, 15.62.
Found C, 54.42; H, 4.56; N, 5.62; F, 15.83.
Mass Spectrum: [M+Na]+ found 266.1.
C n H n N i0 3F2Nai requires 266.1.
IR (KBr): u 3306, 3073, 1739, 1646, 1542, 1276, 966 cm '1.
'H-NM R (400 MHz, DMSO): 5 8.73 (1H, d, J  = 6 . 8  Hz, -Nfl-), 7.66-7.72 (1H, m, -A iH 6 ), 7.32­
7.38 (1H, m, -A iH  5), 7.15-7.20 (1H, m, -A rH 3), 4.46-4.50 (1H, m, a-H), 3.67 (3H, s, -OCH 3), 
1.38 (3H, d, J — 1 2  Hz, -CH3).
13C-NMR (100 MHz, DMSO): 5 173.0 (-COOCH3), 164.1 (dd, -ArC 4), 163.2 (d, -ArCO-), 
160.1 (dd, -ArC 2), 132.2 (dd, -ArC 6 ), 120.4 (dd, -ArC 1), 112.0 (dd, -ArC 3), 104.9 (t, -ArC 5),
52.2 (-OCH3), 48.5 (a -Q , 17.0 (-CH3).
19F-NMR (376 MHz, DMSO) 5: -30.7 (qt, J =  8  Hz), -33.6 (q, J =  8  Hz). 
A ^S -d ifluorobenzoyl-L -a lan ine  m ethyl ester 77
2.5-Difluorobenzoyl chloride (2.00 g, 11 mmol) was used. Recrystallisation from hexane 
furnished 77 as brown crystalline needles (1.15 g, 43%).
m.p. 50-52 °C. [a ] D 25 = -5.8° (c, 2.0, EtOH).
Anal, calcd. for C 11H 11N 1O3F2 : C, 54.32; H, 4.55; N, 5.75; F, 15.62.
Found C, 54.27; H, 4.55; N, 5.72; F, 15.94.
Mass Spectrum: [M+Na]+ found 266.1.
C n H n N i0 3 F2Nai requires 266.1.
IR (KBr): « 3304, 3073, 1760, 1647, 1542, 1184, 747 cm '1.
‘H-NMR (400 MHz, DMSO): 8  8.83 (1H, d, J =  6 . 8  Hz, -NH-), 7.34-7.45 (3H, m, -A iH  3, 4 & 
6 ), 4.44-4.51 (1H, m, a-H), 3.67 (3H, s, -O C H ), 1.39 (3H, d, J =  1 2  Hz, -CH3).
13C-NMR (100 MHz, DMSO): 5 174.1 (-COOCH3), 163.1 (-ArCO-), 158.1 (dd, -ArC 5), 155.7 
(dd, -ArC 2), 125.0 (dd, -ArC 1), 119.4 (dd, -ArC 4), 118.3 (dd, -ArC 3), 116.5 (dd, -ArC 6 ),
52.3 (-OCH3), 48.5 (a -Q , 17.0 (-CH3).
19F-NMR (376 MHz, DMSO): 8  -42.9 - -42.8 (m), -44.1 - -44.0 (m). 
A -2,6-difluorobenzoyl-L-alanine m ethyl ester 78
2.6-Difluorobenzoyl chloride (2.00 g, 11 mmol) was used. Recrystallisation from hexane 
furnished 78 as white crystalline needles (1.65 g, 62%).
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m.p. 62-64 “C. [a ] D 25 = -16.2° (c, 6.5, EtOH).
Anal, calcd. for C 11H 11N 1O 3F2 : C, 54.32; H, 4.55; N, 5.75; F, 15.62.
Found C, 54.40; H, 4.62; N, 5.72; F, 15.42.
Mass Spectrum: [M+Na]+ found 266.1.
C n H n N i0 3 F2Nai requires.266.1.
IR (KBr): u 3308, 3002, 1735, 1656, 1623, 1006, 793 cm '1.
‘H-NMR (400 MHz, DMSO): 6  9.19 (1H, d, J  = 6 . 8  Hz, -NH-), 7.51-7.55 (1H, m, -A rf/4 ), 7.15­
7.19 (2H, m, -A rif 3 & 5), 4.47-4.51 (1H, m, a-H), 3.67 (3H, s, -OC/ft), 1-35 (3H, d, J =  1 2  Hz, 
-CH3).
13C-NMR (100 MHz, DMSO): 5 172.7 (-COOCH3), 160.4 (d, -A rC2), 159.9 (-ArCO-), 157.9 (d, 
-ArC 6 ), 132.1 (t, -A rC 4), 115.2 (-ArC 1), 112.3 (d, -ArC 3), 112.1 (d, -ArC 5), 52.3 (-OCH3),
48.4 (<x-C), 17.1 (-CH3).
19F-NMR (376 MHz, DMSO): 5 -38.0 (t, J =  7.6 Hz).
7V-3,4-difluorobenzoyl-L-alanine methyl ester 79
3,4-Difluorobenzoyl chloride (2.00 g, 11 mmol) was used. Recrystallisation from hexane 
furnished 79 as white crystalline needles (1.57 g, 58%). 
m.p. 72-74 °C. [a ] D 25 = -12.1° (c, 5.0, EtOH).
Anal, calcd. for C 11H 11N 1O3F2 : C, 54.32; H, 4.55; N, 5.75; F, 15.62.
Found C, 54.30; H, 4.57; N, 5.72; F, 15.81.
Mass Spectrum: [M+Na]+ found 266.1.
C iiH iiN i0 3F2Nai requires 266.1.
IR (KBr): u 3291, 3083, 1747, 1641, 1547, 1218, 111 cm '1.
*H-NMR (400 MHz, DMSO): 6  8.92 (1H, d, J =  6 . 8  Hz, -NH-), 7.81-7.96 (1H, m, -ArH 6 ), 7.78­
7.81 (1H, m, -A iH  2), 7.52-7.59 (1H, m, -A iH  5), 4.46-4.49 (1H, m, a-H), 3.66 (3H, s, -OCH3), 
1.41 (3Hf d, J -  1 2  Hz, -CH3).
13C-NMR (100 MHz, DMSO): 5 173.3 (-COOCH3), 164.3 (d, -ArCO), 152.0 (dd, -ArC 4), 149.4 
(dd, -ArC 3), 131.2 (t, -ArC 1), 125.3 (dd, -ArC 2), 117.8 (d, -ArC 5), 117.1 (d, -ArC 6 ), 52.3 (- 
O C H 3 ) ,  48.5 (a -Q , 17.0 ( - C H 3) .
,9F-NMR (376 MHz, DMSO): 5 -58.9 - -58.7 (m), -62.6 - -62.5 (m).
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iY-3,5-difluorobenzoyl-L-alanine methyl ester 80
3,5-Difluorobenzoyl chloride (2.00 g, 11 mmol) was used. Recrystallisation from hexane 
furnished 80 as white crystalline needles (1.42 g, 53%). 
m.p. 64-66 °C. [a]D25 = -13.6° (c, 8.0, EtOH).
Anal, calcd. for C i iH iiN ,0 3F2: C, 54.32; H, 4.55; N, 5.75; F, 15.62.
Found C, 53.93; H, 4.41; N, 5.78; F, 15.98.
Mass Spectrum: [M+Na]+ found 266.1.
C ]iH nN i0 3 F2Nai requires 266.1.
IR (KBr): u 3330, 3097, 1746, 1647, 1535, 1126, 988 cm '1.
'H-NM R (400 MHz, DMSO): 5 8.91 (1H, d, J =  6.8 Hz, -Nfi-), 7.50-7.54 (2H, m, -A rif 2 & 6), 
7.33-7.38 (1H, m, -A rif 4), 4.39-4.46 (1H, m, a-H), 3.59 (3H, s, -OCif3), 1.34 (3H, d, / =  7.2 Hz, 
-C if3).
13C-NMR (100 MHz, DMSO): 8 173.3 (-COOCH3), 164.3 (t, -ArCO-), 163.7 (d, -ArC 3), 161.3 
(d, -ArC 5), 137.3 (-ArC 1), 111.1 (d, -ArC 2), 110.9 (d, -ArC 6), 107.1 (t, -ArC 4), 52.3 (- 
OCH3), 48.5 (a -Q , 17.0 (-CH3).
19F-NMR (376 MHz, DMSO): 8 -33.5 (t, J =  9 Hz).
/V-pentafluorobenzoyl-L-alanine methyl ester 81
Pentafluorobenzoyl chloride (1.52 g, 6.6 mmol) and L-alanine methyl ester (0.92 g, 6.6 mmol) 
were used. Recrystallisation from hexane furnished 81 as white crystalline needles (0.81 g, 41%) 
that were o f  sufficient quality for an X-ray diffraction study, 
m.p. 83-85 °C. [a]D25 = -5.6° (c, 7.2, EtOH).
Mass Spectrum: [M+H]+ found 298.0502.
C iiH9N ,0 3F5 requires 298.0503.
IR (KBr): u 3296, 3102, 1759, 1658,1565, 1357 cm '1.
!H-NMR (400 MHz, DMSO): 8 9.42 (1H, d, J =  6.8 Hz, -NH-), 4.47-4.55 (1H, m, a -H), 3.68 
(3H, s, -OCffs), 1.37 (3H, d, J =  7.2 Hz, -C if3).
13C-NMR (100 MHz, DMSO): 8 172.4 (-COOCH3), 156.9 (-ArCO-), 144.7-144.8 (m, -ArC 2),
140.3-142.8 (m, -ArC 4), 142.1-142.3 (m, -ArC 6), 138.4-138.6 (m, -ArC 3), 135.9-136.1 (m, -
ArC 5), 112.4 (t, -ArC 1), 52.4 (-OCH3), 48.6 (a -Q , 17.0 (-CH3).
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19F-NMR (376 MHz, DMSO): 5 -66.5 (dd, 2F, J A = 6.8 Hz, J 2 = 22 Hz), -77.6 (t, IF, J =  16.8 
Hz), -86.2 - -86.3 (m, 2F).
A -pentafluo robenzoyl- L-alanine 82
L-Alanine (0.45 g, 5.0 mmol) was added to a solution o f water (5 mis) and sodium hydroxide 
(0.4 g, 10 mmol) at room temperature. The reaction mixture was then heated to 85 °C and 
pentafluorobenzoyl chloride (1.16 g, 5mmol) was added over a period o f 20 mins. After the 
addition was complete the reaction was left stirring for an additional 30 mins. The solution was 
then cooled and acidified with conc. HC1. This was washed with water and recrystallisation from 
EtOH gave the title product as a white powder (1.03g, 73%). 
m.p. 136-138 °C. [a]D25 = -12.8° (c, 7.2, EtOH).
Mass Spectrum: [M+Na]+ found 305.9.
CioH6N i0 3 F5Nai requires 306.14.
IR (KBr): u 3497, 3297, 1661, 1555, 1489, 813 cm '1.
’H-NMR (400 MHz, DMSO): 5 12.89 (1H, s, -OH), 9.31 (1H, d, J =  7.6 Hz, -NH -), 4.37-4.45 
(1H, m, a-H), 1.36 (3H, d, J =  7.6 Hz, -CH3).
13C-NMR (100 MHz, DMSO): 5 173.4 (-COOH), 156.7 (-ArCO-), 144.5-144.7 (m, -ArC 2),
140.2-142.7 (m, -ArC 4), 142.1-142.3 (m, -ArC 6), 138.3-138.6 (m, -ArC 3), 135.9-136.1 (m, - 
A rC 5), 112.5 (t, -ArC 1), 48.6 (a -Q , 17.2 (-CH3).
,9F-NMR (376 MHz, DMSO): 5 -66.5 (dd, 2F , J 4 = 6.4 Hz, J 3 = 22.9 Hz), -77.9 (t, IF, J =  22.1 
Hz), -86.4 - -86.5 (m, 2F).
General procedure fo r  the synthesis o f  N-fluorobenzoyl-L-phenylalanine m ethyl esters 83-92 
A'-2-fluorobenzoyl-L-phenylalanine methyl ester 83
A solution o f  2-fluorobenzoyl chloride (2.00 g, 12.6 mmol) in dichloromethane (20 mis) was 
added dropwise to a solution o f L-phenylalanine methyl ester (2.72 g, 12.6 mmol) and 
triethylamine (2.55 g) in dichloromethane (20 mis). The solution was stirred for 8 hrs then 
washed with 5% NaHC 0 3 , 5% HC1 and water. The organic extract was then dried over MgS0 4  
and the solvent was removed in vacuo to yield a crude orange oil. Recrystallisation from ethyl 
acetate gave the title product as a yellow solid (2.22 g, 56%). 
m.p. 47-48 °C. [a]D25 = -3.8° (c, 5.0, EtOH).
Anal, calcd. for C n H ^ O s F i :  C, 67.76; H, 5.35; N, 4.65; F, 6.31.
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Found C, 67.38; H, 5.16; N, 4.58; F, 6.50.
Mass Spectrum: [M+Na]+ found 324.2.
CnHieNiOaFiNai requires 324.2.
IR (KBr): u 3276, 3032, 1736, 1647, 1542, 1216, 759 cm '1.
'H-NM R (400 MHz, DMSO): 8  8.73 (1H, d , J =  5.6 Hz, -NH-), 7.50-7.60 (2H, m, -A rH 4 & 6 ),
7.23-7.35 (7H, m, -ArH  3 & 5, -Phfi), 4.75-4.81 (1H, m, a-H), 3.69 (3H, s, -OCH3), 3.23 (1H, 
d d ,y 3 = 5 .2H z, J 2 = 14.0 H z ,-C i/2-), 3.13 ( lH ,d d , . / 3 = 9.6 Hz, J 2 = 13.6 Hz, -CH2-). 
,3C-NMR (100 MHz, DMSO): 8  172.1 (-COOCH3), 164.2 (-ArCO-), 159.6 (d, -A rC 2), 137.6 (- 
PhC 1), 133.0 (d, -ArC 4), 130.4 (d, -ArC 6 ), 129.4 (-PhC 3 & 5), 128.5 (-PhC 2 & 6 ), 126.9 (-
PhC 4), 124.7 (d, -ArC 5), 123.5 (d, -ArC 1), 116.4 (d, -ArC 3), 54.5 (a-C), 52.3 (-OCH3), 36.7
(-CH2 -, -VE DEPT).
19F-NMR (376 MHz, DMSO): 8  -38.5 - -38.7(m).
7V-3-fluorobenzoyl-L-phenylalanine methyl ester 84
3-Fluorobenzoyl chloride (2.00 g, 12.6 mmol) was used. Recrystallisation from ethyl acetate 
furnished 84 as a pale brown solid (1.78 g, 45%). 
m.p. 63-65 °C. [a ] D25 = -44.5° (c, 7.5, EtOH).
Anal, calcd. for C 17H 16N 1O 3F 1: C, 67.76; H, 5.35; N, 4.65; F, 6.31.
Found C, 67.51; H, 5.16; N, 4.43; F, 6.08.
Mass Spectrum: [M+Na]+ found 324.2.
C i7Hi6N i0 3 FiNai requires 324.2.
IR (KBr): u 3313, 3063, 1741, 1638, 1527, 621 cm '1.
JH-NMR (400 MHz, DMSO): 8  9.03 (1H, d, J= 7.6 Hz, -NH-), 7.68-7.70 (1H, m, -A rif 6 ), 7.61­
7.64 (1H, m, -A ri/2 ), 7.48-7.54 (1H, m, -ArH  5), 7.14-7.17 (6 H, m, -A ri/4  & -Phif), 4.67-4.73 
(1H, m, a-H), 3.67 (3H, s, -OCif3), 3.20 (1H, dd, J 3 = 5.2 Hz, J 2 = 13.6 Hz, -CH2-), 3.12 (1H, 
dd, y 3 = 10.4 Hz, J 2 = 13.6 Hz, -CH 2-).
13C-NMR (100 MHz, DMSO): 8  172.3 (-COOCH3), 165.4 (d, -ArCO-), 163.2 (d, -ArC 3), 137.9 
(-PhC 1), 136.2 (d, -ArC 1), 130.8 (d, -ArC 5), 129.4 (-PhC 3 & 5) 128.5 (-PhC 2 & 6 ), 126.8 (- 
PhC 4), 123.9 (d, -ArC 6 ), 118.7 (d, -ArC 4), 114.5 (d, -ArC 2), 54.7 (a-C), 52.3 ( - O C H 3 ) ,  36.5 
( - C H 2 - ,  -VE DEPT).
19F-NMR (376 MHz, DMSO): 8  -37.5 - -37.6 (m).
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./V-4-fluorobenzoyl-L-phenylalanine methyl ester 85
4-Fluorobenzoyl chloride (2.00 g, 12.6 mmol) was used. Recrystallisation from ethyl acetate 
furnished 85 as a yellow solid (1.98 g, 49%). 
m.p. 70-72 °C. [a ] D 25 = -47° (c, 2.5, EtOH).
Anal, calcd. for C 17H 16N 1O3F 1: C, 67.76; H, 5.35; N, 4.65; F, 6.31.
Found C, 67.34; H, 5.21; N, 4.43; F, 6.32.
Mass Spectrum: [M+Na]+ found 324.2.
C i7H i6N i0 3 FiNai requires 324.2.
IR(K Br): u 3310, 3075, 1737, 1637, 1501,770 cm '1.
'H-NM R (400 MHz, DMSO): 5 8.96 (1H, d, J  = 8.0 Hz, -NH-), 7.92-7.96 (2H, m, -ArH 2 & 6 ), 
7.17-7.35 (7H, m, -A rtf 3&5, -P h tf), 4.72-4.78 (1H, m, a-H), 3.66 (3H, s, - O C / / 3 ) ,  3.23 (1H, dd, 
J 3 = 5.2 Hz, J 2 = 14.0 Hz, -CH2-), 3.15 (1H, dd, J 3 = 10.0 Hz, J 2 = 13.6 Hz, -CH2-).
13C-NMR (100 MHz, DMSO): 5 172.5 (-COOCH3), 165.8 (d, -ArCO-), 164.3 (d, -A rC 4), 138.0 
(-PhC 1), 130.4 (-ArC 1), 130.4 (-ArC 2), 130.4 (-ArC 6 ), 129.3 (-PhC 3 & 5), 128.5 (-PhC 2 &
6 ), 126.8 (-PhC 4), 115.6 (-ArC 3), 115.3 (-ArC 5), 54.7 (a -Q , 52.2 (-OCH3), 36.4 (-CH2-, -VE 
DEPT).
I9F-NMR (376 MHz, DMSO): 5 -33.6 - -33.7 (m).
/V-2,3-difluorobenzoyl-L-phenylalanine methyl ester 86
2,3-Difluorobenzoyl chloride (2.23 g, 12.6 mmol) was used. Recrystallisation from ethyl 
acetate/pet ether 40-60 °C furnished 8 6  as a white solid (2.25 g, 56%). 
m.p. 76-78 °C. [a ] D 25 = -18.5° (c, 5.4, EtOH).
Anal, calcd. for C 17H i5N i0 3F2: C, 63.95; H, 4.74; N, 4.39; F, 11.90.
Found C, 63.85; H, 4.71; N, 4.35; F, 11.61.
Mass Spectrum: [M+Na]+ found 342.2.
C i7H i5N i0 3F2Nai requires 342.2.
IR (KBr): u 3309, 2955, 1737, 1645, 1537, 701 cm '1.
1 H-NMR (400 MHz, DMSO): 5 8.80 (1H, d, J  = 7.6 Hz, -NH-), 7.35-7.38 (1H, m, -ArH 6 ), 7.17­
7.20 (5H, m, -Phfl), 7.11-7.14 (2H, m, -A rif 4 & 5), 4.63-4.66 (1H, m, a-H), 3.57 (3H, s, - 
OCH3), 3.10 (1H, dd, J 3 = 5.2 Hz, J 2 = 14.0 Hz, -CH2-), 2.98 (1H, dd, J 3 = 10.0 Hz, J 2 = 13.6 
Hz, -CH2-).
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l3C-NMR (100 MHz, DMSO): 8  171.9 (-COOCH3), 163.2 (d, -ArCO-), 151.3 (d, -ArC 3), 148.9 
(d, -ArC 2), 146.4 (d, -ArC 1), 137.5 (-PhC 1), 129.4 (-PhC 2 & 6 ), 128.5 (-PhC 3 & 5), 126.8 (- 
PhC 4), 126.0 (d, -ArC 4), 125.1 (dd, -ArC 5), 119.6 (d, -ArC 6 ), 54.5 (a -Q , 52.2 (-OCH3), 36.7 
(-CH2-, -VE DEPT).
i9F-NMR (376 MHz, DMSO): 8  -63.0 - -63.1 (m), -64.8 - -64.9 (m). 
iV-2,4-difluorobenzoyl-L-phenylalanine methyl ester 87
2.4-Difluorobenzoyl chloride (2.23 g, 12.6 mmol) was used. Recrystallisation from ethyl 
acetate/pet ether 40-60 °C furr shed 87 as a yellow solid (2.49 g, 62%).
m.p. 37-38 °C. [a ] D 25 = -13.2” (c, 4.3, EtOH).
Anal, calcd. for C ^ H isN ^ F z : C, 63.95; H, 4.74; N, 4.39; F, 11.90.
Found C, 63.90; H, 4.68; N, 4.37; F, 11.52.
Mass Spectrum: [M+Na]+ found 342.2.
C i7H i5N i0 3 F2Nai requires 342.2.
IR(KBr): u 3244, 2953, 1751, 1618, 1497, 703 cm '1.
'H-NM R (400 MHz, DMSO): 8  8 . 6 8  (1H, d, J =  7.8 Hz, -NH-), 7.60-7.66 (1H, m, -ArH  6 ), 7.22­
7.31 (6 H, m, -ArH  5 & -Phi?), 7.11-7.16 (1H, m, -A rif 3), 4.72-4.78 (1H, m, a-H), 3.68 (3H, s, - 
OCff3), 3.21 (1H, dd, J 3 = 5.2 Hz, J 2 = 14 Hz, -CH 2- \  3.10 (1H, dd, J 3 = 9.6 Hz, J 2 = 14 Hz, - 
C H 2-).
13C-NMR (100 MHz, DMSO): 8  172.0 (-COOCH3), 163.9 (dd, -ArC 4), 163.3 (d, -ArCO-),
160.2 (dd, -ArC 2), 137.5 (-PhC 1), 132.1 (dd, -ArC 6 ), 129.4 (-PhC 2 & 6 ), 128.5 (-PhC 3 & 5),
126.8 (-PhC 4), 120.1 (dd, -ArC 1), 111.9 (dd, -ArC 3), 104.8 (t, -ArC 5), 54.5 (a -Q , 52.2 (- 
OCH 3), 36.7 (-CH2 -, -VE DEPT).
19F-NMR (376 MHz, DMSO): 8  -30.7 (qt, J =  7.5 Hz), -33.6 (q, J=  9.4 Hz). 
/V-2,5-difluorobenzoyl-L-phenylalanine methyl ester 88
2.5-Difluorobenzoyl chloride (2.23 g, 12.6 mmol) was used. Recrystallisation from ethyl 
acetate/pet ether 40-60 °C furnished 88 as a white solid (1.92 g, 48%).
m.p. 42-44 °C. [a ] D 25 = -6.3° (c, 3.0, EtOH).
Anal, calcd. for C 17H 15N 1O3F2 : C, 63.95; H, 4.74; N, 4.39; F, 11.90.
Found C, 63.89; H, 4.59; N, 4.37; F, 11.78.
IR (KBr): u 3318, 2956, 1740, 1638, 1491, 699 cm '1.
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!H-NMR (400 MHz, DMSO): 8  8.83 (1H, d, J =  7.2 Hz, -NT/-), 7.22-7.41 (8 H, m, -A ri/3 , 4, 6  
& Ph//), 4.70-4.76 (1H, m, a-H), 3.68 (3H, s, -OC7/3), 3.20 (1H, dd, J 3 = 5.2 Hz, / 2 = 14.0 Hz, - 
CH2-), 3.08 (1H, dd, J 3 = 9.6 Hz, J 2 = 13.6 Hz, -C/fc-).
,3C-NMR (100 MHz, DMSO): 8  171.9 (-COOCH3), 163.3 (-ArCO), 158.0 (dd, -ArC 5), 155.6 
(dd, -ArC 2), 137.5 (-PhC 1), 129.4 (-PhC 2 & 6 ), 128.5 (-PhC 3 & 5), 126.9 (-PhC 4), 124.8 (dd, 
-ArC 1), 119.5 (dd, -ArC 4), 118.4 (dd, -ArC 3), 116.4 (dd, -ArC 6 ), 54.5 (a -Q , 52.3 ( - O C H 3 ) ,
36.6 (-CH 2-, -VE DEPT).
19F-NMR (376 MHz, DMSO): 8  -43.0 - -43.1 (m), -44.0 - -44.1 (m). 
A'-2,6-difluorobenzoyl-L-phenylalanine methyl ester 89
2,6-Difluorobenzoyl chloride (2.23 g, 12.6 mmol) was used. Recrystallisation from ethyl 
acetate/pet ether 40-60 °C furnished 89 as a white solid (1.68 g, 42%). 
m.p. 78-80 °C. [a ] D25 = -24° (c, 1.5, EtOH).
Anal, calcd. for C 17Hi5N i0 3F2: C, 63.95; H, 4.74; N, 4.39; F, 11.90.
Found C, 63.87; H, 4.66; N, 4.36; F, 11.59.
IR (KBr): u 3301, 2923, 1737, 1656, 1541, 704 cm '1.
*H-NMR (400 MHz, DMSO): 8  9.30 (1H, d, J =  7.6 Hz, -NT/-), 7.48-7.52 (1H, m, -A rff 4), 7.29­
7.34 (5H, m, -Phi/), 7.13-7.16 (2H, m, -A iH  3 & 5), 4.70-4.73 (1H, m, a-H), 3.68 (3H, s, - 
OC7 / 3 ) ,  3.17 (1H, dd, J 3 = 5.2 Hz, J 2 = 13.6 Hz, -CH2-), 3.02 (1H, dd, J 3 = 10.0 Hz, J 2 = 14.0 
Hz, -C //2-).
13C-NMR (100 MHz, DMSO): 8  171.7 (-COOCH3), 160.4 (d, -ArC 2), 160.2 (-ArCO-), 158.0 (d, 
-ArC 6 ), 137.4 (-PhC 1), 132.0 (t, -ArC 4), 129.4 (-PhC 3 & 5), 128.5 (-PhC 2 & 6 ), 126.9 (-PhC 
4), 115.1 (t, -ArC 1), 112.2 (d, -ArC 3), 112.0 (d, -ArC 5), 54.4 (a -Q , 52.3 (-OCH3), 36.7 (-CH2- 
, -VE DEPT).
,9F-NMR (376 MHz, D M $0): 8  -38.1 (t, J - 7.1 Hz).
7V-3,4-difluorobenzoyl-L-phenylalanine methyl ester 90
3,4-Difluorobenzoyl chloride (1.12 g, 6.3 mmol) and L-phenylalanine methyl ester (1.36 g, 6.3 
mmol) were used. Recrystallisation from ethyl acetate/pet ether 40-60 °C furnished 90 as a white 
solid (0.86 g, 44%).
m.p. 97-98 °C. [a ] D25 = -49.1° (c, 4.5, EtOH).
Anal, calcd. for C i7H i5N ,0 3F2 : C, 63.95; H, 4.74; N, 4.39; F, 11.90.
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Found C, 63.55; H, 4.61; N, 4.34; F, 11.56.
IR (KBr): d 3292, 3066, 1741, 1648, 1560, 878 cm '1.
'H-NM R (400 MHz, DMSO): 8  9.04 (1H, d, J =  7.6 Hz, -NH-), 7.86-7.91 (1H, m, -ArH  6 ), 7.76­
7.78 (1H, m, -A iH  2), 7.16-7.47 (6 H, m, -PhH  & -AxH 5), 4.76-4.82 (1H, m, a-H), 3.82 (3H, s, - 
OCHi), 3.17 (1H, dd, J 3 = 5.2 Hz, J 2 = 14 Hz, -CH2-), 3.02 (1H, dd, J 3 = 10.4 Hz, J 2 = 13.6 Hz, 
-CH2-).
13C-NMR (100 MHz, DMSO): 8  172.3 (-COOCH3), 164.7 (-ArCO-), 152.0 (dd, -ArC 4), 149.4 
(dd, -A rC 3), 137.8 (-PhC 1), 131.2 (t, -ArC 1), 129.3 (-PhC3 & 5), 128.5 (-PhC 2 & 6 ), 126.7 (- 
PhC 4), 125.1 (dd, -ArC 2), 117.6 (d, -ArC 5), 117.1 (d, -ArC 6 ), 54.8 (<x-Q, 52.1 (-OCH3), 36.6 
(-CH 2 -, -VE DEPT).
I9F-NMR (376 MHz, DMSO): 8  -58.8 - -58.9 (m), -62.5 - -62.6 (m). 
.V-3,5-difluorobenzoyl-L-phenylalanine methyl ester 91
3,5-Difluorobenzoyl chloride (1.12 g, 6.3 mmol) was used. Recrystallisation from ethyl 
acetate/pet ether 40-60 °C furnished 91 as a white solid (1.01 g, 51%). 
m.p. 78-79 °C. [a] D25 = -54° (c, 3.5, EtOH).
Anal, calcd. for Ci7H 15N i0 3 F2: C, 63.95; H, 4.74; N, 4.39; F, 11.90.
Found C, 63.83; H, 4.71; N, 4.32; F, 11.55.
IR (KBr): d 3326, 2978, 1750, 1647, 1593, 700 cm '1.
•H-NMR (400 MHz, DMSO): 8  9.09 (1H, d, J  = 8.0 Hz, -NH-), 7.55-7.59 (2H, m, -A rif 2 & 6 ), 
7.16-7.33 (6 H, m, -P h fi&  -A rif 4), 4.77-4.83 (1H, m, a-H), 3.67 (3H, s, -OCif3), 3.23 (1H, dd, J  
3 = 5.2 Hz, J 2 = 14 Hz, -CH2-), 3.15 (1H, dd, J 3 = 10.4 Hz, J 2 = 13.8 Hz, -CH 2-).
13C-NMR (100 MHz, DMSO): 8  172.2 (-COOCH3), 164.3 (t, -ArCO-), 163.7 (d, -ArC 3), 161.3 
(d, -ArC 5), 137.8 (-PhC 1), 137.3 (t, -ArC 1), 129.2 (-PhC 3 & 5), 128.4 (-PhC 2 & 6 ), 126.7 (- 
PhC 4), 111.1 (d, -ArC 2), 110.9 (d, -ArC 6 ), 107.0 (t, -ArC 4), 54.8 (a -Q , 52.1 (-OCH3), 36.6 (- 
CH2-, -VE DEPT).
,9F-NMR (376 MHz, DMSO): 8  -33.5 (t, J -  8.5 Hz).
AT-pentafluorobenzoyl-L-phenylalanine methyl ester 92
Pentafluorobenzoyl chloride (2.95 g, 12.6 mmol) and L-phenylalanine methyl ester (2.72 g, 12.6 
mmol) were used. Recryst,allisation from ethyl acetate/pet ether 40-60 °C furnished 92 as a pale 
yellow solid (1.83 g, 39%).
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m.p. 104-106 °C. [a ] D25 = -24.1° (c, 2.75, EtOH).
Anal, calcd. for C l7Hi2N ,0 3 F5: C, 54.70; H, 3.24; N, 3.75; F, 25.45.
Found C, 54.94; H, 3.26; N, 3.72; F, 25.09.
IR (KBr): u 3318, 3034, 1736, 1660, 1518, 699 cm '1.
‘H-NMR (400 MHz, DMSO): 8  9.48 (1H, d, J  = 8.0 Hz, -NH-), 7.22-7.33 (5H, m, -Phfl), 4.71­
4.77 (1H, m, a-H), 3.69 (3H, s, -OCH3), 3.19 (1H, dd, 7 3 = 4.8 Hz, J 2 = 14.0 Hz, -CH2-), 2.99 
(1H, dd, J 3 = 9.6 Hz, J 2 = 13.6 Hz, -CH2-).
13C-NMR (100 MHz, DMSO): 8  171.4 (-COOCH3), 157.1 (-ArCO-), 144.6-144.7 (m, -ArC 2),
140.3-142.8 (m, -ArC 4), 142.0-142.2 (m, -ArC 6 ), 138.3-138.5 (m, -ArC 3), 137.0 (-PhC 1),
135.9-136.1 (m, -ArC 5), 129.4 (-PhC 3 & 5), 128.5 (-PhC 2 & 6 ), 126.9 (-PhC 4), 112.3 (t, -ArC 
1), 54.5 (a -Q , 52.4 (-OCH3), 36.7 (-CH2-, -VE DEPT).
,9F-NMR (376 MHz, DMSO): 8  -66.3 (dd, 2F, J 4 = 6 . 8  Hz, J 3 = 22.9 Hz), -77.5 (t, IF, .7=21.8 
Hz), -86.1-86.2 (m, 2F).
iV-pentafluorobenzoyl-L-phenylalanine 93
L-Phenylalanine (0.83 g, 5.0 mmol) was added to a solution o f water (5 mis) and sodium 
hydroxide (0.4 g, 10 mmol) at room temperature. The reaction mixture was then heated to 85 °C 
and pentafluorobenzoyl chloride (1.16 g, 5mmol) was added over a period o f 20 mins. After the 
addition was complete the reaction was left stirring for an additional 30 mins. The solution was 
then cooled and acidified with conc. HC1. This was washed with water and recrystallisation from 
EtOH gave the title product as a white powder (1.40g, 78%). 
m.p. 158-159 °C. [<x] D 25 = -14.3° (c, 2.75, EtOH).
Mass Spectrum: [M+Na]+ found 382.0.
C i6HioNi0 3 F5Nai requires 382.24.
IR (KBr): v  3292, 3092, 1720, 1669, 1521, 996 cm '1.
1 H-NMR (400 MHz, DMSO): 8  12.74 (1H, s, -OH), 9.36 (1H, d , J =  8.0 Hz, -NH -), 7.20-7.31 
(5H, m, -Ph/Z), 4.62-4.65 (1H, m, a-H), 2.92-3.22 (2H, m, -CH2~).
13C-NMR (100 MHz, DMSO): 8  172.3 (-COOH), 156.9 (-ArCO-), 144.7-144.8 (m, -ArC 2),
140.3-142.8 (m, -ArC 4), 142.1-142.3 (m, -ArC 6 ), 138.4-138.6 (m, -ArC 3), 137.5 (-PhC 1),
135.9-136.1 (m, -ArC 5), 129.4 (-PhC 3 & 5), 128.5 (-PhC 2 & 6 ), 126.8 (-PhC 4), 112.3 (t, -ArC
1), 54.6 (a-C), 36.8 (-CH2-, -VE DEPT).
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19F-NMR (400 MHz, DMSO): 5 -66.2 (dd, 2F, J 4 = 6 . 8  Hz, J 3 = 23.3 Hz), -77.9 (t, IF, J =  15.8 
Hz), -86.4 - -86.5 (m, 2F).
General procedure fo r  thè synthesis o f  N-fluorobenzoyl glycine ethyl esters 94-103 
A-2-fluorobenzoyl-glycine ethyl ester 94
A  solution o f 2-fluorobenzoyl chloride (2.00 g, 12.6 mmol) in dichloromethane (20 mis) was 
added dropwise to a solution o f glycine ethyl ester (1.76 g, 12.6 mmol) and triethylamine (2.55 
g, 25.2 mmol) in dichloromethane (20 mis). The solution was stirred for 8  hrs then washed with 
5% N aH C 03, 5% HC1 and water. The organic extract was then dried over MgSC>4 and the 
solvent was removed in vacuo to yield a crude yellow oil. Recrystallisation from ethyl 
acetate/pet ether 40-60 °C furnished 94 as a yellow oil (1.54 g, 58%).
Anal, calcd. for C n H ^ N ^ F , :  C, 58.66; H, 5.37; N, 6.21; F, 8.44.
Found C, 58.45; H, 5.25; N, 6.41; F, 8.64.
IR(Nujol): i) 3309, 2955, 1737, 1645, 1537, 701 cm '1.
'H-NM R (400 MHz, DMSO): 6  8 . 6 8  (1H, t, J  = 7.6 Hz, -Nfi-), 7.68-7.72 (IH , m, -A rif 6 ), 7.54­
7.56 (1H, m, -A iH  4), 7.26-7.31 (2H, m, -A rif 3 & 5), 4.12 (2H, q, J  = 7.2 Hz, -OCH 2-), 4.02 
(2H, d, J =  6.0 Hz, -CHz-), 1.19 (3H, t, J =  1 2  Hz, -CH3).
13C-NMR (100 MHz, DMSO): 8  169.9 (-COOCH2 CH3), 164.4 (-ArCO-), 159.7 (d, -ArC 2),
133.3 (d, -ArC 4), 130.6 (d, -ArC 6 ), 124.9 (d, -ArC 5), 122.9 (d, -ArC 1), 116.5 (d, -ArC 3),
60.9 (-OCH2 -, -VE DEPT), 41.6 (-CH2-, -VE DEPT), 14.3 (-CH3).
19F-NMR (376 MHz, DMSO): 8  -38.4 - -38.5(m).
A-3-fluorobenzoyl-glycine ethyl ester 95
3-Fluorobenzoyl chloride (2.00 g, 12.6 mmol) was used. Recrystallisation from ethyl acetate/pet 
ether 40-60 °C furnished 95 as a white solid (1.38 g, 52%). 
m.p. 60-62 °C.
Anal, calcd. for C 11H 12N 1O 3F 1: C, 58.66; H, 5.37; N, 6.21; F, 8.44.
Found C, 58.24; H, 5.25; N, 6.22; F, 8.44.
IR (KBr): u 3315, 2986, 1755, 1641, 1542, 679 cm '1.
'H-NM R (400 MHz, DMSO): 8  9.03 (1H, t, 7 =  7.6 Hz, -Nif-), 7.66-7.76 (2H, m, -A rif 2 & 6 ), 
7.47-7.50 (IH , m, -ArH  5), 7.30-7.32 (1H, m, -A rif 4), 4.11 (2H, q, J =  1 2  Hz, -OCif2-), 4.06 
(2H, d , J =  6.0 Hz, -C if2-), 1.18 (3H, t , J =  1 2  Hz, -CH3).
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13C-NMR (100 MHz, DMSO): 8 170.0 (-COOCH2CH3), 166.0 (d, -ArCO-), 162.3 (d, -ArC 3),
136.2 (d, -ArC 1), 130.6 (d, -ArC 5), 123.5 (d, -ArC 6), 118.5 (d, -ArC 4), 114.4 (d, -ArC 2),
60.8 (-OCH2-, -VE DEPT), 41.6 (-CH2-, -VE DEPT), 14.1 ( - C H 3 ) .
19F-NMR(376 MHz, DMSO): 8 -37.4 - -37.5 (m).
A-4-fluorobenzoyl-glycine ethyl ester 96
4-Fluorobenzoyl chloride (2.00 g, 12.6 mmol) was used. Recrystallisation from ethyl acetate/pet 
ether 40-60 °C furnished 96 as a pale yellow crystalline solid (1.67 g, 63%). 
m.p. 101-103 “C. Lit.35 m.p. 102-104 °C.
Anal, calcd. for C n H i^ O a F j :  C, 58.66; H, 5.37; N, 6.21; F, 8.44.
Found C, 58.66; H, 5.23; N, 5.92; F, 8.90.
IR (KBr): v  3277, 2982, 1748, 1648, 1560, 670 cm '1.
]H-NMR (400 MHz, DMSO): 8 8.98 (1H, t , J =  6.0 Hz, -NH-), 7.92-8.02 (2H, m, -A rH 2  & 6), 
7.25-7.30 (2H, m, -A rif 3 & 5), 4.09 (2H, q, J =  7.2 Hz, -OCif2-), 4.01 (2H, d, J = 6.0 Hz, -CH2- 
), 1.17 (3H, t, J -  7.2 Hz, -C if3).
13C-NMR (100 MHz, DMSO): 8 170.1 (-COOCH2CH3), 166.1 (-ArCO-), 164.4 (d, -ArC 4),
130.4 (d, -ArC 1), 130.2 (-ArC 2), 130.1 (-ArC 6), 115.7 (-ArC 3), 115.5 (-ArC 5), 60.8 (-OCH2- 
, -VE DEPT), 41.6 (-CH2-, -VE DEPT), 14.2 (-OCH3).
19F-NMR (376 MHz, DMSO): 8 -33.5 - -33.6 (m).
A'-2,3-difluorobenzoyl-glycine ethyl ester 97
2,3-Difluorobenzoyl chloride (2.23 g, 12.6 mmol) was used. Recrystallisation from ethyl 
acetate/pet ether 40-60 °C furnished 97 as a white solid (1.99 g, 69%). 
m.p. 54-56 °C.
Anal, calcd. for C n H n N i0 3F2: C, 54.32; H, 4.56; N, 5.76; F, 15.62.
Found C, 54.27; H, 4.46; N, 5.77; F, 15.93.
IR (KBr): u 3283, 2988, 1764, 1660, 1542, 722 cm '1.
^ -N M R  (400 MHz, DMSO): 8 8.87 (1H, t, J =  5.2 Hz, -Nif-), 7.52-7.59 (1H, m, -A rfi 6), 7.42­
7.45 (1H, m, -A rif 5), 7.27-7.32 (1H, m, -A rif 4), 4.12 (2H, q, J =  7.0 Hz, -OCif2-),4.01 (2H, d, 
J =  5.6 Hz, -CH2-), 1.20 (3H, t, J -  7.2 Hz, -C if3).
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I3C-NMR (100 MHz, DMSO): 5 169.7 (-COOCH2CH3), 163.5 (d, -ArCO-), 150.1 (dd, -ArC 3),
147.6 (dd, -ArC 2), 125.5 (d, -ArC 1), 125.4 (t, -ArC 4), 120.1 (-ArC 5), 119.9 (-ArC 6), 60.9 (- 
OCH2-, -VE DEPT), 41.6 (-CH2-, -VE DEPT), 14.3 (-CH3).
19F-NMR (376 MHz, DMSO): 8 -62.9 - -63.0 (m), -65.0 - -65.1 (m).
,V-2,4-diiluorobenzoy 1-glycine ethyl ester 98
2.4-Difluorobenzoyl chloride (2.23 g, 12.6 mmol) was used. Recrystallisation from ethyl 
acetate/pet ether 40-60 °C furnished 98 as a white solid (1.76 g, 61%).
m.p. 77-79 °C. Lit.35 m.p. 80-81 °C.
Anal, calcd. for C n H nN i0 3F2: C, 54.32; H, 4.56; N, 5.76; F, 15.62.
Found C, 54.06; H, 4.40; N, 5.80; F, 15.94.
IR (KBr): u 3411, 2992, 1749, 1656, 1534, 772 cm '1.
•H-NMR (400 MHz, DMSO): 8 8.66 (1H, bs, -NH-), 7.75-7.81 (1H, m, -A iH  6), 7.29-7.34 (1H, 
m, -ArH  5), 7.15-7.19 (1H, m, -ArH  3), 4.12 (2H, q, J =  7.0 Hz, -OCH 2~), 4.02 (2H, d , J =  5.2 
Hz, -CH2-), 1.21 (3H, t , J ~  7.2 Hz, -CH3).
13C-NMR (100 MHz, DMSO): 8 169.8 (-COOCH2CH3), 164.0 (dd, -ArC 4), 163.4 (-ArCO-),
160.3 (dd, -ArC 2), 132.5 (dd, -ArC 6), 119.7 (d, -ArC 1), 112.2 (d, -ArC 3), 104.9 (t, -ArC 5),
60.8 (-OCH2-, -VE DEPT), 41.7 (-CH2-, -VE DEPT), 14.2 (-CH3).
19F-NMR (376 MHz, DMSO): 8 -30.5 (qt, J =  8.3 Hz), -33.5 (q, J =  9.8 Hz).
A-2,5-difluoro-benzoyl-glycine ethyl ester 99
2.5-Difluorobenzoyl chloride (2.23 g, 12.6 mmol) was used. Recrystallisation from ethyl 
acetate/pet ether 40-60 °C furnished 99 as a white solid (1.58 g, 55%).
m.p. 51-52 °C.
Anal, calcd. for C n H n N i0 3F2: C, 54.32; H, 4.56; N, 5.76; F, 15.62.
Found C, 54.29; H, 4.53; N, 5.84; F, 15.23.
IR (KBr): u 3436, 2995, 1732, 1659, 1523, 763 cm '1.
‘H-NMR (400 MHz, DMSO): 8 8.78 (1H, t, J  = 6.0 Hz, -NH-), 7.35-7.47 (3H, m, -A iH  3,4 & 6),
4.13 (2H, q, J  = 7.2 Hz, -O C ii2-), 4.02 (2H, d, J -  6.0 Hz, -CH2- \  1.21 (3H, t,J =  7.0 Hz, -CH3).
13C-NMR (100 MHz, DMSO): 8 169.7 (-COOCH2CH3), 163.1 (-ArCO-), 158.2 (dd, -ArC 5),
155.8 (dd, -ArC 2), 124.4 (dd, -ArC 1), 119.8 (dd, -ArC 4), 118.5 (dd, -ArC 3), 116.6 (dd, -ArC
6), 60.9 (-OCH2-, -VE DEPT), 41.7 (-CH2-, -VE DEPT), 14.3 (-CH3).
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19F-NMR (376 MHz, DMSO): 5 -42.8 - -42.9 (m), -43.8 - -43.9 (m).
/V-2,6-difluurobenzoyl-glycine ethyl ester 100
2,6-Difluorobenzoyl chloride (2.23 g, 12.6 mmol) was used. Recrystallisation from ethyl 
acetate/pet ether 40-60 °C furnished 100 as a yellow solid (1.90 g, 66%). 
m.p. 67-68 °C.
Anal, calcd. for C n H iiN i0 3F2: C, 54.32; H, 4.56; N, 5.76; F, 15.62.
Found C, 54.22; H, 4.43; N, 5.85; F, 15.39.
IR (KBr): it 3278, 2985, 1734, 1654, 1543, 800 cm '1.
^ -N M R  (400 MHz, DMSO): 5 9.17 (1H, t, J =  6.0 Hz -Nif-), 7.50-7.54 (1H, m, -A rif 4), 7.13­
7.17 (2H, m, -A rif 3 & 5), 4.16 (2H, q, J =  7.0 Hz, -OCH2-% 4.06 (2H, d, J  = 6.0 Hz, -CH2~), 
1.24 (3H, t, .7=7.2  Hz, -C if3).
13C-NMR (100 MHz, DMSO): 5 169.4 (-COOCH2CH3), 160.7 (-ArCO-), 160.5 (d, -ArC 2), 
158.0 (d, -ArC 6), 132.0 (t, -ArC 4), 115.1 (t, -ArC 1), 112.2 (d, -ArC 3), 112.0 (d, -ArC 5), 60.9 
(-OCH2-, -VE DEPT), 41.4 (-CH2-, -VE DEPT), 14.1 (-CH3).
19F-NMR (376 MHz, DMSO): 8 -38.1 (t, J=  6.8 Hz).
A-3,4-difluorobenzoy 1-glycine ethyl ester 101
3,4-Difluorobenzoyl chloride (1.12g, 6.3 mmol) and glycine ethyl ester (0.88 g, 6.3 mmol) were 
used. Recrystallisation from ethyl acetate/pet ether 40-60 °C furnished 101 as yellow crystals 
(0.89 g, 61%) which were o f sufficient quality for an X-ray diffraction study, 
m.p. 91-92 *C.
Anal, calcd. for C n H nN i0 3F2: C, 54.32; H, 4.56; N, 5.76; F, 15.62.
Found C, 54.04; H, 4.17; N, 5.49; F, 16.00.
IR (KBr): u 3327, 2992, 1742, 1647, 1560, 760 cm '1.
•H-NMR (400 MHz, DMSO): 8 9.03 (1H, t, J =  5.6 Hz -NH-), 7.84-7.90 (1H, m, -A rif 6), 7.75­
7.79 (1H, m, -A rif 2), 7.30-7.35 (1H, m, -A rii5 ), 4.10 (2H, q , J =  7.2 Hz, -OCif2-) ,4.00 (2H, d, 
J =  5.6 Hz, -CH 2-), 1.19 (3H, t, J =  7.2Hz, -C i/3).
13C-NMR (100 MHz, DMSO): 8 170.0 (-C 00C H 2CH3), 164.8 (-ArCO-), 152.0 (dd, -ArC 4),
149.6 (dd, -ArC 3), 131.3 (t, -ArC 1), 125.0 (dd, -ArC 2), 118.1 (t, -ArC 5), 117.0 (d, -ArC 6),
60.8 (-OCH2-, -VE DEPT), 41.6 (-CH2-, -VE DEPT), 14.3 (-CH3).
19F-NMR (376 MHz, DMSO): 8 -58.8 - -58.9 (m), -62.4 - -62.5 (m).
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jV-3,5-difluorobenzoyl-glycine ethyl ester 102
3,5-Difluorobenzoyl chloride (1.12 g, 6.3 mmol) was used. Recrystallisation from ethyl 
acetate/pet ether 40-60 °C furnished 102 as a yellow solid (0.75 g, 52%). 
m.p. 80-81 °C.
Anal, calcd. for C i iH iiN i0 3F2: C, 54.32; H, 4.56; N, 5.76; F, 15.62.
Found C, 54.20; H, 4.43; N, 5.83; F, 15.27.
IR (KBr): u 3403, 3075, 1723, 1667, 1536, 672 cm '1.
'H-NMR (400 MHz, DMSO): 8 9.08 (1H, t, J =  6.0 Hz -NH-), 7.55-7.58 (2H, m, -ArH 2 & 6),
7.23-7.28 (1H, m, -ArH  4), 4.12 (2H, q, J =  7.2 Hz, -OCH2-), 4.04 (2H, d, J= 6.0 Hz, -CH2-),
1.20 (3H, t, J -  7.2 Hz, -CH3).
13C-NMR (100 MHz, DMSO): 8 169.7 (-COOCH2CH3), 164.5 (t, -ArCO-), 163.8 (d, -ArC 3),
161.4 (d, -ArC 5), 137.4 (t, -ArC 1), 110.9 (d, -ArC 2), 110.7 (d, -ArC 6), 106.8 (t, -ArC 4), 60.8 
(-OCH2 -, -VE DEPT), 41.5 (-CH2 -, -VE DEPT), 14.0 (-CH3).
19F-NMR (376 MHz, DMSO): 8 -33.9 (t, J =  8.3 Hz).
/V-pentafluorobenzoyl-glycine ethyl ester 103
Pentafluorobenzoyl chloride (1.52 g, 6.6 mmol) and glycine ethyl ester (0.92 g, 6.6 mmol) were 
used. Recrystallisation from ethyl acetate/pet ether 40-60 °C furrnjhed 103 as a yellow solid 
(1.28 g, 72%). 
m.p. 79-80 °C.
Anal, calcd. for C ,,H 8N i0 3F5: C, 44.46; H, 2.71; N, 4.71; F, 31.97.
Found C, 44.25; H, 2.58; N, 4.71; F, 32.01.
IR (KBr): u 3271, 2989, 1737, 1658, 1519, 786 cm '1.
'H-NM R (400 MHz, DMSO): 8 9.39 (1H, t, J =  6.0 Hz -NH-), 4.15 (2H, q ,J =  7.2 Hz, -OCH2~),
4.08 (2H, d, J -  6.0 Hz, -CH2-), 1.23 (3H, t, J  = 7.2 Hz, -GH3).
13C-NMR (100 MHz, DMSO): 8 169.2 (-COOCH2CH3), 157.6 (-ArCO-), 144.7-144.8 (m, -ArC
2), 140.4-142.9 (m, -ArC 4), 142.3-142.4 (m, -ArC 6), 138.4-138.6 (m, -ArC 3), 135.9-136.1 (m, 
-ArC 5), 112.3 (t, -ArC 1), 61.0 (-OCH2-, -VE DEPT), 41.5 (-CH2-, -VE DEPT), 14.2 (-CH3). 
19F-NMR (376 MHz, DMSO): 8 -66.6 (dd, 2F , J 4 = 6.4 Hz, J 3 = 23.3 Hz), -77.7 (t, IF, J -  15.8 
Hz), -86.3 - -86.4(m, 2F).
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iV-pentafluorobenzoyl-glycine nitrile 104
A solution o f pentafluorobenzoyl chloride (2.90 g, 12.6 mmol) in dichloromethane (20 mis) was 
added dropwise to a solution o f glycine nitrile hydrochloride (1.17 g, 12.6 mmol) and 
triethylamine (2.55 g, 25.2 mmol) in dichloromethane (20 mis). The solution was stirred for 8  hrs 
then washed with 5% NaHCCb, 5% HC1 and water. The organic extract was then dried over 
MgSC>4 and the solvent was removed in vacuo to yield a crude yellow oil. Recrystallisation from 
hexane/ethyl acetate furnished 104 as a yellow solid (2.15 g, 6 8 %). 
m.p. 126-127 °C.
Mass Spectrum: [M+Na]+ found 273.0.
CqHsNzOiFsNai requires 273.1.
IR (KBr): u 3279, 2993, 2365, 1675, 1527, 988 cm '1.
'H-NM R (400 MHz, DMSO): 6  9.77 (1H, bs, -NH-), 4.41 (2H, bs, -CH2~).
13C-NMR (100 MHz, DMSO): 8  157.8 (-ArCO-), 144.7-144.8 (m, -ArC 2), 140.7-143.2 (m, - 
ArC 4), 142.2-142.4 (m, -ArC 6 ), 138.5-138.7 (m, -ArC 3), 135.9-136.1 (m, -ArC 5), 117.1 (- 
CN), 111.3 (d, -ArC 1), 27.9 (-CH2-, -VE DEPT).
19F-NMR (376 MHz, DMSO): 8  -6 6 . 6  (dd, 2F, J 4 = 6.4 Hz, J 3 = 23.5 Hz), -77.7 (t, IF, J= 22.1 
Hz), -86.3 - -86.4(m, 2F).
General procedure for the synthesis of N-fluorobenzoyl-L-leucine methyl esters 105-114 
A-2-fluorobenzoyl-L-leucine methyl ester 105
A solution o f 2-fluorobenzoyl chloride (2.00 g, 12.6 mmol) in dichloromethane (20 mis) was 
added dropwise to a solution o f L-leucine methyl ester (2.28 g, 12.6 mmol) and triethylamine
(2.55 g) in dichloromethane (20 mis). The solution was stirred for 8  hrs then washed with 5%
NaHCOs, 5% HC1 and water. The organic extract was then dried over MgS0 4  and the solvent 
was removed in vacuo furnished 105 as a viscous brown oil (1.96 g, 62%).
[a ] D 25 = -13° (c, 1.5, EtOH).
Anal, calcd. for C n H ^ N ^ F ! :  C, 62.91; H, 6.79; N, 5.24; F, 7.11.
Found C, 62.80; H, 6.83; N, 5.01; F, 7.33.
IR (Nujol): u 3304, 2959, 1739, 1648, 1525, 731 cm '1.
'H-NM R (400 MHz, DMSO): 8  8.70 (1H, d, J =  1 2  Hz, -NH-), 7.55-7.62 (1H, m, -A iH 6 ), 7.51­
7.54 (1H, m, -A rH  4), 7.25-7.31 (2H, m, -ArH  3 & 5), 4.50-4.56 (1H, m, a-H ), 3.68 (3H, s, -
1 0 0
OCH3), 1.57-1.79 (3H, m, -CH2- & -CH-), 0.92 (3H, d, J  = 6 . 8  Hz, -CH 3), 0.88 (3H, d, J =  6.4 
Hz, -CH3).
13C-NM R(100 MHz, DMSO): 5 173.0 (-COOCH3), 164.5 (-ArCO-), 159.5 (d, -A rC2), 132.8 (d, 
-ArC 4), 130.4 (d, -ArC 6 ), 124.6 (d, -ArC 5), 124.0 (d, -ArC 1), 116.4 (d, -ArC 3), 52.2 (- 
OCH 3), 51.2 (<x-C), 39.7 (-CH2-, -VE DEPT), 24.7 (-CH-), 23.0 (-CH3), 21.3 (-CH3).
19F-NMR (376 MHz, DMSO): 6  -38.8 - -38.9 (m).
A'-3-fluorobenzoyl-L-leucine methyl ester 106
3-Fluorobenzoyl chloride (1.8 g, 11.3 mmol) and L-leucine methyl ester (2.05 g, 11.3 mmol) 
were used. Recrystallisation from ethyl acetate furnished 106 as a fine dark brown powder (2.41 
g, 79%).
m.p. 92-94 °C. [a ] D 25 = -20° (c, 1.5, EtOH).
Anal, calcd. for Ci4H 18N ,0 3F,: C, 62.91; H, 6.79; N, 5.24; F, 7.11.
Found C, 62.70; H, 6.55; N, 5.31; F, 7.31.
IR (KBr): u 3286, 3076, 1747, 1637, 1543, 757 cm '1.
‘H-NMR (400 MHz, DMSO): 5 8.85 (1H, d, J =  7.6 Hz, -N7Í-), 7.68-7.72 (2H, m, -A rH 2  & 6 ),
7.50-7.56 (1H, m, -ArH  5), 7.36-7.41 (1H, m, -ArH  4), 4.49-4.55 (1H, m, a-H), 3.67 (3H, s, - 
OCH 3), 1.49-1.83 (3H, m, -CH2- & -CH-), 0.91 (3H, d, J  = 6 . 8  Hz, -CH3), 0.87 (3H, d, 6.4 
Hz, -CH 3).
13C-NMR (100 MHz, DMSO): 8  173.3 (-COOCH3), 165.1 (d, -ArCO-), 162.3 (d, -ArC 3), 136.3 
(d, -ArC 1), 130.8 (d, -ArC 5), 124.0 (d, -ArC 6 ), 118.7 (d, -ArC 4), 114.5 (d, -ArC 2), 52.2 (- 
OCH3), 51.3 (a -Q , 39.5 (-CH2-, -VE DEPT), 24.7 (-CH-), 23.1 (-CH3), 21.3 (-CH3).
19F-NMR (376 MHz, DMSO): 8  -37.5 - -37.6 (m).
7V-4-fluorobenzoyl-L-leucine methyl ester 107
4-Fluorobenzoyl chloride (1.8 g, 11.3 mmol) was used. Recrystallisation from ethyl acetate 
furnished 107 as a fine yellow powder (2.29 g, 76%).
m.p. 88-91 °C. [a ] D25 = -17° (c, 1.5, EtOH).
Anal, calcd. for C l4H 18N i0 3F,: C, 62.91; H, 6.79; N, 5.24; F, 7.11.
Found C, 63.12; H, 6.54; N, 5.01; F, 6.99.
IR (KBr): i) 3279, 3077, 1747, 1637, 1506, 852 cm '1.
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'H-NM R (400 MHz, DMSO): 5 8.78 (1H, d, J =  7.6 Hz, -NH-), 7.95-8.00 (2H, m, -A iH 2  & 6), 
7.27-7.33 (2H, m, -A rif 3 & 5), 4.48-4.54 (1H, m, a-H),3.64  (3H, s, -OCH 3), 1.54-1.83 (3H, m, - 
CH2- & -CH-), 0.91 (3H, d, J =  6.4 Hz, -CH3), 0.88 (3H, d, J =  6.4 Hz, -CH3).
I3C-NMR (100 MHz, DMSO): 5 173.4 (-COOCH3), 165.9 (-ArCO-), 164.3 (d, -A rC 4), 130.5 (­
ArC 1), 130.4 (-ArC 2), 130.3 (d, -ArC 6), 115.6 (-ArC 3), 115.4 (-ArC 5), 52.2 (-OCH3), 51.3 
(a-C), 39.5 (-CH 2-, -VE DEPT), 24.7 (-CH-), 23.1 (-CH3), 21.4 (-CH3).
,9F-NMR (376 MHz, DMSO): 5 -33.7 - -33.8 (m).
/V-2,3-difluorol)enzoyI-L-leucine methyl ester 108
2.3-Difluorobenzoyl chloride (1.99 g, 11.3 mmol) was used. Recrystallisation from ethyl acetate 
furnished 108 as a viscous orange oil (2.09 g, 65%).
[<x]D25 = -20° (c, 1.5, EtOH).
Anal, calcd. for C ^ H n N O ^ :  C, 58.94; H, 6.01; N, 4.91; F, 13.32.
Found C, 58.61; H, 6.13; N, 4.79; F, 13.01.
IR (Nujol): u 3279, 2907, 1730, 1670, 1460, 852 cm '1.
'H-NM R (400 MHz, DMSO): 8  8.89 (1H, d, J =  7.6 Hz, -NH-), 7.51-7.58 (1H, m, -A rif 6), 7.26­
7.39 (2H, m. -A rii4  & 5), 4.48-4.54 (1H, m, <x-ii),3.68 (3H, s, -OCH3), 1.51-1.76 (3H, m, -CH2- 
& -Cif-), 0.92 (3H, d , J =  6.4 Hz, -CH3), 0.90 (3H, d, J =  6.4 Hz, -CH3).
I3C-NMR (100 MHz, DMSO): 8  172.9 (-COOCH3), 163.4 (d, -ArCO-), 150.1 (dd, -ArC 3),
147.5 (dd, -ArC 2), 126.4 (d, -ArC 1), 125.2 (d, -ArC 4), 125.1 (d, -ArC 5), 119.6 (d, -ArC 6),
52.2 (-OCH3), 51.3 (<x-C), 39.6 (-CH2-, -VE DEPT), 24.7 (-CH-), 23.1 (-CH3), 21.3 (-CH3). 
,9F-NM R (376 MHz, DMSO): 8  -63.1 - -63.2 (m), -64.9 - -65.0 (m).
/V-2,4-difluorobenzoyl-L-Ieucine methyl ester 109
2.4-Difluorobenzoyl chloride (1.99 g, 11.3 mmol) was used. Recrystallisation from ethyl acetate 
furnished 109 as a viscous yellow oil (2.28 g, 71%).
[a ] D 25 = -14° (c, 1.5, EtOH).
Anal, calcd. for C,4H 17N 10 3F2: C, 58.94; H, 6.01; N, 4.91; F, 13.32.
Found C, 58.55; H, 6.33; N, 4.86; F, 13.14.
IR (Nujol): u 3284, 2918, 1750, 1648, 1361, 856 cm '1.
'H-NM R (400 MHz, DMSO): 8  8.70 (1H, d, J =  7.6 Hz, -NH-), 7.65-7.71 (1H, m, -A r i/ 6 ), 7.26­
7.32 (1H, m, -A rif 5), 7.13-7.18 (1H, m, -A ri/3 ), 4.48-4.54 (1H, m, a -ii),3 .68  (3H, s, -OCH3),
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1.56-1.77 (3H, m, -C /ft- & -CH-), 0.91 (3H, d, J =  6.4 Hz, -C/ft), 0.89 (3H, d, J  = 6.4 Hz, -C/ft). 
13C-NMR (100 MHz, DMSO): 8  173.0 (-COOCH3), 163.8 (dd, -ArC 4), 163.6 (d, -ArCO-),
160.1 (dd, -A rC 2), 132.1 (dd, -A rC 6 ), 120.6 (dd, -ArC 1), 111.9 (dd, -A rC3), 104.7 (t, -A rC 5),
52.1 (-OCH3), 51.2 (a -Q , 39.6 (-CH2-, -VE DEPT), 24.7 (-CH-), 23.0 (-CH3), 21.3 (-CH3). 
,9F-NMR (376 MHz, DMSO): 8-31.0  (qt, J =  9 Hz,), -33.8 (q, J =  9.4 Hz).
,V-2,5-difluorobenzoyl-L-leucine methyl ester 110
2.5-Difluorobenzoyl chloride (1.99 g, 11.3 mmol) was used. Recrystallisation from ethyl acetate 
furnished 110 as a colourless viscous oil (1.89 g, 59%).
[a ] D 25 = -14° (c, 1.5, EtOH).
Anal, calcd. for C uH nN jO aF^ C, 58.94; H, 6.01; N, 4.91; F, 13.32.
Found C, 59.02; H, 5.99; N, 4.65; F, 13.50.
IR (Nujol): u 3268, 2957, 1750, 1638, 1342, 798 cm '1.
'H-NM R (400 MHz, DMSO): 8  8.80 (1H, d, J =  7.6 Hz, -NH-), 7.32-7.43 (3H, m, -A iH  3, 4 & 
6 ), 4.45-4.51 (1H, m, a-H), 3.67 (3H, s, -OC/ft), 1.53-1.75 (3H, m, -CH 2- & -CH-), 0.91 (3H, d, 
J =  6.4 Hz, -C /ft), 0.89 (3H, d, 6.4 Hz, -C/ft).
13C-NMR (100 MHz, DMSO): 8  172.8 (-COOCH3), 163.2 (-ArCO-), 158.0 (dd, -ArC 5), 155.6 
(dd, -ArC 2), 125.3 (dd, -ArC 1), 119.3 (dd, -ArC 4), 118.3 (dd, -ArC 3), 116.4 (dd, -ArC 6 ),
52.2 (-OCH3), 51.2 (a-C), 39.6 (-CH2-, -VE DEPT), 24.6 (-CH-), 23.0 (-CH3), 21.4 (-CH3). 
19F-NMR (376 MHz, DMSO): 8  -43.0 - -43.1 (m), -44.1 - -44.2 (m).
A-2,6-difluorobenzoyl-L-leucine methyl ester 111
2.6-Difluorobenzoyl chloride (1.99 g, 11.3 mmol) was used. Recrystallisation from ethyl acetate 
furnished 111 as an orange crystalline solid (2.02 g, 63%).
m.p. = 70-72 °C. [a ] D25 = -18° (c, 1.5, EtOH).
Anal, calcd. for C ,4H ]7N 10 3F2: C, 58.94; H, 6.01; N, 4.91; F, 13.32.
Found C, 58.16; H, 6.03; N, 4.74; F, 13.42.
IR (KBr): u 3268, 2920, 1756, 1654, 1442, 816 cm '1.
'H-NM R (400 MHz, DMSO): 8  9.15 (1H, d, J =  8.4 Hz, -N//-), 7.49-7.56 (1H, m, -A r//4 ), 7.13­
7.19 (2H, m, -A r//3  & 5), 4.48-4.54 (1H, m, a-H), 3.68 (3H, s, -OC/ft), 1.58-1.75 (3H, m, -C/ft-
& -CH-), 0.91 (6 H, t, J =  6 . 6  Hz, -C/ft).
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13C-NMR (100 MHz, DMSO): 5 172.7 (-COOCH3), 160.4 (d, -A rC 2) 160.2 (-ArCO-), 157.9 (d, 
-ArC 6), 132.0 (t, -ArC 4),' 115.2 (t, -ArC 1), 112.2 (d, -A rC3), 112.0 (d, -A rC 5), 52.2 (-OCH3),
50.9 (a -Q , 39.7 (-CH2-, -VE DEPT), 24.5 (-CH-), 23.0 (-CH3), 21.2 (-CH3).
19F-NMR (376 MHz, DMSO): 5 -38.5 (t, J =  6.8 Hz).
A-3,4-difluorobenz(>yl-L-leucine methyl ester 112
3.4-Difluorobenzoyl chloride (1.12 g, 6.3 mmol) and L-leucine methyl ester (1.14 g, 6.3 mmol) 
were used. Recrystallisation from ethyl acetate furnished 112 as a brown powder (0.92 g, 51%). 
m.p. = 75-76 °C. [a]D25 = -16° (c, 3.0, EtOH).
Anal, calcd. for C 14H,7N i0 3F2: C, 58.94; H, 6.01; N, 4.91; F, 13.32.
Found C, 58.63; H, 6.16; N, 5.11; F, 13.18.
IR (KBr): u 3287, 2961, 1747, 1638, 1551, 779 cm-1.
‘H-NMR (400 MHz, DMSO): 8 8.81 (1H, d, J =  7.6 Hz, -NH-), 7.91-7.96 (1H, m, -A1 H 6 ), 7.80­
7.83 (1H, m, -A rH  2), 7.39-7.46 (1H, m, -ArH  5), 4.51-4.56 (1H, m, a-H), 3.65 (3H, s, -OCH3), 
1.68-1.82 (3H, m, -CH2- & -CH-), 0.91 (3H, d, J =  6.4 Hz, -CH3), 0.87 (3H, d, J =  6.4 Hz, -CH3). 
13C-NMR (100 MHz, DMSO): 8 173.2 (-COOCH3), 164.7 (-ArCO-), 152.0 (dd, -ArC 4), 149.4 
(dd, -ArC 3), 131.2 (t, -ArC 1), 125.2 (dd, -A rC 2), 117.4 (d, -ArC 5), 117.1 (d, -ArC 6 ), 51.9 (- 
O C H 3 ) , 51.4 (a-C), 39.5 (-CH2-, -VE DEPT), 24.6 (-CH-), 22.8 (-CH3), 21.1 (-CH3).
19F-NMR (376 MHz, DMSO): 8  -59.0 - -59.1 (m), -62.8 - -62.9 (m).
A-3,5-difluorobenzoyl-L-leucine methyl ester 113
3.5-Difluorobenzoyl chloride (1.99 g, 11.3 mmol) and L-leucine methyl ester (2.05 g, 11.3 
mmol) were used. Recrystallisation from ethyl acetate furnished 113 as a brown powder (2.35 g, 
73%).
m.p. = 69-71 °C. [a ] D 25 = -15° (c, 1.5, EtOH).
Anal, calcd. for C i4H i7N i0 3F2: C, 58.94; H, 6.01; N, 4.91; F, 13.32.
Found C, 58.75; H, 5.90; t i ,  5.04; F, 12.98.
IR (KBr): u 3268, 2913, 1727, 1642, 1468, 721 cm’1.
'H-NM R (400 MHz, DMSO): 8  8.93 (1H, d, J =  7.6 Hz, -NH-), 7.38-7.52 (3H, m, -ArH  2, 4 & 
6 ), 4.46-4.52 (1H, m, a-H), 3.68 (3H, s, -OCH 3), 1.52-1.73 (3H, m, -CH2- & -CH-), 0.90 (3H, d, 
J =  6.4 Hz, -CH3), 0.86 (3H, d, J =  6.4 Hz, -CH 3).
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13C-NMR (100 MHz, DMSO): 5 173.0 (-COOCH3), 164.3 (t, -ArCO-), 163.8 (d, -A rC 3), 161.3 
(d, -ArC 5), 137.3 (t, -ArC 1), 111.2 (d, -ArC 2), 111.0 (d, -ArC 6 ), 107.3 (t, -ArC 4), 52.2 (- 
OCH3), 51.4 (a-C), 39.4 (-CH2-, -VE DEPT), 24.7 (-CH-), 23.0 (-CH3), 21.3 (-CH3).
19F-NMR (376 MHz, DMSO): 5 -33.7 (t, J =  8.3 Hz).
JV-pentafluorobenzoyl-L-leucine methyl ester 114
Pentafluorobenzoyl chloride (2.19 g, 11.3 mmol) was used. Recrystallisation from ethyl acetate 
furnished 114 as white needles (1.55 g, 45%) that were o f sufficient quality for an X-ray 
diffraction study.
m.p. = 64-66 °C. [a ] D 25 = -18° (c, 1.5, EtOH).
Anal, calcd. for C 14H 14N 1O3F5 : C, 49.56; H, 4.16; N, 4.13; F, 28.00.
Found C, 49.50; H, 4.09; N, 3.83; F, 27.54.
IR (KBr): d 3233, 3067, 1752, 1655, 1519, 996 c m 1.
'H-NM R (400 MHz, DMSO): 5 9.39 (1H, d, J  = 7.6 Hz, -NH-), 4.47-4.53 (1H, m, a-H), 3.69 
(3H, s, -OCH3), 1.54-1.73 (3H, m, -CH 2- & -CH-), 0.92 (3H, d, J =  6.4 Hz, -CH3), 0.90 (3H, d, J  
= 6.4 Hz, -CH 3).
,3C-NMR (100 MHz, DMSO): 5 172.3 (-COOCH3), 157.1 (-ArCO-), 144.7-144.8 (m, -ArC 2),
140.3-142.8 (m, -ArC 4), 142.1-142.3 (m, -ArC 6 ), 138.3-138.6 (m, -ArC 3), 136.0-136.1 (m, - 
ArC 5), 112.3 (t, -ArC 1), 52.3 (-OCH3), 51.2 (a-C), 39.6 (-CH2-, -VE DEPT), 24.5 (-CH-), 22.9 
(-CH3), 21.1 (-CH3).
19F-NMR (376 MHz, DMSO): 5 -66.7 (dd, 2F, J 4 = 6.4 Hz, J 3 = 22.9 Hz), -77.8 (t, IF, 7 =  21.8 
Hz), -86.3 - -86.4 (m, 2F).
A-pentafluorobenzoyl-L-tryptophan methyl ester 115
A solution o f pentafluorobenzoyl chloride (1.45 g, 6.3 mmol) in dichloromethane (10 mis) was 
added dropwise to a solution o f L-tryptophan methyl ester (1.60 g, 6.3 mmol) and triethylamine 
(1.27 g) in dichloromethane (10 mis). The solution was stirred for 8  hrs then washed with 5% 
NaHCOs, 5% HC1 and water. The organic extract was then dried over MgS0 4  and the solvent 
was removed in vacuo furnished and recrystallisation from ethyl acetate/hexane furnished 115 as 
a brown powder (1.12 g, 43%). 
m.p. = 139-140 °C. [a ] D 25 = -9.1° (c, 1.8, EtOH).
Mass Spectrum: [M+Na]+ found 435.0.
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C i9H i3N 2 0 3 F5Nai requires 435.3.
IR (KBr): u 3392, 1754, 1678, 1518, 1004 cm '1.
'H-NM R (400 MHz, DMSO): 10.91 (1H, bs, -NH ),  9.49 (1H, d, J =  7.6 Hz, -NH-), 7.51 (1H, d, 
J =  7.6 Hz, -PhH  1), 7.36 (1H, d, J  = 8.0 Hz, -Phtf 4), 7.18 (1H, d, J =  2.4 Hz, -C=C-H), 7.08 
(1H, t, y =  8.0 Hz, -PhH 2), 7.00 (1H, t, J =  8.0 Hz, -Phi? 3), 4.71-4.75 (1H, m, a-H ), 3.66 (3H, s, 
-OCHi), 3.13-3.29 (2H, m, -CH 2-).
13C-NMR (100 MHz, DMSO): 8  171.7 (-COOCH3), 157.2 (-ArCO-), 144.7-144.8 (m, -ArC 2),
140.3-142.8 (m, -ArC 4), 142.1-142.3 (m, -ArC 6 ), 138.3-138.5 (m, -ArC 3), 136.4 (-C=C-H),
135.8-136.0 (m, -ArC 5), 127.2 (-PhC5), 124.1 (-C=C-H), 121.4 (-PhC2), 118.8 (-PhC3), 118.2 
(-PhC 4), 112.3 (t, -ArC 1), 111.8 (-PhCl), 109.1 (-PhC 6 ), 54.0 (a -Q , 52.5 (-OCH3), 27.1 (- 
CH2-, -VE DEPT).
19F-NMR (376 MHz, DMSO): 8  -66.5 (dd, 2F, / 4 = 6.4 Hz, J 3 = 22.9 Hz), -78.2 (t, IF, J =  22.5 
Hz), -86.5 - - 8 6 . 6  (m, 2F).'
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Chapter 3
Fluorobenzoyl dipeptidyl derivatives as inhibitors of the Fasciola hepatica
cathepsin L endoproteases
3.1 Introduction
The group o f cysteine proteases known as the cathepsins have been shown to play a 
crucial function in diseases such as osteoporosis, rheumatoid arthritis, cancer metastasis and 
infectious diseases . 1 Cathepsins are important targets for the development o f inhibitors as 
therapeutic agents. FasciQlosis is caused by infection with F a s c io la  h e p a tic a  and F a s c io la  
g ig a n t ic a  parasites. It is not only an important human disease but also affects cattle and sheep 
worldwide causing economic losses o f approx 2 billion dollars .2 It is caused by the ingestion of 
vegetation or water contaminated with the encysted infectious liver fluke larvae known as 
metacercariae . 3 It has become clear that the predominant protease activity in this parasite was 
associated with cells o f the gut epithelium .4  Like many other parasitic helminths, F a s c io la  
h e p a tic a  liver flukes release many proteolytic enzymes that belong to the group o f cysteine 
proteases. It has been suggested that these proteases may be involved in protecting the parasite 
against immune attack . 5 Most o f the current approaches to cathepsin inhibition involve 
molecules o f a peptidic nature. The hydrolysable amide is replaced by an electrophilic 
functionality and the catalytic thiol o f the enzyme reacts with the inhibitor to form a covalent 
complex. Until recently the most potent cysteine protease inihibitors were irreversible inhibitors 
with the electrophilic functionality alkylating the enzyme. Inhibitors containing electrophilic 
moieties such as aldehyde, halomethyl ketone and epoxide have been shown to be potent 
cysteine protease inhibitors . 6 Previous work in these laboratories has identified A^-benzoyl 
dipeptidyl derivatives as potent inhibitors o f F a s c io la  h e p a tic a  protease. For this study all o f the 
compounds prepared are based on a fluorobenzoyl dipeptidyl scaffold. The fluorobenzoyl moiety 
has been shown to be an effective ^-term inal substitution in various potent inhibitors . 7 There are 
generally two consequences o f introducing fluorine into a drug molecule. Firstly there are the 
physiochemical properties, i.e. increased lipophilicity, increased acidity, decreased basicicity and 
a change in hydrogen bonding properties. The inductive electron withdrawing effect o f fluorine
1 1 0
is expected due to its electronegative nature but electron donation by resonance effects attributed 
to the three lone pair electrons is a distinctive property o f  fluorine. Secondly, there is the 
influence o f fluorine substitution on the biological stability o f a drug molecule through altering 
susceptibility to metabolism. Fluorine has been used as a means to developing safer and more 
reactive pharmaceuticals due to the strength o f the carbon-fluorine bond that is very difficult to 
metabolise, so harmful and unproductive side reactions are unlikely to occur.
3.2 Synthesis of dipeptidyl derivatives.
The synthesis o f dipeptides containing the amino acids L-leucine, glycine, p-alanine and 
y-aminobutyric acid with N- and C-terminal modifications was carried out. The amino acids were 
coupled using an activating agent 1,3-dicyclohexylcarbodiimide (DCC) 119. The mode o f action 
o f  DCC involves the formation o f an O-acylisourea intermediate 120 that is a potent acylating 
agent (Figure 3.1).
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O y O
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Figure 3.1 Mode o f action o f peptide coupling with 1,3-dicyclohexylcarbodiimide.
Unfortunately there are some disadvantages in using DCC as a coupling agent. Activation by 119 
is shown to cause racemisation o f  the carboxy terminal residue. Reactive intermediates produced 
during coupling contain a basic center, which causes an intramolecular proton abstraction from 
the chiral carbon atom (Figure 3.2).
\  /?
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Figure 3.2 The mode o f racemisation o f the carbonyl terminal residue upon activation with 1,3- 
dicyclohexylcarbodiimide .
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Chiral integrity can be preserved by the use of 1-hydroxybenzotriazole (HOBt) 122. HOBt acts
decreasing the occurrence o f racémisation. An acylating agent o f lower potency is formed which 
is still reactive to aminolysis, but is less susceptible to racémisation or other side reactions. 1 - 
hydroxybenzotriazole also offers an acidic hydrogen that can be more easily removed by bases 
than the proton at the chiral center.
Figure 3.3 Structure of 1-hydroxybenzotriazole (HOBt).
Low yields are often another feature o f peptide coupling using 1,3- 
dicyclohexylcarbodiimide 119. These low yields can be accounted for due to the formation o f a 
TV-acylurea derivative 123 via an intramolecular rearrangement o f the (9-acyl derivative 120
Figure 3.4 Formation o f  an TV-acyl derivative 123 via intramolecular rearrangement o f the O- 
acylisourea derivative.
The disadvantages o f coupling peptides with 1,3-dicyclohexylcarbodiimide include low 
yields and poor reaction rates. The employment o f HOBt and similar derivatives has greatly 
enhanced the ability o f DCC to couple amino acids effectively. More recently, the design of 
peptide coupling reagents has concentrated on the ability o f the reagent to limit the onset of 
racemisation while at the same time offer a highly competent coupling agent whose side products
as an auxiliary nucleophile and reduces the lifetime o f the O-acylisourea intermediate thus
OH
122
formed by activation with 1,3-dicyclohexylcarbodiimide 119 (Figure 3.4). The attack o f the 
activated carbonyl group by the nearby nucleophilic -NH- results in an O to N  shift yielding a N- 
acylurea side product 123.
120 123 0
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can be easily removed. This method o f design has resulted in coupling reagents incorporating the
coupling ability o f DCC and the racémisation suppression activity o f HOBt being developed and
• 8 utilised as effective combination type reagents.
3.2.1 Synthesis and characterization of ./V-fluorobenzoyl dipeptidyl benzyl esters
Dipeptidyl derivatives have been shown to be effective inhibitors o f the liver fluke 
Fasciola hepatica cysteine cathepsin L over the known commercial inhibitor Z-Phe-Ala-CHN2 
124 at varying concentrations . 9 The synthesis o f a series o f benzoyl dipeptidyl benzyl esters 
incorporating a fluorine atom into four different positions on the phenyl ring was undertaken to 
assess the effect o f  the fluorobenzoyl substituent. It has been shown that benzyl esters are potent 
protease inhibitors mainly due to their potential prodrug ability . 10 A series o f derivatives were 
synthesized as illustrated in Scheme 3.1.
NaOH/HCI
+  TsOlI
CH2C12, HOBt
1 125-136
Scheme 3.1 Synthesis o f N -fluorobenzoyl dipeptidyl benzyl ester derivatives.
The benzyl ester tosylate salts were synthesized by refluxing the amino acid, p- 
toluenesulphonic acid, benzyl alcohol and toluene in a Dean and Stark apparatus . 11 The obtained 
yields ranged between 75 and 95 %. The fluorobenzoyl amino acids were synthesized in high 
yields (>75%) but often contained the by-product benzoic acid and therefore were purified by 
recrystallisation from ethanol and water. The fluorobenzoyl leucine derivatives displayed a 
tendency to absorb water and several recrystallisations were often needed. It was found that the
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hydrolysis o f jV-fluorobenzoyl-L-leucine methyl ester derivatives using sodium hydroxide caused 
racemisation at the chiral center. In general the pentafluorobenzoyl dipeptidyl derivatives gave 
the lowest yields. This is probably due to two factors. Firstly, iV-pentafluorobenzoyl-L-leucine 
was obtained as a viscous oil. Several attempts to recrystallise failed to furnish any crystalline 
solid. From the 19F NMR o f this compound the purity o f this starting material was estimated at 
approx 95%. Secondly, TV-pentafluorobenzoyl-L-leucine was found to be only partially soluble in 
dichloromethane, the solvent o f choice for peptide coupling. The utilization o f chloroform or 
tetrahydrofuran failed to improve the solubility o f this compound. When the reaction was carried 
out at elevated temperatures increased solubility occurred but inactivation o f the coupling 
reagents was prevalent.
X )
F
Table 3.1. iV-fluorobenzoyl dipeptidyl ester derivatives
Compound F n % Yield
TV-2-fluorobenzoyl-L-Leu-Gly-OBn 125 2-F 1 37
TV-3-fluorobenzoyl-L-Leu-Gly-OBn 126 3-F 1 45
AM-fluorobenzoyl-L-Leu-Gly-OBn 127 4-F 1 6 6
TV-pentafluorobenzoyl-L-Leu-Gly-OBn 128 2,3,4,5,6-F 1 42
iV-2-fluorobenzoyl-L-Leu- P-Ala-OBn 129 2-F 2 58
N-3-fluorobenzoyl-L-Leu- P-Ala-OBn 130 3-F 2 50
AM-fluorobenzoyl-L-Leu- p-Ala-OBn 131 4-F 2 46
TV-pentafluorobenzoyl-L-Leu- P-Ala-OBn 132 2,3,4,5,6-F 2 47
TV-2-fluorobenzoyl-L-Leu- y-ABA -OBn 133 2-F 3 63
yV-3-fluorobenzoyl-L-Leu-y-ABA-OBn 134 3-F 3 50
7V-4-fluorobenzoyl-L-Leu- y-ABA -OBn 135 4-F 3 63
TV-pentafluorobenzoyl-L-Leu- y-ABA -OBn 136 2,3,4,5,6-F 3 46
3.2.2 *H N M k Study of the N-fluorobenzoyl dipeptidyl benzyl esters
The 1B NMR spectra o f the TV-fluorobenzoyl dipeptidyl benzyl ester derivatives show the 
characteristic aromatic protons between 5 7 and 8 . Due to the effect o f 'H -^F  coupling the 
aromatic peaks o f  the fluorobenzoyl group appear as multiplets. The amide protons appear
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between 5 8  and 9 with the aryl amide appearing at a lower field. One o f the most interesting 
results shows that the amide proton o f the 2 -fluorobenzoyl dipeptides appears as double doublets. 
It has been proposed that a coplanar arrangement o f the phenyl and amide residue is beneficial 
for inhibition and this is enhanced by an interaction between the 2 -fluorine and the amide 
hydrogen bond . 12 A fluorine atom in any other position on the phenyl ring prevents coplanarity 
and additional ^F -'H  coupling is not seen. This conformational control feature o f  a single 2- 
fluorine substituent has been incorporated into many anti-cancer drugs . 13 The methylene group 
o f the benzyl moiety appears as a singlet at 8  5.1 due the electron deshielding effect o f the 
attached oxygen atom. The methyl groups o f the leucyl 'butyl side chain appear as two individual 
doublets at 8  0.85 although they seem to appear in the same chemical environment. The 
methylene group o f glycipe appears as a double doublet due to its diastereotopic nature. The 
methylene groups o f  P-Ala appear as a triplet at 8  2.5 and a multiplet at 8  3.4. The methylene 
units o f the y-aminobutyric acid derivatives appear as a quartet at 8  3.13, a triplet at 8  2.38 and a 
multiplet centered at 8  1.63. The 'H  NMR spectrum o f compound 129 is shown in Figure 3.5.
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Figure 3.5 ‘H NMR spectrum o f 7V-2-fluorobenzoyl-L-leucine-P-alanine benzyl ester 129.
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Table 3.2 Selected 'H NMR data (8) for the iV-fluorobenzoyl dipeptidyl benzyl esters
Compound No. NH NH a-H -CH2-
125 8.49 8.35 4.52-4.66 3.99, 3.88
128 9.13 8.70 4.60-4.64 4.03, 3.84
130 8.58 8.17 4.46-4.52 3.29-3.43, 2.54
134 8.55 8.06 4.44-4.50 3.10, 2.37, 1.50-1.73
136 9.16 8.23 4.48-4.51 3.09-3.16, 2.40, 1.47-1.75
The l3C NM R spectra show distinctive doublets representing the carbon atoms attached to the 
fluorine atoms at approximately 8  160. The carbon atoms on the fluorobenzoyl ring system 
appear as doublets due to the effect o f 13C-19F coupling. The methyl groups o f the leucine side 
chain appear at 8  21 and 8  23. The Infrared spectra show distinct peaks at 1642 and 1727 cm ' 1 
due to amide and ester carbonyls respectively. Peaks at 1468 cm ' 1 can be attributed to N-H 
bending and C-N stretching o f the C-N-H group. A  peak at 3268 cm ' 1 is due to N-H stretching.
3.2.3 Synthesis and characterisation of iV-pentafluorobenzoyl dipeptidyl methyl esters
7V-pentafluorobenzoyl-L-alanine derivatives have been shown to be bioactive 
compounds. Dipeptidyl derivatives containing the A^pentafluorobenzoyl-L-alanine scaffold and 
the amino acid methyl esters o f glycine 137, P-alanine 138, y-aminobutyric acid 139, L-alanine 
140, L-leucine 141, L-phenylalanine 142, L-valine 143, L-tryptophan 144, L-aspartic acid 145 
and L-methionine 146 were prepared (Scheme 3.2). It is hoped that by varying the size and 
hydrophobicity o f the side chain o f the amino acid in the PI position an optimized dipeptidyl 
compound will be achieved. These compounds will be tested for their biological activity as 
protease inhibitors o f the liver fluke Fasciola hepatica cysteine cathepsin L endoproteases.
M W.
147 148
Figure 3.6 Urea side products formed by DCC 147 and EDC 148
The dipeptidyl derivatives were synthesized using the coupling reagent 1-ethyl-3-(3- 
dimethylaminopropyl)carbodiimide (EDC) 149. The mode o f action o f EDC is analogous to 
DCC 119 with the main advantage o f EDC over DCC being the fact that the urea side product 
148 formed during the reaction is water-soluble and hence purification is simplified. EDC has
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been proposed to exist as a tautomeric mixture . 14 It has been shown that both tautomers are 
potentially involved in the addition reactions o f nucleophiles to EDC . 15
Figure 3.7 Tautomerisation o f EDC
iV-pentafluorobenzoyl-L-alanine was synthesized in an analogous manner to N- 
pentafluorobenzoyl-L-leucine. The pentafluorobenzoic acid impurity was removed by 
recrystallisation from ethanol and water. The amino acid methyl esters were prepared as 
hydrochloride salts using thionyl chloride and methanol. 16 Yields for this reaction were as high 
as 80%. The dipeptidyl derivatives were purified using an acid water wash cycle.
Scheme 3.2 Synthesis o f the
Compound 145 gave the highest yield o f 61%. The ester moiety o f the L-aspartic acid 
side chain is the most polar derivative prepared. This compound gave a crystalline solid although 
due to its fine nature an x-ray crystal structure was not possible. The L-phenylalanine derivative 
142 gave the lowest yield o f 34 %. The benzyl side chain o f L-phenylalanine is one o f the largest 
groups present on a naturally occurring amino acid. L-tryptophan has a similarly large aromatic
jV-pentafluorobenzoyl dipeptidyl derivatives.
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side chain and its derivative 144 only gave a yield o f 37%. This indicates that a bulky aromatic 
side chain has a distinct steric effect on the yield o f these dipeptidyl derivatives.
The 'H NMR spectra o f the TV-pentafluorobenzoyl dipeptidyl derivatives have the 
characteristic a-hydrogens located between 8  4 and 8  5. The amide proton signal appears 
downfield at 8  ~  9.4 due to the deshielding effect o f a pentafluorobenzoyl moiety. The methyl 
group o f  alanine is found as a doublet at 8  1.2. The 19F NMR shows three peaks, a double 
doublet representing the fluorine atoms in the 2 - and 6 - positions, a multiplet representing the 
fluorine atoms in the 3- and 5- positions and one triplet that represents the 4-fluoro substituent. 
The Infrared spectra show distinct peaks at 1653 and 1752 cm ' 1 due to amide and ester carbonyls 
respectively. Peaks at 1560 cm ' 1 can be attributed to N-H bending and C-N stretching o f the C- 
N-H group. At 3292 cm ' 1 a peak due to N-H stretching is observed.
Table 3.3 7V-pentafluorobenzoyl dipeptidyl ester derivatives
Compound R % Yield
W-pentafluorobenzoyl-L-Ala-Gly-OMe 137 - c h 2 42
iV-pentafluorobenzoyl-L-Ala-P-Ala-OMe 138 -(CH2) 2 54
TV-pentafluorobenzoyl-L-Ala-y-ABA-OMe 139 -(CH2) 3 49
iV-pentafluorobenzoyl-L- Ala-L- Ala-OMe 140 - c h 3 58
7V-pentafluorobenzoyl-L-Ala-L-Leu-OMe 141 -CH2CH(CH 3) 2 55
vV-pentafluorobenzoyl-L-Ala-L-Phe-OMe 142 -CH2Ph 34
iV-pentafluorobenzoyl-L-Ala-L-Val-OMe 143 -CH(CH3 ) 2 51
/V-pentafluorobenzoyl-L-Ala-L-T ry -0  Me 144 -CH2-Indole 37
iV-pentafluorobenzoyl-L-Ala-L-Asp-OMe 145 -CH2COOCH3 61
TV-pentafluorobenzoyl-L-Ala-L-Met-OMe 146 -(CH2 )2 SCH3 52
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3.2.4 13C NMR study of the jV-pentafluorobenzoyl-L-alanine dipeptidyl methyl esters
The 13C NMR spectrum o f ALpentafluorobenzoyl-L-Ala-L-Asp-(OMe) 2  145 is shown 
in Figure 3.8. The two ester carbonyls o f L-aspartic acid dimethyl ester appear at 5 ~171. The 
peptide carbonyl appears further downfield at 8  -172 with the carbonyl o f the benzoyl group 
shown at 8  -156. The carbon atoms o f the pentafluorobenzoyl moiety show a very distinct 
pattern. Four multiplets are shown centered at 8  -145, -142, -138 and —136. These multiplets 
represent the ortho and meta carbons. Two further multiplets are located at 8  -140  and 8  -143. 
These multiplets represent the para  carbon. Finally the ipso carbon is located as a triplet at 8  
-111. The methyl esters appear as individual carbons at 8  -52  due to the deshielding effect o f the 
attached oxygen atom.
Figure 3.8 13C NM R spectrum o f vV-pentafluorobenzoyl-L-Ala-L-Asp dimethyl ester 145.
The methylene group o f L-aspartic acid appears at 8  -38 . This was confirmed by the DEPT 135 
spectrum. The a-carbons o f alanine and aspartic acid are located at 8  -48.9 and 8  -48.8
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respectively with the methyl group o f the alanine side chain appearing at 8  -18 . The a-carbon of 
the L-valine derivative 143 appears the furthest downfield at approx 8  57.6 due to the proximity 
o f  the 'propyl side chain.
Table 3.4 Selected 13C NMR data (8 ) for the TV-fluorobenzoyl-L-alanine dipeptidyl methyl esters
Compound No. C —O E s te r C —O Amide C = 0Amide u - C -OMe
137 170.5 156.6 172.2 49.0, 40.8 52.0
140 171.5 156.5 173.2 48.9, 47.9 52.1
143 172.0 156.5 172.4 48.9, 57.6 52.1
144 171.7 156.5 172.4 48.9, 53.5 52.1
146 171.9 156.5 172.4 49.0,51.2 52.3
3.2.5 Synthesis and characterisation o f iV-fluorobenzoyl dipeptidyl nitrile derivatives
Peptidic molecules bearing the electrophilic nitrile warhead have been reported to be 
potent inhibitors o f cathepsin proteases . 17 One o f the first such examples was the dipeptidyl 
derivative iV-benzoyl-L-Leu-Gly-CN synthesized by Suzue et al in 1968.18 Previous work in our 
group has shown this to be a potent inhibitor o f the liver fluke Fasciola hepatica cathepsin L 
endoproteases. The majority o f  recent research with nitrile derivatives has concentrated on 
developing the iV-terminal substituent next to the P2 position with the fluorobenzoyl moiety 
showing increased selectivity . 19 Dipeptidyl nitrile derivatives are believed to function as 
reversible inhibitors with the nitrile moiety undergoing attack by the activated thiol group o f 
cysteine in the active site o f the protease (Figure 3.9).
Figure 3.9 M echanism o f nitrile inhibition o f cysteine proteases.
*H NM R studies have shown that inhibition occurs through the formation o f  a thioimidate 
intermediate and this process is fully reversible . 20 A series o f fluorobenzoyl dipeptidyl nitrile 
derivatives based on the TV-benzoyl-L-Leu-Gly-CN scaffold have been synthesised. It is hoped 
that by extending the number o f methylene units in the PI position and the size o f the P2 
position, superior inhibitory activities will result. The fluorobenzoyl amino acids were prepared 
as previously described using the Schotten-Baumann reaction.
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Scheme 3.3 Synthesis o f 7V-fluorobenzoyl dipeptidyl nitrile derivatives.
The dipeptidyl derivatives gave yields varying from 42 to 69 % (Table 3.5). The highest 
yields recorded were for the 2-fluorobenzoyl-L-leucine derivatives with both the glycyl 150 and 
P-alanyl 154 analogues giving yields o f over 6 8  %. The lowest yield recorded was for compound 
153. This pentafluorobenzoyl derivative was obtained in a yield o f just 42 %. The fluorobenzoyl 
dipeptidyl nitriles were found to be partially insoluble in organic solvents but they were 
completely insoluble in aqueous media. These solubility problems often hindered successful 
isolation. A large amount o f solvent was often required to dissolve the nitrile derivatives 
completely. The pentafluoro derivatives were found to be the least soluble in organic solvents 
such as dichloromethane, chloroform, ethyl acetate or methanol. Overall the L-leucine 
derivatives gave higher yields than their L-alanine analogues. This is probably due to the fact 
that the leucine derivatives were slightly more soluble in an organic medium.
The *H NMR spectra o f these compounds show the distinctive amide protons appearing 
at 5 ~ 8.5. The a-hydrogen o f L-leucine or L-alanine shows up as a multiplet due to coupling 
with the amide and the side chain group at approx 8  4.5. The methylene protons o f the glycyl 
derivatives appear as singlets at 8  ~4.15. This is in sharp contrast to the previously discussed 
benzyl ester derivatives 125-136 where the methylene group appears as a double doublet due to 
its diastereotopic nature where coupling with both the amide proton and the methylene protons 
occurs. The 13C NMR spectra show a distinctive peak for the nitrile moiety at 8  ~ 117. The nitrile 
moiety shifted the chemical shifts o f the attached methylene units upfield. The methylene carbon
121
atom o f the amino acid glycine usually appears at 5 ~ 40.5 but the methylene unit o f glycine 
nitrile is seen appearing at approximately 8  27.4. The fluorobenzoyl moiety causes the carbon 
atoms o f  the phenyl ring to appear as doublets and triplets due to l3C -19F coupling. The 19F NMR 
spectra o f  these compounds show the monofluoro derivatives appearing as multiplets due to 19F- 
lH coupling. The Infrared spectra o f these compounds show a distinctive band at ~2370 cm ' 1 
responsible for the nitrile moiety. The amide bond is represented by two peaks. Peaks at -1505 
cm ' 1 can be attributed to N-H bending and C-N stretching o f  the C-N-H group. A peak at ~3286 
cm "1 is due to N  H stretching.
Table 3.5 7V-pentafluorobenzoyl dipeptidyl nitrile derivatives
Compound F R n % Yield
150 2-F -CH2CH(CH3) 2 1 69
151 4-F -CH2CH(CH3) 2 1 64
152 2-F - c h 3 1 55
153 Penta-F - c h 3 1 42
154 2-F -CH2CH(CH3) 2 2 6 8
155 4-F -CH2CH(CH3) 2 2 53
156 2-F - c h 3 2 49
157 Penta-F - c h 3 2 53
3.2.6 HMQC study of 4-fluorobenzoyl-L-leucine-glycine nitrile 151
Table 3.6 and Figure 3.10 show the C-H correlation spectrum o f AM-fluorobenzoyl-L- 
leucine-glycine nitrile 151.
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Table 3.6 C-H correlation o f 7V-4-fluorobenzoyl-L-leucine-glycine nitrite 151
Site *H 13c H M Q C
1 130.7
2 7.99-8.02 130.66
3 7.28-7.32 115.5
4 164.3
5 7.28-7.32 115.3
6 7.99-8.02 130.62
7 165.7
8 4.48-4.54 51.9
9 1.52-1.76 40.2
1 0 1.52-1.76 24.7
1 1 0.90 23.3
1 2 0 . 8 6 21.5
13 173.3
14 4.14 27.4
15 117.9
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Figure 3.10 HMQC Spectrum o f  7V-4-fluorobenzoyl-L-leucine-glycine nitrile 151.
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3.3 Protease inhibitory activity of iV-fluorobenzoyl dipeptidyl derivatives
3.3.1 Introduction
Cathepsins are a complex group o f cysteine proteases that cleave peptide bonds. They 
have been implicated as essential components o f  various diseases such as rheumatoid arthritis, 
cancer and malaria . 1 Their broad-spectrum biological activities render them as key therapeutic 
targets. Fasciolosis or liver fluke as it is commonly known has been estimated to be present in up 
to 2  million humans worldwide and its economic losses on cattle and sheep livestock is estimated 
at $2 billion annually . 2 Increasing resistance to the present chemotherapy against fasciolosis in 
animals requires novel chemotherapeutic approaches. A series o f potential cathepsin inhibitors 
have been developed and their bioactivity was assessed with the cathepsin protease Fasciola 
hepatica that has been implicated in the reproduction o f  the parasites . 21
Commercially available peptide substrates with substituents added to either the N- or C- 
termini are most commonly used to assay, characterize and perform inhibition studies on 
proteases. The C-terminal substituents usually involve a chromophoric amine such as 4- 
naphtylamine(-NHNap) or a fluorogenic group such as 7-amino-4-methylcoumarin (-NHMec) 
159. These species are highly absorbent or fluorescent when cleaved from the substrate and can 
be detected spectrophotometrically or fluorometrically. The fluorogenic substrates are far more 
sensitive due to the ability o f fluorescence to be detected against a low background in contrast to 
absorption spectrophotometry that requires measurement o f transmitted light relative to high 
incident light levels at the same wavelength .22 Although these substrates are useful in evaluating 
the inhibitory potency o f potential therapeutic agents, in vivo testing has shown the 
physiochemical properties o f the enzyme can vary against natural protein substrates.
3.3.2 Fluorescent assay to determine the inhibitory potency of dipeptidyl derivatives 
against the Fasciola hepatica cysteine cathepsin L endoproteases
A standard fluorometric assay has been developed using a fluorogenic substrate to test 
the activity o f these compounds. In this assay activity was determined by measuring the release 
o f  the fluorescent species 7-amino-4-methyl-coumarin (-NHMec) 159 from the substrate Z-Phe- 
Arg-NHMec 158 upon enzymatic hydrolysis by cathepsin L protease isolated from Fasciola 
hepatica. Assays were carried out using a final concentration o f 10 (xM substrate in 0.1 M 
sodium acetate buffer pH 10, containing 0.5 mM dithiotheritol in a final volume o f 1 ml. The
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mixture o f  enzyme and inhibitor were incubated together at 37 °C for 15 mins. The substrate was 
then added and the mixture was further incubated for 30 mins. The reaction was stopped by the 
addition o f 200 |j.L o f a 10% acetic acid solution. The amount o f  7-amino-4-methyl-coumarin (- 
NHMec) 159 released was measured using a Perkin-Elmer fluorescence spectrophotometer with 
excitation at 370 nm and emission at 440 nm. The positive control contained only the enzyme 
extract and the substrate Z-Phe-Arg-NHMec 158. There were two negative controls used. One 
contained the enzyme and inhibitor and the other contained just the inhibitor and the substrate. 
All assays were performed in triplicate with the mean result being taken.
Figure 3.11 Hydrolysis o f  Z-Phe-Arg-NHMec 158 by cathepsin L protease with liberation o f the 
fluorescent 7-amino-4-methyl coumarin (-NHMec) 159.
3.3.3 Protease inhibition o f the A-fluorobenzoyl dipeptidyl benzyl ester derivatives
The TV-benzoyl-L-Leu-Gly scaffold has been shown to be crucial for the inhibition of 
various cathepsins. Benzyl esters increase the lipophilicity o f amino acid derivatives but they are 
easily hydrolyzed by cellular processes. It is proposed that the benzyl ester moiety will function 
as a prodrug with the deprotected acid derivative in fact being the potent derivative. It is hoped 
that by modifying the length o f the PI side chain between one and three methylene groups, 
employing glycine, P-alanine and y-aminobutyric acid will furnish potent inhibitors o f Fasciola 
hepatica cathepsin L endoproteases. The benefits o f introducing fluorine into a molecule have 
been well documented.
The y-amino butyric acid derivatives were found to be the most effective inhibitors. The 
incorporation o f three methylene units into the PI position gave inhibitors with activity up to 2 -
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fold greater than their P-alanine analogues and as much as 7-fold greater than the glycine 
derivatives. The most active compound was found to be Ar-2-fluorobenzoyl-L-leucine-y- 
aminobutyric acid benzyl ester 133 with an IC50 value o f 15.32 (xM (Table 3.7). The P3 
substitutions demonstrated an influence on the overall activity o f these derivatives. In the case of 
the P-Ala and y-ABA derivatives mono-substitution o f the benzoyl ring gave the best results but 
it was the pentafluoro group that gave the best results with glycine compounds. Overall the 
benzyl ester moiety failed to achieve single digit micromolar inhibition due to the fact that the 
benzyl ester moiety is probably not electrophilic enough.
P2
Table 3.7 Inhibitory activity o f iV-fluorobenzoyl dipeptidyl benzyl ester derivatives
% Protease Inhibition
Compound 10 pM 50 pM 100 pM IC50 pM
125 3.46 26.50 33.71 > 1 0 0
126 4.29 12.79 20.53 > 1 0 0
127 16.12 54.21 74.67 43.35
128 18.55 57.23 80.87 39.52
129 24.68 66.32 86.50 29.38
130 18.24 56.85 79.32 40.08
131 13.33 44.26 59.34 62.34
132 14.87 47.08 70.42 57.68
133 46.52 74.65 92.24 15.32
134 34.88 67.04 87.75 24.78
135 42.34 69.82 90.15 19.25
136 38.58 68.58 89.21 21.38
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3.3.4 Protease inhibition of the /V-pentafluorobenzoyl dipeptidyl methyl ester derivatives
We have shown that jV-pentafluorobenzoyl-L-alanine derivatives are efficient inhibitors 
o f the MRP-1 cancer resistant mechanism. We were interested to assess the potential biological 
activity o f analogous dipeptidyl derivatives on the inhibition o f Fasciola hepatica cathepsin L 
endoproteases. It was hoped that by modifiying the size and hydrophobicity o f the P I substituent 
an optimum dipeptidyl scaffold will be prepared.
P2
Rl
PI
Table 3.8 Inhibitory activity o f iV-pentafluorobenzoyl dipeptidyl methyl ester derivatives
% Protease Inhibition
Compound 10 fiM 50 fiM 100 jiM IC50 fiM
137 1 2 . 1 0 51.02 65.56 48.58
138 8.47 46.35 60.73 59.82
139 6.40 14.79 2 0 . 1 1 > 1 0 0
140 20.62 61.14 74.36 29.34
141 33.25 69.84 83.20 18.69
142 24.95 65.22 79.38 2 0 . 2 1
143 23.87 62.88 77.64 23.65
144 16.70 57.42 70.09 35.47
145 1 . 2 2 3.68 7.98 > 1 0 0
146 3.45 4.24 8.54 > 1 0 0
iV-pentafluorobenzoyl-L-Ala-L-Leu-OMe 141 was found to be the most potent inhibitor 
o f  the pentafluoro derivatives with an IC50 value o f 18.69 }jM (Table 3.8). Previously it has been 
shown that an 'butyl group in the P2 position is often needed for efficient inhibition. In this case 
the leucyl side chain is in the PI position but similarities persist. Compound 143 has an 'propyl
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group in the PI substitution. The hydrogen bonding interactions, hydrophobicity and polarity o f 
this group are very similar to the 'butyl group and inhibitory potency seems to be similar with 
compound 142 having an IC50 value o f 20.21 |xM. The two most polar compounds, the aspartic 
acid derivative 145 and the methionine derivative 146 recorded IC50 values o f greater than 1 0 0  
(xM. This illustrates that the presence o f a polar side chain in the PI position is not suitable for 
efficient inhibition o f the Fasciola hepatica cathepsin L endoproteases.
3.3.5 Protease inhibition o f the /V-fluorobenzoyl dipeptidyl nitrile derivatives
jV-benzoyl-L-Leu-Gly nitrile is a potent inhibitor o f Fasciola hepatica cathepsin L 
endoproteases . 9 The electrophilic nature o f the nitrile moiety is believed to be crucial to the 
effectiveness o f this compound as a potent inhibitor. Fluorinated analogues o f similar derivatives 
have been prepared with modifications to the PI and P2 positions carried out.
Table 3.9 Inhibitory activity o f ,/V-fluorobenzoyl dipeptidyl nitrile derivatives
% Protease Inhibition
Compound IO jiM 50 jiM 100 jiM IC 50  | iM
150 77.74 93.17 95.61 3.04
151 82.92 93.91 96.05 2.78
152 10.35 33.51 54.23 87.55
153 13.54 41.43 67,11 68.34
154 35.25 68.58 8 8 . 0 2 24.32
155 39.22 69.95 91.12 21.61
156 7.24 25.78 41.54 > 1 0 0
157 9.31 29.33 42.68 > 1 0 0
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By modifying the length o f the side chain in the P2 position and by extending number of 
methylene units in the PI position it was hoped to improve the inhibitory activity. The inhibitory 
activities o f the compounds are shown in Table 3.9. Modifications o f the P I, P2 and P3 positions 
were carried out. Three different fluorine positions on the phenyl ring were analysed. The 
pentafluoro and 4-fluoro derivatives were shown to be more potent derivatives than the 2-fluoro 
analogues. A reduction o f the P2 substituent size by using L-alanine resulted in a decrease in 
activity o f up to 30 fold. To increase the number o f methylene units present at the PI position a 
P-Alanine derivative was employed in place o f glycine. By increasing the number o f methylene 
units to two, the inhibitory activity was shown to decrease by up to 8  fold. This clearly shows 
that a glycine residue in the PI position and a leucine residue in the P2 position are essential for 
effective inhibition.
3.3.6 True inhibitory activity of the most potent protease inhibitors
The activity o f Fasciola hepatica cysteine cathepsin L endoprotease against the substrate 
Z-Phe-Arg-NHMec can be blocked by micromolar concentrations o f the commercially available 
diazomethane, Z-Phe-Ala-CHN2 124.23 An assay comparing the nitrile derivatives, 150 and 151 
to Z-Phe-Ala-CHN2 124 was undertaken in order to evaluate the true inhibitory potency o f the 
nitrile analogues. The assay was carried out using six different micromolar concentrations of 
each compound and inhibition was measured as previously described. From this study the 
inhibitory activity o f iV-2-fluorobenzoyl-L-leu-gly nitrile 150 was shown to be slightly less than 
the activity o f 124. Compound 150 records an IC50 value o f 3.04 (iM compared to 2.96 |xM of 
compound 124. However compound 150 records greater inhibition at concentrations o f 1.25 
and 20 jxM over compound 124.
Table 3.10 Bioactivity o f compounds 150,151 and 124 against Fasciola hepatica endoprotease
% Protease Inhibition
Compound 0.63 jiM 1.25 ]iM 2.5 nM 5 \iM 10 \iM 20 jiM IC 50  ]iM
150 9.38 29.49 35.64 59.67 77.74 8 8 . 1 0 3.04
151 10.41 21.62 48.21 69.89 82.92 90.57 2.78
124 11.92 28.11 45.56 63.75 78.80 87.47 2.96
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Alternatively it was found that compound 151 has superior inhibitory potency than the 
commercial inhibitor 124 at almost all concentrations. yV-4-fluorobenzoyl-L-leucine-glycine 
nitrile 151 was found to have an IC50 value o f 2.78 |xM compared to the 2.96 (iM for compound 
124. At a concentration o f 5 |xM compound 151 is approximately 4% more effective as an 
inhibitor o f Fasciola hepatica cathepsin L endoproteases than compound 124. These results 
show that 7V-fluorobenzoyl dipeptidyl nitrile derivatives have potential as commercial inhibitors 
o f Fasciola hepatica cysteine cathepsin L endoprotease.
100 1
Concentration/micromolar
Figure 3.12 A bar graph illustration o f the % inhibition o f 7V-2-fluorobenzoyl-L-Leu-Gly-CN 
150, Ar-4-fluorobenzoyl-L-Leu-Gly-CN 151 and Z-Phe-Ala-CHN2 124 towards Fasciola 
hepatica cysteine cathepsin L endoprotease at varying concentration /|xM
3.4 Conclusion
In summary, we have identified potent inhibitors o f the Fasciola hepatica liver fluke 
cathepsin L proteases with the two most successful derivatives being the nitrile compounds 150 
and 151. From the protease inhibition results it is very clear that the presence o f an electrophilic 
isostere adjacent to the PI position is essential for effective inhibition. It has been shown that the 
introduction o f  a benzyl or methyl ester moiety decreases the inhibitory activity in comparison
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with the nitrile moiety. We have also shown that the importance o f the L-Leu-Gly scaffold varies 
as the C-terminal is modified. The scaffold is the most effective dipeptide when a nitrile moiety 
is attached. This is not the case with the benzyl ester derivatives with the dipeptide L-Leu-y- 
ABA producing the most active derivatives. It has been shown that different fluoro-substitution 
patterns on the benzoyl ring have a distinct effect on the inhibitory ability o f these compounds. 
The most effective substitution is monofluorination although this is often dependent on the 
structure o f  the remaining molecule. From this study it has been shown that the fluorobenzoyl 
moiety is an effective TV-terminal substituent for dipeptidyl inhibitors o f the Fasciola hepatica 
cathepsin L endoproteases. The inhibitory potency o f the nitrile compounds ¿V-2-fluorobenzoyl- 
L-leucine-glycine nitrile 150 and AM-fluorobenzoyl-L-leucine-glycine nitrile 151 relative to the 
commercial inhibitor Z-Phe-Ala-CHN2 124 shows that such fluorobenzoyl dipeptidyl derivatives 
m ay have a role to play as commercial inhibitors o f Fasciola hepatica cathepsin L 
endoproteases.
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3.5 Experimental
General Procedures.
All chemicals were purchased from Sigma/Aldrich and used as received. When necessary solvents 
were purified prior to use and stored under nitrogen. Dichloromethane was distilled from CaH2 and 
triethylamine was distilled and stored over potassium hydroxide pellets. Commercial grade reagents 
were used without further purification. Riedel-de Haen silica gel was used for thin layer and column 
flash chromatography. Melting points were determined using a Griffin melting point apparatus and 
are uncorrected. Specific rotation [a]o studies were recorded on a Perkin Elmer 241 polarimeter. 
Infrared spectra (IR) were recorded on a Nicolet 405 FT-IR spectrometer. Elemental analysis was 
carried out by the Microanalytical Laboratory at University College Dublin. Electrospray mass 
spectra were recorded on a Bruker Esquire 3000 series LC/MS. NMR spectra were obtained on a 
Bruker AC 400 NMR spectrometer operating at 400 MHz for 'H  NMR, 376 MHz for 19F NM R and 
100 MHz for 13C NMR. The 'H  and 13C NMR chemical shifts (ppm) are relative to 
tetramethylsilane and the 19F NM R chemical shifts (ppm) are relative to trifluoroacetic acid. All 
coupling constants (J) are in Hertz.
General procedure fo r  the synthesis o f  N-fluoro benzoyl dipeptides 125-136 
7V-2-fluorobenzoyl-L-leucine-glycine benzyl ester 125
7V-2-fluorobenzoyl-L-leucine (0.8 g, 3.16 mmol) was dissolved in dichloromethane (50 ml) with 
glycine benzyl ester tosylate (1.12 g, 3.16 mmol), 1-hydroxybenzotriazole (0.43 g, 3.16 mmol) 
and triethylamine (0.44 ml). The mixture was cooled to 0 °C, and 1,3-dicyclohexylcarbodiimide 
(0.65 g, 3.16 mmol) was added. After 30 min. the solution was raised to room temperature and 
the reaction was allowed to proceed for 8  hrs. The precipitated N, TV-dicyclohexylurea was 
removed by filtration and the filtrate was washed with 1 0 % potassium hydrogen carbonate, 1 0 % 
citric acid, water and dried over magnesium sulphate. The solvent was evaporated in vacuo and 
recrystallisation from ethyl acetate/hexane furnished 125 as a white powder (0.45 g, 37%). 
m.p. = 101-103 °C. [a ] D 25 = -18.2° (c, 3.0, EtOH).
Anal, calcd. for C2 2H25N2O4F 1: C, 65.98; H, 6.29; N, 6.99.
Found C, 65.59; H, 6.04; N, 7.12.
Mass Spectrum: [M+Na]+ found 423.2.
C22H25N20 4FiNai requires 423.44.
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IR (KBr): u 3290, 2957, 1720, 1638, 1542, 752 cm '1.
‘H-NMR (400 MHz, DMSO): 5 8.49 (1H, t , J =  6.0 Hz, -NH-), 8.35 (1H, dd, J H'F = 2.8 Hz, J H'H 
= 8.4 Hz, -NH-), 7.62-7.66 (1H, m, -A rtf 6 ), 7.50-7.55 (1H, m, -A rtf 4), 7.24-7.36 (7H, m, -ArH  
3, 5 & -Ph/f), 5.12 (2H, s, -OCH2-), 4.52-4.66 (1H, m, a-H ), 3.99 (1H, dd, J 3 = 6.4 Hz, J 2 = 17.2 
Hz, -CH2-), 3.88 (1H, dd, J 3 = 5.6 Hz, J 2 = 17.6 Hz, -CH2-), 1.50-1.73 (3H, m, -CH2- &-CH-) ,  
0.89 (3H, d, J =  3.6 Hz, -CH 3), 0.88 (3H, d, J =  3.6 Hz, -CH3).
I3C-NMR (100 MHz, DMSO): 6  172.9 (-CONH-), 169.9 (-COOCH2Ph), 164.0 (-ArCO-), 159.5 
(d, -ArC 2), 136.1 (-PhC 1), 132.9 (d, -ArC 4), 130.5 (d, -ArC 6 ), 128.7 (-PhC 3 & 5), 128.4 (- 
PhC 4), 128.2 (-PhC 2 & 6 ), 124.7 (d, -ArC 5), 123.8 (d, -ArC 1), 116.4 (d, -ArC 3), 66.2 (- 
OCH2-, -VE DEPT), 51.8 (a-C), 41.1 (-CH2-, -VE DEPT), 41.0 (-CH2-, -VE DEPT), 24.6 (-CH­
), 23.3 (-CH3), 21.7 (-CH3).
19F-NMR (376 MHz, DMSO): 5 -38.7 - -38.8 (m).
TV-3-fluorobenzoyl-L-leucine-glycine benzyl ester 126
A^-3-fluorobenzoyl-L-leucine (0.8 g, 3.16 mmol) and glycine benzyl ester tosylate (1.12 g, 3.16 
mmol) were used. Recrystallisation from ethyl acetate/hexane furnished 126 as a white powder 
(0.55 g, 45%).
m.p. = 76-78 °C. [a ] D 25 = -21.3° (c, 3.2, EtOH).
Anal, calcd. for C22H25N204F i : C, 65.98; H, 6.29; N, 6.99.
Found C, 65.72; H, 6.41; N, 6 .8 8 .
Mass Spectrum: [M+Na]+ found 423.1.
C2 2H25N 20 4 FiNai requires 423.44.
IR (KBr): u 3275, 2958, 1744, 1637, 1560, 754 c m 1.
!H-NMR (400 MHz, DMSO): 6  8.63 (1H, d, J  = 8.4 Hz, -Ntf-), 8.49 (1H, t, J  = 6.0 Hz, -N//-), 
7.73-7.79 (2H, m, -A r//2  & 6 ), 7.49-7.53 (1H, m, -A iH  5), 7.31-7.41 (6 H, m, -A rH 4  & -Phfl), 
5.12 (2H, s, -OCH2-), 4.54-4.58 (1H, m, a-H), 3.95 (1H, dd, J 3 = 6.0 Hz, J 2 = 17.6 Hz, -CH2-), 
3.87 (1H, dd, J 3 = 5.6 Hz, J 2 = 17.2 Hz, -CH2-), 1.54-1.74 (3H, m, -CH2- & -CH-), 0.89 (3H, d, 
J =  6.4 Hz, -CH 3), 0.85 (3H, d, J =  6.0 Hz, -CH 3).
13C-NMR (100 MHz, DMSO): 8  173.1 (-CONH-), 170.0 (-COOCH2Ph), 165.3 (d, -ArCO-),
162.2 (d, -ArC 3), 136.7 (d, -ArC 1), 136.2 (-PhC 1), 130.6 (d, -ArC 5), 128.7 (-PhC 3 & 5),
128.4 (-PhC 4), 128.2 (-PhC 2 & 6 ), 124.1 (d, -ArC 6 ), 118.5 (d, -ArC 4), 114.7 (d, -ArC 2), 66.2
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(-OCH2-, -VE DEPT), 52.0 (a -Q , 41.1 (-CH2-, -VE DEPT) 40.6 (-CH2-, -VE DEPT), 24.6 (­
CH-), 23.3 (-CH3), 21.6 (-CH3).
19F-NMR (376 MHz, DMSO): 5 -37.8 - -37.9 (m).
jV-4-fluorobenzoyl-L-leucine-glycine benzyl ester 127
jV-4-fluorobenzoyl-L-leucine (0.8 g, 3.16 mmol) and glycine benzyl ester tosylate (1.12 g, 3.16 
mmol) were used. Recrystallisation from ethyl acetate/hexane furnished 127 as a brown powder 
(0.80 g, 6 6 %).
m.p. = 108-110 °C. [a ] D25 = -22.2° (c, 3.2, EtOH).
Anal, calcd. for C22H 25N2G4Fi: C, 65.98; H, 6.29; N, 6.99.
Found C, 65.77; H, 6.31; N, 7.21.
Mass Spectrum: [M+Na]+ found 423.2.
C 22H25N 20 4FiNai requires 423.44.
IR (KBr): x> 3285, 2957, 1742, 1632, 1502, 695 cm '1.
•H-NMR (400 MHz, DMSO): 5 8.51 (1H, d, J =  8.4 Hz, -Nfl-), 8.43 (1H, t, J  = 6.0 Hz, -NH-), 
7.92-7.98 (2H, m, -ArH  2 & 6 ), 7.26-7.40 (7H, m, -ArH  3, 5 & -Phif), 5.10 (2H, s, -OCH 2-),
4.50-4.56 (1H, m, a-H), 3.93 (1H, dd, J 3 = 6.0 Hz, J 2 = 17.6 Hz, -CH 2-), 3.84 (1H, dd, J 3 = 6.0 
Hz, J 2 = 17.2 Hz, -CH2- \  1.52-1.71 (3H, m, -CH2- & -CH-), 0.88 (3H, d, J =  6.4 Hz, -Gift), 0.84 
(3H, d, J -  6.4 Hz, -C/ft).
13C-NMR (100 MHz, DMSO): 5 173.2 (-CONH-), 170.0 (-COOCH2Ph), 165.6 (-ArCO-), 164.2 
(d, -ArC 4), 136.1 (-PhC 1), 130.8 (-ArC 1), 130.6 (-A rC2), 130.5 (-A rC 6 ), 128.7 (-PhC3 & 5),
128.3 (-PhC 4), 128.2 (-PhC 2 & 6 ), 115.4 (-ArC 3), 115.2 (-ArC 5), 66.1 (-OCH2-, -VE DEPT),
51.9 (a -Q , 41.1 (-i H 2-, -VE DEPT) 40.6 (-CH2-, -VE DEPT), 24.7 (-CH-), 23.3 (-CH3), 21.6 (-
CH3).
19F-NMR (376 MHz, DMSO): 5 -34.1 - -34.2 (m).
A-pentafluorobenzoyl-L-leucine-glycine benzyl ester 128
jV-pentafluorobenzoyl-L-leucine (2.64 g, 8.1 mmol) and glycine benzyl ester tosylate (2.88 g, 8.1 
mmol) were used. Recrystallisation from ethyl acetate/hexane furnished 128 as a white powder 
(1.56 g, 42%).
m.p. = 165-167 °C. [a ] D25 = -20.8° (c, 1.5, EtOH).
Anal, calcd. for C2 2H21N 2O4F5 : C, 55.93; H, 4.48; N, 5.93.
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Found C, 56.15; H, 4.62; N, 6.11.
Mass Spectrum: [M+Na]+ found 495.1.
C22H2 iN2 0 4 F5Nai requires 495.39.
IR (KBr): u 3287, 2966, 1745, 1662, 1546, 996 cm '1.
'H-NM R (400 MHz, DMSO): 8  9.13 (1H, d, J =  8.4 Hz, -NZT-), 8.70 (1H, t, J  = 6.0 Hz, -N/i-),
7.31-7.38 (5H, m, -Ph/i), 5.13 (2H, s, -OCH 2-), 4.60-4.64 (1H, m, a-H), 4.03 (1H, dd, J 3 = 6.0 
Hz, J 2 = 17.2 Hz, -CH2-), 3.84 (1H, dd, J 3 = 6.0 Hz, J 2 = 17.6 Hz, -CH 2-), 1.49-1.70 (3H, m, - 
CH2- & -CH-), 0.90 (3H, d, J =  6.4 Hz, -CH 3), 0.89 (3H, d, J =  6.4 Hz, -CH3).
13C-NMR (100 MHz, DMSO): 8  172.0 (-CONH-), 169.9 (-COOCH2Ph), 156.6 (-ArCO-), 144.7­
144.8 (m, -ArC 2), 140.3-142.8 (m, -ArC 4), 142.1-142.3 (-ArC 6 ), 138.4-138.6 (m, -ArC 3),
136.1 (-PhC 1), 135.9-136.1 (m, -ArC 5), 128.7 (-PhC 3 & 5), 128.4 (-PhC 4), 128.3 (-PhC 2 &
6 ), 112.7 (t, -ArC 1), 66.2 (-OCH2-, -VE DEPT), 51.7 (a -Q , 41.3 (-CH2-, -VE DEPT) 40.1 (- 
CH2-, -VE DEPT), 24.4 (-CH-), 23.3 (-CH3), 21.6 (-CH3).
19F-NMR (376 MHz, DMSO): 8  -66.5 dd, 2F, J 4 = 6.7 Hz, J 3 = 22.9 Hz), -78.1 (t, J =  16.1 Hz), 
-86.4 - -86.5 (m, 2F).
yV-2-fluorobenzoyl-L-leucine-P-alanine benzyl ester 129
jV-2-fluorobenzoyl-L-leucine (0.8 g, 3.16 mmol) and P-alanine benzyl ester tosylate (1.16 g, 3.16 
mmol) were used. Recrystallisation from ethyl acetate/hexane furnished 129 as a brown powder 
(0.73 g, 58%).
m.p. = 69-71 °C. [a ] D 25 = -4.2° (c, 1.4, EtOH).
Anal, calcd. for C23H 27N 2O4F 1: C, 66.65; H, 6.56; N, 6.75.
Found C, 66.60; H, 6.62; N, 6.77.
Mass Spectrum: [M+Na]+ found 437.2.
C23H 27N 2 0 4 FiNai requires 437.46.
IR (KBr): u 3268, 2913, 1727, 1642, 1468, 721 cm '1.
‘H-NMR (400 MHz, DMSO): 8  8.31 (1H, dd, J H'F = 2.4 Hz, / H'H = 8.0 Hz, -NH-), 8.16 (1H, t, J  
= 5.6 Hz, -Nif-), 7.61-7.65 (1H, m, -A rif 6 ), 7.50-7.55 (1H, m, -A rif 4), 7.24-7.36 (7H, m, -A r/f 
3, 5 & -Ph/i), 5.09 (2H, s, -OCH 2-), 4.46-4.50 (1H, m, a-H), 3.29-3.44 (2H, m, p-CH2), 2.54 (2H, 
t, J =  6 . 8  Hz, a-CH2), 1.46-1.67 (3H, m, -CH2- & -C/i-), 0.89 (3H, d, J =  2.8 Hz, -C if3), 0.87 
(3H, d , J — 2.8 Hz, -C i/3).
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13C-NMR (100 MHz, DMSO): 5 172.2 (-CONH-), 171.5 (-COOCH2Ph), 163.8 (-ArCO-), 159.5 
(d, -ArC 2), 136.3 (-PhC 1), 132.8 (d, -ArC 4), 130.5 (d, -ArC 6 ), 128.7 (-PhC 3 & 5), 128.3 (- 
PhC 4), 128.2 (-PhC 2 & 6 ), 124.7 (d, -ArC 5), 123.9 (d, -ArC 1), 116.4 (d, -ArC 3), 65.9 (- 
OCH2-, -VE DEPT), 52.0 (a-C), 41.1 (-CH2-, -VE DEPT), 35.1 (P-CH2, -VE DEPT), 34.0 (a- 
CH2, -VE DEPT), 24.6 (-CH-), 23.3 (-CH3), 21.8 (-CH3).
19F-NMR (376 MHz, DMSO): 5 -38.7 - -38.8 (m).
A -S-fluorobenzoyl-L-leucine-p-alanine benzyl ester 130
yV-3-fluorobenzoyl-L-leucine (0.8 g, 3.16 mmol) and P-alanine benzyl ester tosylate (1.16 g, 3.16 
mmol) were used. Recrystallisation from ethyl acetate/hexane furnished 130 as a brown powder 
(0.63 g, 50%).
m.p. = 63-65 °C. [a ] D25 = -9.1° (c, 2.4, EtOH).
Anal, calcd. for C23H27N 20 4F,: C, 66.65; H, 6.56; N, 6.75.
Found C, 66.89; H, 6.90; N, 6.55.
Mass Spectrum: [M+Na]+ found 437.2.
C23H27N 2 0 4 FiNai requires 437.46.
IR (KBr): u 3324, 2960, 1736, 1655, 1542, 752 cm '1.
'H-NM R (400 MHz, DMSO): 8  8.58 (1H, d , J =  8.0 Hz, -NH-), 8.17 (1H, t , J =  5.6 Hz, -NH-),
7.67-7.78 (2H, m, - A i H 2 &  6 ), 7.48-7.53 (1H, m, -ArH  5), 7.28-7.39 (6 H, m, -A iH  4 & -Ph/i),
5.07 (2H, s, -OCH2-), 4.46-4.52 (1H, m, a-H), 3.29-3.43 (2H, m, P-CH2), 2.54 (2H, t, J =  6 . 8  Hz, 
a-CH 2), 1.47-1.72 (3H, m, -CH 2- & -CH-), 0.88 (3H, d, / =  6.4 Hz, -C //3), 0.85 (3H, d, J  = 6.4 
Hz, -CHi).
13C-NMR (100 MHz, DMSO): 8  172.6 (-CONH-), 171.5 (-COOCH2Ph), 165.3 (d, -ArCO-),
162.2 (d, -ArC 3), 136.7 (d, -ArC 1), 136.3 (-PhC 1), 130.6 (d, -ArC 5), 128.7 (-PhC 3 & 5),
128.3 (-PhC 4), 128.2 (-PhC 2 & 6 ), 124.0 (d, -ArC 6 ), 118.4 (d, -ArC 4), 114.6 (d, -ArC 2), 65.9 
(-OCH2-, -VE DEPT), 52.0 (a-C), 40.7 (-CH2-, -VE DEPT), 35.1 (p-CH2, -VE DEPT), 34.0 (a- 
CH2, -VE DEPT), 24.7 (-CH-), 23.3 (-CH3), 21.6 (-CH3).
19F-NMR (376 MHz, DMSO): 8  -37.6 - -37.7 (m).
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iV-4-fluorobenzoyl-L-leucine-p-alanine benzyl ester 131
AM-fluorobenzoyl-L-leucine (0.8 g, 3.16 mmol) and P-alanine benzyl ester tosylate (1.16 g, 3.16 
mmol) were used. Recrystallisation from ethyl acetate/hexane furnished 131 as a brown powder 
(0.58 g, 46%).
m.p. = 103-105 °C. [<x] D 25 = -12.3° (c, 1.6, EtOH).
Anal, calcd. for C23H 27N 2O4F 1: C, 66.65; H, 6.56; N, 6.75.
Found C, 66.29; H, 6.35; N, 6.49.
Mass Spectrum: [M+Na]+ found 437.2.
C23H27N 2C>4FiNai requires 437.46.
IR (KBr): d 3330, 2959, 1734, 1632, 1502, 857 cm '1.
!H-NMR (400 MHz, DMSO): 8  8.49 (1H, d, J  = 8.0 Hz, -NÜ-), 8.14 (1H, t, J =  5.6 Hz, -NÜ-),
7.96-7.99 (2H, m, -A rif 2 & 6 ), 7.26-7.36 (7H, m, -A rif 3, 5 & -Phü), 5.07 (2H, s, -O Cif2-), 
4.46-4.48 (1H, m, a-Ü), 3.29-3.39 (2H, m, p-CÜ2), 2.54 (2H, t, J  = 6 . 8  Hz, a-CH 2), 1.47-1.70 
(3H, m, -C if2- & -Cif-), 0.88 (3H, d, J =  6.4 Hz, -C if3), 0.85 (3H, d, J =  6.4 Hz, -C if3).
13C-NMR (100 MHz, DMSO): 8  172.6 (-CONH-), 171.5 (-COOCH2Ph), 165.5 (-ArCO-), 164.3 
(d, -ArC 4), 136.4 (-PhC 1), 130.9 (-ArC 1), 130.6 (-ArC 2), 130.5 (-ArC 6 ), 128.7 (-PhC 3 & 5),
128.3 (-PhC 4), 128.2 (-PhC 2 & 6 ), 115.5 (-ArC 3), 115.3 (-ArC 5), 65.9 (-OCH2-, -VE DEPT),
52.1 (a-C), 40.7 (-CH2-, -VE DEPT), 35.1 (p-CH2, -VE DEPT), 34.0 (a-CH2, -VE DEPT), 24.7 
(-CH-), 23.3 (-CH 3), 21.7 (-CH3).
19F-NMR (376 MHz, DMSO): 8  -34.1 - -34.2 (m).
7V-pentafluorobenzoyl-L-leucine-p-alanine benzyl ester 132
jV-pentafluorobenzoyl-L-leucine (2.93 g, 9.0 mmol) and P-alanine benzyl ester tosylate (3.33 g,
9.0 mmol) were used. Recrystallisation from ethyl acetate/hexane furnished 132 as a brown oil 
(1.99 g, 47%).
[a ] D 25 = -6.5° (c, 2.1, EtOH).
Anal, calcd. for C23H23N204F5: C, 56.79; H, 4.76; N, 5.75.
Found C, 56.61; H, 4.85; N, 6.01.
Mass Spectrum: [M+Na]+ found 509.2.
C23H23N 20 4 F5Nai requires 509.42.
IR (KBr): u 3267, 3083, 1745, 1638, 1560, 734 cm '1.
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'H-NM R (400 MHz, DMSO): 8  9.16 (1H, d, J =  8.4 Hz, -NH-), 8.35 (1H, t, J  = 5.6 Hz, -NH-),
7.31-7.38 (5H, m, -Ph/i), 5.10 (2H, s, -O C i/2-), 4.51-4.55 (1H, m, a-H), 3.30-3.44 (2H, m, p- 
CH2), 2.56 (2H, t, J  = 6.4 Hz, a-CH2), 1.45-1.64 (3H, m, -CH2- & -CH-), 0.90 (3H, d , J =  6.4 
Hz, -CH3), 0.89 (3H, d, 6.4 Hz, -C i/3).
13C-NMR (100 MHz, DMSO): 8  171.4 (-COOCH2Ph & -CONH-), 156.6 (-ArCO-), 144.5-144.7 
(m, -ArC 2), 140.0-142.2 (m, -A rC 4), 142.1-142.3 (-ArC 6 ), 138.2-138.4 (m, -ArC 3), 136.4 (- 
PhC 1), 135.8-136.0 (m, -ArC 5), 128.7 (-PhC3 & 5), 128.3 (-PhC4), 128.1 (-PhC 2 & 6 ), 112.7 
(t, -ArC 1), 65.9 (-OCH2-, -VE DEPT), 51.9 (a-C), 41.3 (-CH2-, -VE DEPT), 35.1 (p-CH2, -VE 
DEPT), 33.9 (a-CH2, -VE DEPT), 24.4 (-CH-), 23.1 (-CH3), 21.7 (-CH3).
19F-NMR (376 MHz, DMSO): 8  -6 6 . 6  (dd, 2F, J 4 = 6 . 8  Hz, J 3 = 23.6 Hz), -78.4 (t, J =  21.6 Hz), 
-8 6 . 6  - -86.7 (m, 2F).
7V-2-fluorobenzoyl-L-leucine-y-aniinobutyric acid benzyl ester 133
jV-2-fluorobenzoyl-L-!eucine (0.8 g, 3.16 mmol) and y-aminobutyric acid benzyl ester tosylate 
(1.21 g, 3.16 mmol) were'used. Recrystallisation from ethyl acetate/hexane furnished 133 as a 
brown oil (0.79 g, 63%).
[a]D25 = -19° (c, O .li ,  EtOH).
Anal, calcd. for C ^ H ^ N ^ F , :  C, 67.27; H, 6.82; N, 6.53.
Found C, 67.60; H, 6.58; N, 6.32.
Mass Spectrum: [M+Na]+ found 451.2.
C24H 2 9N 2 0 4 FiNai requires 451.49.
IR(KBr): u 3301, 2985, 1737, 1662, 1435, 728 cm '1.
‘H-NMR (400 MHz, DMSO): 8  8.30 (1H, dd, J H'F = 2.4 Hz, J H'H= 8.0 Hz, -N//-), 8.05 (1H, t, J  
= 5.6 Hz, -N//-), 7.61-7.65 (1H, m, -A r/f 6 ), 7.49-7.55 (1H, m, -A r/i4 ), 7.24-7.38 (7H, m, -A iH  
3, 5 & -Ph/i), 5.08 (2H, s, -O C ii2-), 4.45-4.50 (1H, m, a-H), 3.13 (2H, q , J =  6 . 8  Hz, y-C i/2), 
2.38 (2H, t, J =  7.6 Hz, a-CH2), 1.48-1.73 (5H, m, p-C ii2, -CH2- & -CH-), 0.89 (6 H, t, J =  6.4 
Hz, -CH3).
I3C-NMR (100 MHz, DMSO): 8  172.9 (-CONH-), 172.1 (-COOCH2Ph), 163.8 (-ArCO-), 159.5 
(d, -ArC 2), 136.5 (-PhC 1), 132.8 (d, -ArC 4), 130.5 (d, -ArC 6 ), 128.7 (-PhC 3 & 5), 128.3 (- 
PhC 4), 128.2 (-PhC 2 & 6 ), 124.7 (-ArC 5), 123.9 (d, -ArC 1), 116.3 (d, -ArC 3), 65.7 (-OCH2-,
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-VE DEPT), 52.2 (o-C), 41.1 (-CH2-, -VE DEPT), 38.1 (y-CH2, -VE DEPT), 31.1 (a-CH2, -VE 
DEPT), 24.75 (-CH-), 24.72 (P-CH2, -VE DEPT), 23.2 (-CH3), 21.9 (-CH3).
19F-NMR (400 MHz, DMSO): 8  -38.7 - -38.8 (m).
7V-3-fluorobenzoyl-L-leucine-Y-aminobutyric acid benzyl ester 134
TV-3-fluorobenzoyl-L-leucine (0.8 g, 3.16 mmol) and y-aminobutyric acid benzyl ester tosylate 
(1.21 g, 3.16 mmol) were used. Recrystallisation from ethyl acetate/hexane furnished 134 as a 
white powder (0.63 g, 50%). 
m.p. = 69-71 °C. [a ] D25 = -2.5° (c, 1.2, EtOH).
Anal, calcd. for Q mH ^ N ^ F , :  C, 67.27; H, 6.82; N, 6.53.
Found C, 67.65; H, 7.01; N, 6.38.
Mass Spectrum: [M+Na]+ found 451.2.
C 24H29N 2 0 4 FiNai requires 451.49.
IR (KBr): u 3330, 2954, 1725, 1634, 1534, 754 cm '1.
'H-NM R (400 MHz, DMSO): 8  8.55 (1H, d, J  = 8.0 Hz, -N//-), 8.06 (1H, t, J =  5.6 Hz, -NH-), 
7.70-7.77 (2H, m, -A xH 2 & 6 ), 7.47-7.54 (1H, m, -A iH  5), 7.29-7.39 (6 H, m, -ArH  4 & -Ph/f),
5.07 (2H, s, -OCH2-), 4.44-4.50 (1H, m, a -//), 3.10 (2H, q, J =  6.4 Hz, y-CH2), 2.37 (2H, t, J  =
7.2 Hz, a-C /ft), 1.50-1.73 (5H, m, P-CH2, -CH2- & -CH-), 0.89 (3H, d, J  = 6.0 Hz, -C/ft), 0.85 
(3H, d, J -  6.0 Hz, -CH3).
13C-NMR (100 MHz, DMSO): 8  172.9 (-CONH-), 172.4 (-COOCH2Ph), 165.3 (d, -ArCO-),
162.2 (d, -ArC 3), 136.7 (t, -ArC 1), 136.5 (-PhC 1), 130.6 (d, -ArC 5), 128.7 (-PhC 3 & 5),
128.3 (-PhC 4), 128.2 (-PhC 2 & 6 ), 124.0 (d, -ArC 6 ), 118.4 (d, -ArC 4), 114.6 (d, -ArC 2), 65.7 
(-OCH2-, -VE DEPT), 52.4 (a-C), 40.7 (-CH2-, -VE DEPT), 38.1 (y-CH2, -VE DEPT), 31.1 (a- 
CH2, -VE DEPT), 24.79 (-CH-), 24.77 (P-CH2, -VE DEPT), 23.3 (-CH3), 21.7 (-CH3).
,9F-NMR (376 MHz) (DMSO): 8  -37.7 - -37.8 (m).
Ar-4-fluorobenzoyl-L-leucine-y-aminobutyric acid benzyl ester 135
AM-fluorobenzoyl-L-leucine (0.8 g, 3.16 mmol) and y-aminobutyric acid benzyl ester tosylate 
(1.21 g, 3.16 mmol) were used. Recrystallisation from ethyl acetate/hexane furnished 135 as a 
brown powder (0.73 g, 63%). 
m.p. = 83-85 °C. [a ] D 25 = -2.9° (c, 1.2, EtOH).
Anal, calcd. for C24H 29N 20 4Fi: C, 67.27; H, 6.82; N, 6.53.
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Found C, 67.55; H, 7.13; N, 6.69.
Mass Spectrum: [M+Na]+ found 451.2.
C24H 29N 2 0 4FiNai requires 451.49.
IR (KBr): u 3330, 2954, 1725, 1634, 1534, 754 cm"1.
■H-NMR (400 MHz, DMSO): 6  8.49 (1H, d, J = 8.0 Hz, -Ni?-), 8.06 (1H, t, J = 5.6 Hz, -NH-),
7.96-8.02 (2H, m, -A iH  2 & 6 ), 7.25-7.39 (7H, m, -Ari? 3, 5 & -PhH), 5.08 (2H, s, -OCi?2-), 
4 .4 4 .4 .5 O (1H, m, a-H), 3.11 (2H, q, J =  6.4 Hz, y-CH2), 2.37 (2H, t , J  = 7.2 Hz, a-CH 2), 1.50­
1.73 (5H, m, p-CH2, -CH2- &  -C if-), 0.89 (3H, d, J =  6.4 Hz, -Ci?3), 0.86 (3H, d, J= 6.4 Hz, - 
C i?3).
13C-NMR (100 MHz, DMSO): 8  172.9 (-CONH-), 172.5 (-COOCH2Ph), 165.6 (-ArCO-), 164.4 
(d, -ArC 4), 136.5 (-PhC 1), 130.9 (-ArC 1), 130.6 (-ArC 2), 130.5 (-ArC 6 ), 128.7 (-PhC 3 & 5),
128.3 (-PhC 4), 128.2 (-PhC 2 & 6 ), 115.4 (-ArC 3), 115.2 (-ArC 5), 65.7 (-OCH2-,-Y E  DEPT),
52.3 (a-C), 40.8 (-CH2-, -VE DEPT), 38.1 (y-CH2, -VE DEPT), 31.1 (a-CH2, -VE DEPT), 24.8 
(-CH-), 24.7 (P-CH2, -VE DEPT), 23.3 (-CH3), 21.7 (-CH3). 19F-NMR (376 MHz, DMSO): 8  -
34.1 --34 .2  (m).
yV-pentafluorobenzoyl-L-leucine-y-aminobutyric acid benzyl ester 136
iV-pentafluorobenzoyl-L-leucine (2.69 g, 8.2 mmol) and y-aminobutyric acid benzyl ester 
tosylate (3.15 g, 8.2 mmol) were used. Recrystallisation from ethyl acetate/hexane furnished 136 
as a white powder (1.82 g, 46%). 
m.p. = 54-56 °C. [a ] D25 =  -4.2° (c, 1.2, EtOH).
Anal, calcd. for C2 4H 25N 2O4F5 : C, 57.59; H, 5.04; N, 5.59.
Found C, 57.32; H, 4.77; N, 5.91.
Mass Spectrum: [M+Na]+ found 523.1.
C24H25N 2 0 4 F5Nai requires 523.45.
IR (KBr): u 3329, 2962, 1736, 1655, 1508, 991 cm '1.
■H-NMR (400 MHz, DMSO): 8  9.16 (1H, d, J =  8.4 Hz, -NH-), 8.23 (1H, t, J  = 5.6 Hz, -N/T-),
7.31-7.37 (5H, m, -Phi?), 5.10 (2H, s, -OCi?2-), 4.48-4.51 (1H, m, a-H), 3.09-3.16 (2H, m, y- 
Ci?2), 2.40 (2H, t, J  = 7.2 Hz, a-Ci?2), 1.47-1.75 (5H, m, P-Ci?2, -Ci?2- & -CH-), 0.90 (6 H, t, J =
6.0 Hz, -Ci?3).
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13C-NMR (100 MHz, DMSO): 8  172.8 (-CONH-), 171.3 (-COOCH2Ph), 156.6 (-ArCO-), 144.5­
144.7 (m, -ArC 2), 140.0-142.6 (m, -ArC 4), 142.1-142.3 (-ArC 6 ), 138.2-138.5 (m, -ArC 3),
136.5 (-PhC 1), 135.8-136.0 (m, -ArC 5), 128.7 (-PhC 3 & 5), 128.3 (-PhC 4), 128.1 (-PhC 2 &
6 ), 112.7 (t, -ArC 1), 65.7 (-OCH2-, -VE DEPT), 52.1 (a -Q , 41.3 (-CH2-, -VE DEPT), 38.1 (y- 
CH2, -VE DEPT), 31.0 (a-CH2, -VE DEPT), 24.7 (p-CH2, -VE DEPT), 24.5 (-CH-), 23.1 (- 
CH3), 21.7 (-CH3).
19F-NM R (376 MHz, DMSO): 8  -6 6 . 6  (dd, 2F, J 4 = 6 . 8  Hz, J 3 = 23.3 Hz), -78.4 (t, J =  22.1 
Hz), -8 6 . 6  - -86.7 (m, 2F).
General procedure fo r  the synthesis ofN-pentafluorobenzoyl-L-alanine dipeptides 137-146 
/V-pentafluorobenzoyl-L-alanine-glycine methyl ester 137
/V-pentafluorobenzoyl-L-alanine (1.13 g, 4 mmol), glycine methyl ester (0.5 g, 4 mmol), 
triethylamine (0.56 ml) and 1-hydroxybenzotriazole hydrate (0.54 g, 4 mmol) were dissolved in 
dichloromethane (50 ml). The mixture was cooled to 0 °C, and l-[3-dimethylaminopropyl]-3- 
ethyl carbodiimide hydrochloride (EDC) (0.84 g, 4.4 mmol) was added. After 30 min. the 
solution was raised to room temperature and the reaction was allowed to proceed for 8  hrs. The 
filtrate was washed with 10% citric acid, water and dried over magnesium sulphate. The solvent 
was evaporated in vacuo and recrystallisation from ethyl acetate/hexane furnished 137 as a light 
yellow powder (0.60 g, 42%). 
m.p. = 144-146 °C. [a ] D 25 = -15.1° (c, 1.6, EtOH).
Anal, calcd. for C i3H ,iN 20 4F5: C, 44.07; H, 3.13; N, 7.91.
Found C, 44.02; H, 2.92; N, 7.80.
IR(KBr): u 3292, 3105, 1752, 1653, 1560, 995 cm '1.
’H-NMR (400 MHz, DMSO): 8  9.19 (1H, d, 8.0 Hz, -NH-), 8.53 (1H, t, J =  5.6 Hz, -Ntf-),
4.56-4.61 (1H, m, a-H), 3.96 (1H, dd, J 3 = 6.0 Hz, J 2 = 17.6 Hz, -CH2-), 3.86 (1H, dd, J 3 = 6.0 
Hz, J 2 = 17.6 Hz, -CH2-), 3.65 (3H, s, -OCH 3), 1.32 (3H, d, J =  7.2 Hz, -C tf3).
,3C-NMR (100 MHz, DMSO): 8  172.2 (-CONH-), 170.5 (-COOCH3), 156.6 (-ArCO-), 144.7­
144.8 (m, -ArC 2), 140.3-142.8 (m, -ArC 4), 142.1-142.3 (-ArC 6 ), 138.3-138.5 (m, -ArC 3),
135.8-136.0 (m, -ArC 5), 112.7 (t, -ArC 1), 52.0 (-OCH3), 49.0 (a-C), 40.8 (-CH2-, -VE DEPT),
18.6 (-CH3).
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19F-NMR (376 MHz, DMSO): 5 -6 6 . 6  (dd, 2F, J 4 = 6 . 8  Hz, J 3 = 23.7 Hz), -78.4 (t, J =  21.8 
Hz), -86.7 - -8 6 . 8  (m. 2F).
./V-pentafluorobenzoyl-L-alanine-(3-Alanine methyl ester 138
(3-Alanine methyl ester (0.56 g, 4 mmol) was used. Recrystallisation from ethyl acetate/hexane 
fum  hed 138 as a white powder (0.80 g, 54%). 
m.p. = 154-155 °C. [a ] D 25 = -8.2° (c, 1.5, EtOH).
Anal, calcd. for C 14H 13N2O4 F5 : C, 45.66; H, 3.56; N, 7.61.
Found C, 45.59; H, 3.29; N, 7.52.
IR (KBr): u 3289, 3110, 1738, 1646, 1523,992 cm '1.
JH-NM R (400 MHz, DMSO): 5 9.13 (1H, d, J =  7.6 Hz, -N//-), 8.17 (1H, t, J =  5.6 Hz, -N//-),
4 .4 3 .4 . 4 8  (1H, m, a-H), 3.60 (3H, s, -OC/ft), 3.24-3.38 (2H, m, P-C/ft), 2.48 (2H, t, J =  6.4 Hz, 
a-C /ft), 1.26 (3H, d, J =  6 . 8  Hz, -C/ft).
13C-NMR (100 MHz, DMSO): 6  172.0 (-CONH-), 171.6 (-COOCH3), 156.5 (-ArCO-), 144.7­
144.8 (m, -ArC 2), 140.3-142.8 (m, -ArC 4), 142.1-142.3 (-ArC 6 ), 138.3-138.5 (m, -ArC 3),
135.8-136.0 (m, -ArC 5), 112.7 (t, -ArC 1), 51.6 (-OCH3), 49.2 (a-C), 35.1 (p-C/ft, -VE DEPT),
33.8 (a-C /ft, -VE DEPT), 18.6 (-CH3).
19F-NMR (376 MHz, DMSO): 5 -66.7 (dd, 2F, J 4 -  6 . 8  Hz, J 3 = 23.3 Hz), -78.5 (t, J =  21.8 
Hz), -86.7 - -8 6 . 8  (m, 2F).
./V-pentafluorobenzoyl-L-alanine-Y-aminobutyric acid methyl ester 139
Y-Aminobutyric acid methyl ester (0.61 g, 4 mmol) was used. Recrystallisation from ethyl 
acetate/hexane yielded the title product as a light yellow powder (0.75 g, 49%). 
m.p. = 138-139 °C. [a ] D25 = -2.9° (c, 1.7, EtOH).
Anal, calcd. for C i5H i5N20 4 F5 : C, 47.12; H, 3.96; N, 7.33.
Found C, 47.00; H, 3.70; N, 7.26.
IR (KBr): u 3331, 2960, 1736, 1648, 1560, 992 cm '1.
•H-NMR (400 MHz, DMSO): 5 9.13 (1H, d, J =  7.6 Hz, -N//-), 8.10 (1H, t, J =  5.6 Hz, -N//-),
4 .4 3 .4 . 4 8  (1H, m, a-H), 3.60 (3H, s, -OC/ft), 3.08-3.14 (2H, m, y-CH2), 2.33 (2H, t , J =  7.6 Hz, 
a-C /ft), 1.64-1.71 (2H, m, P-CH 2), 1.28 (3H, d, J =  7.2 Hz, -C/ft).
13C-NMR (100 MHz, DMSO): 6  173.4 (-CONH-), 171.4 (-COOCH3), 156.5 (-ArCO-), 144.7­
144.8 (m, -ArC 2), 140.3-142.8 (m, -ArC 4), 142.1-142.3 (-ArC 6 ), 138.3-138.5 (m, -ArC 3),
142
135.8-136.0 (m, -ArC 5), 112.7 (t, -ArC 1), 51.6 (-OCH3), 49.3 (a-C), 38.1 (y-CH2, -VE DEPT),
30.8 (a-CH2, -VE DEPT), 24.7 (P-CH2, -VE DEPT), 18.6 (-CH3).
19F-NMR (376 MHz, DMSO): 8  -6 6 . 6  (dd, 2F, J 4 = 6 . 8  Hz, J 3 = 22.9 Hz), -78.5 (t, J  = 21.8 Hz), 
-86.7 - -8 6 . 8  (m, 2F).
7V-pentafluorobenzoyl-L-alanine-L-alanine methyl ester 140
L-Alanine methyl ester (0.56 g, 4 mmol) was used. Recrystallisation from ethyl acetate/hexane 
furnished 140 as a white powder (0.85 g, 58 %). 
m.p. = 188-190 °C. [a ] D25 = -34.1° (c, 3.0, EtOH).
Anal, calcd. for Ci4 H 13N 2 0 4 F5: C, 45.66; H, 3.56; N, 7.61.
Found C, 45.55; H, 3.27; N, 7.54.
IR (KBr): u 3299, 2961, 1740, 1643, 1560, 994 cm '1.
'H-NM R (400 MHz, DMSO): 8  9.17 (1H, d, J =  7.6 Hz, -NH-), 8.10 (1H, d, J - 7.2 Hz, -NH-),
4.52-4.59 (1H, m, a-H), 4.28-4.35 (1H, m, a-H), 3.64 (3H, s, -OCH3), 1.33 (3H, d, J =  3.2 Hz, - 
CH3), 1.31 (3H, d, J =  2.8 Hz, -CH3).
13C-NMR (100 MHz, DMSO): 8  173.2 (-CONH-), 171.5 (-COOCH3), 156.5 (-ArCO-), 144.6­
144.8 (m, -ArC 2), 140.3-142.8 (m, -ArC 4), 142.1-142.3 (-ArC 6 ), 138.3-138.5 (m, -ArC 3),
135.8-136.0 (m, -ArC 5), 112.7 (t, -ArC 1), 52.1 (-OCH3), 48.9 (a -Q , 47.9 (a-C), 18.4 (-CH3),
17.0 (-CH3).
19F-NMR (376 MHz, DMSO): -66.7 (dd, 2F, J 4 = 6 . 8  Hz, J 3 = 22.9 Hz), -78.4 (t, J =  21.8 Hz), 
-86.7 - -8 6 . 8  (m, 2F).
iV-pentafluorobenzoyl-L-alanine-L-leucine methyl ester 141
L-Leucine methyl ester (0.73 g, 4 mmol) was used. Recrystallisation from ethyl acetate/hexane 
furnished 141 as a white powder (0.9 g, 55%). 
m.p. = 140-142 °C. [a ] D 25 = -28.6° (c, 3.8, EtOH).
Anal, calcd. for C i7H 19N 20 4F5 : C, 49.76; H, 4.67; N, 6.83.
Found C, 49.72; H, 4.38; N, 6.80.
IR (KBr): d 3260, 2963, 1752, 1648, 1555, 995 cm '1.
'H-NM R (400 MHz, DMSO): 8  9.15 (1H, d, J -  7.6 Hz, -NH-), 8.43 (1H, d, J =  7.6 Hz, -NH-),
4.53-4.60 (1H, m, a-H), 4.31-4.35 (1H, m, a-H), 3.63 (3H, s, -OCH 3), 1.48-1.70 (3H, m, -CH2- &
143
-CH-), 1.30 (3H, d , J =  6 . 8  Hz, -CH3), 0.91 (3H, d , J =  6.4 Hz, -C tf3), 0.86 (3H, d, / =  6.4 Hz, - 
CHi).
13C-NMR (100 MHz, DMSO): 173.1 (-CONH-), 171.7 (-COOCH3), 156.5 (-ArCO-), 144.7­
144.8 (m, -ArC 2), 140.3-142.8 (m, -ArC 4), 142.2-142.3 (-ArC 6 ), 138.3-138.5 (m, -ArC 3),
135.8-136.0 (m, -ArC 5), 112.7 (t, -ArC 1), 52.1 (-OCH3), 50.6 (a-C), 48.9 (a-C), 40.0 (-CH2-, - 
VE DEPT), 24.5 (-CH-), 22.9 (-CH3), 21.5 (-CH3), 18.4 (-CH3).
19F-NMR (376 MHz, DMSO): 5 -66.7 (dd, 2F, J 4 = 6 . 8  Hz, J 3 = 22.9 Hz), -78.4 (t, J =  21.4 
Hz), -86.7 - -8 6 . 8  (m, 2F).
iV-pentafluorobenzoyl-L-alanine-L-phenylalanine methyl ester 142
L-Phenylalanine methyl ester (0.86 g, 4 mmol) was used. Recrystallisation from ethyl 
acetate/hexane furnished 142 as a white powder (0.6 g, 34%). 
m.p. = 184-186 °C. [<x] D 25 = -9.1° (c, 2.6, EtOH).
Anal, calcd. for C20H 17N 2O4 F5 : C, 54.09; H, 3.86; N, 6.30.
Found C, 54.10; H, 3.61; N, 6.15.
IR (KBr): u 3302, 2954, 1740, 1643, 1508, 995 cm '1.
‘H-NM R (400 MHz, DMSO): 9.13 (1H, d, J =  7.6 Hz, -NH-), 8.54 (1H, d, J =  7.6 Hz, -NH-), 
7.20-7.30 (5H, m, -Phif), 4.49-4.58 (2H, m, a -H), 3.59 (3H, s, -OCH3), 2.95-3.07 (2H, m, -CH 2- 
), 1.28 (3H, d, J -  6 . 8  Hz, -CHi).
I3C-NMR (100 MHz, DMSO): 172.0 (-CONH-), 171.7 (-COOCH3), 156.5 (-ArCO-), 144.5­
144.7 (m, -ArC 2), 140.3-142.8 (m, -ArC 4), 142.1-142.3 (-ArC 6 ), 138.3-138.5 (m, -ArC 3),
137.2 (-PhC 1), 135.8-136.0 (m, -ArC 5), 129.3 (-PhC 3 & 5), 128.6 (-PhC 2 & 6 ), 126.9 (-PhC
4), 112.7 (t, -ArC 1), 54.0 (a-C), 52.1 (-OCH3), 48.9 (a-C), 36.8 (-CH2-, -VE DEPT), 18.6 (- 
CH3).
19F-NMR (376 MHz, DMSO): -6 6 . 6  (dd, 2F, J 4 = 6 . 8  Hz, J 3 = 23.3 Hz), -78.3 (t, J - 21.8 Hz), 
-8 6 . 6  - -86.7 (m, 2F).
7V-pentafluorobenzoyl-L-alanine-L-valine methyl ester 143
L-Valine methyl ester (0.67 g, 4 mmol) was used. Recrystallisation from ethyl acetate/hexane 
furnished 143 as a white powder (0.8 g, 51%). 
m.p. = 152-154 °C. [a ] D 25 = -25.2° (c, 2.7, EtOH).
Anal, calcd. for C 16H 17N 2 0 4 F5 : C, 48.49; H, 4.32; N, 7.07.
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F ound  C, 4 8 .3 9 ; H , 4 .04 ; N , 6 .93 .
IR  (K Br): u  3 2 5 6 , 2 9 7 6 , 1751 , 1648 , 1508 , 9 9 4  cm '1.
'H -N M R  (4 0 0  M H z, D M SO ): 5 9 .1 7  (1H , d, J =  7 .2  H z, -N / / - ) ,  8 .2 9  (1H , d, J =  8 .0  H z, -NH-),
4 .6 2 -4 .6 7  (1H , m , a-H), 4 .2 0 -4 .2 4  (1H , m , a-H), 3 .63  (3H , s, -O C /ft) , 2 .0 4 -2 .0 9  (1H , m , -CH-),
1 .29  (3H , d, J= 7 .2  H z, -Q /ft) , 0 .9 0  (6H , t, J= 6.8 H z, -C /ft) .
13C -N M R  (1 0 0  M H z, D M SO ): 8 172.1 (-C O N H -), 172 .0  (-C O O C H 3), 156 .5  (-A rC O -), 1 4 4 .7 ­
144 .8  (m , -A rC  2), 1 4 0 .3 -1 4 2 .8  (m , -A rC  4 ), 1 4 2 .1 -1 4 2 .3  (-A rC  6), 1 3 8 .3 -1 3 8 .5  (m , -A rC  3),
1 3 5 .8 -1 3 6 .0  (m , -A rC  5), 112 .6  (t, -A rC  1), 5 7 .6  (<x-C), 52.1 (-O C H 3), 4 8 .9  (a -C ), 30 .2  (-C H -),
19.1 (-C H 3), 18.35 (-C H 3), 18.31 (-C H 3).
19F -N M R  (3 7 6  M H z, D M SO ): 8 -6 6 .7  (dd, 2F , J4 =  6.8 H z, J3 =  2 2 .6  H z), -7 8 .4  (t, J = 2 1 .8  H z), 
- 86.6 - -8 6 .7  (m , 2F).
A'-pentafluorobenzoyl-L-alanine-L-tryptophan methyl ester 144
L -T ryptophan m eth y l ester (1 .0 2  g , 4  m m ol) w as u sed . R ecrysta llisa tion  from  ethyl 
acetate /h exan e furnished 144 as a brow n p ow d er (0 .71  g, 37% ). 
m .p. =  1 7 4 -1 7 5  °C. [a ]D25 =  + 10 .1° (c, 1.8, E tO H ).
A nal, calcd . for C22H isN 304F5: C, 54 .66; H , 3 .75; N , 8 .69.
F ound  C, 5 4 .3 4 ; H , 3 .62; N , 8 .51 .
IR  (K Br): u  3 3 1 5 , 2 9 7 3 , 1736 , 1648 , 1508 , 995  cm ’1.
'H -N M R  (4 0 0  M H z, D M S O ): 10.91 (1H , b s, -NZT-), 9 .1 6  (1H , d, J= 7 .6  H z, -NH-), 8 .53  (1H , d, 
J= 7 .2  H z, -N /Z -), 7 .51  (1H , d, J= 8 .0  H z, - P h / /  1), 7 .35  (1H , d, J= 8 .0  H z, -PhH 4), 7 .20  (1H , 
d, J= 2 .0  H z, -C = C-H), 7 .0 8  (1H , t, J= 7 .2  H z, -P h f f2 ) ,  7 .0 0  (1H , t, J= 7 .2  H z, - P h / /3 ) ,  4 .5 5 ­
4 .6 3  (2H , m , a-H), 3 .5 8  (3H , s, -OCftft), 3 .1 2 -3 .2 3  (2H , m , -C /ft-) , 1.31 (3H , d, J =  6.8 H z, - 
C /ft) .
13C -N M R  (1 0 0  M H z, D M SO ): 8 1 7 2 .4  (-C O N H -), 171 .7  (-C O O C H 3), 156.5  (-A rC O -), 1 4 4 .7 ­
144 .8  (m , -A rC  2 ), 1 4 0 .3 -1 4 2 .6  (m , -A rC  4 ), 1 4 2 .1 -1 4 2 .3  (-A rC  6), 1 3 8 .3 -1 3 8 .5  (m , -A rC  3),
1 3 6 .4  (-C = C -H ), 1 3 5 .8 -1 3 6 .0  (m , -A rC  5), 127 .4  (-P hC  5), 124 .0  (-C = C -H ), 121 .3  (-P h C  2),
118 .7  (-P h C  3), 118 .3  (-P h C  4 ), 112 .6  (t, -A rC  1), 111 .7  (-P h C  1), 109 .4  (-P h C  6), 53 .5  (a -C ),
52 .1  (-OCH3), 4 8 .9  (a -C ), 27 .1  (-C H 2-, -V E  D E P T ), 18.3 (-C H 3).
19F -N M R  (3 7 6  M H z, D M SO ): 8 -6 6 .5  (dd, 2F ,J 4 = 6.8 H z, J 3 =  2 3 .3  H z), -7 8 .2  (t, 2 2 .5
H z), -8 6 .5  - -86.6 (m , 2F).
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7V-pentafluorobenzo,vl-L-alanmc-L-aspartic acid dimethyl ester 145
L-Aspartic acid dimethyl ester (0.79 g, 4 mmol) was used. Recrystallisation from ethyl 
acetate/hexane furnished 145 as yellow crystals (1.04 g, 61%). 
m.p. = 124-125 °C. [a ] D25 = -12.5° (c, 1.2, EtOH).
Anal, calcd. for C i6H 15N 2 0 6F5 : C, 45.08; H, 3.55; N, 6.57.
Found C, 44.99; H, 3.49; N, 6.72.
IR (KBr): u 3299, 2958, 1744, 1654, 1508, 994 cm '1.
‘H-NMR (400 MHz, DMSO): 6  9.18 (1H, d, J =  7.6 Hz, -NH-), 8.57 (1H, d, J= 8.0 Hz, -NH-), 
4.64-4.71 (1H, m, a-H), 4.53-4.59 (1H, m, a-H ), 3.63 (6 H, s, -O C //3), 2.74-2.87 (2H, m, -CH2-),
1.30 (3H, d , J  = 7.2 Hz, -CH3).
,3C-NMR (100 MHz, DMSO): 171.6 (-CONH-), 171.2 (-COOCH3), 170.7 (-COOCH3), 156.5 (­
ArCO-), 144.7-144.8 (m, -ArC 2), 140.3-142.8 (m, -ArC 4), 142.1-142.3 (-ArC 6 ), 138.3-138.5 
(m, -ArC 3), 135.8-136.0 (m, -ArC 5), 112.7 (t, -ArC 1), 52.4 (-OCH3), 51.9 (-OCH3), 48.9 (a­
C), 48.8 (a-C), 35.7 (-CH2:, -VE DEPT), 18.4 (-CH3).
19F-NMR (376 MHz, DMSO): 5 -66.7 (dd, 2F, J 4 = 6 . 8  Hz, J 3 = 22.9 Hz), -78.4 (t, J =  21.8 
Hz), -8 6 . 8  - -86.9 (m, 2F).
7V-pentailuorobenzoyl-L-alanine-L-methionine methyl ester 146
L-Methionine methyl ester (0.8 g, 4 mmol) was used. Recrystallisation from ethyl acetate/hexane 
furnished 146 as a light yellow powder (0.90 g, 52%). 
m.p. = 116-118 °C. [a ] D25 = -17° (c, 2.5, EtOH).
Anal, calcd. for C 16H 17N 2 O4 S 1F5 : C, 44.86; H, 4.00; N, 6.54.
Found C, 44.73; H, 3.78; N, 6.26.
IR (KBr): n 3299, 2973, 1743, 1648, 1522, 994 cm '1.
!H-NMR (400 MHz, DMSO): 9.18 (1H, d , J =  7.2 Hz, -NH-), 8.57 (1H, d, J  = 7.2 Hz, -NH-), 
4.43-4.56 (2H, m, a-H), 3.64 (3H, s, -OCH 3), 2.52 (2H, t, J =  7.0 Hz, -C tf2 S-), 1.88-2.04 (5H, m, 
-CH2- & -SCtf3), 1-30 (3H, d , J  = 6 . 8  Hz, -CH3).
13C-NMR (100 MHz, DMSO): 5 172.4 (-CONH-), 171.9 (-COOCH3), 156.5 (-ArCO-), 144.7­
144.8 (m, -ArC 2), 140.3-142.8 (m, -ArC 4), 142.1-142.3 (-ArC 6 ), 138.3-138.5 (m, -ArC 3),
135.8-136.0 (m, -ArC 5), 112.6 (t, -ArC 1), 52.3 (-OCH3), 51.2 (a-C), 49.0 (a-C), 30.8 (-CH2-, - 
VE DEPT), 29.7 (-CH2S-, -VE DEPT), 18.4 (-CH3), 14.8 (-SCH3).
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19F-NMR (376 MHz, DMSO): -6 6 . 6  (dd, 2F, J 4 = 6 . 8  Hz, J 3 = 22.9 Hz), -78.2 (t, J =  21.8 Hz), 
-8 6 . 6  - -86.7 (m, 2F).
General procedure fo r  the synthesis o f  N-fluorobenzoyl dipeptidyl nitriles 150-157 
./V-2-fluorobenzoyl-L-leucine-glycine nitrile 150
7V-2-fluorobenzoyl-L-leucine (1.01 g, 4 mmol) was dissolved in dichloromethane (50 ml) with 
glycine nitrile hydrochloride (0.37 g, 4 mmol), 1-hydroxybenzotriazole (0.54 g, 4 mmol) and 
triethylamine (0.56 ml). The mixture was cooled to 0 °C, and 1,3-dicyclohexylcarbodiimide 
(0.83 g, 4 mmol) was added. After 30 min. the solution was raised to room temperature and the 
reaction was allowed to proceed for 8  hrs. The precipitated N, iV-dicyclohexylurea was removed 
by filtration and the filtrate was washed with 1 0 % potassium hydrogen carbonate, 1 0 % citric 
acid, water and dried over magnesium sulphate. The solvent was evaporated in vacuo and 
recrystallisation from ethyl acetate/hexane furnished 150 as a white powder (0.81 g, 69%). 
m.p. = 91-92 °C. [a ] D 25 = -4.5° (c, 2.1, EtOH). .
Anal, calcd. for CisHjgNaChF,: C, 61.84; H, 6.23; N, 14.42.
Found C, 61.98; H, 6.18; N, 14.17.
IR (KBr): u 3277, 2961, 2372, 1637, 1534, 751 c m 1.
!H-NM R (400 MHz, DMSO): 5 8.78 (1H, t, J =  5.6 Hz, -NH-), 8.35 (1H, d, J =  7.6 Hz, -Nff-), 
7.60-7.65 (1H, m, -A rif 6 ), 7.51-7.56 (1H, m, -ArH 4), 1.26-1.34 (2H, m, -A tH 3  & 5), 4.48-4.53 
(1H, m, a-H ), 4.17 (2H, d , J  = 5.6 Hz, -CH2-), 1.47-1.72 (3H, m, -C H2- & -CH-), 0.90 (6 H, t, J  =
3.6 Hz, -CH3).
13C-NMR (100 MHz, DMSO): 8  172.9 (-CONH-), 164.2 (-ArCO-), 159.5 (d, -A rC2), 132.8 (d, - 
ArC 4), 130.5 (d, -ArC 6 ), 124.6 (d, -ArC 5), 124.0 (d, -ArC 1), 117.9 (-CN), 116.4 (d, -ArC 3),
51.7 (a -Q , 40.5 (-CH2-, -VE DEPT), 27.4 (-CH2-, -VE DEPT), 24.6 (-CH-), 23.3 (-CH3), 21.6 (-
ch3).
19F-NMR (376 MHz, DMSO): 5 -38.5 - -38.7 (m).
7V-4-fluorobenzoyl-L-leucine-glycine nitrile 151
vV-4-fluorobenzoyl-L-leucine (1.01 g, 4 mmol) and glycine nitrile hydrochloride (0.37 g, 4 mmol) 
were used. Recrystallisation from ethyl acetate/hexane furnished 151 as a white powder (0.75 g, 
64%).
m.p. = 138-139 °C. [a ] D 25 = -8 .6 ° (c, 2.2, EtOH).
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Anal, calcd. for C i5H 18N 3 0 2Fi: C, 61.84; H, 6.23; N, 14.42.
Found C, 61.72; H, 6.27; N, 14.29.
IR (KBr): u 3286, 3070, 2346, 1674, 1634, 1505, 854 c m 1.
•H-NMR (400 MHz, DMSO): 5 8.76 (1H, t, J =  5.6 Hz, -NH-), 8.43 (1H, d, J  = 8.0 Hz, -NH-), 
7.99-8.02 (2H, m, -ArH  2 & 6 ), 7.28-7.32 (2H, m, -ArH  3 & 5), 4.48-4.54 (1H, m, a-H), 4.14 
(2H, d, J  = 5.6 Hz, -CH2-), 1.52-1.76 (3H, m, -CH2- & -CH-), 0.90 (3H, d, J =  6.4 Hz, -C /i,), 
0.86 (3H, d, J =  6.0 Hz, -CH3).
13C-NMR (100 MHz, DMSO): 8  173.3 (-CONH-), 165.7 (-ArCO-), 164.3 (d, -ArC 4), 130.7 (­
ArC 1), 130.66 (-ArC 2), 130.62 (-ArC 6 ), 117.9 (-CN), 115.5 (-ArC 3), 115.2 (-ArC 5), 51.9 (a- 
Q , 40.2 (-CH2-, -VE DEPT) 27.4 (-CH2-, -VE DEPT), 24.7 (-CH-), 23.3 (-CH3), 21.5 (-CH3). 
19F-NMR (376 MHz, DMSO): 8  -33.8 - -34.0 (m).
7V-2-fluorobenzoyl-L-alanine-glycine nitrile 152
W-2-fluorobenzoyl-L-alanine (0.84 g, 4 mmol) and glycine nitrile hydrochloride (0.37 g, 4 mmol) 
were used. Recrystallisation from ethyl acetate/hexane furnished 152 as a white powder (0.55 g, 
55%).
m.p. = 109-111 °C. [a ] D 25 = -12.2° (c, 1.6, EtOH).
Anal, calcd. for C 12H 12N 3O2F 1: C, 57.83; H, 4.85; N, 16.86.
Found C, 57.91; H, 4.77; N, 16.56.
IR (KBr): u 3336, 2944, 2364, 1677, 1638, 1534, 758 cm’1.
‘H-NMR (400 MHz, DMSO): 8  8.71 (1H, t, J =  5.6 Hz, -NH-), 8.51 (1H, d, J =  6.4 Hz, -NH-),
7.67-7.71 (1H, m, -A r i / 6 ), 7.52-7.57 (1H, m, -A rif 4), 7.27-7.31 (2H, m, -A rif 3 & 5), 4.45-4.52 
(1H, m, a-H), 4.18 (2H, d, J  = 5.6 Hz, -CH2-), 1.33 (3H, d, J  = 7.2 Hz, -C //3).
,3C-NMR (100 MHz, DMSO): 8  173.0 (-CONH-), 163.8 (-ArCO-), 159.7 (d, -ArC 2), 133.0 (d, - 
A rC 4), 130.7 (d, -ArC 6 ), 124.7 (d, -ArC 5), 123.7 (d, -ArC 1), 117.9 (-CN), 116.4 (d, -ArC 3),
49.0 (a-C), 27.5 (-CH2-, -VE DEPT), 18.0 (-CH3).
19F-NMR (376 MHz, DMSO): 8  -38.4 - -38.6 (m).
A-pentafluorobenzoyl-L-alanine-glycine nitrile 153
iV-pentafluorobenzoyl-L-alanine (1.13 g, 4 mmol) and glycine nitrile hydrochloride (0.37 g, 3.16 
mmol) were used. Recrystallisation from ethyl acetate/hexane furnished 153 as a white powder 
(0.54 g, 42%).
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m.p. = 150-151 °C. [a ] D 25 = -16.8° (c, 2.4, EtOH).
Anal, calcd. for C i2H 8N 30 2F5 : C, 44.87; H, 2.51; N, 13.08.
Found C, 45.04; H, 2.44; N, 12.93.
IR (KBr): u 3293, 3061, 2258, 1662, 1523, 999 cm '1.
•H-NMR (400 MHz, DMSO): 5 9.30 (1H, d, J =  7.2 Hz, -NH-), 8 . 8 6  (1H, t, J  =  5.6 Hz, -NH-),
4 .4 7 .4 . 5 4  (1H, m, a -H), 4.20 (2H, d, J  = 5.6 Hz, -CH 2-), 1.30 (3H, d, J =  7.2 Hz, -CH 3). 
13C-NMR (100 MHz, DMSO): 5 172.2 (-CONH-), 156.6 (-ArCO-), 144.7-144.8 (m, -ArC 2), 
140.2-142.7 (m, -ArC 4), 142.1-142.3 (-ArC 6 ), 138.2-138.5 (m, -ArC 3), 135.8-136.0 (m, -ArC
5), 117.8 (-CN), 112.5 (t, -ArC 1), 48.9 (a-C), 27.4 (-CH2-, -VEDEPT), 18.1 (-CH3).
19F-NMR (376 MHz, DMSO): 5 -66.3 (dd, 2F, J A = 6 . 8  Hz, J 3 = 22.9 Hz), -77.9 (t, J -  15.4
Hz), -86.4 - -8 6 . 6  (m, 2F).
A-2-fluorobenzoyl-L-leucine-p-alanine nitrile 154
7V-2-fluorobenzoyl-L-leucine (1.01 g, 4 mmol) and P-alanine nitrile (0.28 g, 4 mmol) were used. 
Recrystallisation from ethyl acetate/hexane furnished 154 as a white powder (0.83 g, 6 8 %). 
m.p. = 84-85 °C. [a ] D25 = -8.3° (c, 1.2, EtOH).
Anal, calcd. for C 16H 2oN3 0 2 Fi: C, 62.94; H, 6.60; N, 13.76.
Found C, 63.31; H, 6.98; N, 13.40.
IR (KBr): u 3293, 2960, 2247, 1655, 1542, 755 cm '1.
:H-NMR (400 MHz, DMSO): 5 8.41 (1H, t, J =  5.6 Hz, -NH-), 8.37 (1H, d, J -  7.6 Hz, -NH-),
7.63-7.67 (1H, m, -A iH  6 )', 7.50-7.55 (1H, m, -A r//4 ), 7.25-7.30 (2H, m, -A rtf 3 & 5), 4.48-4.54 
(1H, m, a-H), 3.27-3.42 (2H, m, p-CH2), 2.66 (2H, t, 6.0 Hz, a-CH 2), 1.51-1.71 (3H, m, - 
CH2- & -CH-), 0.92 (3H, d, 6.0 Hz, -G if,), 0.90 (3H, d, J =  6.0 Hz, -CH3).
13C-NMR (100 MHz, DMSO): 5 172.6 (-CONH-), 163.9 (-ArCO-), 159.5 (d, -ArC 2), 132.8 (d, - 
ArC 4), 130.6 (d, -ArC 6 ), 124.6 (d, -ArC 5), 124.0 (d, -ArC 1), 119.4 (-CN), 116.4 (d, -ArC 3),
52.0 (a-C), 41.1 (-CH2-, -VE DEPT), 35.2 (p-CH2, -VE DEPT), 24.6 (-CH-), 23.3 (-CH3), 21.8 (- 
CH3), 17.8 (a-CH2, -VE DEPT).
19F-NMR (376 MHz, DMSO): 8  -38.6 - -38.7 (m).
7V-4-fluorobenzoyl-L-leucine-P-alanine nitrile 155
jV-4-fluorobenzoyl-L-leucine (1.01 g, 4 mmol) and P-alanine nitrile (0.28 g, 4 mmol) were used. 
Recrystallisation from ethyl acetate/hexane furnished 155 as a white powder (0.64 g, 53%).
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m.p. = 119-120 "C. [a]o25 = -17.5° (c, 1.5,EtOH).
Anal, calcd. for C i6H 2oN30 2Fi: C, 62.94; H, 6.60; N, 13.76.
Found C, 63.14; H, 6 .8 6 ; N, 13.62.
IR (KBr): x> 3326, 2957, 2249, 1649, 1604, 1502, 847 cm '1.
'H-NM R (400 MHz, DMSO): 8  8.53 (1H, d, J =  8.4 Hz, -N/7-), 8.36 (1H, t, J  = 8.0 Hz, -NH-),
7.97-8.01 (2H, m, -ArH  2 & 6 ), 7.27-7.32 (2H, m, -ArH  3 & 5), 4.45-4.50 (1H, m, a -H), 3.25­
3.36 (2H, m, p-CH2), 2.64 (2H, t, J =  6.0 Hz, a -CH2), 1.52-1.74 (3H, m, -CH2- & -CH-), 0.90 
(3H, d, J =  6.0 Hz, -CH3), 0.87 (3H, d, J =  6.0 Hz, -CH 3).
13C-NMR (100 MHz, DMSO): 8  173.1 (-CONH-), 165.6 (-ArCO-), 164.3 (d, -A rC 4), 130.8 (d, - 
A rC  1), 130.6 (-ArC 2), 130.5 (-ArC 6 ), 119.5 (-CN), 115.5 (-ArC 3), 115.3 (-ArC 5), 52.1 (a­
C), 40.7 (-CH2-, -VE DEPT) 35.1 (P-CH2, -VE DEPT), 24.7 (-CH-), 23.3 (-CH3), 21.6 (-CH3),
17.8 (a-CH2, -VE DEPT).
19F-NMR (376 MHz, DMSO): 8  -34.0 - -34.1 (m).
7V-2-fluorobenzoyl-L-alauine-(i-alii]iine nitrite 156
A^-2-fluorobenzoyl-L-aIanine (0.84 g, 4 mmol) and P-alanine nitrile (0.28 g, 4 mmol) were used. 
Recrystallisation from ethyl acetate/hexane furnished 156 as a white powder (0.51 g, 49%). 
m.p. = 127-128 °C. [a ] D25 = -11.3° (c, 1.8, EtOH).
Anal, calcd. for G 3H 14N 3O2F 1: C, 59.31; H, 5.36; N, 15.96.
Found C, 59.72; H, 5.67; N, 15.69.
IR (KBr): u 3376, 3278, 2250, 1677, 1648, 1542, 901 cm '1.
!H-NMR (400 MHz, DMSO): 8  8.36-8.39 (2H, m, -NH-), 7.68-7.72 (1H, m, -ArH  6 ), 7.51-7.56 
(1H, m, -ArH  4), 7.27-7.31 (2H, m, -ArH  3 & 5), 4.44-4.48 (1H, m, a-H), 3.27-3.41 (2H, m, p- 
CH2), 2.66 (2H, t, J =  6.4 Hz, a-CH2), 1.33 (3H, d, J =  1 2  Hz, -CHi).
13C-NMR (100 MHz, DMSO): 8  172.7 (-CONH-), 163.4 (-ArCO-), 159.7 (d, -ArC 2), 133.0 (d, - 
A rC  4), 130.7 (d, -ArC 6 ), 124.7 (d, -ArC 5), 123.6 (d, -ArC 1), 119.4 (-CN), 116.4 (d, -ArC 3),
49.1 (a-C), 35.1 (p-CH2, -VE DEPT), 18.6 (-CH3), 17.8 (a-CH2, -VE DEPT).
19F-NMR (376 MHz, DMSO): 8  -38.5 - -38.6 (m).
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7V-pentafluorobenzoyl-L-alanine-f3-alanine nitrile 157
jV-pentafluorobenzoyl-L-alanine (1.13 g, 4 mmol) and P-alanine nitrile (0.28 g, 4 mmol) were 
used. Recrystallisation from ethyl acetate/hexane furnished 157 as a white powder (0.71 g, 53%). 
m.p. = 150-152 °C. [a ] D25 = -13.6° (c, 2.3, EtOH).
Anal, calcd. for CuHuNsC^Fs: C, 46.57; H, 3.01; N, 12.54.
Found C, 46.92; H, 3.23; N, 12.33.
IR (KBr): u 3365, 3274, 2252, 1672, 1626, 1522, 992 cm '1.
‘H-NMR (400 MHz, DMSO): 5 9.19 (1H, d, J =  7.6 Hz, -N//-), 8.48 (1H, t, J =  5.6 Hz, -NH-), 
4.45-4.53 (1H, m, a-H ), 3.26-3.45 (2H, m, p-CH2), 2.62-2.70 (2H, m, a-CH2), 1.31 (3H, d, J  =
7.2 Hz, -CH 3).
13C-NMR (100 MHz, DMSO): 5 171.9 (-CONH-), 156.5 (-ArCO-), 144.6-144.8 (m, -ArC 2), 
140.1-142.6 (m, -ArC 4), 142.1-142.3 (m, -ArC 6 ), 138.3-138.5 (m, -ArC 3), 135.8-136.0 (m, - 
A rC 5), 119.4 (-CN), 112.7 (t, -ArC 1), 49.2 (a-C), 35.1 (P-CH2, -VE DEPT), 18.7 (-CH3), 17.8 
(a-CH2, -VE DEPT).
19F-NMR (376 MHz, DMSO): 8  -66.4 (dd, 2F, J  4 = 6 . 8  Hz, J 3 = 23.3 Hz), -78.2 (t, J  = 15.8 
Hz), -8 6 . 6  - -86.7 (m, 2F).
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Chapter 4
Dipeptidyl phosphonate diphenyl esters as inhibitors of the serine protease
bovine pancrease a-chymotrypsin
4.1 In tro d u c tio n
Serine proteases have been implicated in a number o f pathological conditions, 
including rheumatoid arthritis, tum our metastasis and neurodegenerative diseases . 1 The 
involvement o f  serine proteases in proteolysis associated w ith these diseases has led to the 
design o f synthetic inhibitors as therapeutic agents. Traditional inhibition has been based on 
the design o f inhibitors w ith electrophilic warheads that alkylate the serine hydroxyl o f the 
active site. This theory has resulted in successful inhibition although some inhibitors have 
shown some adverse effects . 2 a-Chymotrypsin (a-CT) is the m ost well studied serine protease 
whose structure and catalytic mechanism have been well established .3 The active site o f a-CT 
contains a large hydrophobic pocket in  the SI subsite that prefers to accommodate a PI 
residue having a bulky hydrophobic side chain such as phenylalanine or tryptophan. a-CT has 
served as a prototypical enzyme for a large family o f  enzymes and has been very useful as a 
model target enzyme for the development o f design strategies that can be applied for other 
serine proteases o f  pharmacological interest. Consequentially a vast number o f a-CT 
inhibitors have been reported .4
il  /  S
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Serine protease inhibitors containing phosphorus have been known as potent
inhibitors for over eighty years. The organophosphorus compound 
diisopropylfluorophosphate (DFP) 44 is historically one o f the m ost widely used serine 
protease inhibitors . 5 Compound 44 is an extremely toxic compound that phosphorylates the 
active site serine hydroxy group due to the electrophilicity o f the phosphorus induced by the 
adjacent fluorine atom. The phosphorylated enzymes are good transition-state analogues due 
to the presence o f a tetrahedral phosphorus centre, similar to that formed between peptides 
and enzymes. DFP reacts less rapidly w ith trypsin-like serine proteases than the a- 
chymotrypsin-like enzymes. The toxicity o f  DFP and its instability in aqueous media limits
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its practical use as a protease inhibitor . 6 Compound 44 is considered to be a general serine 
inhibitor w ith poor selectivity towards individual enzymes. It cannot discriminate between 
various serine proteases as it lacks a peptidyl moiety and hence it does not possess structural 
similarity to natural peptide substrates. Various analogues o f DFP have been developed 
including the nerve gas sarin 158. Peptidyl analogues o f 44 did improve specificity but 
unwanted alkylation was still prevalent. 7
The study o f  phosphorus analogues o f  the natural a-am ino acids began in the late 
forties and due to recent discoveries o f  biologically active compounds interest in this area has 
increased dramatically . 8 Diphenyl esters o f a-aminoalkylphosphonic acids have been shown 
to be particularly potent and selective inhibitors o f  various serine proteases . 9 These 
derivatives are generally non-toxic and stable in plasma. They have advantageously been 
shown to be unreactive w ith nitrogen nucleophiles . 10 Peptidyl a-aminoalkylphosphonate
» • • • • • 7 .diphenyl esters have been shown to inhibit various a-chymotrypsin like enzymes. The 
inhibition o f  serine proteases involves nucleophilic substitution on the phosphorus atom by 
the oxygen atom o f the catalytic Seri 95 residue in the active site o f the protease. The 
substitution proceeds through a penta-coordinate phosphorus transition state to give a stable 
irreversible tetrahedral monophenoxyphosphonyl derivative. X-ray structural studies have 
shown that the second phenoxy group is hydrolysed during an ageing process . 11
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F igu re  4.1 M echanism o f inhibition for peptidyl a-aminoalkylphosphonate diphenyl esters
The prodrug potential o f  phosphonate esters has been the subject o f  much 
discussion . 12 Numerous potent phosphonate ester derivatives have been developed that show 
a hydrolysed phosphate analogue is responsible for the biological activity o f  the compound.
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Phosphonic acids usually have a low pKa value between 1 and 2 . 12 W hen they are subjected 
to the physiological pH range o f 7-7.4 phosphates are deprotonated and therefore negatively 
charged. These negatively charged species repel other nucleophilic or negatively charged 
compounds due to Coulombic interactions. This results in phosphates being extremely stable
• ■ 13against non-enzymatic hydrolysis with half-lives in the range o f hundreds o f years. 
Phosphates are generally unable to penetrate cellular membranes unless active transport is 
involved. Therefore phosphates serve as functional units that prevent spreading o f the 
chemical signal from one cell to another.
Chemists have created masking groups such as phenyl esters to allow the delivery of 
phosphates to the interior o f the cell and to increase bioavailability . 14 The resulting non­
charged species are usually able to diffuse across the membrane. Once inside the cells, the 
masking groups are removed by chemical or enzymatic hydrolysis regenerating the charged 
phosphate species making the molecule impermeable to cell membranes and biologically 
active. Masking groups for the negative charged species o f phosphate that are cleaved by 
intracellular enzymes but stable outside cells are o f particular interest to medicinal chemists. 
The principal o f  prodrug action requires sufficient stability o f  the masked compound to 
ensure the cells or tissue being investigated are being reached. The design o f enzyme 
activating protecting groups should ensure that these groups are unaffected by enzymes in 
plasma, blood or other body fluids. Once the phosphonate bearing compounds enter cells, the 
masking groups should be rapidly broken down by endogenous intracellular enzymes 
predominantly esterases or more rarely by phosphodiesterases or reductases.
M ost bioactivatable masking groups release more or less toxic compounds upon 
degradation but m ost cells are equipped to maintain a stable pH. It is the liberation o f 
formaldehyde that usually raises concern due to its potentially carcinogenic properties . 15 
Diaryl phosphonates can be viewed as mildly activated esters o f phosphonic acids. They 
should undergo more facile hydrolysis than the corresponding dialkyl phosphonates. The 
overall rate o f hydrolysis is crucial for them  to perform as efficient phosphonic acid prodrugs. 
A  diphenyl phosphonate has been hydrolysed rapidly with sodium hydroxide and slowly in 
strongly acidic medium. The resulting species was not the expected dianion species but in 
fact the monophenyl phosphonate . 16 The synthesis o f  dipeptidyl diphenyl phosphonate esters 
not only offers a possible route to serine protease inhibition but also the incorporation o f a 
masked phosphate group that increases the bioavailability and cellular specificity o f the 
potential therapeutic agent.
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4.2 Synthesis and structural characterisation o f diphenyl-a-am ino phosphonates
a-Aminoalkyl phosphonate esters can be broadly defined as analogues o f a-amino 
acids in which the COOH group is replaced w ith PO(OR ) 2  and have received considerable 
interest due to the occurrence o f analogous derivatives in nature. The discovery o f 2- 
aminoethanephosphonic acid (AEP) in sheep rum en protozoa in 1959 was a seminal 
discovery . 17 This was the first example o f a naturally occurring aminophosphonate and is 
both the simplest and m ost common o f the natural aminophosphonates. Early studies on 
naturally occurring aminophosphonates were hindered due to the absence o f  sensitive 
methods for the detection o f  the C-P bond. This has been overcome with the use o f 31P N M R 
studies. The synthesis o f dipeptidyl a-am inophosphonates has generated potent inhibitors o f
aminopeptidases and serine proteases. 18
R = CH3, Ph or CH2Ph
P(OPh)
Scheme 4.1 Synthesis o f  diphenyl-a-am ino phosphonates
The diphenyl-a-aminoalkyl phosphonates 159-161 were prepared in a method 
analogous to Oleksyszyn . 19 Triphenyl phosphite, benzyl carbamate and an aldehyde were 
reacted together in the presence o f acetic acid via a Michaelis-Arbuzov reaction to give a 
racemic TV-protected diphenyl ester. Yields o f  this reaction varied between 40 and 60 %. The 
protected amino group was then deprotected using hydrogen bromide in acetic acid solution. 
Removal o f the benzyloxycarbonyl group was practically quantitative. Although the overall 
yields o f the diphenyl-a-aminoalkyl phosphonates were modest, their synthesis is easily 
achieved in two steps giving pure compounds. The majority o f reported methods involve the
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synthesis o f a phosphonic acid derivative. The a-aminophosphonic acids are generally
prepared by hydrolysis
conditions. Improved
o f the diethyl phosphonate ester analogues .20 Diethyl-a-amino
phosphonate esters have recently been synthesised from reactions involving solvent-free
yields have been reported using acidic alumina w ith microwave 
irradiation .22 The separation o f  enantiomers was not deemed essential. Firstly, the a- 
aminophosphonates are to be coupled to achiral amino acid derivatives yielding racemates. 
Characterization o f  these dipeptidyl derivatives w ill not be hindered by their racemic nature. 
Secondly the most important aspect o f  this research is to assess the biological activity o f 
these compounds. It was decided that i f  a particular compound resulted in potent inhibition in 
the nanom olar range the racemates would be then separated. It was considered highly 
unlikely that one enantiomer would have an antagonistic effect on the inhibitory potency o f 
the other enantiomer. The reason the phosphorus analogues o f phenylglycine and 
phenylalanine were synthesised was due to the affinity o f  a-chymotrypsin for a bulky 
aromatic side chain in the P I position. The alanine analogue was not only prepared to further 
demonstrate this fact but also to reveal that the electrophilic phosphonate ester moiety does 
have a role to play in the inhibition o f serine proteases.
T ab le  4.1 Diphenyl-a-amino phosphonates
C om pound R %  Y ield 31P  N M R  ô ppm
(D, Z)-Phenylglycinep-(OPh ) 2 159 - c 6h 5 59 11.53, d
(D, Z)-Phenylalaninep-(OPh ) 2 160 - c h 2 c 6h 5 43 14.51, m
(A  Z)-Alaninep-(OPh ) 2 161 - c h 3 41 15.72, m
The a-am inophosphonates show a distinctive pattern in the 31P N M R spectra (Table 
4.1). The phenylalanine and alanine derivatives appear as multiplets due to coupling o f  the 
phosphorus nucleus w ith the nearby protons. The phenylglycine analogue with only one
• * 1 3 1 'proton in proximity o f  the phosphorus atom appears as a doublet with a H- P coupling
constant o f  ~ 21 Hz. The chemical shift o f  these peaks is dependent on the side chain
» 1 1
substituent w ith the methyl group giving the m ost downfield shift. The C N M R spectra o f 
these derivatives show the a-carbon atoms appearing as a doublet with coupling constants 
ranging from  156 to 158 Hz. The effect o f 3 1P-13C coupling is also seen on the methyl group 
o f  the alanine derivative and the methylene group o f  the phenylalanine analogue. The IR 
spectra o f these derivatives show a strong P = 0  band at 1275 cm ' 1 and amino N-H stretching 
at 3100 cm’1.
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4.3 Dipeptidyl phosphonate diphenyl esters
4.3.1 Synthesis and structural characterisation of A'-4-fluorobenzenesulphonyl 
dipeptidyl phosphonate diphenyl esters
The series o f  pharmaceuticals known as the sulphonamides have been one o f the 
greatest success stories in medicinal chemistry. The 4-fluorobenzenesulphonyl moiety has 
been previously described as an efficient TV-terminal substitution for potent protease 
inhibition .23 Its success can be explained by two reasons. Firstly the fluorobenzenesulphonyl 
group has an electrophilic centre at the sulphur atom. This centre is strongly electrophilic due 
to the electron withdrawing nature o f  the two attached oxygen atoms. This centre has the 
ability to act as a target for the active site serine residue o f serine proteases such as a- 
chymotrypsin and trypsin. Secondly, it has also been shown that the SO2 moiety o f  such 
inhibitors is involved in several strong hydrogen bonds w ith amino acid residues in the active 
site that can strongly stabilize the enzyme-inhibitor adduct.24  The geometry o f the sulphonyl 
group gives a unique configuration unattainable by the planar amide bond.
Scheme 4.2 Synthesis o f iV-4-fluorobenzenesulphonyl amino acids
The first step o f the synthesis involves the preparation o f  AM-fluorobenzenesulphonyl 
derivatives incorporating the amino acids glycine, P-alanine and y-aminobutyric acid. This 
step is carried out in  the presence o f  NaOH and is analogous to the Schotten Baumann 
reaction .25 The presence o f a fluorine atom allowed the progress o f  the reaction to be 
m onitored by 19F NM R. The starting material 4-fluorobenzenesulphonyl chloride gave a 
m ultiplet centred at 8 -37 .4  w hereas the amino acid derivatives gave a multiplet centred at 8  - 
31.7. Yields o f  up to 80% were recorded for the synthesis o f the jV-4-fluorobenzenesulphonyl 
amino acid derivatives that w ere in accordance w ith the literature . 26 The synthesis o f  these 
compounds is confirmed by the presence o f  a triplet at ~ 8  8.1 in the *H N M R spectrum due 
to the sulphonyl amide proton. The aromatic protons o f the benzenesulphonyl moiety appear 
as multiplets between 8  7 and 8  due to ^ F - 'H  intemuclear coupling. The Infrared spectra 
show a distinct peak at 1675 cm ' 1 due to the amide carbonyl. A  strong band at 1155 cm ' 1 is 
responsible for the sulphonamide moiety in the Infrared spectra.
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Schem e 4.3 Synthesis o f AM-fluorobenzenesulphonyl dipeptidyl phosphonate esters
The dipeptidyl phosphonate diphenyl ester derivatives were prepared using standard 
EDC/HOBt protocol. The dipeptides were purified by an acid w ater wash cycle followed by 
recrystallisation from diethyl ether. The yields ranged from 29 to 61 %  (Table 4.2). The 
highest yield recorded was for the alanine derivatives. This is probably due to steric factors as 
the methyl group o f the alanine derivative is considerably smaller than the phenyl or benzyl 
groups o f  phenylglycine and phenylalanine respectively.
The iV-4-fluorobenzenesulphonyl dipeptidyl phosphonate esters (Table 4.2) are 
characterised by a multiplet at 5 ~ -31.7 in the l9F NM R spectra. This appears as a multiplet 
as the fluorine atom has the ability to interact w ith each o f the four protons present on the 
aromatic ring. The 13C NM R spectra o f these compounds show a distinctive peak at 8  ~ 167 
that represents the amide carbonyl formed by the coupling reaction. Electrospray ionisation 
mass spectrometry (ESIMS) carried out on these compounds gave two distinct peaks. The 
sodium adduct peak was present at molecular ion + 23 mass units while the potassium adduct 
appeared at m /z molecular ion + 39 mass units.
T ab le  4.2. 7V-4-fluorobenzenesulphonyl dipeptidyl phosphonate ester derivatives
C om pound n R %  Y ield 31P N M R  8  ppm
162 1 - c 6h 5 29 14.83, d
163 2 - c 6h 5 35 15.12, d
164 3 - c 6h 5 29 15.35, d
165 1 - c h 2 c 6h 5 45 17.65, t
166 2 - c h 2c 6h 5 36 17.81, t
167 3 - c h 2 c 6 h 5 33 18.24, t
168 1 - c h 3 59 19.30, m
169 2 - c h 3 61 19.57, m
170 3 - c h 3 50 19.79, m
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4.3.2 *H NM R Study of iV-4-fluorobenzenesulphonyl dipeptidyl phosphonate esters
The 'H N M R  spectrum o f AL4-fluorobenzenesulphonyl-Gly-(D, Z)-Alap-(OPh) 2  168 is 
shown in Figure 4.2. The effect o f ^ F ^ H  and 3 IP-*H coupling is seen throughout the spectra 
o f  the AM-fluorobenzenesulphonyl dipeptidyl phosphonate esters. The amide protons appear 
at 5 - 8 . 6  and 5 -8 .1  as a doublet and triplet respectively. The aromatic region o f the spectrum 
shows the peaks responsible for the phenyl ester protons and the hydrogen atoms present on 
the 4-fluorophenyl rings. The coupling pattern o f these protons is complicated due to 
coupling w ith nearby phosphorus and fluorine atoms. The a-H  is present at 5 -4 .6  as a 
m ultiplet due to coupling w ith the amide proton, the side chain and also the phosphorus atom 
o f the phosphonate moiety. The methylene group o f  glycine appears as two double doublets 
at 5 -3 .5  and 5 -3 .6  w ith coupling constants o f -5 .6  and -1 6 .4  Hz.
ppm
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Figure 4.2 ]H N M R o f iV-4-fluorobenzenesulphonyl-Gly-(A Z)-Alap-(OPh ) 2  168.
This coupling is due to the diastereotopic nature o f these protons and corresponds to coupling 
between the two methylene protons and further coupling between the methylene protons and 
the amide proton. The methyl side chain o f the phosphorus analogue o f alanine appears at 5 
-1 .4  as a double doublet also. This methyl group couples w ith the a-H  to give a coupling 
constant o f  7.2 Hz. The methyl protons also couple w ith the phosphorus atom three bonds
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away. This 31P-1H coupling gives a coupling constant o f 18.0 Hz. There is a water peak found 
at -3 .5  ppm  due to H20  in the DMSO. Suppression o f the water peak also suppressed the 
methylene protons o f glycine. It should be noted that the chemical shift o f the a-H  is 
dependent on the side chain substituent. In the case o f the phenylglycine derivatives the a-H 
appears downfield as a double doublet 5 - 5 .9 0  due to the electron withdrawing effect o f the 
phenyl moiety attached. It appears as a double doublet as the a-H  couples w ith the amide 
proton and also the phosphorus atom.
Table 4.3 Selected !H N M R  data (5) for the AM-fluorobenzenesulphonyl dipeptidyl 
phosphonate esters
Compound No. NH NH a-H -c h 2-
162 9.35 8.14 5.81 3.75, 3.63
164 9.33 6.91-7.83 5.92 2.71-2.76,2.27, 1.60-1.66
166 8.73 7.15-7.85 4.71-4.81 2.69,2.16-2.22
168 8 . 6 6 8.16 4.62-4.71 3.68, 3.54
170 8.69 7.13-7.91 4.71-4.78 2.93-3.00, 2.32-2.43
4.3.3 Synthesis and structural characterisation o f A'-cinnamoyl dipeptidyl phosphonate 
diphenyl esters
TV-terminal cinnamoyl dipeptidyl derivatives have been reported as potent inhibitors o f 
the protease papain .27 The design o f  such M ichael acceptors is based on the fact that the 
active site nucleophile may attack the strongly electrophilic P-carbon o f  the unsaturated unit, 
leading to irreversible covalent bonding to the active site o f the enzyme. The concept o f 
extending greater distances from  the NH 2  term inal amide with conformational restraint has 
resulted in enhanced potency due to additional favourable interactions that are unavailable to 
shorter N H 2 -term ini . 28
The synthesis o f  TV-cinnamoyl amino acid derivatives was carried out in two steps. 
Cinnamoyl chloride was reacted w ith glycine, P-alanine and y-amino butyric acid methyl 
esters in the presence o f  triethylamine to yield 7V-cinnamoyl amino acid esters in yields 
between 57 and 75 %. The esters were then hydrolysed using potassium  carbonate to give the 
free acid moiety. Alternatively, the synthesis o f  iV-cinnamoyl amino acid derivatives was 
carried out by the one step Schotten-Baumann  reaction w ith the free amino acid. However the 
yields obtained were less than 30 %. This low yield was due to the fact that the cinnamoyl 
chloride w as also attacked by the amino acid to form cinnamoyl anhydride derivatives.
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The synthesis o f  the dipeptidyl derivatives was achieved using the standard 
EDC/HOBt protocol. Yields ranged from  15 to 55 %. Although these yields were very 
m odest the purity o f  the compounds was very high as shown by N M R  studies. The highest 
yield was for iV-cinnamoyl-P-Ala-(A Z)-Alap-(OPh ) 2  178 which gave a  value o f  55%. The 
lowest yield recorded was for the phenylglycine derivative compound 172. The low yield o f 
this compound was also observed in the synthesis o f  the 4-fluorobenzenesulphonyl 
derivatives.
Table 4.4 jV-cinnamoyl dipeptidyl phosphonate ester derivatives
Compound n R % Yield 31P NM R 5 ppm
171 1 - c 6h 5 32 15.15, d
172 2 - c 6h 5 15 15.30, d
173 3 - c 6h 5 37 15.39, d
174 1 - c h 2 c 6h 5 37 17.99, t
175 2 -CH 2 C6Hs 45 18.19, t
176 3 - c h 2 c 6h 5 36 18.26, t
177 1 - c h 3 53 19.61, m
178 2 - c h 3 55 19.75, m
179 3 - c h 3 49 19.85, m
163
The 'H  N M R spectra o f  these compounds show the unsaturated unit appearing as two 
doublets at 5 -6 .7  and 5 -7 .9  w ith coupling constants o f  -  15.6 Hz. In some cases, the 
protons o f the cinnamoyl double bond are obscured by the aromatic protons o f  the phenyl 
esters. The protons o f  the amide bonds formed between the cinnamoyl group and the amino 
acid appears downfield at -8 .5  due to two factors. Firstly there is the deshielding effect o f the 
cinnamoyl system that shifts the chemical shift to a lower field and secondly there is the 
effect o f  using deuterated dimethyl sulphoxide as solvent. The additional hydrogen bonding
31properties o f  DM SO-d6 makes the amide proton resonate at a lower field. The P N M R 
spectra o f the cinnamoyl derivatives show an interesting pattern. The chemical shift o f the 
phosphorus atom is influenced by the amino acid bonded to the a-aminophosphonate. The
more methylene units that are present in the attached amino acid the more downfield the
11
phosphorus signal appears. This shows the sensitivity o f  J,P N M R spectroscopy as an 
analytical tool as the attached amino acid derivatives are at least three bonds away and often 
further. The TV-cinnamoyl dipeptidyl phosphonate esters 174, 175 and 176 appear as triplets 
in the 31P NM R. This result is due to coupling o f  the phosphorus atom w ith two protons and
is unique to  the phenylalanine containing derivatives. Although the amide bond protons are
• 3 1 1also only two bond lengths from the phosphorus atom, there is no evidence o f P- H 
coupling between the amide protons and phosphorus atom occurring in  174 ,175  or 176. The 
Infrared spectra o f these compounds show the characteristic amide carbonyl stretching at 
-1675  and -1 5 9 0  cm '1. N -H  stretching o f  the amides is seen as a broad band at -3265 cm '1. 
The phosphonate P = 0  band is located as a broad peak at -1270  cm '1.
4.3.4 13C N M R  study o f JV-cinnamoyl dipeptidyl phosphonate esters
The 13C N M R spectrum o f  compound 175 is shown in Figure 4.3. The two amide 
carbon atoms appear at 8  -1 7 0  and 8  -165 . The ipso carbons o f the phenyl esters show a 
distinctive pattern. The two phenyl rings come into resonance at slightly different frequencies 
and each appear as a doublet due to the effect o f  13C-31P coupling in the NM R. The downfield 
location o f  these carbon peaks is due to the electron deshielding effect o f the attached oxygen 
atom. The remaining aromatic carbons appear between 8 - 1 3 7  and 8  -120 .7  as a series o f 
singlets and doublets due to the effects o f  13C-31P intemuclear coupling. There is a substantial 
difference between the chemical shifts o f  the unsaturated unit carbons. The a-carbon is 
present at 5 -138 .9  and the (3-carbon o f  the unsaturated is seen at 8  -122 . The a-carbon is 
further downfield due to the attached deshielding carbonyl moiety.
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Figure 4.3 13C N M R  o f iV-cinnamoyl-P-Ala-fD, Z)-Phep-(OPh ) 2  175.
31The a-carbon o f  the phenylalanine derivative 175 appears as a doublet at 8  ~  47 with a P- 
13C coupling constant o f  -156.5  Hz. The methylene groups o f  fi-Ala appear as two singlets at 
8  35.5 and 8  35.3 and this was confirmed from analysis o f  the DEPT135 spectra. Finally the 
side chain methylene group o f phenylalanine is found as a doublet at 5 -34 .7  as it is only 
three bonds from  the phosphorus atom. On the other hand, in the case o f  the phenylglycine 
and alanine analogues the a-carbons appear at 8  -5 0 .4  and 8  -41 .6  respectively with similar 
coupling constants. The methylene groups o f  y-aminobutyric acid appear at 8  -42 .5 , 8  -32 .4  
and 8  -25 .6  w ith the methylene group attached to the amino group appearing the furthest 
downfield. The presence o f a racemic m ixture was undetectable by C NMR.
Table 4.5 Selected 13C N M R  data (8 ) for the JV-cinnamoyl dipeptidyl phosphonate esters
Compound No. c=o C—O \rvi -OPhC,/;v„ c=c a-C
171 169.4 165.7 150.3, 150.1 139.5, 122.1 50.4
173 172.2 165.3 150.4, 150.1 138.9, 122.5 50.3
175 170.7 165.3 150.4, 150.1 138.9, 122.5 47.2
177 169.0 165.6 150.4, 150.1 139.4, 122.2 41.6
179 172.0 165.4 150.4, 150.2 139.0, 122.5 41.2
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4.3.5 Synthesis and structural characterisation o f iV-trifluoroacetyl dipeptidyl 
phosphonate diphenyl esters
The trifluoroacetyl moiety has been shown to be an effective TV-terminal substituent in 
potent protease inhibitors .29  The trifluoroacetyl moiety gives a powerful electrophilic 
substituent that may undergo attack by the serine residue o f the a-chymotrypsin active site. 
The trifluoroacetyl group has been shown to be an effective protecting group for TV-terminal 
amino acids and is easily removed by strong acid . 29 This indicates that these derivatives may 
undergo hydrolysis in vivo to yield free amino dipeptidyl phosphonate esters.
The TV-trifluoroacetyl amino acids were synthesised according to the procedure o f 
Giordano et a l .30 The amino acid was added to trifluoroacetic anhydride at 0 °C and then the 
reaction was heated at 80 °C for 1 hour. The excess trifluoroacetic acid and trifluoroacetic 
anhydride w ere removed to yield 7V-trifluoroacetyl-glycine and [5-alanine derivatives as 
crystalline solids. Previous syntheses o f trifluoroacetyl amino acids have used trifluoroacetyl 
chloride but due to its gaseous nature this was not utilised. The synthesis o f  TV-triflouroacetyl- 
y-aminobutyric acid using trifluoroacetic anhydride has not been previously described 
although success has been achieved with trifluoroacetic methyl ester . 31 Our attempts to 
synthesise this compound resulted in a series o f  oily mixtures. The amino acid derivative was 
synthesised but in very low yield. This was seen from the 19F N M R spectra o f this reaction. 
All attempts to remove the acetic acid/anhydride byproducts resulted in a viscous oil. W hen 
this oil was coupled with the diphenyl-a-amino phosphonates there was no reaction recorded. 
This is due to the presence o f  excess trifluoroacetic acid and trifluoroacetic anhydride present 
in the reaction. The coupling reagent EDC is not extremely acid stable.
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Scheme 4.5 Synthesis o f TV-trifluoroacetyl amino acids
The synthesis o f M-trifluoroacetyl-dipeptidyl phosphonate esters was achieved using 
the standard EDC/HOBt protocol. The dipeptidyl derivatives prepared were racemates and 
this was confirmed by their optical rotation. Yields ranged from 20% for compound 181 to 
59% for compound 182. The glycine derivatives gave the higher yields than the P-alanine 
analogues used. Uniquely, in comparison to the 4-fluorobenzenesulphonyl- and cinnamoyl 
analogues, it was the phenylalanine derivatives that gave the highest yields. The reduced size
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o f the trifluoroacetyl moiety limits the amount o f  steric hindrance present in the coupling 
reaction. This also indicates that in fact the A7-terminal substituents o f 4- 
fluorobenzenesulphonyl and cinnamoyl have a role to play w ith steric hindrance.
// ^
Table 4.6. ALtrifluoroacetyl dipeptidyl phosphonate ester derivatives
Compound n R % Yield 31P NM R 6 ppm
180 1 - c 6h 5 29 15.23, d
181 2 - c 6h 5 2 0 15.94,d
182 1 - c h 2 c 6h 5 59 18.01,t
183 2 - c h 2 c 6h 5 39 18.52, t
184 1 - c h 3 48 19.71,m
185 2 - c h 3 40 2 0 .0 2 , m
The 7V-trifluoroacetyl dipeptidyl phosphonates are characterized by the presence o f 
quartets at 8  -1 5 7  representing the carbonyl and at 8  -1 1 6  representing the trifluoromethyl 
group in the 13C NMR. A  singlet at 5 -  0.9 characterizes the trifluoromethyl moiety in the 19F 
N M R  spectra. The *11, 13C and 31P N M R spectra correspond favourably to the previously 
discussed 4-fluorobenzenesulphonyl and cinnamoyl derivatives. The Infrared spectra o f these 
compounds show the characteristic bands o f  dipeptidyl derivatives. Peaks at -1255 cm ' 1 can 
be attributed to the P = 0  group. A t 3242 cm "1 a peak due to N-H stretching is observed.
4.3.6 HM QC Study o f A-trifluoroacetyl dipeptidyl phosphonate esters
Heteronuclear multiple quantum correlation (HMQC) is a 2D N M R spectroscopic 
technique which correlates the carbon and proton spectra. Table 4.7 and Figure 4.4 show the 
C-H correlation for the structure Af-trifluoroacetyl-(3-Ala-Phep-(OPh ) 2  186.
A .
F , C  2  N  
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Table 4.7 C-H correlation of 7V-trifluoroacetyl-ß-Ala-Phep-(OPh)2 183
Site ln 13c HMQC
1 116.6
2 156.5
3 3.18-3.22 35.9
4 2.27-2.37 34.1
5 169.8
6 4.86-4.89 47.3
7 3.29-3.34, 2.95-3.04 34.7
8 137.1
9 7.18-7.43 128.5
1 0 7.18-7.43 129.4
1 1 7.18-7.43 126.9
1 2 150.4
13 7.18-7.43 1 2 1 . 0
14 7.18-7.43 130.29
15 7.18-7.43 125.7
16 150.1
17 7.18-7.43 120.7
18 7.18-7.43 130.21
19 7.18-7.43 125.6
10 9 8  7 6 b 4 3 2
Figure 4.4 HM QC Spectrum o f AMrifluoroacetyl-ß-Ala-Phep-(OPh) 2 183.
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4.4 Structural study o f the dipeptidyl phosphonate esters
Crystals suitable for single crystal x-ray crystallographic determinations o f  164, 169,
183 and 184 were grown from methanol, yielding colourless block shaped crystals. All 
pertinent crystallographic information is summarized in Tables 4.8 and 4.10 and selected 
bond distances and angles o f  non-hydrogen atoms are given in Tables 4.9 and 4.11. Figures
4.5 - 4.14 show perspective views o f  each crystal structure w ith atomic numbering scheme.
Compound 164 crystallizes in the monoclinic space group P2i/n  with four 
independent molecules per asymmetric unit. The range o f  the phenyl C-C bond distances is 
1.357(4) to 1.394(3) A (mean 1.375(3) A). The sulphonyl S= 0  distance is 1.436(15) A. The 
F-C-C bond angles range from 117.9(19)° to 118.4(19)°. The amide C (0)-N  distance C (l)- 
N ( l)  1.340(3) A and sulphonamide S(0)-N  distance S(2)-N(2) 1.608(17) A exhibit a lot o f 
single bond character. The principle interactions in  164 involve the amide N -H  and carbonyl 
groups o f  neighbouring residues interacting as N -H ...O = C  and forming a one-dimensional 
chain. There is also an intermolecular hydrogen bond formed between the phosphonate P = 0  
and the amide N -H  (Figure 4.5).
Figure 4.5 PLATON drawing of the X-ray crystal structure o f A/-4-fluorobenzenesulphonyl-
y-aminobutyric acid-(D, L)-phenylglycinep diphenyl ester 164 depicting the intermolecular
interactions.
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Table 4.8 Crystal data and structure refinement for AM-fluorobenzenesulphonyl-y- 
aminobutyric acid-(D, L)-phenylglycinep diphenyl ester 164 and N-4- 
fluorobenzenesulphonyl-P-alanine-(D, L)-alaninep diphenyl ester 169.
164 169
Empirical formula C29H 28N 2 O 6F 1S 1P 1 C2 3H24N 2 0 6F 1SiPi
M,. 582.56 506.47
Ciystal color Colorless, block Colorless, block
Crystal System Monoclinic Triclinic
Space group P2[/n Pi
a/A 10.0971(2) 9.7421(3)
b/A 12.0113(2) 15.6322(6)
c/A 23.2360(6) 16.3509(6)
a/° 86.7309(17)
p/° 90.5379(12) 74.052(2)
y/° 87.070(2)
v/A3 2817.92(10) 2388.72(15)
z 4 4
Temperature/K 150 150
Dcalc/gcm' 3 1.373 1.408
F(ooo) 1216 1056
(x/mm-1 0.224 0.252
Crystal dimensions/mm 0 .3 4 x 0 .3 4 x 0 .2 8 0 .2 4 x 0 .2 2 x 0 .1 6
Index ranges -13-13; /r, -14-15; /, -30-30 h, - 1 2 - 1 2 ; k, -2 0 -2 0 ; I, -2 0 - 2 1
Max. and min. transmission 0.922 to 0.939 0.942 to 0.961
Refinement method Full matrix on F2 Full matrix on F2
Reflections collected/unique 21343/6448 26371/10888
Data/parameters 4537/370 7181/631
Goodness o f  fit 1.04 1 . 0 2
Final R  indices (I>2o(I)) 0.046 (Ri), 0.106 (Rw) 0.046 (Ri), 0.103 (Rw)
Density range in final diff. m ap/eA 3 -0.42, +0.41 -0.47, +0.29
Compound 169 crystallizes in the triclinic space group Pi with four independent 
molecules per asymmetric unit. The range o f the phenyl C-C bond distances is 1.361(3) to 
1.393(3) A (mean 1.375(3) A). The sulphonyl S = 0  distances S(1A)-0(2A) 1.430(14) and 
S(1A)-0(3A ) 1.434(15) A and S(1B)-0(2B) 1.431(16) and S(1B)-0(3B) 1.434(16) A 
compare w ith the literature values . 32 The F-C-C bond angles range from 117.8(2)° to 
118.8(2)° in molecule A  and 118.0(2)° to 118.2(2)° in molecule B. The amide C(0)-N  
distances C(1A)-N(1A) 1.343(3) A and C(1B)-N(1B) 1.342(3) A and sulphonamide S(0)-N  
distances S(1A)-N(2A) 1.614(17) A and S(1B)-N(2B) 1.620(19) A exhibit a lot o f  single
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bond character. The principle interactions in 169 involve the amide N-H  and carbonyl groups 
o f  neighbouring residues interacting as N -H .. .0 = C  and forming a one-dimensional chain. 
There is also an intermolecular hydrogen bond formed between the phosphonate P = 0  and the 
amide N -H  (Figure 4.9).
Table 4.9 Selected bond distances (A) and angles (°) for 164 and 169 with estimated standard 
deviations.
164 169
(a) Bond distances A A B
P (l)-0 (4 ) 1.463(15) 1.465(14) 1.466(14)
P (l)-0 (5 ) 1.564(16) 1.585(16) 1.576(16)
0(1)-C (1) 1.233(2) 1.231(2) 1.235(2)
N (l)-C (l) 1.340(3) 1.343(3) 1.342(3)
S(l)-N (2) 1.608(17) 1.614(17) 1.620(19)
C(14/24)-F(l) 1.355(2) 1.360(3) 1.360(3)
(b) Bond angles
0(2)-S (l)-N (2) 106.44(9) 106.67(9) 106.29(10)
F(l)-C (14/24)-C (l 5/25) 117.89(19) 117.80(2) 118.20(2)
0(1)-C(1)-N(1) 122.71(19) 122.60(2) 122.60(2)
0 (4 )-P (l)-0 (5 ) 116.40(9) 115.28(9) 116.89(9)
P(l)-0(5)-C (31) 129.91(15) 120.09(13) 126.27(14)
Figure 4.6 ORTEP view o f the X-ray crystal structure of iV-4-fluorobenzenesulphonyl-y-
aminobutyric acid-(D, L)-phenylglycinep diphenyl ester 164.
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Figure 4.7 PLATON drawing o f  the X-ray crystal structure o f  iV-4-fhiorobenzenesulphonyl- 
y-aminobutyric acid-(D, L)-phenylglycinep diphenyl ester 164 depicting the best fit between 
the two molecules in 164.
Figure 4.8 ORTEP view o f the X-ray crystal structure o f  7V-4-fluorobenzenesulphonyl-(3- 
alanine-(D, L)-alaninep diphenyl ester 169.
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Figure 4.9 PLATON drawing o f  the X-ray crystal structure o f  A^-4-fluorobenzenesulphonyl- 
(3-alanine-(D, L)-alaninep diphenyl ester 169 depicting the intermolecular interactions.
According to the Cambridge Crystal Structure Database Version 5.25 April 2004 
there are only fifteen examples o f  diphenyl phosphonate esters reported. The average distance 
o f  the P= 0  bond in these derivatives is 1.460 A w hich compares favourably w ith the values 
o f  1.463 A and 1.465 A for compounds 164 and 169 respectively. The average angle between 
the phosphonate double bond and the phenoxy moiety o f  these fifteen derivatives is reported 
as 122.66°. Compound 164 and 169 have similar angles o f  116.4° and 115.3° respectively. 
The difference in these angles is probably due to steric effects caused by the peptidyl nature 
o f  phosphonate esters 164 and 169. At present there are only four crystal structures 
containing the 4 -fluoroben2 :enesulphonamide moiety reported. The average sulphonamide 
bond distance is 1.633 A. This is compared to values o f  1.608 A for compound 164 and 1.614 
A for compound 169. The average sulphonamide (0)-(S)-(N ) bond angle has recorded as 
106.45°. This corresponds to the value o f  106.44° for compound 164 and 106.67° for 
compound 169.
There is only one example o f a crystal structure o f  a dipeptidyl diphenyl phosphonate 
ester previously described .33 This isoleucyl-proline derivative has an amide bond distance o f 
1.345 A and a (0)-(C)-(N ) amide bond angle o f  122.92°. These values are very close to the 
values obtained for compounds 164 and 169.
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Compound 183 crystallizes in the monoclinic space group P2j/n with four 
independent molecules per asymmetric unit. The range o f the phenyl C-C bond distances is 
1.369(4) to 1.389(3) A (mean 1.380(3) A). The phosphonate P= 0  distance is 1.461(13) A. 
The F-C-C bond angles range from 110.2(2)° to 114.32(19)°. The amide C (0)-N  distances 
C (l)-N (l)  1.341(2) A and C(4)-N(2) 1.329(3) A exhibit a lot o f single bond character. The 
principle interactions in 183 involve the amide N -H  and carbonyl groups o f neighbouring 
residues interacting as N -H ...O = C  and forming a one-dimensional chain. There is also an 
intermolecular hydrogen bond formed between the phosphonate P = 0  and the amide N-H 
(Figure 4.10).
Table 4.10 Crystal data and structure refinement for 7V-trifluoroacetyl-J3-alanine-(D, L)- 
phenylalaninep diphenyl ester 183 and yV-trifluoroacetyl-glycine-(D, L)-alaninep diphenyl
ester 184
183 184
Empirical formula C2 5H 24N 2 O 5F3P 1 C 18H 18N 2 O 5F3P 1
M, 520.43 430.31
Crystal color Colorless, block Colorless, block
Crystal System M onoclinic Triclinic
Space group ?2i/n Pi
a/A 12.2319(5) 10.1264(8)
b/A 10.3096(4) 11.6424(8)
c/A 20.2734(5) 17.5757(16)
a/° - 80.166(5)
p r 102.685(2) 81.012(4)
Yr - 88.841(5)
v/A3 2494.20(15) 2016.5(3)
z 4 4
Temperature/K 150 150
Dcaic/gcm 1.386 1.417
F(ooo) 1080 8 8 8
(x/mm" 1 0.171 0.195
Crystal dimensions/mm 0 .2 0 x 0 .1 8 x 0 .1 0 0.26 x 0.26 x 0 . 1 0
Index ranges h, -15-15; k, -13-13; /, -26-26 h, -12-13; k, -15-15; /, -22-22
Max. and min. transmission 0.967 to 0.983 0.951 to 0.981
Refinement method Full matrix on F2 Full matrix on F2
Reflections collected/unique 23370/5717 19628/9096
Data/parameters 3615/333 4846/570
Goodness o f  fit 1 . 0 2 1.03
Final R  indices (I>2o(I)) 0.049 (R,), 0.108 (Rw) 0.068 (Ri), 0.161 (Rw)
Density range in final diff. m ap/eA 3 -0 .3 9 ,+ 0 . 2 2 -0.47, +0.40
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Compound 184 crystallizes in the triclinic space group Pi with four independent 
molecules per asymmetric unit and the molecular structure w ith atomic numbering is depicted 
in  Figure 4.12. The range o f  the phenyl C-C bond distances is 1.371(5) to 1.388(5) A (mean 
1.380(5) A). The phosphonate P = 0  distances P(1A )-0(3A ) 1.468(2) A and P(1B)-0(3B) 
1.465(3) A compare favourably w ith literature values . 33 The F-C-C bond angles range from 
110.6(3)° to 113.40(3)° in molecule A  but from 110.2(8)° to 117.20(15)° in molecule B. 
Refinem ent has shown that there is disorder associated w ith molecule B in 184. The 
trifluoromethyl group is disordered over two sites which differ in their orientation with 
respect to the amide moiety and w ith site occupancy factors subsequently fixed at 50%. The 
amide C (0)-N  distances C(1A)-N(1A) 1.325(4) A, C(3A)-N(2A) 1.335(5), A C(1B)-N(1B) 
1.320(5) A and C(3B)-N(2B) 1.321(5) A exhibit a lot o f  single bond character. The principle 
interactions in 184 involve the amide N-H and carbonyl groups o f  neighbouring residues 
interacting as N -H ...O = C  and forming a one-dimensional chain. There is also an 
intermolecular hydrogen bond formed between the phosphonate P = 0  and the amide N-H  
(Figure 4.13).
Figure 4.10 PLATON drawing o f the X-ray crystal structure o f jV-trifluoroacetyl-[3-alaninc-
(D, L)-phenylalaninep diphenyl ester 183 depicting the intermolecular interactions.
175
Table 4.11 Selected bond distances (Â) and angles (°) for 183 and 184 w ith estimated 
standard deviations.
Figure 4.11 ORTEP view of the X-ray crystal structure o f AMrifluoroacetyl-P-alanine-(D, L)-
phenylalaninep diphenyl ester 183.
183 184
(a) Bond distances A A B
P (l)-0 (3 ) 1.461(14) 1.468(2) 1.465(3)
P (l)-0 (4 ) 1.584(15) 1.577(2) 1.575(3)
0(1)-C (1) 1.234(2) 1.241(4) 1.230(4)
N (l)-C (l) 1.341(2) 1.325(4) 1.320(5)
C(4/3)-N(2) 1.329(3) 1.335(5) 1.321(5)
C (5/4)-F(l) 1.333(3) 1.321(5) 1.306(8)
(b) Bond angles
0(2)-C(4/3)-N (2) 122.60(2) 126.60(3) 126.10(4)
F(l)-C(5/4)-C(4/3) 111.10(4) 111.90(3) 114.30(5)
0(1)-C(1)-N(1) 122.28(19) 123.60(3) 123.70(4)
0 (3 )-P (l)-0 (4 ) 115.19(9) 114.81(14) 114.75(16)
P(1 )-0 (5 )-C (31/21) 124.57(13) 120.70(2) 123.20(2)
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Figure 4.12 ORTEP view of the X-ray crystal structure of yV-trifluoroacetyl-glycine-(D, L)-
alaninep diphenyl ester 184 showing both molecules present in 184.
Figure 4.13 PLATON drawing o f  the X-ray crystal structure o f  A-trifluoroacetyl-glycine-CD, 
L)-alaninep diphenyl ester 184 depicting the intermolecular interactions between pairs o f B 
molecules in  184.
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Figure 4.14 Platon drawing o f  the X-ray crystal structure o f  iV-trifluoroacetyl-glycine-(D, L)- 
alaninep diphenyl ester 184 depicting the best fit between the two molecules in 184.
The X-ray crystal structure o f compounds 183 and 184 relate favourably to the 
previously described diphenyl phosphonate esters and their dipeptidyl analogues. The 
Cambridge Crystal Structure Database V ersion 5.25 April 2004 shows that there are one 
hundred and thirty one examples o f  a trifluoroacetamide bond reported. The average bond 
length o f  the amide is shown to be 1.329 À  w ith the bond angle o f  the amide (0)-(C)-(N) 
given as 126.12°. Structure 183 has a corresponding bond length o f  1.329 À with a (O)-(C)- 
(N) bond angle o f  122.6°. The average length o f  the bond between the fluorine atom and the 
carbon atom in the trifluoromethyl group is 1.315 Â. This value compares w ith a value o f 
1.321 Â  for structure 184. Finally the average bond angle between the fluorine atom, the 
carbon o f  the trifluoromethyl group and the carbonyl moiety is 111.83°. Compounds 183 and
184 have similar bond angles o f  111.10° and 111.90° respectively. The study o f the dipeptidyl 
phosphonate esters show that the structure o f  these compounds is very similar to previously 
described structures.
178
4.5 Protease inhibitory activity of dipeptidyl phosphonate esters
4.5.1 Introduction
Serine proteases have been implicated in  a variety o f  diseases including rheumatoid 
arthritis, tum our metastasis and neurodegenerative diseases . 1 They are characterised by the 
presence o f the catalytic triad o f Asp-His-Ser in the active site. Chymotrypsin-like proteases 
are the m ost abundant serine proteases found in nature. They have been shown to be involved 
in  pathological processes such as digestion, apoptosis and immune response .34
Peptidyl phosphonates have been described as potent irreversible inhibitors o f serine 
proteases. They function as transition state analogues whereby the electrophilic phosphorus 
centre undergoes attack by the active site serine hydroxyl group to give a pentacoordinate 
intermediate. The loss o f  a phenoxy and a phenyl group gives a tetrahedral geometry with one 
o f  the phosphonate oxygens extended into the oxyanion hole. The inhibitory potency o f the 
synthesised dipeptidyl phosphonates was assessed against a-chymotrypsin due to its use as a 
m odel target enzyme for the development o f  design strategies that can be applied for other 
serine proteases o f  pharmacological interest.
4.5.2 Assay to determine the inhibitory potency of dipeptidyl phosphonate esters on 
bovine pancrease a-chymotrypsin serine protease
A  standard ultraviolet assay has been developed using an ultraviolet active substrate 
to test the activity o f  these compounds. In this assay activity was determined by measuring 
the release o f  the ultraviolet species 4-nitroaniline from the substrate jV-succinyl-L-Phe-p- 
nitroanilide upon enzymatic hydrolysis by bovine pancrease a-chymotrypsin serine protease 
purchased from  Sigma-Aldrich. The absorbance increase at 405 nm  is proportional to 
chymotrypsin activity. The a-chym otrypsin used was diluted w ith 1 m M  HC1 to activate the 
enzyme. Assays were carried out using a final concentration o f 10 |xM substrate in 0.1 M 
Tris-HCl/20 m M  CaCl2 buffer pH  8.0. The m ixture o f  enzyme and inhibitor were incubated 
together at 25 °C for 15 mins. The substrate was then added and the mixture was further 
incubated for 30 mins. The amount o f  4-nitroaniline released was measured using an ICN 
flow  m ultiscan plus MKII titretek reader w ith absorbance at 405 nm. The positive control 
contained only the enzyme extract and the substrate iV-succinyl-L-Phe-p-nitroanilide. This 
positive control corresponded to 100% inhibition. There were two negative controls used. 
One contained the enzyme and inhibitor and the other contained just the inhibitor and the 
substrate. All assays were performed in triplicate w ith the mean result being taken.
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Figure 4.15 Hydrolysis o f  JV-succinyl-L-Phe-p-nitroanilide by bovine pancrease a- 
chymotrypsin serine protease w ith liberation o f  the ultraviolet species /»-nitroaniline.
4.5.3 Protease inhibition of the iV-4-fluorobenzenesulphonyl dipeptidyl phosphonate 
ester derivatives
Sulphonamide derivatives have been shown to be potent inhibitors o f various 
proteases . 35 The geometry and the additional hydrogen bonding properties o f the sulphonyl 
moiety often leads to superior inhibitory potency in  contrast to their carbonyl analogues. The
presence o f  a bulky aromatic substituent such as the phenyl ring bonded to the sulphonyl
i t  . • » 
group has been shown to improve activity. The introduction o f a fluorine atom into a
molecule has distinct effects on its physiochemical properties such as lipophilicity and the
influence o f  fluorine substitution on the biological stability o f  a drug molecule through
altering susceptibility to m etabolism .37 Scozzafava et al have developed a hypothesis that
puts forward the possibility that F-H hydrogen bonds between the inhibitor and the active site
residues o f  the protease contribute in stabilizing the enzyme-inhibitor adduct .24
The m ost potent 4-fluorobenzenesulphonyl inhibitor o f  bovine pancrease a- 
chymotrypsin w as compound 165. This compound was shown to have an IC5o value o f  16.15 
pM. A t a concentration o f 100 pM  86.41% inhibition was recorded. The specificity o f  a- 
chymotrypsin for an aromatic group in the P I position is well docum ented .3 From this study 
it is very clear that the phenylalanine derivatives are by far the m ost potent compounds. 
Surprisingly the phenylglycine derivatives w ith their aromatic side chain do not show great 
inhibitory potencies against a-chymotrypsin. The m ost potent phenylglycine derivative 164 
recorded an IC 50  value o f  76.75 pM. The phenylalanine analogues have inhibitory potencies 
up to 2-fold greater than the phenylglycine compounds. This shows that the inclusion o f a 
spacer group such as a methylene is crucial for effective inhibition. The alanine derivatives 
give somewhat expected results. A t a concentration o f  100 pM each o f the alanyl derivatives 
fail to achieve greater inhibition than 28%.
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Table 4.12 Inhibitory activity o f AM-fl uorobenzenesulphonyl dipeptidyl phosphonate ester 
derivatives
% Protease Inhibition
Compound 10*iM 50 fiM 100 p M IC 5 0  fiM
162 12.90 38.16 41.09 > 1 0 0
163 19.31 37.25 47.22 > 1 0 0
164 30.60 45.69 51.66 76.75
165 33.23 81.60 86.41 16.15
166 26.84 73.16 83.01 25.76
167 20.82 74.94 83.19 26.73
168 19.08 17.88 27.58 > 1 0 0
169 15.62 20.31 24.91 > 1 0 0
170 7.56 14.66 14.89 > 1 0 0
The small side chain methyl group o f  alanine has previously not been shown to fit 
effectively into the SI subsite o f  the a-chym otrypsin active site. The effect o f increasing the 
number o f  methylene units in the P2 position was achieved by using the amino acids glycine, 
P-alanine and Y-aminobutyric acid. The phenylalanine and alanine derivatives generally give 
higher inhibition when there is only one methylene unit present in the P I position. The 
phenylglycine derivatives gave superior inhibition w hen Y-aminobutyric acid was used.
4.5.4 Protease inhibition o f the iV-cinnamoyl dipeptidyl phosphonate ester derivatives
jV-cinnamoyl peptidyl derivatives are potent inhibitors o f  angiotension converting 
enzyme . 38 The cinnamoyl moiety is a potential M ichael acceptor and may undergo enzyme 
attack. The phenyl ring in the cinnamoyl group has been shown to bind w ith the active site o f 
the enzyme with a  preferred conformation involving the phenyl ring being twisted out o f
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plane o f the adjacent olefin . 28 This conformation has been shown to improve activity 
substantially. More rigid conformers such as the coumarinoyl moiety have showed decreased 
activity .28
Table 4.13 Inhibitory activity o f iV-cinnamoyl dipeptidyl phosphonate ester derivatives
% Protease Inhibition
Compound 10 *iM 50 fiM 100 nM ICso ]iM
171 21.33 49.26 50.71 52.00
172 12.89 21.37 21.89 > 1 0 0
173 16.11 16.75 19.57 > 1 0 0
174 22.49 81.27 82.36 19.54
175 26.11 58.50 68.99 37.00
176 25.30 49.72 52.75 50.75
177 15.99 23.74 27.76 > 1 0 0
178 12.76 14.56 14.99 > 1 0 0
179 11.56 15.88 18.27 > 1 0 0
The inhibitory potency o f  the TV-cinnamoyl dipeptidyl phosphonate esters showed 
similar results to the 4-fluorobenzenesulphonyl dipeptidyl derivatives. The m ost active 
compound was 174 w ith an IC 50  value o f  19.54 jxM. The least activity recorded was for 
compound 178. A t a concentration o f  100 jjM a percentage inhibition o f  ju s t 14.99 was 
achieved. The phenylalanine derivatives w ere once again the m ost potent derivatives. The 
presence o f  a benzyl group in the PI position seems to be the undermining factor in potent 
inhibition. Once again the phenylglycine derivatives fail to show effective inhibition o f a- 
chymotrypsin. The most potent phenylglycine derivative 171 only records inhibition o f 
50.71% at the 100 (J.M level. The presence o f  a methyl group in the P I position reflects very
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poor inhibition. The alanine derivatives are probably unable to bind w ith the SI subsite o f a- 
chymotrypsin due to the side chain methyl group being extremely short. The presence o f a 
glycine residue in the P2 position has shown the best results. In the case o f  the phenylglycine 
derivatives the drug molecules w ith only one methylene unit are up to three fold more potent 
than the a-aminobutyric acid analogues.
4.5.5 Protease inhibition of the /V-trifluoroacetyl dipeptidyl phosphonate ester 
derivatives
The incorporation o f  a trifluoroacetyl substituent into a biologically active compound 
has often improved activity and specificity .39  The trifluoromethyl moiety although very 
similar sterically to its hydrogen analogue displays distinct properties and is found in various 
drug compounds such as prozac .4 0  The strongly electron withdrawing trifluoromethyl group 
causes the amide carbonyl to be increasingly electrophilic and hence the carbon-oxygen bond 
is more susceptible to enzyme attack. The lipophilic, hydrophilic and hydrogen bonding 
properties o f  a molecule are influenced by the introduction o f a trifluoroacetyl group.
Table 4.14 Inhibitory activity o f  ^ /-trifluoroacetyl dipeptidyl phosphonate ester derivatives
% Protease Inhibition
Compound 10 jiM 50 \iM 100 (iM IC 50 *iM
180 17.80 37.94 55.19 82.38
181 14.53 32.96 44.55 > 1 0 0
182 27.06 77.71 89.58 21.15
183 23.61 62.06 79.59 30.67
184 11.56 17.51 16.15 > 1 0 0
185 13.24 14.11 18.86 > 1 0 0
183
Due to the unsuccessful synthesis o f A'-trifluoroacetyl-y-aminobutyric acid we were 
unable to assess the biological activity o f compounds containing three methylene units in the 
P2 position. This was not deemed imperative, as previous research had indicated that the 
GABA derivatives synthesised were generally not very potent inhibitors o f a-chymotrypsin. 
The m ost potent trifluoroacetyl derivative was found to be compound 182. iV-trifluoroacetyl- 
glycine-phenylalaninep-(OPh ) 2  182 expresses an IC 50 value o f 21.15 jxM and inhibits 89.58% 
o f  a-chymotrypsin at a concentration o f  100 (xM. The phenylglycine derivatives 180 and 181 
inhibit a-chymotrypsin but up to 2 fold less than their phenylalanine analogues. The alanyl 
derivatives once again fail to effectively inhibit a-chymotrypsin at micromolar 
concentrations. A t a concentration o f  10 (xM compound 184 only inhibits 11.56% o f the 
available enzyme. The glycine derivatives w ith their one methylene in the P2 position unit 
gave substantially greater inhibition than their (3-alanine analogues.
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Figure 4.16 Bar graph representing the %  inhibition o f  dipeptidyl phosphonate esters against 
bovine pancrease a-chymotrypsin at a concentration o f  50 (xM.
4.6 Conclusion
W e have successfully designed, synthesised and structurally characterized a series o f 
dipeptidyl phosphonate diphenyl esters as potential inhibitors o f  the serine protease a- 
chymotrypsin. These derivatives showed varying degrees o f biological activity depending on
162 163 164 165 166 167 168 169 170 171 172 173 174 175 176 177 178 179 180 181 182 183 184 185
Compound
184
their amino acid sequence and structure. The most active compound was 7V-4-fluoro- 
benzenesulphonyl-Gly-Phep-(OPh ) 2  165 that recorded an IC 50 value o f 16.15 (oM. Three 
different TV-terminal substituents were assessed for their effect on the potency o f  the 
dipeptidyl derivatives. Concentrating on the m ost active compounds o f each series, it is 
shown that the 4-fluorobenzenesulphonyl moiety is the m ost potent TV-terminal substituent. 
Compound 165 has an IC 50  value o f 16.15 (.iM compared to 19.54 (iM for the cinnamoyl 
derivative 174 and 21.15 |iM for the trifluoroacetyl analogue 182.
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Figure 4.17 Bar chart representing the IC 50 values o f the most potent dipeptidyl phosphonate 
esters against bovine pancrease a-chymotrypsin
From this study it is very clear that the most potent dipeptidyl derivatives contain the 
Gly-Phep scaffold. A lthough the phenylglycine and alanine derivatives do inhibit a- 
chymotrypsin it is the phenylalanine derivatives that give the most successful results. The 
specificity o f a-chymotrypsin for a phenylalanine unit in the SI subsite is further 
demonstrated here. The incorporation o f methylene units into the P2 position failed to 
increase the potency o f these derivatives. It was the glycine derivatives w ith just one 
methylene unit that showed a higher inhibitory potency.
We have shown that the diphenyl phosphonate ester moiety can be successful as a 
method for serine protease inhibiton. Although potent inhibition is sequence specific, the 
inhibition o f a-chymotrypsin by unfavourable dipeptidyl arrangements shows that the 
phosphonate ester moiety has the ability to be a vital ingredient o f serine protease inhibitors.
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4.7 Experimental
General Procedures.
All chemicals were purchased from Sigma/Aldrich and used as received. When necessary 
solvents were purified prior to use and stored under nitrogen. Dichloromethane was distilled 
from CaHi and triethylamine was distilled and stored over potassium hydroxide pellets. 
Commercial grade reagents were used without further purification. Riedel-de Haèn silica gel 
was used for thin layer and column flash chromatography. Melting points were determined using 
a Griffin melting point apparatus and are uncorrected. Specific rotation [ cx] d  studies were 
recorded on a Perkin Elmer 241 polarimeter. Infrared spectra were recorded on a Nicolet 405 
FT-IR spectrometer and elemental analysis was carried out by the Microanalytical Laboratory at 
University College Dublin. Electrospray ionisation mass spectra were recorded on a Bruker 
Esquire 3000 series LC/MS. N M R spectra were obtained on a Bruker AC 400 NMR 
spectrometer operating at 400 M Hz for 'H NMR, 376 M Hz for 19F NMR, 161.9 M Hz for 31P 
N M R and 100 M Hz for 13C NMR. The ]H and 13C NM R chemical shifts (ppm) are relative to 
tetramethylsilane, the 19F N M R chemical shifts (ppm) are relative to trifluoroacetic acid and the 
3IP NM R chemical shifts are relative to phosphoric acid. All coupling constants (J) are in Hertz.
General procedure for the synthesis of dipeptidyl phosphonate esters 162-185 
iV-4-fluorobenzenesulphonyl-glycme-(D, L)-phenylglycinep diphenyl ester 162 
AM-fluorobenzenesulphonylglycine (1.47 g, 7 mmol), (D, L)-phenylglycinep diphenyl ester 
hydrobromide (2.94 g, 7 mmol), triethylamine (0.97 ml) and 1-hydroxybenzotriazole hydrate 
(0.94 g, 7 mmol) were dissolved in dichloromethane (50 ml). The mixture was cooled to 0 °C, 
and l-[3-dimethylaminopropyl]-3-ethyl carbodiimide hydrochloride (EDC) (1.47 g, 7.7 
mmol) added. After 30 min. the solution was raised to room  temperature and the reaction was 
allowed to proceed for 8  hrs. The filtrate was washed w ith 10% citric acid, 10% potassium 
hydrogen carbonate, water and dried over magnesium sulphate. The solvent was evaporated 
in vacuo and recrystallisation from diethyl ether furnished 162 as a white powder (0.63 g, 
29%).
m.p. = 170-172 "C.
Anal, calcd. for Q ^ N - O e P iS iF ! :  C, 58.48; H, 4.36; N , 5.05.
Found C, 58.27; H, 4.50; N, 5.04.
M ass Spectrum: [M+Na]+ found 577.2.
C2 7H 24N 2 0 6 PiSiFiN ai requires 577.5.
IR (K B r): u3261 , 3061, 1675, 1590, 1546, 1491, 1155, 940, 691 cm '1.
186
*H-NMR (400 MHz, DMSO): 8  9.35 (1H, d , J  = 9.2 Hz, -NT/-), 8.14 (1H, t, J =  4.4 Hz, -NH ­
), 6.90-7.84 (19H, m, -ArH), 5.81 (1H, dd, J H'H= 9.6 Hz, J H‘P = 21.6 Hz, a-H), 3.75 (1H, dd, 
J 3 = 4.8 Hz, J 2 = 16.4 Hz, -CH 2-), 3.63 (1H, dd, J 3 = 4.4 Hz, J 2 = 16.8 Hz, -CH 2-). 
°C -N M R  (100 M Hz, DMSO): 5 167.9 (d, -CONH-), 164.4 (d, -ArC 4), 150.2 (d, -OPhC 1),
150.0 (d, -OPhC 1), 137.2 (d, -ArC 1), 134.3 (-PhC 1), 130.25 (-OPhC 3), 130.20 (-OPhC 3),
129.8 (-ArC 2), 129.7 (-ArC 6 ), 128.8 (-PhC 3), 128.7 (-PhC 2), 128.6 (-PhC 4), 125.7 (- 
OPhC 4), 120.7 (d, -OPhC 2), 120.6 (d, -OPhC 2), 116.9 (-ArC 3), 116.7 (-ArC 5), 49.4 (d, a- 
Q ,  45.1 (-CH2-, -VE DEPT).
19F-NM R (376 MHz, DMSO): 5 -31.6 - -31.7 (m).
3 1P-NM R (161.9 MHz, DMSO): 5 14.83 (d, J P_H= 21.5 Hz).
iV-4-fluorobenzenesulphonyl-p-alanine-(D, L)-phenylglycinep diphenyl ester 163
A^-4-fluorobenzenesulphonyl-P-alanine (0.90 g, 4 mmol) and (D, L)-phenylglycinep diphenyl 
ester hydrobromide (1.68 g, 4 mmol) were used. Recrystallisation from diethyl ether 
furnished 163 as a  white powder (0.77 g, 35%). 
m.p. =  138-140 °C.
Anal, calcd. for C28H26N20 6P iS iF i : C, 59.15; H, 4.61; N , 4.93.
Found C, 58.85; H, 4.68; N , 4.86.
M ass Spectrum: [M+Na]+ found 591.2.
C2 8H2 6N2 06PiS iF iN ai requires 591.5.
IR  (KBr): u 3247, 3058, 1670, 1591,1542, 1491, 1163, 953, 549 cm '1.
^ -N M R  (400 MHz, DMSO): 5 9.40 (1H, d, J =  9.2 Hz, -NH-), 6.93-7.87 (20H, m, -A iH & -  
N //-) , 5.93 (1H, dd, J H'H= 10.0 Hz, J H'P = 22.0 Hz, a-H), 2.92-2.98 (2H, m, p-CH2), 2.47 
(2H, t , J =  7.2 Hz, a-CH2).
1 3C-NM R (100 MHz, DMSO): 8  170.1 (-CONH-), 164.4 (d, -ArC 4), 150.3 (d, -OPhC 1),
150.0 (d, -OPhC 1), 136.8 (d, -ArC 1), 134.6 (-PhC 1), 130.2 (-OPhC 3), 130.1 (-OPhC 3),
129.9 (-ArC 2), 129.8 (-ArC 6 ), 128.9 (-PhC 3), 128.8 (-PhC 2), 128.5 (-PhC 4), 125.7 (- 
OPhC 4), 125.6 (-OPhC 4), 120.7 (t, -OPhC 2), 116.8 (-ArC 3), 116.6 (-ArC 5), 50.3 (d, a- 
Q ,  39.2 (P-CH2, -VE DEPT), 35.5 (a-CH2, -VE DEPT).
19F-NM R (376 MHz, DMSO): 8  -31.5 - -31.6 (m).
3 1P-NM R (161.9 MHz, DMSO): 8  15.12 (d, J P’H = 21.9 Hz).
187
JV-4-fluorobenzenesulphonyl-y-aminobuytric acid (0.93 g, 4 mmol) and (D, L)- 
phenylglycinep diphenyl ester hydrobromide (1.68 g, 4 mmol) were used. Recrystallisation 
from diethyl ether furnished 164 as a white powder (0.64 g, 29%). 
m.p. = 158-160 °C.
Anal, calcd. for C29H 2 8N2 O 6P 1S 1F 1 : C, 59.79; H, 4.84; N , 4.81.
Found C, 59.81; H, 4.87; N , 4.71.
M ass Spectrum: [M+Na]+ found 605.2.
C29H2gN20 6PiSiFiN ai requires 605.5.
IR (KBr): d 3266, 3069, 1648, 1591,1545, 1491, 1165, 958, 763 cm’1.
'H -N M R (400 MHz, DMSO): 8  9.33 (1H, d, J =  9.2 Hz, -NH-), 6.91-7.83 (20H, m, -ArH & -  
N H-), 5.92 (1H, dd, J H’H = 9.6 Hz, J H'P = 22.0 Hz, a-H), 2.71-2.76 (2H, m, y-CH i), 2.27 
(2H, t, J =  7.6 Hz, a-CHi), 1.60-1.66 (2H, m, p-CHi).
13C-NMR (100 MHz, DMSO): 5 171.9 (-CONH-), 164.4 (d, -ArC 4), 150.3 (d, -OPhC 1),
150.0 (d, -OPhC 1), 137.1 (d, -ArC 1), 134.7 (-PhC 1), 130.2 (-OPhC 3), 130.2 (-OPhC 3),
129.8 (-ArC 2), 129.7 (-ArC 6 ), 128.86 (-PhC 3), 128.8 (-PhC 2), 128.5 (-PhC 4), 125.7 (- 
O PhC 4), 120.6 (t, -OPhC 2), 116.7 (-ArC 3), 116.5 (-ArC 5), 50.2 (d, a-C), 42.4 (y-CH2, - 
V E DEPT), 32.4 (a-CH2, -VE DEPT), 25.6 (p-CH2, -VE DEPT).
19F-NM R (376 M Hz, DMSO): 8  -31.7 - -31.8 (m).
3 1 P-NM R (161.9 MHz, DMSO): 5 15.35 (d, J P'H= 2 1 .9  Hz).
iV-4-fliiorobenzenesulphonyl-glycine-(D, L)-phenylalaninep diphenyl ester 165
AM-fluorobenzcnesulphonylglycine (0.84 g, 4 mmol) and (D, L)-phenylalaninep diphenyl 
ester hydrobromide (1.74 g, 4 mmol) were used. Recrystallisation from diethyl ether 
furnished 165 as a w hite powder (0.99 g, 45%). 
m.p. = 152-154 "C.
Anal, calcd. for C2 8H 2 6N20 6P iS iF i: C, 59.15; H, 4.61; N, 4.93.
Found C, 58.89; H, 4.31; N , 4.54.
M ass Spectrum: [M+Na]+ found 591.2.
C2 8H26N 206PiS iF iN ai requires 591.5.
IR (KBr): u 3262, 3079, 1664, 1592, 1545, 1491, 1151, 939, 771 cm’1.
TV-4-fluorobenzenesulphonyl-y-aininobutyric acid-(D, L)-phenylglycinep diphenyl ester
188
^ -N M R  (400 MHz, DMSO): 5 8.74 (1H, d , J  = 9.6 Hz, -NH-), 8.04 (1H, t, J =  6.0 Hz, -NH ­
), 7.32-7.53 (19H, m, -A iH ), 4.72-4.82 (1H, m, a-H), 3.36-3.50 (2H, m, -CH2-), 3.25-3.30 
(1H, m, -C //2 Ph), 2.92-3.00 (1H, m, -C tf2Ph).
1 3C-NM R (100 MHz, DMSO): 5 167.7 (d, -CONH-), 164.4 (d, -ArC 4), 150.2 (d, -OPhC 1),
150.0 (d, -OPhC 1), 137.1 (d, -PhC 1), 137.0 (-ArC 1), 130.3 (-OPhC 3), 130.2 (-OPhC 3),
129.9 (-ArC 2), 129.8 (-ArC 6 ), 129.4 (-PhC 3), 128.6 (d, -PhC 2), 127.0 (-PhC 4), 125.8 (- 
OPhC 4), 125.7 (-OPhC 4), 121.0 (d, -OPhC 2), 120.8 (d, -OPhC 2), 116.5 (-ArC 3), 116.3 (­
A rC  5), 47.7 (d, a -Q ,  44.9 (-CH2-, -YE DEPT), 34.7 (d, -CH 2Ph, -YE DEPT).
19F-NM R (376 MHz, DMSO): 5 -31.7 - -31.8 (m).
3 1P-NM R (161.9 MHz, DMSO): 5 17.65 (t, J P'H= 7.4 Hz).
A'-4-fluoroben/.enesulphonyl-|5-alanine-(D, L)-phenylalaninep diphenyl ester 166
/V-4-fluorobenzcnesulphonyl-(3-alanine (0.90 g, 4 mmol) and (D, L)-phenylalaninep diphenyl 
ester hydrobromide (1.74 g, 4 mmol) were used. Recrystallisation from diethyl ether 
furnished 166 as a white powder (0.81 g, 36%). 
m.p. = 107-109 °C.
Anal, calcd. for C2 9H 28N 2 0 6PiS iF i: C, 59.78; H, 4.85; N , 4.81.
Found C, 60.00; H, 4.87; N , 4.57.
M ass Spectrum: [M+Na]+ found 605.2.
C2 9H 28N 2OfiPiSiFiN ai requires 605.5.
IR  (KBr): u 3285, 3068, 1670, 1592, 1546, 1490,1167, 932, 687 cm '1.
‘H-NM R (400 MHz, DMSO): 5 8.73 (1H, d, J =  9.6 Hz, -NH-), 7.15-7.85 (20H, m, -ArH 8c - 
N H-), 4.71-4.81 (1H, m, a-H), 3.26-3.31 (1H, m, -C //2Ph), 2.92-3.01 (1H, m, -C tf2Ph), 2.69 
(2H, q, J =  7.2 Hz, p-CH2), 2.16-2.22 (2H, m, a-CH2).
13C-NM R (100 MHz, DMSO): 5 169.8 (d, -CONH-), 164.4 (d, -ArC 4), 150.4 (d, -OPhC 1),
150.1 (d, -OPhC 1), 137.1 (d, -PhC 1), 136.7 (d, -ArC 1), 130.3 (-OPhC 3), 130.1 (-OPhC 3),
129.9 (-ArC 2), 129.8 (-ArC 6 ), 129.4 (-PhC 3), 128.5 (-PhC 2), 126.9 (-PhC 4), 125.7 (- 
OPhC 4), 125.6 (-OPhC 4), 120.9 (d, -OPhC 2), 120.6 (d, -OPhC 2), 116.8 (-ArC 3), 116.6 (­
A rC  5), 47.4 (d, a-C), 39.2 (P-CH2, -VE DEPT), 35.6 (a-CH 2, -VE DEPT), 34.7 (-CH2Ph, - 
VE DEPT).
19F-NM R (376 MHz, DMSO): 5 -31.5 - -31.7 (m)
31P-NM R (161.9 MHz, DMSO): 5 17.81 (t, J P'H= 7 .2  Hz).
189
7V-4-fluorobenzenesulphonyl-y-aminobiityric acid-(D, L)-phenylalaninep diphenyl ester 
167
V-4-fluorobenzenesulphonyl-y-aminobutyric acid (0.95 g, 4 mmol) and (D, L)-phenylalaninep 
diphenyl ester hydrobromide (1.74 g, 4 mmol) were used. Recrystallisation from diethyl ether 
furnished 167 as a white powder (0.76 g, 33%). 
m.p. = 128-130 "C.
Anal, calcd. for C3 0H 3 0N2O 6P 1S 1F 1 : C, 60.40; H, 5.07; N , 4.70.
Found C, 60.10; H, 4.95; N , 4.50.
M ass Spectrum: [M+Na]+ found 619.3.
C 3oH3oN2 0 6 PiS iF iN ai requires 619.5.
IR  (KBr): u 3264, 3068, 1664, 1592,1490, 1153, 946, 768 cm '1.
’H-NMR (400 MHz, DMSO): 5 8.58 (1H, d, J =  9.2 Hz, -NH-), 7.16-7.82 (20H, m, -ArH & - 
N H-), 4.81-4.86 (1H, m, a -H), 3.27-3.30 (1H, m , -C //2Ph), 2.96-3.01 (1H, m, -C tf2 Ph), 2.58­
2.62 (2H, m, y-C i/2), 2.02 (2H, t, J =  6.4 Hz, a-CH2), 1.46-1.50 (2H, m, (3-C//2).
13C-NM R (100 M Hz, DMSO): 8  171.7 (d, -CONH-), 164.4 (d, -ArC 4), 150.4 (d, -OPhC 1),
150.1 (d, -OPhC 1), 137.3 (d, -PhC 1), 137.1 (d, -ArC 1), 130.28 (-OPhC 3), 130.21 (-OPhC
3), 129.7 (-ArC 2), 129.6 (-ArC 6 ), 129.3 (-PhC 3), 128.4 (-PhC 2), 126.9 (-PhC 4), 125.7 (- 
OPhC 4), 125.6 (-OPhC 4), 121.0 (d, -OPhC 2), 120.7 (d, -OPhC 2), 116.7 (-ArC 3), 116.5 (­
A rC  5), 47.3 (d, a-C), 42.3 (y-CH2, -VE DEPT), 34.6 (-CH2Ph, -VE DEPT), 32.5 (a-CH2, - 
V E  DEPT), 25.5 (P-CH2, -VE DEPT).
19F-NM R (376 M Hz, DMSO): 5 -31.7 - -31.9 (m).
3 1P-NM R (161.9 MHz, DMSO): 5 18.24 (t, J P_H= 7.6 Hz).
Ar-4-fluorobenzenesulphonyl-glycine-(D, L)-alaninep diphenyl ester 168
TV-4-fluorobenzenesulphonylglycine (0.84 g, 4 mmol) and (D, L)-alaninep diphenyl ester 
hydrobromide (1.43 g, 4 mmol) were used. Recrystallisation from diethyl ether furnished 168 
as a white pow der (1.10 g, 59%). 
m.p. = 130-132 °C.
Anal, calcd. for C2 2H 22N 2 0 6PiS iF i: C, 53.66; H, 4.50; N , 5.69.
Found C, 53.49; H, 4.30; N , 5.65.
M ass Spectrum: [M+Na]+ found 515.2.
C2 2H22N 206PiS iF iN ai requires 515.4.
IR  (KBr): u 3221, 3069, 1675, 1591, 1489, 1154, 953, 766 cm '1.
190
*H-NMR (400 MHz, DMSO): 5 8 . 6 6  (1H, d, . /=  9.2 Hz, -NT/-), 8.16 (1H, t, J =  6.0 Hz, -N H­
), 7.14-7.93 (14H, m, -ArH), 4.62-4.71 (1H, m, a-H), 3.68 (1H, dd, J 3 = 6.4 Hz, J 2 = 16.8 
Hz, -CH2-), 3.54 (1H, dd, J 3 = 5.6 Hz, J 2 = 16.4 Hz, -CH 2-), 1.42 (3H, dd, J H'H = 7.2 Hz, J  
H'p = 18.0 Hz).
13C-NM R (100 MHz, DMSO): 5 167.6 (d, -CONH-), 164.4 (d, -ArC 4), 150.3 (d, -OPhC 1),
150.1 (d, -OPhC 1), 137.2 (d, -ArC 1), 130.24 (-O PhC 3), 130.21 (-O PhC 3), 130.0 (-A rC 2),
129.9 (-ArC 6 ), 125.7 (-OPhC 4), 125.6 (-OPhC 4), 120.9 (d, -OPhC 2), 120.7 (d, -OPhC 2),
116.6 (-ArC 3), 116.3 (-ArC 5), 45.2 (-CH2-, -VE DEPT), 41.5 (d, a -Q , 15.4 (-CH3). 
19F-NM R (376 M Hz, DMSO): 5 -31.5 - -31.7 (m).
3 1P-NM R (161.9 MHz, DMSO): 8  19.16-19.45 (m).
ZV-4-fluorobenzenesulphonyI-p-aIanine-(D, L)-alaninep diphenyl ester 169
Af-4-fluorobenzenesulphonyl-P-alanine (0.90 g, 4 mmol) and (D, L)-alaninep diphenyl ester 
hydrobromide (1.43 g, 4 mmol) were used. Recrystallisation from diethyl ether furnished 169 
as a white powder (1.18 g, 61%). 
m.p. = 123-125 °C.
Anal, calcd. for C23H 24N 2O 6 P 1S1F 1 : C, 54.54; H, 4.78; N , 5.53.
Found C, 54.48; H, 4.91; N, 5.41.
M ass Spectrum: [M+Na]+ found 529.2.
C2 3H 24N 2 0 6 PiSiFiN ai requires 529.4.
IR (KBr): u 3257, 3066, 1667, 1591, 1491, 1160, 939, 764 cm '1.
^ -N M R  (400 MHz, DMSO): 5 8.69 (1H, d, J =  9.2 Hz, -NH-), 7.13-7.91 (15H, m, -ArH  8c - 
N H-), 4.71-4.78 (1H, m, a-H), 2.93-3.00 (2H, m, p-CH2), 2.32-2.43 (2H, m, a-CH2), 1.45 
(3H, dd, J  H'H = 7 .2  Hz, J  H'p = 18.0 Hz).
13C-NM R (100 MHz, DMSO): 5 169.7 (d, -CONH-), 164.4 (d, -ArC 4), 150.4 (d, -OPhC 1),
150.1 (d, -OPhC 1), 136.9 (d, -ArC 1), 130.2 (-OPhC 3), 130.1 (-OPhC 3), 129.9 (-ArC 2),
129.8 (-ArC 6 ), 125.6 (-OPhC 4), 125.5 (-OPhC 4), 120.9 (d, -OPhC 2), 120.8 (d, -OPhC 2),
116.8 (-ArC 3), 116.5 (-ArC 5), 41.4 (d, a-C), 39.2 (p-CH2, -VE DEPT), 35.6 (a-CH2, -VE 
DEPT), 15.4 (-CH3).
19F-NM R (376 MHz, DMSO): 5 -31.5 - -31.7 (m).
3 1P-NM R (161.9 MHz, DMSO): 5 19.37-19.77 (m).
191
A^-fluorobenzenesulphonyl-y-am inobutyric acid-(D, L)-alaninep diphenyl ester 170
AM-fluorobenzenesulphonyl-y-aminobutyric acid (0.95 g, 4 mmol) and (D, L)-alaninep 
diphenyl ester hydrobromide (1.43 g, 4 mmol) w ere used. Recrystallisation from diethyl ether 
furnished 170 as a white powder (0.99 g, 50%). 
m.p. = 129-131 "C.
Anal, calcd. for C24H 2 6N 2O 6P 1S 1F 1 : C, 55.38; H, 5.04; N, 5.38.
Found C, 55.25; H, 5.00; N, 5.56.
M ass Spectrum: [M+Na]+ found 543.2.
C2 4H 26N 2 0 6 PiS iF iN ai requires 543.5.
IR (KBr): u 3266, 3060, 1678, 1593, 1490, 1186, 948, 766 cm '1.
•H-NMR (400 MHz, DMSO): 5 8.55 (1H, d, J =  9.6 Hz, -NH-), 7.12-7.86 (15H, m, -A iH  & - 
N H-), 4.68-4.74 (1H, m, a-H), 2.75 (2H, q, J  = 6 . 8  Hz, y-CH 2), 2.14-2.20 (2H, m, a-CH2),
1.63 (2H, qt, J =  7.2 Hz, p-CH2), 1.42 (3H, dd, J H'H= 7.2 Hz, J H’P = 18.4 Hz).
13C-NM R (100 M Hz, DMSO): 8  171.6 (d, -CONH-), 164.4 (d, -ArC 4), 150.4 (d, -OPhC 1), 
150.2 (d, -OPhC 1), 137.1 (d, -ArC 1), 130.2 (-OPhC 3), 130.1 (-OPhC 3), 129.8 (-ArC 2),
129.7 (-ArC 6 ), 125.6 (-OPhC 4), 125.5 (-OPhC 4), 120.9 (d, -OPhC 2), 120.7 (d, -OPhC 2),
116.7 (-ArC 3), 116.5 (-ArC 5), 42.4 (y-CH2, -VE DEPT), 41.4 (d, a-C), 32.5 (a-CH2, -VE 
DEPT), 25.5 (p-CH2, -VE DEPT), 15.5 (-CH3).
19F-NM R (376 MHz, DMSO): 5 -31.7 - -31.9 (m).
31P-NM R (161.9 MHz, DMSO): 5 19.61-19.98 (m).
A-cinnamoyl-f>lycine-(l), L)-phenylglycinep diphenyl ester 171
yV-cinnamoylglyci ne (0.82 g, 4 mm ol) and (D, L)-phenylglycinep diphenyl ester 
hydrobromide (1.68 g, 4 mmol) were used. Recrystallisation from diethyl ether furnished 171 
as a white powder (0.68 g, 32%). 
m.p. = 152-153 °C.
Anal, calcd. for CboH ^ O sP i : C, 68.43; H, 5.17; N, 5.32.
Found C, 68.42; H, 5.18; N , 5.21.
Mass Spectrum: [M+K]+ found 565.2.
C3 0 H 27N 2 O 5P 1K 1 requires 565.6.
IR (KBr): v 3276, 3075, 1655, 1618, 1490, 1213, 941 cm’1.
^ -N M R  (400 M Hz, DMSO): 8  9.53 (1H, d, J =  9.6 Hz, -NH-), 8.50 (1H, t, J =  5.6 Hz, -NH ­
), 6.98-7.67 (21H, m, -A iH  & -C=C-H), 6.82 (1H, d, J=  15.6 Hz, -C=C-H), 5.99 (1H, dd, J H~ 
H = 10.0 Hz, J H'P = 22.0 Hz, a-H), 4.09 (2H, d , J =  5.6 Hz, -CH2~).
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13C-NM R (100 MHz, DMSO): 5 169.43 (d, -CONH-), 165.7 (-ArCO-), 150.3 (d, -OPhC 1),
150.1 (d, -OPhC 1), 139.5 (C=C), 135.1 (-ArC 1), 134.6 (-PhC 1), 130.25 (-OPhC 3), 130.22 
(-OPhC 3), 129.9 (-ArC 4), 129.3 (-ArC 3), 128.96 (-PhC 3), 128.91 (-PhC 2), 128.6 (-PhC 
4), 127.9 (-ArC 2), 125.7 (-OPhC 4), 122.1 (C=C), 120.8 (d, -OPhC 2), 120.7 (d, -OPhC 2),
50.4 (d, a-C), 42.3 (-CH2-, -VE DEPT).
3 IP-NM R (161.9 M Hz, DMSO): 5 15.15 (d, J P'H= 21.9 Hz).
iV-cmnamoyl-P-alanine-(D, L)-phenylglycinep diphenyl ester 172
iV-cinnamoyl-P-alanine (0.88 g, 4 mm ol) and (D, L)-phenylglycinep diphenyl ester 
hydrobromide (1.68 g, 4 mmol) were used. Recrystallisation from diethyl ether furnished 172 
as a white powder (0.33 g, 15%). 
m.p. = 163-164 °C.
Anal, calcd. for C3iH29N20 5Pi: C, 6 8 .8 8 ; H, 5.41; N, 5.18.
Found C, 68.59; H, 5.30; N , 5.11.
M ass Spectrum: [M+Na]+ found 563.2.
C3 iH 29N 2 0 5 PiN ai requires 563.5.
IR (K B r): u 3284, 3068, 1661, 1621, 1489,1183, 934 cm '1.
!H-NM R (400 MHz, DMSO): 5 9.43 (1H, d, J =  9.6 Hz, -NH-), 8.24 (1H, t, J =  6.0 Hz, -NH ­
), 6.94-7.63 (21H, m, -ArH  8c -C=C-H), 6.63 (1H, d, J =  15.6 Hz, -C=C-H), 5.99 (1H, dd, J H' 
H= 10.0 Hz, J H'P = 22.0 Hz, a-H), 3.35-3.45 (1H, m, p-CH2), 2.50-2.57 (1H, m, a-CH2). 
13C-NMR (100 MHz, DMSO): 8  170.87 (d, -CONH-), 165.4 (-ArCO-), 150.3 (d, -OPhC 1),
150.0 (d, -OPhC 1), 139.0 (C=C), 135.2 (-ArC 1), 134.7 (-PhC 1), 130.2 (-OPhC 3), 129.7 (­
A rC  4), 129.2 (-ArC 3), 128.9 (-PhC 3), 128.8 (-PhC 2), 128.5 (-PhC 4), 127.8 (-ArC 2),
125.6 (-OPhC 4), 122.4 (C=C), 120.7 (t, -O PhC 2), 50.3 (d, a-C), 35.5 (p-CH2, -VE DEPT), 
35.3 (a-CH2, -VE DEPT).
3 1P-NM R (161.9 MHz, DMSO): 8  15.30 (d, J P'H= 22.0 Hz).
/V-cinnamoyl-y-aminobutyric acid-(D, L)-phenylglycinep diphenyl ester 173
Af-cinnamoyl-y-aminobutyric acid (0.93 g, 4 mmol) and (D, L)-phenylglycinep diphenyl ester 
hydrobromide (1.68 g, 4 mmol) were used. Recrystallisation from diethyl ether furnished 173 
as a white pow der (0.83 g, 37%). 
m.p. = 100-101 °C.
Anal, calcd. for C3 2H 3 iN 2 0 5Pi: C, 69.30; H, 5.63; N, 5.05.
Found C, 69.10; H, 5.63; N , 5.04.
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M ass Spectrum: [M+K]+ found 593.3.
C32H 31N 2 O 5P 1K 1 requires 593.6.
IR (KBr): u 3256, 3060, 1654, 1618, 1490, 1182, 940 cm '1.
'H -N M R (400 MHz, DMSO): 5 9.37 (1H, d, J=  9.6 Hz, -NH-), 8.20 (1H, t, J =  5.6 Hz, -NH ­
), 6.94-7.64 (21H, m, -ArH & -C ^C -H ), 6.64 (1H, d, J=  15.6 Hz, -C=C-H), 5.98 (1H, dd, J H~ 
H = 9.6 Hz, / H-p = 22.0 Hz, a-H), 3.20 (2H, q, J =  6.4 Hz, y-CH 2), 2.33 (2H, t, ./=  7.6 Hz, a- 
CH 2), 1.70-1.74 (2H, m, p-CH 2).
13C-NMR (100 MHz, DMSO): 5 172.2 (d, -CONH-), 165.3 (-ArCO-), 150.4 (d, -OPhC 1),
150.1 (d, -OPhC 1), 138.9 (C=C), 135.2 (-ArC 1), 134.8 (-PhC 1), 130.2 (-OPhC 3), 129.7 (­
A rC 4), 129.2 (-ArC 3), 128.9 (-PhC 3), 128.8 (-PhC 2), 128.5 (-PhC 4), 127.8 (-ArC 2),
125.6 (-OPhC 4), 122.5 (C=C), 120.6 (t, -OPhC 2), 50.3 (d, a-C), 38.7 (y-CH2, -VE DEPT),
32.9 (a-CH2, -YE DEPT), 25.8 (p-CH2, -VE DEPT).
3 1P-NM R (161.9 MHz, DMSO): 5 15.39 (d, J P’H= 22.0 Hz).
iV-cinnamoyl-glycine-(D, L)-phenylalaninep diphenyl ester 174
JV-cinnamoylglycine (0.82 g, 4 mmol) and (D, L)-phenylalaninep diphenyl ester 
hydrobromide (1.74 g, 4 mmol) w ere used. Recrystallisation from diethyl ether furnished 174 
as a w hite powder (1.15 g, 37%). 
m.p. -  127-128 °C.
Anal, calcd. for C3 iH 29N 2 0 5Pi: C, 6 8 .8 8 ; H, 5.40; N , 5.18.
Found C, 68.96; H, 5.44; N, 5.12.
M ass Spectrum: [M+K]+ found 579.2.
C3 iH 29N 2 0 5 PiK i requires 579.6.
IR (KBr): u 3268, 3061, 1656, 1618, 1489, 1189, 940 cm’1.
^ -N M R  (400 MHz, DMSO): 8  8 . 8 6  (1H, d, J =  9.2 Hz, -NH-), 8.35 (1H, bs, -NH-), 7.19­
7.59 (21H, m, -A iH  & -C=C -H), 6.78 (1H, d, J=  16.0 Hz, -C=C-H), 4.86-4.91 (1H, m, a-H), 
3.93 (1H, dd, J 3 =  4.8 Hz, J 2 = 16.0 Hz -CH2-), 3.75 (1H, dd, J 3 = 4.8 Hz, J 2 = 16.0 Hz, - 
CH2-), 3.30-3.35 (1H, m, -C tf2Ph), 3.00-3.08 (1H, m, -C tf2Ph).
13C-NM R (100 MHz, DMSO): 5 169.2 (d, -CONH-), 165.5 (-ArCO-), 150.3 (d, -OPhC 1),
150.1 (d, -O PhC 1), 139.4 (C=C), 137.2 (d, -PhC 1), 135.1 (-ArC 1), 130.3 (-OPhC 3), 130.2 
(-OPhC 3), 129.8 (-ArC 4), 129.4 (-PhC 3), 129.3 (-ArC 3), 128.6 (-PhC 2), 127.9 (-ArC 2),
127.0 (-PhC 4), 125.8 (-OPhC 4), 125.7 (-OPhC 4), 122.1 (C=C), 121.0 (d, -OPhC 2), 120.9 
(d, -OPhC 2), 47.7 (d, a-C), 42.1 <-CH2-, -VE DEPT), 34.7 (d, -CH2 Ph, -VE DEPT). 
3 1P-NM R (161.9 MHz, DMSO): 5 17.99 (t, J P_H= 7.3 Hz).
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A-cinnamoyl-p-alanine-(I), L)-phenylalaninep diphenyl ester 175
V-cinnamoyl-P-alanine (0.75 g, 3.45 mmol) and (D, L)-phenylalaninep diphenyl ester 
hydrobromide (1.50 g, 3.45 mmol) were used. Recrystallisation from diethyl ether furnished 
175 as a white powder (0.85 g, 45%). 
m.p. = 116-118 °C.
Anal, calcd. for C3 2H 31N 2 O 5P 1: C, 69.30; H, 5.63; N, 5.05.
Found C, 69.08; H, 5.72; N , 5.02.
M ass Spectrum: [M+K]+ found 593.3.
C3 2H 31N 2O 5P 1K 1 requires 593.6.
IR (KBr): u 3268, 3062,1655, 1618, 1489, 1189, 940 cm '1.
^ -N M R  (400 MHz, DMSO): 5 8.77 (1H, d, J =  9.2 Hz, -NH-), 8.10 (1H, t, J =  5.6 Hz, -NH­
), 7.18-7.55 (21H, m, -A iH  & -C=C-H), 6.59 (1H, d, J =  16.0 Hz, -C=C-H), 4.87-4.96 (1H, 
m , a-H), 3.24-3.33 (3H, m, -CH2? h  & p-CH2), 2.98-3.06 (1H, m  -Otf2Ph), 2.26-2.38 (2H, m, 
a-C  H 2).
13C-NM R (100 M Hz, DMSO): 5 170.7 (d, -CONH-), 165.3 (-ArCO-), 150.4 (d, -OPhC 1),
150.1 (d, -OPhC 1), 138.9 (C=C), 137.2 (d, -PhC 1), 135.2 (-ArC 1), 130.3 (-OPhC 3), 130.2 
(-OPhC 3), 129.7 (-ArC 4), 129.4 (-PhC 3), 129.2 (-ArC 3), 128.5 (-PhC 2), 127.8 (-ArC 2),
126.9 (-PhC 4), 125.7 (-OPhC 4), 125.6 (-OPhC 4), 122.5 (C=C), 121.0 (d, -OPhC 2), 120.7 
(d, -OPhC 2), 47.2 (d, a-C), 35.5 (p-CH2, -VE DEPT), 35.3 (a-CH2, -VE DEPT), 34.7 (d, - 
CH2Ph, -VE DEPT).
3 1P-NM R (161.9 MHz, DMSO): 8  18.19 (t, J P'H= 6.9 Hz).
TV-cinnamoyl-y-aminobutyric acid-(D, L)-phenylalaninep diphenyl ester 176
V-cinnamoyl-y-aminobutyric acid (0.50 g, 2.18 mmol) and (D, L)-phenylalaninep diphenyl 
ester hydrobromide (0.95 g, 2.18 mmol) were used. Recrystallisation from  diethyl ether 
furnished 176 as a w hite powder (0.45 g, 36%). 
m.p. =  150-150 °C.
Anal, calcd. for C33H 3 3N 2 0 5Pi: C, 69.70; H, 5.85; N , 4.92.
Found C, 69.40; H, 5.88; N , 4.94.
M ass Spectrum: [M+Na]+ found 591.3.
C33H 33N 2 0 5 PiN ai requires 591.5.
IR (KBr): u 3292, 3065,1651, 1618,1489, 1187, 942 cm '1.
JH-NM R (400 MHz, DMSO): 8  8 . 6 6  (1H, d, J =  9.6 Hz, -NH-), 8.09 (1H, t, J=  5.6 Hz, -NH ­
), 7.14-7.57 (21H, m, -A iH  8c-C=C-H ), 6.61 (1H, d, J =  16.0 Hz, -C=C-H), 4.84-4.93 (1H,
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m, a-H), 3.29-3.39 (1H, m, -CH2?h), 2.95-3.03 (3H, m -CH2Ph & y-CH 2), 2.06 (2H, t, J=  7.2 
Hz, a-CH2), 1.48-1.55 (2H, m, (3-CH 2).
13C-NM R (100 M Hz, DMSO): 5 172.1 (d, -CONH-), 165.2 (-ArCO-), 150.4 (d, -OPhC 1),
150.1 (d, -OPhC 1), 138.8 (C=C), 137.2 (d, -PhC 1), 135.2 (-ArC 1), 130.3 (-OPhC 3), 130.2 
(-OPhC 3), 129.7 (-ArC 4), 129.4 (-PhC 3), 129.2 (-ArC 3), 128.5 (-PhC 2), 127.8 (-ArC 2),
126.9 (-PhC 4), 125.7 (-OPhC 4), 125.6 (-OPhC 4), 122.5 (C = Q , 121.0 (d, -OPhC 2), 120.7 
(d, -OPhC 2), 47.3 (d, a-C), 38.5 (y-CH2, -VE DEPT), 34.6 (d, -CH 2Ph, -VE DEPT), 33.0 (a- 
CH2, -VE DEPT), 25.7 (P-CH2, -VE DEPT).
31P-NM R (161.9 MHz, DMSO): 5 18.26 (t, J P'H= 7.3 Hz).
A-cinnam oyl-jilycinc-(l), L)-alaninep diphenyl ester 177
V-cinnamoylglycine (0.56 g, 2.74 mmol) and (D, L)-alaninep diphenyl ester hydrobromide 
(0.98 g, 2.74 mmol) were used. Recrystallisation from diethyl ether furnished 177 as a white 
powder (0 . 6 8  g, 53%). 
m.p. = 138-140 °C.
Anal, calcd. for C2 5H 25N 20 5Pi: C, 64.65; H, 5.43; N, 6.03.
Found C, 64.39; H, 5.30; N, 6.02.
M ass Spectrum: [M+K]+ found 503.2.
C2 5H 25N 20 5PiK i requires 503.5.
IR (KBr): u 3266, 3071, 1655, 1619, 1489, 1190, 948 cm '1.
'H -N M R  (400 MHz, DMSO): 5 8.76 (1H, d, J =  9.2 Hz, -NH-), 8.44 (1H, t, J=  6.0 Hz, -NH ­
), 7.16-7.60 (21H, m, -A iH  & -C=C -H), 6.80 (1H, d, J =  16.0 Hz, -C=C-H), 4.73-4.81 (1H, 
m, a-H), 4.02 (1H, dd, J 3 = 6.0 Hz, J 2 = 16.8 Hz, -CH 2-), 3.89 (1H, dd, J 3 = 5.6 H z, J 2 =
16.8 Hz, -CH 2-), 1.48 (3H, dd, J H~H = 7.2 Hz, J H'P = 18.4 Hz, -CH 3).
13C-NM R (100 M Hz, DMSO): 5 169.0 (d, -CONH-), 165.6 (-ArCO-), 150.4 (d, -OPhC 1),
150.1 (d, -OPhC 1), 139.4 (C=C), 135.1 (-ArC 1), 130.27 (-OPhC 3), 130.22 (-OPhC 3),
129.8 (-ArC 4), 129.3 (-ArC 3), 127.9 (-ArC 2), 125.7 (-OPhC 4), 125.6 (-OPhC 4), 122.2 
(C=C), 121.0 (d, -OPhC 2), 120.8 (d, -OPhC 2), 42.3 (-CH2-, -VE DEPT), 41.6 (d, a-C), 15.5 
(-CH3).
3 1P-NM R (161.9 M Hz, DMSO): 5 19.39-19.82 (m).
196
V-cinnamoyl-|5-aIanine-(D, L)-alaninep diphenyl ester 178
7V-cinnamoyl-(3-alanine (0.43 g, 2.0 mmol) and (D, L)-alaninep diphenyl ester hydrobromide 
(0.70 g, 2.0 mm ol) were used. Recrystallisation from diethyl ether furnished 178 as a white 
powder (0.54 g, 55%). 
m.p. = 155-156 °C.
Anal, calcd. for C26H 27N 2O 5P 1 : C, 65.26; H, 5.69; N , 5.85.
Found C, 64.96; H, 5.49; N, 5.93.
M ass Spectrum: [M+Na]+ found 501.2.
C2 6H27N 2C>5PiN ai requires 501.5.
IR  (KBr): u 3249, 3066, 1655, 1618,1491, 1188,937 cm '1.
*H-NMR (400 MHz, DMSO): 8  8 . 6 8  (1H, d, J =  9.2 Hz, -NH-), 8.19 (1H, t, J =  5.6 Hz, -NH ­
), 7.15-7.55 (21H, m, -AxH  & -C=C-H), 6.64 (1H, d, J =  15.6 Hz, -C=C-H), 4.74-4.82 (1H, 
m , a-H), 3.39-3.45 (2H, m, p-C H2), 2.36-2.49 (2H, m, a-CH 2), 1.47 (3H, dd, 7 H_H = 7.2 Hz, J  
H'p = 18.4 Hz, -CH 3).
1 3C-NM R (100 MHz, DMSO): 8  170.5 (d, -CONH-), 165.3 (-ArCO-), 150.4 (d, -OPhC 1),
150.1 (d, -OPhC 1), 138.9 (C=C), 135.2 (-ArC 1), 130.2 (-OPhC 3), 130.1 (-OPhC3), 129.7 (­
A rC  4), 129.2 (-ArC 3), 127.8 (-ArC 2), 125.6 (-OPhC 4), 125.5 (-OPhC 4), 122.5 (C=C),
120.9 (d, -OPhC 2), 120.7 (d, -OPhC 2), 41.2 (d, a-C), 35.6 (p-CH2, -VE DEPT), 35.4 (a- 
CH2, -V ED EPT), 15.5 (-CH3).
3 1P-NM R (161.9 M Hz, DMSO): 8  19.55-19.95 (m).
j\-cinnam oyl-y-am inobutyric acid-(D, L)-alaninep diphenyl ester 179
7V-cinnamoy 1-y-aminobutyric acid (0.46 g, 2.0 mmol) and (D, L)-alaninep diphenyl ester 
hydrobromide (0.70 g, 2.0 mm ol) were used. Recrystallisation from diethyl ether furnished 
179 as a w hite powder (0.48 g, 49%). 
m.p. = 150-152 "C.
Anal, calcd. for C2 7H 2 9N 2O 5P 1 : C, 65.85; H, 5.94; N , 5.69.
Found C, 65.58; H, 5.83; N , 5.51.
M ass Spectrum: [M+K]+ found 531.2.
C2 7H29N 2O 5P 1K4  requires 531.6.
IR  (KBr): u 3256, 3062, 1662, 1628, 1490, 1186, 941 cm’1.
XH-NM R (400 MHz, DMSO): 8  8 . 6 6  (1H, d, J =  9.2 Hz, -NH-), 8.24 (1H, t, J=  5.6 Hz, -NH ­
), 7.19-7.58 (21H, m, -A rH  & -C=C-H), 6.69 (1H, d, J =  16.0 Hz, -C=C-H), 4.77-4.85 (1H,
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m, a -H), 3.24-3.32 (2H, m, y-CH2), 2.23-2.30 (2H, m, a-CH2), 1.73-1.80 (2H, m, p-CH2),
1.47 (3H, dd, J H'H = 7.2 Hz, J H'P = 18.4 Hz, -C //3).
13C-NMR (100 MHz, DMSO): 5 172.0 (d, -CONH-), 165.4 (-ArCO-), 150.4 (d, -OPhC 1),
150.2 (d, -OPhC 1), 139.0 (C=C), 135.2 (-ArC 1), 130.2 (-OPhC 3), 130.1 (-OPhC 3), 129.7 
(-ArC 4), 129.2 (-ArC 3), 127.8 (-ArC 2), 125.6 (-OPhC 4), 125.5 (-OPhC 4), 122.5 (C=C),
120.9 (d, -OPhC 2), 120.7 (d, -OPhC 2), 41.2 (d, a-C), 38.7 (y-CH2, -VE DEPT), 33.1 (a- 
CH2, -VE DEPT), 25.8 (p-CH2, -VE DEPT), 15.5 (-CH3).
3 1P-NM R (161.9 MHz, DMSO): 5 19.65-20.05 (m).
A'-trilluoroacetvl-ghcine-(I), L)-phenylglycinep diphenyl ester 180
7V-trifluoroacetyl glycine (0.68 g, 4 mmol) and (D, L)-phenylglycinep diphenyl ester 
hydrobromide (1.68 g, 4 mm ol) were used. Recrystallisation from diethyl ether furnished 180 
as a white powder (0.54 g, 29%). 
m.p. = 147-149 °C.
Anal, calcd. for C2 3 H 2oN2 0 5 PiF3: C, 56.10; H, 4.09; N , 5.69.
Found C, 55.85; H, 4.02; N, 5.48.
M ass Spectrum: [M+K]+ found 531.2.
C 23H 2oN2 0 5 PiF 3Ki requires 531.4.
IR (Nujol): u 3270, 3079, 1676, 1535, 1458, 1188, 936 cm-1.
■H-NMR (400 MHz, DMSO): 8  9.75 (1H, t, J =  6.0 Hz, -NH-), 9.61 (1H, d, J =  9.6 Hz, -NH ­
), 6.94-7.64 (15H, m, -Artf), 5.93 (1H, dd, J H'H = 10.0 Hz, J H‘P = 22.0 Hz, a-H), 3.35-3.41 
(2H, m, -CH2-).
1 3C-NMR (100 MHz, DMSO): 8  167.5 (d, -CONH-), 157.1 (q, F3CCO-), 150.2 (d, -OPhC 1),
150.0 (d, -OPhC 1), 134.5 (-PhC 1), 130.25 (-OPhC 3), 130.20 (-OPhC 3), 128.9 (-PhC 3),
128.8 (-PhC 2), 128.7 (-PhC 4), 125.8 (-OPhC 4), 125.7 (-OPhC 4), 120.8 (d, -OPhC 2),
120.7 (d, -OPhC 2), 116.3 (q, F 3C-), 50.6 (d, a-C), 42.0 (-CH2-, -VE DEPT).
19F-NM R (376 MHz, DMSO): 8  0.86.
3 1 P-NM R (161.9 MHz, DMSO): 8  15.23 (d, J P'H = 5.5 Hz).
Ar-trifluoroacetyl-|5-alanine-(I), L)-phenylglycinep diphenyl ester 181
TV-trifluoroacetyl-P-alanine (0.74 g, 4 mmol) and (D, L)-phenylglycinep diphenyl ester 
hydrobromide (1.68 g, 4 mm ol) were used. Recrystallisation from diethyl ether furnished 181 
as a white powder (0.46 g, 20%). 
m.p. = 119-120 °C.
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Anal, calcd. for C24H 22N 2 O 5P 1F3 : C, 56.92; H, 4.38; N , 5.53.
Found C, 56.66; H, 4.27; N, 5.39.
M ass Spectrum: [M+Na]+ found 529.2.
C24H22N20 5PiF3Nai requires 529.4.
IR (Nujol): u 3371, 3259, 1773,1660, 1452, 1171, 953 cm '1.
'H -N M R  (400 MHz, DMSO): 5 9.48-9.53 (2H, m, -NH-), 6.94-7.62 (15H, m, -AiH), 6.00 
(1H, dd, J H H= 9.6 Hz, J H‘P =  17.6 Hz, a-H), 3.42-3.45 (2H, m, p-CH 2), 2.58-2.62 (2H, m, a ­
C H2).
13C-NM R (100 MHz, DMSO): 5 170.3 (d, -CONH-), 156.7 (q, F3CCO-), 150.3 (d, -OPhC 1),
150.0 (d, -OPhC 1), 134.5 (-PhC 1), 130.1 (-OPhC 3), 128.8 (-PhC 3), 128.7 (-PhC 2), 128.6 
(-PhC 4), 125.7 (-OPhC 4), 120.6 (d, -OPhC 2), 116.3 (q, F3 C-), 50.2 (d, a-C), 36.1 (p-CH2, - 
VE DEPT), 34.1 (a-CH2, -VE DEPT).
19F-NM R (376 MHz, DMSO): 5 0.72.
3 1P-NM R (161.9 MHz, DMSO): 5 15.94 (d, J ?'H= 21.85 Hz).
A'-trifluoroacetyl-glycine-(I), L)-phenylalaninep diphenyl ester 182
7V-trifluoroacetylglycine (0.68 g, 4 mmol) and (D, L)-phenylalaninep diphenyl ester 
hydrobromide (1.71 g, 4 mm ol) were used. Recrystallisation from diethyl ether furnished 182 
as a w hite powder (1.19 g, 59%). 
m.p. = 167-168 °C.
Anal, calcd. for Q m^ N sO sP ^ :  C, 56.92; H, 4.38; N, 5.53.
Found C, 57.14; H, 4.30; N, 5.46.
M ass Spectrum: [M+Na]+ found 529.2.
C2 4H 2 2N 2 0 5 PiF 3Nai requires 529.4.
IR (Nujol): d 3225, 3079, 1727, 1650, 1463, 1188, 953 cm '1.
1 H-NM R (400 MHz, DMSO): 5 9.71 (1H, t, J =  6.0 Hz, -NH-), 9.00 (1H, d, J=  6.0 Hz, -NH ­
), 7.19-7.44 (15H, m, -Artf), 4.84-4.93 (1H, m, a-H), 3.92 (1H, dd, J 3 = 6.0 Hz, J  1 = 16.8 
Hz, -C //2 -), 3.73 (1H, dd, J 3 = 6.0 Hz, J 2 = 16.8 Hz, -CH2~) 3.33-3.38 (1H, m , -CH2?h), 
3.03-3.09 (1H, m, -C i/2Ph).
13C-NM R (100 MHz, DMSO): 5 167.5 (d, -CONH-), 157.0 (q, F3 CCO-), 150.3 (d, -OPhC 1),
150.1 (d, -OPhC 1), 137.1 (d, -PhC 1), 130.29 (-OPhC 3), 130.24 (-OPhC 3), 129.4 (-PhC 3),
128.6 (-PhC 2), 127.0 (-PhC 4), 125.8 (-OPhC 4), 125.7 (-OPhC 4), 121.0 (d, -OPhC 2),
120.9 (d, -OPhC 2), 116.3 (q, F3 C-), 47.8 (d, a-C), 41.8 (-CH2-, -VE DEPT), 34.8 (-CH2Ph, - 
VE DEPT).
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19F-NM R (376 MHz, DMSO): 5 0.92.
3 1P-NM R (161.9 MHz, DMSO): 8  18.01 (t, J P'H= 7.28 Hz).
jV-trifluoroacetyl-P-alanine-(I), L)-phenylalaninep diphenyl ester 183
7V-trifluoroacetyl-[3-alanine (0.74 g, 4 mmol) and (D, L)-phenylalaninep diphenyl ester 
hydrobromide (1.71 g, 4 mm ol) were used. Recrystallisation from diethyl ether furnished 183 
as a white powder (0.82 g, 39%). 
m.p. = 139-140 °C.
Anal, calcd. for C2 5H24N 2 O 5P 1F3 : C, 57.69; H, 4.65; N , 5.38.
Found C, 57.40; H, 4.65; N, 5.25.
M ass Spectrum: [M+K]+ found 559.2.
C25H24N20 5P,F3K, requires 559.5.
IR (Nujol): u 3270, 3086, 1704, 1654, 1446,1183, 947 cm '1.
!H-NM R (400 MHz, DMSO): 5 9.39 (1H, t, J=  5.2 Hz, -NH-), 8.78 (1H, d, J =  9.6 Hz, -NH ­
), 7.18-7.43 (15H, m, -ArH), 4.86-4.89 (1H, m, a-H), 3.29-3.34 (1H, m, -C if2Ph), 3.18-3.22 
(2H, m, p -C //2), 2.95-3.04 (1H, m, -CH2?ti), 2.27-2.37 (2H, m, a-C H2).
13C-NM R (100 MHz, DMSO): 5 169.8 (d, -CONH-), 156.5 (q, F3CCO-), 150.4 (d, -OPhC 1),
150.1 (d, -OPhC 1), 137.1 (d, -PhC 1), 130.29 (-OPhC 3), 130.21 (-OPhC 3), 129.4 (-PhC 3), 
128.5 (-PhC 2), 126.9 (-PhC 4), 125.7 (-OPhC 4), 125.6 (-OPhC 4), 121.0 (d, -OPhC 2),
120.7 (d, -OPhC 2), 116.6 (q, F3 C-), 47.3 (d, a-C), 35.9 ((3-CH2, -VE DEPT), 34.7 (d, - 
CH 2Ph, -VE DEPT), 34.1 (a-CH 2, -VE DEPT).
19F-NM R (376 MHz, DMSO): 8  0.74.
3 1 P-NM R (161.9 MHz, DMSO): 8  18.52 (t, J P'H= 8.24 Hz).
iV-trifluoroacetyl-glycine-(D, L)-alaninep diphenyl ester 184
jV-trifluoroacetylglycine (0.68 g, 4 mmol) and (D, L)-alaninep diphenyl ester hydrobromide 
(1.43 g, 4 mmol) were used. Recrystallisation from diethyl ether furnished 184 as a white 
powder (0.77 g, 48%). 
m.p. = 117-119 °C.
Anal, calcd. for C i8H 18N 2 0 5P iF 3: C, 50.24; H, 4.22; N, 6.51.
Found C, 49.95; H, 4.13; N , 6.25.
M ass Spectrum: [M+Na]+ found 453.2.
C i8HigN2 0 5PiF 3N ai requires 453.3.
IR (Nujol): u 3242, 3068, 1733, 1676, 1373, 1188, 958 cm '1.
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‘H-NM R (400 MHz, DMSO): 6  9.76 (1H, t, J=  5.2 Hz, -NH-), 8 . 8 8  (1H, d, ./=  9.2 Hz, -NH ­
), 7.15-7.40 (10H, m, -ArH), 4.71-4.79 (1H, m, a-H), 3.96 (1H, dd, J 3 = 5.6 Hz, J 2 = 16.4 
Hz, -CH2-), 3.87 (1H, dd, J 3 = 5.6 Hz, J 2 = 16.4 Hz, -CH 2-), 1.47 (3H, dd, J H'H = 7.2 Hz, J  
H‘p = 18.4 Hz, -CHi).
13C-NMR (100 MHz, DMSO): 5 167.2 (d, -CONH-), 157.4 (q, F3CCO-), 150.3 (d, -OPhC 1),
150.1 (d, -OPhC 1), 130.26 (-OPhC 3), 130.22 (-OPhC 3), 125.7 (-OPhC 4), 125.6 (-OPhC
4), 120.9 (d, -OPhC 2), 120.8 (d, -OPhC 2), 116.4 (q, F 3C-), 42.0 (-CH2-, -VE DEPT), 41.7 
(d, a-C), 15.5 (-CH3).
19F-NM R (376 MHz, DMSO): 5 0.89.
3 1P-NM R (161.9 MHz, DMSO): 6  19.42-20.00 (m).
AT-trifluoroacetyl-P-alanme-(D, L)-alaninep diphenyl ester 185
iV-trifluoroacetyl-P-alanine (0.74 g, 4 mmol) and (D, L)-alaninep diphenyl ester hydrobromide 
(1.43 g, 4 mmol) were used. Recrystallisation from diethyl ether furnished 185 as a white 
powder (0.67 g, 40%). 
m.p. = 129-130 °C.
Anal, calcd. for C 19H20N 2O 5P 1F 3 : C, 51.36; H, 4.54; N, 6.30.
Found C, 51.06; H, 4.50; N , 6.08.
M ass Spectrum: [M+Na]+ found 467.2.
C i9H 2oN2 0 5 PiF 3Nai requires 467.3.
IR  (Nujol): « 3276, 3074, 1721, 1648, 1458,1183, 958 cm '1.
!H-NM R (400 MHz, DMSO): 5 9.50 (1H, t, J=  5.2 Hz, -NH-), 8.73 (1H, d, J=  9.2 Hz, -NH ­
), 7.15-7.40 (10H, m, -ArH), 4.71-4.79 (1H, m, a-H), 3.41 (2H, q, J =  6.4 Hz, p-CH 2), 2.40­
2.52 (2H, m, a-CH i), 1.45 (3H, dd, J H'H = 7.2 Hz, J H'P = 18.4 Hz, -CH ) .
1 3C-NM R (100 MHz, DMSO): 8  170.0 (d, -CONH-), 156.6 (q, F3 CCO-), 150.3 (d, -OPhC 1),
150.1 (d, -OPhC 1), 130.2 (-OPhC 3), 130.1 (-OPhC 3), 125.7 (-OPhC 4), 125.6 (-OPhC 4),
120.9 (d, -OPhC 2), 120.6 (d, -OPhC 2), 116.4 (q, F3 C-), 41.4 (d, a-C), 36.1 (p-CH2, -VE 
DEPT), 34.2 (a-CH2, -VE DEPT), 15.3 (-CH3).
19F-NM R (376 MHz, DMSO): 8  0.68.
3 1P-NM R (161.9 M Hz, DMSO): 8  19.74-20.30 (m).
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Chapter 5
Fluorinated analogues of resveratrol as potential anticancer agents
5.1 In tro d u c tio n
Resveratrol 186, (3, 4 ’, 5-trihydroxy-iraws-stilbene) is a naturally occurring 
phytoalexin found in grapes and is formed in response to fungal infections . 1 Resveratrol is 
present only in small amounts in Vitis vivifera (vines) and its quantity is dependent on the 
stress situation o f the plant. The isolation o f resveratrol from plant sources is therefore not 
viable and it was not until synthetic methodologies were developed that the biological 
activity o f  resveratrol was com pletely assessed. It has been shown to exhibit various 
biological properties including antifungal, antibacterial, anticancer, estrogenic and 
cardioprotective activities . 2 Resveratrol came to prominence during the course o f  research 
into the so-called ‘French paradox’. The ‘French paradox’ is the realisation that the 
population o f  France have a relatively high fat diet accompanied by a steady albeit moderate 
intake o f  alcohol in the form o f  red wine whilst their incidence o f  coronary heart disease is 
lower than expected . 3 It has been shown that total phenolic compounds extracted from red 
wine inhibit the oxidatioh o f  human low-density lipoproteins (LDL). As the oxidised LDL 
m ay be responsible for prom oting atherogenesis, resveratrol may play a role in the prevention 
o f  cardiovascular diseases .4
on
F igu re  5.1 Resveratrol
Resveratrol has been suggested as a potential cancer chemopreventative agent based 
on its striking inhibitory effects on cellular events associated with cancer initiation, 
prom otion and progression . 5 This triphenolic stilbene has also displayed in vitro growth 
inhibition in a number o f  hum an cancer cells . 6 The mechanistic basis for the wide range o f 
biological activity o f  resveratrol remains unknown. Numerous studies point to its ability to 
function as a cellular antioxidant while others have demonstrated the inhibition o f s ignal l ing 
kinases as its key function . 7
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5.2 Biosynthetic pathway o f resveratrol
Resveratrol is a stilbene derivative formed from a p-coum aroyl CoA starter unit, w ith 
chain extension using three molecules o f  malonyl CoA . 8 M alonyl CoA is derived from the 
elongation o f  acetyl CoA units and the p-coum aroyl from phenylalanine. Phenylalanine loses 
the amino group moiety through oxidative deamination catalysed by the enzyme 
phenylalanine ammonia lyase to yield cinnamic acid which is then converted to 4-coumaric 
acid by enzymatic hydroxylation.
coon ,coon
Phenylalanine Ammonia Lyase
P h e n y la la n in e Cinnamic acid
1
HO
„CO-SCo A
CoASH
Cìnnamate-4-Hydroxyìase
COOH
4-hydroxy cinnamoyl-CoA 4-coumaric acid
Stilhene synthase T Y
OH O
Resveratrol
Figure 5.2 The biosynthesis o f  resveratrol
4-coumaric acid is then transformed to p-coum aroyl CoA after treatment with the free co­
enzyme o f a specific CoA ligase. The condensation o f  three malonyl CoA units w ith p -
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coumaroyl CoA results in a polyketide that undergoes a Claisen condensation to yield a 
stilbene acid derivative. Four moles o f  carbon dioxide are released for every mole o f 
resveratrol formed. 9 The formation o f resveratrol is facilitated by a stilbene synthase namely 
resveratrol synthase that is present in most species o f  the Vitaceae.
5.3 Syntheses o f resv era tro l
Resveratrol is present only in small amounts in plant sources and its quantity depends 
on the stress situation o f the plant. Isolation from plant sources is not viable, as it has been 
reported that only 92 (xgs o f  resveratrol are present in one gram o f dried grape skins . 10 
Reliable and efficient synthetic routes to resveratrol are therefore highly desirable. The first 
synthetic preparation o f resveratrol was achieved in 1941 by  Späth and K rom p . 11 The 
synthesis o f carbon-carbon double bonds can be achieved by various reactions including the 
Perkin and Suzuki reactions but it was not until the discovery o f  the W ittig reaction in 1953 
that this area o f  chemistry intensified. The majority o f  published routes for the synthesis o f 
resveratrol are based on W ittig like reactions.
OR
F ig u re  5.3 Retrosynthetic analysis o f  resveratrol
The W ittig reaction involves the reaction o f an aldehyde or ketone with a phosphorus 
ylid in the presence o f  a strong base to furnish an alkene . 12 Phosphorus ylids are prepared by 
treatm ent o f  a phosphonium salt with a base, with the phosphonium salts being prepared from
Resveratrol
Witt igPerkin
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a phosphine and an alkyl halide. The reaction proceeds w ith the formation o f  an 
oxaphosphetane that in turn due to energetic reasons furnishes a mixture o f  E- and Z- alkenes 
and a triphenylphosphine oxide by-product. The synthesis o f  resveratrol has been 
successfully achieved by the W ittig reaction . 5 The hydroxy groups o f  the starting materials 
m ust be protected for the reaction to proceed successfully. Protection has been achieved with 
methyl, benzyl and more recently /er/-butyldimethylsilyl groups . 13 The main disadvantage o f 
the W ittig reaction is the lack o f  stereoselectivity in relation to the newly formed double 
bond. Stereoselectivity has been improved with the use o f  trialkyl phosphines, a change in 
solvent or by the addition o f  salts. The E- and Z- isomers formed by the W ittig reaction were 
isolated by column chromatography . 5
RO
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RO RO
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F igu re  5.4 Synthesis o f resveratrol via the Wittig reaction
The condensation o f  non-enolizable aromatic aldehydes w ith anhydrides is called the 
Perkin reaction . 14 W hen-the anhydride has two a-hydrogen’s present, dehydration always 
occurs giving an aromatic alkenyl carboxylic acid derivative. Usually the salt o f  the acid is 
used so that nucleophilic attack on the anhydride regenerates the anhydride. This compound
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can then be decarboxylated using a variety o f  reagents to furnish a mixture o f  Z- and E- 
isomers w ith the cis isom er generally being the m ost abundant.
Solladié et a l have developed a synthesis o f  resveratrol using the Perkin reaction . 15 
They reacted 3,5-diisopropoxybenzaldehyde w ith 4-isopropoxyphenylacetic acid in the 
presence o f  acetic anhydride. Isopropyl ethers w ere used as the protecting groups as they can 
be easily rem oved at lower temperatures than their methyl analogues thus avoiding 
isomérisation o f  the product. Decarboxylation was carried out using copper chromate 
yielding the protected resveratrol analogue in a ratio o f  79:21 Z-: E-. Isomérisation was 
achieved by refluxing the mixture with phenyl disulfide in THF. This step was followed by 
deprotection o f  the isopropyl ethers using boron trichloride at -78 °C resulting in a 85% yield 
o f  resveratrol.
+
„on
(CH,CO)jO
CuCr,0-BaCr20/Quinoline
(PhS),
BC1,
Figure 5.5 Synthesis o f resveratrol using the Perkin reaction
The palladium cross coupling o f  boronic acids with organic halides is know n as the 
Suzuki reaction . 16 It is a highly selective reaction that is generally tolerant o f  functionality on 
either coupling partner. This reaction has been used as a successful method for the 
preparation o f  fluorinated analogues o f  resveratrol. 17 The first step o f  the reaction involved 
the synthesis o f  a bromofluoroolefm from the reaction o f  fluorotribromethane with a 
substituted aromatic aldehyde in the presence o f  zinc and a tertiary phosphine. Once again 
each o f  the hydroxy groups o f  resveratrol must be protected. The final step o f  the reaction 
involves coupling o f  the aromatic boronic acid with the bromoolefin. The reaction is
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catalysed by a palladium  catalyst and is most likely to occur via oxidative addition o f  Pd(0) to 
a carbon-boron bond.
F ig u re  5.6 Synthesis o f  fluorinated resveratrol derivatives using the Suzuki reaction.
Resveratrol has been prepared using a variety o f synthetic methodologies. The 
discovery o f  the W ittig reaction has been seminal in the synthesis o f  resveratrol and its 
analogues. To date the m ajority o f  synthetic routes available for the synthesis o f  stilbenes are 
based loosely on the W ittig reaction with deviations such as the W adsworth-Emmons and 
W ittig-H om er prevalent. The success o f  these routes has been mainly down to the availability 
o f  starting materials. The main disadvantage o f  these routes has been the low yields obtained 
due in part to the lack o f  stereoselectivity.
M ore recently, synthetic routes involving catalysis such as the Heck, Stille and 
Negishi reactions have come to the fore . 18 These reactions offer a stereospecific synthesis o f 
stilbenes. The main advantage o f  these coupling reactions is that the yield o f  a particular 
isom er is maximised. The other key component with the synthesis o f  resveratrol analogues is 
the protection o f  the hydroxy moieties with easily removable groups. To date there are very 
few protecting groups that can be removed under mild conditions. This will be a key 
challenge for the development o f stilbene analogues that contain highly reactive substituents.
O H
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5.4 Synthesis and structural characterisation o f fluorinated analogues o f resveratrol
Resveratrol is a natural phytoalexin produced in various plants and has been shown to 
have a variety o f  biological properties including antileukemic, antiplatelet aggregation,
- • • • * . . 9
antifungal, antibacterial, anticancer, estrogenic and cardioprotective activities. The synthesis 
o f  resveratrol has been achieved by various methods including the Wittig, Perkin and Suzuki 
reactions. Fluorinated resveratrol analogues have been shown to possess potent anti cancer 
activity . 19 The incorporation o f  a fluorine atom into a drug molecule has been well 
documented. Aromatic fluorination increases lipophilicity, acidity and alters the hydrogen 
bonding properties o f  a molecule. Fluorine also influences the biological stability o f  a drug 
molecule through altering susceptibility to metabolism. Fluorine has been used as a means to 
developing safer and more reactive pharmaceuticals due to the strength o f  the carbon-fluorine 
bond that is very difficult to metabolise, so harmful and unproductive side reactions are 
unlikely to occur. The replacem ent o f  a hydroxyl group by a fluorine atom is a strategy
• • 90 •widely used in drug development to alter biological function." Fluorine has a Van der Waals 
radius o f  1.47 A that is positioned between oxygen (1.52 A) and hydrogen ( 1 . 2 0  A) allowing 
it to mimic a hydroxyl group and play a part in hydrogen bonding properties. Fluorine 
substitution has been widely used to extend the half-life o f  m any synthetic compounds and 
thereby produce drugs w ith a longer duration o f  action.^
. R'
Figure 5.7 Targeted fluorinated analogues o f resveratrol
The synthesis o f  the fluorinated analogues 187-195 was first attempted by the 
classical W ittig reaction. The triphenyl phosphonium salts were prepared from the reaction o f 
triphenylphosphine and the relevant benzyl bromide in high yield. The benzyl bromides were 
synthesised from the reaction o f  the benzyl alcohol and phosphorus tribromide. The Wittig 
reaction was carried out using «-butyl lithium at -78 °C. The W ittig reaction yielded both the 
cis and trans isomers in alm ost equal quantities. Separation o f  these isomers proved difficult 
and the overall yield o f  the trans isomer was poor. This problem led to the utilisation o f  a 
stereospecific reaction w hereby only the required trans isomer was prepared. The reaction 
selected was the W adsworth-Emmons deviation o f  the W ittig reaction. The two main
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advantages o f  the W adsworth-Emmons reaction over the W ittig reaction was that the 
phosphonate byproduct formed from the W adsworth-Emmons reaction is water soluble and 
hence easily removable and secondly the reaction yields only the E- configuration. 
W adsworth and Emmons believed that the reaction was not in fact stereospecific and that
• 99initially both cis and trans isomers were formed as in the W ittig reaction.' However under 
strongly basic conditions at elevated temperatures the isomerisation o f  c/s-stilbene to trans­
stilbene would be expected. The phosphonate esters were prepared from the M ichaelis- 
Arbuzov  reaction whereby a benzyl bromide was reacted with triethyl phosphite to yield the 
benzyl phosphonate ester in quantitative yield. These ester derivatives were purified by 
vacuum  distillation. The W adsworth-Emmons reaction was carried out in 1,2- 
dimethoxyethane, using sodium hydride as a powerful base. The reaction proceeded as 
expected but there was a large quantity o f  unreacted aldehyde observed in the 'H  NMR. The 
separation o f  this aldehyde starting material from the product was often unattainable 
depending on the substitution on the phenyl ring. This failure led to the utilisation o f  another 
stereospecific reaction, nam ely the Heck reaction.
P(OEt),
OEt
'O Et
NaH
\  ✓OEl
<j> Na+
E tO -'fj- '-O E t
O
Water Soluble
Figure 5.8 The Wadsworth-Emmons reaction
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A decarbonylative Heck reaction has been described as an efficient method o f 
synthesising resveratrol. 23 Aroyl chlorides react with activated alkenes in presence o f a 
tertiary amine and a catalytic amount o f  palladium  acetate to give arylated alkenes . 24 The 
reaction involves a highly efficient decarbonylation o f the aroyl chloride. The reaction is not 
particularly sensitive to substituents in the aroyl chloride although strongly electron-donating 
groups have been shown to be advantageous. W ith mono-substituted alkenes the trans isomer 
was formed with almost complete specificity.
F igu re  5.9 The decarbonylative Heck reaction
The best results have been obtained by using tertiary bases w ith pK a values in the 
range 7.5-11. W eak bases were shown to facilitate a slower reaction whereas strong bases 
would react w ith the aroyl chloride .24  TV-Ethylmorpholine (NEM) was shown to be the most 
effective base as it did not react with aroyl chlorides nor did it cleave the bond between 
strongly electron-withdrawing groups and the aroyl chloride. The solvent used was /»-xylene 
as optimisation o f  the reaction showed that the best results were achieved at 120-130 °C.
Blaser and Spencer have proposed a mechanism for the decarbonylative Heck 
reaction . 24  Only the reacting groups are shown as little is known about the ligands occupying 
the vacant coordination sites. The first step is believed to involve oxidative addition o f  the 
aroyl chloride to a palladium  (0) species. The palladium (0) species is believed to be the 
product o f  a prelim inary reduction o f palladium acetate caused by  perhaps the alkene or the 
base. I f  there are no strongly bound ligands occupying the other coordination sites, aryl 
m igration to the metal should be facilitated. The release o f  carbon monoxide is expected as 
there is no ligands present capable o f  stabilising a palladium (II) carbonyl at high 
temperature. A lkene coordination is proposed as the next step although it is quite probable 
that the alkene is present as a ligand throughout the reaction. Syn addition o f  the alkene gives 
an intermediate that undergoes internal rotation about the central carbon-carbon bond to place 
H  and H-Pd-Cl syn  to each other. Following this the palladium is cleaved, the double bond is 
form ed w ith the regeneiation o f  Pd(0). It has been shown that the cumulative effect o f 
multiple electron-withdrawing groups has a detrimental effect on the yield o f  the reaction . 24
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F ig u re  5.10 Proposed m echanism  o f the decarbonylative Heck reaction
The decarbonylative Heck reaction gives almost complete specificity for the 
form ation o f  .E-isomers with monosubstituted alkenes. There are no sterically bulky ligands 
present so this steric specificity must be due to electronic factors. The expense o f  this 
reaction is somewhat reduced due to the regeneration o f  a palladium adduct.
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The synthesis o f  the fluorinated analogues 187-195 was successfully achieved using 
the decarbonylative H eck reaction. 3,5-Diacetoxybenzoyl chloride was prepared from the 
reaction o f  3,5-diacetoxybenzoic acid with phosphorus pentachloride. This benzoic acid was 
synthesised according to the literature . 25 The highest yield recorded for the decarbonylative 
Heck reaction was 65% for compound 193 with the lowest yield o f  19% for compound 190. 
The results o f  this reaction show that the difluoro-substituted phenyl ring always gives a 
poorer yield in contrast with the yields involving a monofluoro-substituted phenyl ring. For 
example the difluoro derivative 190 gave a yield o f  19%. The analogous monofluoro 
derivative 191 gave a higher yield o f 29%. This fact is due to the cumulative effects o f 
multiple electron-withdrawing groups on the aroyl chloride. Electron-donating groups have 
been shown to improve the yield o f the decarbonylative Heck reaction but electron- 
withdrawing groups have been shown to have a negative effect on the yield . 24 Compound 194 
was prepared by  firstly synthesising its acetoxy analogue followed by treatment with 
am monium acetate to deprotect the acetoxy group. Compound 195 was prepared using 
analogous m ethodology but in this case am monium acetate only deprotected one o f  the 
available two acetoxy groups.
Table 5.1 Fluorinated analogues o f  resveratrol
Compound R i R 2 r 3 % Yield
187 -F -F -F 48
188 -F -F - O C H 3 2 2
189 - O C H 3 - O C H 3 -F 26
190 -F -F - O C H 2 C H 3 19
191 - O C H 2C H 3 - O C H 2 C H 3 -F 29
192 -F -F - O C O C H 3 58
193 - O C O C H 3 - O C O C H 3 -F 65
194 -F -F - O H 81a
195 - O H - O C O C H 3 -F 76a
a %  Y ield o f  deprotection step.
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The Infrared spectra o f  these derivatives show distinctive bands at ~1100 cm ' 1 representing 
the ether moieties. Compounds 192 and 193 show carbonyl bands at ~ 1700 cm '1. The 19F 
NMR spectra o f  these derivatives show the 3,5 difluoro analogues appearing as triplets at 5 — 
35 w ith coupling constants o f  approx. 5 Hz. The 4-fluoro derivatives appear as multiplets 
centred at 5 —38 due to the effect o f 19F - 'h  coupling.
5.4.1 *H NM R study o f the fluorinated resveratrol analogues
The 'H  NMR spectrum o f compound 191 is shown in Figure 5.12. The 
stereoselectivity o f the decarbonylative Heck reaction was confirmed by ’H NMR. The 
unsaturated unit appeared as two doublets at 8  ~7.28 and 5 ~7.13 w ith coupling constants o f 
approx. 16.4 Hz. They appear as doublets due to vicinal coupling with each other. I f  there 
was any Z-isomer present the double bond protons would also appear as doublets. The main 
difference between E- and Z-isomers in 'H  NMR is the size o f  the coupling constant. E-
isomers show greater coupling constants due to superior overlap o f orbitals. The orbitals o f a
on
Z-isomer are not parallel so not as much orbital overlap is possible. Z-isomers generally 
record coupling constants between 7 and 11 Hz whereas E-isomers have coupling constants 
between 15 and 18 Hz.
h y
w
D #
Figure 5.11 Orbital alignment for E- and Z-isomers
The 3,5-dialkoxy derivatives 189, 191, 193 and 195 are good examples o f  mete- 
coupling in the !H NMR. The proton in the para  position couples with the two protons in the 
ortho  positions to give a-triplet at 5 -6 .43  w ith a coupling constant o f  ~ 2.4 Hz. This four- 
bond coupling is facilitated by effective orbital overlap. The same coupling is responsible 
for the doublets that appear for the ortho protons in analogous compounds. These appear as 
doublets at 8  ~  6.78 with a coupling constants o f  ~2.4 Hz. Similar coupling patterns is not 
seen for the 3,5-difluoro analogues as 'H -19F coupling obscures the spectra. The hydrogen 
atoms attached to fluorinated phenyl rings appear as multiplets due to 'H -^ F  coupling. The 
only exception is the protons that appear in the ortho position next to the fluorine substituent
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in compound 191. The protons in the meta positions o f  this compound appear as multiplets 
due to ^ - ^ F  coupling. The alkoxy substituents appear as expected. The hydroxy, m ethoxy 
and acetoxy appear as singlets at 5 -6 .13 , 5 ~3.76 and 5 -2 .32  respectively. The ethoxy 
methylene group appears as a quartet w ith a coupling constant o f  7.2 Hz at 5 4.03 and as a 
triplet representing the methyl group w ith a coupling constant o f  7.2 Hz at 5 1.33.
Table 5.2 Selected 'H  NM R data (5) for the fluorinated resveratrol derivatives
Compound No._______ A rfl 4_______ArH  2 & 6  C -C -H _________ArH  3 & 5
187 7.15-7.20 7.24-7.32 7.48,7.24-7.32 7.38-7.41
188 7.01-7.10 7.27-7.30 7.35,7.01-7.10 6.96
191 6.39 6.74 7.27,7.10 7.20
192 7.08-7.14 7.32-7.36 7.44,7.23 7.17
195 6.49 6.78 6.97,6.85 7.01-7.06
 ............ 1 . . . . . . . . . .  t—...................................................  -------------  r -----------------i------------------1----------------- i----------------- i 
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Figure 5.12 *H N M R spectrum o f (E)-l-(4-fluorostyryl)-3,5-diethoxybenzene 191.
5.4.2 13C NM R  study o f ithe fluorinated resveratrol analogues
The 13C NM R spectrum o f compound 191 is shown in Figure 5.13. The effect o f  19F- 
13C coupling is seen throughout the spectra. The aromatic carbons o f  the fluorinated ring 
appear as doublets and triplets due to this coupling. The carbon atom o f the phenyl ring to 
w hich the fluorine atom is bonded appear as doublets. This appears the furthest downfield at 
5 ~163 due to the electronegative nature o f  fluorine. There are some notable differences 
between the m ono- and difluoro analogues. The chemical shifts o f  the double bond carbon 
atoms in the difluoro derivative compound 188 appear at 5 131.4 and 5 124.2. The chemical
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shift o f  the analogous carbon atoms in the monofluoro derivative compound 189 appear a lot 
closer together at 8  128.7 and 8  128.0. The trifluoro derivative compound 187 has chemical 
shifts o f  8  -1 3 0  and 8  ~126 for the carbon atoms o f the unsaturated unit. The carbon atoms o f 
the phenyl rings that are bonded to an oxygen atom appear downfield at 8  ~159 due to the 
deshielding effect o f  the attached oxygen. The acetoxy derivatives 192 and 193 show the 
analogous carbon atoms appearing further upfield at 8  ~150. The chemical shift o f  the para  
carbon in the disubstituted phenyl ring appears at approximately the same resonance 
frequency for both the difluoro and dialkoxy derivatives. The main difference is the fact that 
it appears as a triplet in the difluoro- derivatives due to 19F-13C coupling but as a singlet in the 
dialkoxy derivatives. The only exceptions are compounds 193 and 195 that have an acetoxy 
group in the 3- and/or 5- position. The acetoxy moiety has the ability to shift the attached 
carbon upfield but it also alters the chemical shift o f  the carbon atom ortho to the substituted 
carbon. The para  carbon appears downfield at 8  ~ 114.2 with the ortho  carbon also appearing 
downfield at 8  -  117.2.
Table 5.3 Selected 13C NMR data (8) for the fluorinated resveratrol derivatives
Compound No. C-F C=C C-OR Cpara
187 164.2, 162.3, 161.8 130.6, 126.4 - 102.9
188 164.2, 161.8 131.4, 124.2 159.8 102.4
191 162.0 128.6, 127.9 160.2 100.9
192 164.2, 161.8 130.8, 126.6 150.7 102.7
195 162.9 129.1, 127.6 157.2, 151.9 108.8
7 0
T r*"
40170  16 0 1 4 0  1 3 0 1 1 0  1 0 0
Figure 5.13 13C NMR spectrum o f (E )-1 -(4-fluorostyryl)-3,5-diethoxybenzene 191.
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5.5 Biological activity of the fluorinated resveratrol analogues
5.5.1 Introduction
Resveratrol exhibits a wide range o f  biological properties including antifungal, 
antibacterial, antiviral, estrogenic, platelet aggregation and anticancer activities.' Cancer is a 
group o f  diseases characterized by uncontrolled growth and spread o f  abnormal cells often 
leading to death . 28  Resveratrol has been shown to inhibit the growth o f  various cancer cell 
lines. It has been shown to provide cancer chemopreventative effects in different systems 
based on its potent inhibition o f  diverse cellular events associated w ith tumour initiation, 
prom otion and progression . 5
Chemoprevention can be defined as the prevention or reduction o f  cancer risk by the 
ingestion o f  natural or synthetic compounds w ith low toxicity that are able to suppress, delay 
or reverse carcinogenesis . 3 The use o f  tamoxifen in breast cancer is one o f  the best examples 
o f  chem oprevention .3 This stilbene derivative is administered for five years following surgery 
for breast cancer and it has been found to reduce the risk o f  tumour recurrence. The cancer 
chemopreventative activity o f  resveratrol is due to its ability to activate apoptosis.
Apoptosis is defined as programmed cell death . 29  Commonly used chemotherapeutic 
drugs can induce this form o f  cell death. Apoptosis may therefore function as a common 
m echanism  o f  rem oving unrepairable genetic lesions from cells. Recent studies have shown 
that cytochrome c release from the mitochondria is a key component in the activation o f 
caspases leading to apoptosis . 29  Resveratrol has been shown to have the ability to selectively 
induce apoptosis in  leukemic cells but not in normal haematopoietic cells . 30  The p53 gene is 
one o f the m ost important tumour suppressor genes and mutation or loss o f  this gene is 
believed to be responsible for more than half o f  human cancers . 31 The p53 protein is critical 
for apoptosis and lack o f  p53 expression or function is associated with an increased risk o f  
tum our formation. Resveratrol induces p53 dependent transcriptional activation. Reveratrol 
induced apoptosis occurs in cells expressing p53 but not in p53 deficient cells. This 
resveratrol-induced activation o f  p53 is also partly due to the activities o f  extracellular signal 
regulated protein kinases and p38 kinase and their phosphorylation o f  p53 at serine 15 that 
plays a critical role in the stabilization, up-regulation and functional activation o f  p53 . 32
The synthesis o f fluorinated stilbene analogues has provided potent cell growth 
inhibitors o f  leukaemia. ' The introduction o f  a fluorine atom often brings about an 
im provem ent in bioactivity mainly due to alteration o f  metabolization and increased 
lipophilicity. It is hoped that the synthesis o f  novel fluorinated analogues o f  resveratrol will 
produce potent selective drugs w ith anticancer activity against a range o f  cancer cell lines.
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5.5.2 Anticancer potential o f fluorinated resveratrol analogues
Four compounds nam ely 187, 188, 189 and 192 were assessed for their anticancer 
ability by the National Cancer Institute under the Development Therapeutic Program (DTP). 
It was hoped that these preliminary results would indicate the potential anticancer activity o f 
the fluorinated resveratrol analogues. The compounds were firstly assessed using a primary 
anticancer screen. Previous work carried out by the DTP has used an in vitro model 
consisting o f  60 human tumour cell lines as the prim ary anticancer screen. Analysis o f  this 
data indicated that approx. 95% o f the actives from the 60 cell line screen can be identified 
using only three lines. For this reason the DTP is now using a three cell line panel consisting 
o f  M CF7 (Breast), NCI-H460 (Lung) and SF-268 (CNS) as its prim ary anticancer assay. This 
3-cell line, one dose assay has been in use by the DTP for several years for the evaluation o f 
com binatorial libraries and has proven to be an effective pre-screen. The inclusion o f this 
assay allows for a more detailed evaluation o f  agents that have exhibited some ability to 
inhibit the growth o f  human tum our cells in culture.
In this assay each cell line was inoculated and preincubated on a m icrotiter plate. Test 
agents were then added at a single concentration and the culture was incubated for 48 hours. 
End point determinations were made w ith alamar blue. Results for each test agent were 
reported as the percent o f growth o f  the treated cells when compared to the untreated control 
cells. Compounds that reduce the growth o f any one o f the cell lines to approx. 32% or less 
are passed on for evaluation in the full panel o f  60 cell lines over a 5-log dosage. Negative 
numbers indicate cell kill.
Table 5.4 The growth percentage o f  human tum our cells in culture when treated w ith various 
fluorinated analogues o f  resveratrol compared to the untreated control cells
Compound Cone. pM Breast Lung CNS
187 1 0 0 82 1 0 1 1 1 1
188 1 0 0 84 105 1 1 1
189 1 0 0 67 60 105
192 1 0 0 2 2 7 1
The results o f  this assay indicate that fluorinated analogues o f  resveratrol m ay have 
potential as anticancer agents. Compounds 187 and 188 showed mild toxicity against the 
breast tum our cell lines with approx 2 0 % inhibition recorded but no inhibition o f  growth was 
m easured against the lung or CNS cell lines. Compound 189 showed improved activity
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against both the breast and lung cell lines with 40% inhibition recorded for the lung tumour 
cell lines. The difluoro derivative compound 192 was the most potent analogue against 
breast, lung and central nervous system tumour cells. It was shown to limit the growth o f 
breast cancer by 78 %. The lung cancer cells only increased by only 7% when treated with 
com pound 192. The most interesting result is the fact that this compound managed to limit 
the growth o f CNS tum our cells by 99% over a two-day period. These results indicated that 
compound 192 was a prime candidate for evaluation in the full panel o f 60 cell lines.
Compound 192 was then assessed in the 60 cell line assay that included human 
tum our cells from leukaemia, lung cancer, colon cancer, central nervous system, melanoma, 
ovarian cancer, renal cancer, prostate cancer and breast cancer. The I C 5 0  and G I 5 0  values were 
calculated for each cell line. The I C 5 0  value refers to the concentration required to achieve a 
50% survival o f  the available cells whereas the G I 5 0  value refers to the concentration required 
to inhibit the growth o f  the tum our by 50%.
T ab le  5.5 Pharmacological values o f  compound 192 against various tumour cell lines
T u m o u r Cell L ine IC 5 0  j i M G I50 j i M
Leukaemia HL-60 (TB) 116.74 54.59
Lung EKVX ' 116.74 78.26
Colon HT29 80.64 73.69
CNS SNB-75 90.92 60.34
M elanom a SK-MEL-28 83.09 70.11
Ovarian SK-OV-3 96.54 83.09
Renal RXF 393 202.35 75.94
Prostate D U -145 127.74 100.48
Breast T-47D 127.74 79.84
From  these results it can be seen that compound 192 has broad spectrum anticancer 
activity. This compound yvas seen to be most active as an anticancer agent against the colon 
tum our cell line and gave an I C 5 0  value o f  80.64 (xM. It was seen to inhibit the growth o f 
cancer m ost effectively with the leukaemia cell line giving a G I 5 0  value o f  54.29 (iM. 
A lthough the cytotoxicity o f  compound 192 is not dramatic it is comparable to previously 
published results . 33 The biological activities o f  resveratrol analogues have been best utilised 
by chem oprevention and cancer growth inhibition. Cytotoxicity has not been shown to be an 
essential component o f  potent growth inhibition and chemopreventative agents.
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5.6 Synthesis and characterisation ot 3,5-difluorophenyl resveratrol analogues
Preliminary results indicated that compound 192 exhibited anticancer activity against 
a variety o f tum our cell lines. This led to the development o f a series o f  analogues based on 
the scaffold o f  192. The unique nature o f  a 3,5-difluorostilbene exhibiting anticancer 
properties led to the derivitisation o f  the 4-position. It was hoped that by altering the 
lipophilicity, hydrogen bonding properties and steric size o f  the substituent present at the 4- 
position that an enhancement o f  anticancer activity would be achieved. It was decided to 
incorporate the trichloroacetyl, trifluoroacetyl, trimethylacetyl, methanesulphonyl, 4- 
fluorobenzenesulphonyl and 2 -fluorobenzoyl moieties in an attempt to improve bioactivity.
F igure 5.14 Synthesis o f  3,5-difluorophenyl resveratrol derivatives
The synthesis o f  these compounds was achieved by firstly preparing compound 194 
from the decarbonylative Heck reaction. This compound was then reacted w ith a series o f 
chlorides and anhydrides to synthesise the desired derivatives in yields ranging between 50 
and 78 %. The highest yield was recorded for compound 198 with a value o f  78%. The 4- 
fluorobenzenesulphonyl derivative 200 gave the lowest yield. A lthough the trifluoroacetyl 
m oiety is sterically related to the trichloroacetyl and trimethylacetyl groups, the yield o f  197 
was less than its trichloro- and trimethyl- analogues. This is probably due to the fact that an
222
anhydride was used to prepare 197 and not a chloride. The use o f  trifluoroacetyl chloride was 
not used as it was only available in a gaseous form. The yields o f  compounds 200 and 201 
were the lowest due to steric hindrance as the substituents being introduced were by  far the 
bulkiest groups.
T ab le 5.6 3,5-difluorinated analogues o f  resveratrol
C om pound R ,3C N M R  8  C ipso m .p. °C %  Yield
196 -COCCI3 150.6 92-94 74
197 -COCF3 141.4 139-141 61
198 -COC(CH 3) 3 151.5 79-81 78
199 -S0 2 CH 3 149.2 85-87 71
2 0 0 -S02-p-F-C 6H4 149.4 71-73 50
2 0 1 -CO-o-F-C 6H4 150.9 118-120 52
The 'El N M R spectra o f  these derivatives were very similar to the previously 
described 3,5-difluoro resveratrol analogues 188,190, 192 and 194. The substituent present at 
the 4-position had little effect on the attached phenyl ring. The 2-fluorobenzoyl substituent in 
com pound 201 shifted the protons in the meta  and ortho positions the furthest downfield to 5
7.47 and 5 7.09-7.20 respectively. The tert-butyl and methylsulphonyl moieties appear as
1 'j
singlets at 5 ~1.27 and 5 -3 .08 . The ,',C N M R spectra show analogous pattern to that o f  the 
previously discussed 3,5-difluoro resveratrol analogues. The only exception is compound 197 
where the effect o f  the trifluoroacetyl m oiety is seen throughout the spectra o f  the attached 
phenyl ring. The trifluoromethyl group appears as a triplet at 5 141.4 due to 19F -13C coupling 
w ith the carbonyl appearing at 5 156.3. This carbonyl appears at considerably higher field to 
that o f compounds 196 and 201. The carbonyls o f  these derivatives generally appear at 8  
-162 . The carbonyl o f  the trimethylacetyl moiety is seen the furthest downfield at 8  177.4. 
The trifluoroacetyl moiety had a distinct effect on the chemical shifts o f  the carbon atoms in 
the attached phenyl ring. The ipso carbon generally appeared at 8  -1 5 0  but in compound 197
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the analogous carbon was shifted upfield to 8  141.4. A similar result was observed for the 
ortho and para  carbons although this effect was not seen for the meta  carbons that appeared 
at a chemical shift common to each derivative. The 19F NM R spectra showed the 3,5- 
difluorophenyl ring appearing as a triplet at 8  —34.6 w ith a 19F -13C coupling constant o f ~ 7.8 
Hz. The fluorine atoms present on the phenyl rings o f  the benzoyl and benzenesulphonyl 
moieties appeared as multiplets centred at 8  —32 and 8  —26 with the benzoyl fluorine 
appearing at lower field: The fluorine atoms o f the trifluoromethyl group appeared as a 
singlet at 5 —0.5 due to their equivalence. The Infrared spectra o f these derivatives show C-H 
stretching o f the unsaturated unit appearing at ~  3050 cm '1. There are two or three bands 
shown at ~  1550 cm ' 1 responsible for the aromatic rings. Compound 199 has two strong 
bands present at -1200  and 1400 cm ' 1 due to the O-SO 2 moiety. Compounds 196, 197, 198 
and 201 show absorption peaks due to the carbonyl groups at -  1740 cm '1.
5.6.1 H M Q C  study o f (iS)-4-(3,5-difluorostyryI)phenylmethanesulphonate 199
Heteronuclear multiple quantum correlation (HMQC) is a 2D NM R spectroscopic 
technique which correlates the carbon and proton spectra. Table 5.7 and Figures 5.15 to 5.16 
show the C-H correlation spectrum o f (E)-4-(3,5-difluorostyryl)phenylmethanesulphonate 
199.
Table 5.7 C-H correlation o f  (¿’)-4-(3,5-difluorostyryl)phenylmethanesulphonate 199
Site 'H I3C H M Q C
1 140.6
2 6.84-6.92 109.6
3 164.8
4 6.59-6.62 103.4
5 162.5
6 6.84-6.92 109.5
7 6.96 128.1
8 6.84-6.92 129.9
9 136.1
1 0 & 1 1 7.43 128.6
12 & 13 7.19 1 2 2 . 8
14 149.2
15 3.08 37.8
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Figure 5.15 HM QC Spectrum o f (£)-4-(3,5 difluorostyryl)phenylmethanesulphonate 199
7.5 7.4 7.3 7.2 7.1 7.0 6.9 6.8 6.7 6.6 6.5 6.4 6.3 6.2 ppm
Figure 5.16 Expanded HMQC Spectrum of compound 199
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5.7 Conclusion
The synthesis and characterisation o f  a series o f novel fluorinated analogues o f 
resveratrol has been achieved. Their preparation was carried out using the decarbonylative 
Heck reaction as devised by Spencer et a l 2A This reaction was preferentially selected as it 
formed only the E-isom er and the starting materials were readily available. It was shown that 
the W ittig and W adsworth-Emmons reactions formed compounds that were difficult to 
isolate and w hose yields were not remarkable. The compounds were characterized by H, i3C, 
19F, DEPT and HM QC NM R studies. Structural elucidation was further supplemented by 
electrospray ionisation mass spectrometry and Infrared spectroscopy.
Prelim inary biological results indicated that (E)-l-(4-acetoxystyryl)-3,5- 
difluorobenzene 192 was a potent growth inhibitor o f breast, lung and central nervous system 
cancer lines. A t a concentration o f  100 pM the growth o f  central nervous system cancer was 
inhibited by 99%. Compound 192 was assessed as a prim e candidate for evaluation in the full 
panel o f  60 cell lines as used by the by the National Cancer Institute under the Development 
Therapeutic Program  (DTP). The results o f  this assay indicated that compound 192 was a 
broad spectrum anticancer derivative as success was seen against leukaemia, colon, lung, 
breast, melanoma, prostate, ovarian, cenirai nervous system and renal cancer lines.
These results indicate that fluorinated analogues o f  resveratrol have the ability to be 
potent inhibitors o f  carcinogenesis. Further analogues o f  compound 192 were prepared based 
on the 3,5-difluoro-4-oxostilbene scaffold. It is hoped that derivatisation o f  compound 192 at 
the 4-oxo position will improve the potency o f  these derivatives. The anticancer activities o f 
these compounds along with the previously untested compounds are currently under 
investigation. Further research w ill be based on the results from these assays.
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5.8 Experim ental
General Procedures.
All chemicals were purchased from Sigma/Aldrich and used as received. W hen necessary 
solvents were purified prior to use and stored under nitrogen. Dichloromethane was distilled 
from CaH2 and triethylamine was distilled and stored over potassium hydroxide pellets. 
Commercial grade reagents were used without further purification. Riedel-de Haen silica gel 
was used for thin layer and column flash chromatography. Melting points were determined using 
a Griffin melting point apparatus and are uncorrected. Infrared spectra were recorded on a 
Nicolet 405 FT-IR spectrometer and elemental analysis was carried out by the Microanalytical 
Laboratory at University College Dublin. Electrospray ionisation mass spectra were recorded on 
a Bruker Esquire 3000 series LC/MS. NM R spectra were obtained on a Bruker AC 400 NMR 
spectrometer operating at 400 MHz for 'H  NMR, 376 MHz for 19F NM R and 100 MHz for 13C 
NMR. The 'H  and 13C NM R chemical shifts (ppm) are relative to tetramethylsilane and the 19F 
N M R chemical shifts (ppm) are relative to trifluoroacetic acid. All coupling constants (J) are in 
Hertz.
(£ )-l-(4 ' -fluorosty ryl)-3',5-difluorobenzene 187
3,5-Difluorobenzoyl chloride (1.45 g, 8.2 mmol) and 4-fluorostyrene (1.0 g, 8.2 mmol) were 
added to a solution o f  palladium acetate (0.092 g, 0.41 mmol) and /V-ethylmorpholine (3.37 g,
8.2 mmol) in xylene (50 mis). The solution was heated at 120 °C for 18 hrs and then filtered. 
The solvent was removed in vacuo to yield a crude brown solid. Recrystallisation from 
hexane/ethyl acetate 50:1 gave the title product as white crystalline needles (0.93 g, 48%). 
m.p. 48-50 °C. L it . 19 m.p. 47 "C.
Anal, calcd. for C i4 H 9F3: C, 71.79; H, 3.87.
Found C, 72.04; H, 3.99.
IR  (KBr): u 2956, 2857, 1597, 1510, 1233, 961, 831 cm’1.
]H-NM R (400 M Hz, DMSO): 5 7.69-7.73 (2H, m, -A rtf 2 '&  6 ') , 7.48 (1H, d , J =  16.4 Hz, - 
C=C -H), 7.38-7.41 (2H, m, -ArH  3 '&  5 '), 7.24-7.32 (3H, m, -A rH  2, 6  & -C=C -H), 7.15­
7.20 (1H, m, -A rH  4).
13C-NM R (100 MHz, DMSO): 5 164.2 (d, -ArC 3), 162.3 (d, -ArC 4 '), 161.8 (d, -ArC 5),
141.4 (t, -A rC 1), 133.2 (d, -A rC 1'), 130.6 (-C=C-H), 129.0 (d, -ArC T  & 6 ') , 126.4 (d, - 
C=C-H), 116.0 (-A rC 3 ' & 5 '), 109.6 (d, -ArC 2), 109.4 (d, -ArC 6 ), 102.9 (t, -ArC 4). 
19F-NM R (376 MHz, DMSO): 5 -34.8 - -34.9 (2F, m), -37.8 - -37.9 (IF , m).
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(£)-l-(4'-m ethoxystyryl)-3,5-difluorobenzene 188
3.5-Difluorobenzoyl chloride (1.32 g, 7.5 mmol) and 4-vinylanisole (1.0 g, 7.5 mmol) were 
used. Recrystallisation from hexane/ethyl acetate 12:1 furnished 188 as yellow crystalline 
needles (0.41 g, 2 2 %).
m.p. 107-109 °C. Lit. 19 imp. 108-110 °C.
Anal, calcd. for C i5H i20 iF 2: C, 73.16; H, 4.91.
Found C, 73.49; H, 5.35.
IR (KBr): v  2963, 2833, 1586, 1511, 1240, 962, 838 c m 1.
'H -N M R  (400 M Hz, DMSO): 5 7.54 (2H, d , J  = 8.4 Hz, -A rH 2 '&  6 ') , 7.35 (1H, d, J =  16.4 
Hz, -C=C-H), 7.27-7.30 (2H, m, -A rH  2 & 6 ), 7.01-7.10 (2H, m, -A rH  4 & -C=C-H), 6.96 
(2H, d, J =  8 . 8  Hz, -A r H 3' & 5 '), 3.76 (3H, s, -O CH3).
13C-NM R (100 MHz, DMSO): 6  164.2 (d, -ArC 3), 161.8 (d, -ArC 5), 159.8 (-A rC 4 '), 141.8 
(t, -ArC 1), 131.4 (-C=C-H), 129.2 (-ArC 1'), 128.5 (-ArC 2 ' & 6 ') , 124.2 (t, -C=C-H), 114.5 
(-A rC 3 ' & 5 '), 109.3 (d, -A rC 2), 109.1 (d, -A rC 6 ), 102.4 (t, -ArC 4), 55.4 (-OCH3). 
19F-NM R (376 MHz, DMSO): 5 -35.0 (2F, t, . / C'F= 5.2 Hz).
(£)-l-(4'-fluorostyryl)-3,5-dim ethoxybenzene 189
3.5-Dimethoxybenzoyl chloride (1.65 g, 8.2 mmol) and 4-fluorostyrene (1.0 g, 8.2 mmol) 
w ere used. Recrystallisation from hexane/ethyl acetate 50:1 furnished 189 as yellow 
crystalline needles (0.55 g, 26%).
m.p. 48-49 °C. L it . 19 m.p. 46-48 °C.
Anal, calcd. for C i5H i2 0 iF 2: C, 73.16; H, 4.91.
Found C, 72.93; H, 4.98.
IR (KBr): n 2933, 2830, 1598, 1506, 1306, 961, 847 cm ’1.
!H-NM R (400 MHz, DMSO): 5 7.62-7.66 (2H, m, -A rH 2 '&  6 ') , 7.28 (1H, d, J =  16.4 Hz, - 
C=C-H), 7.19-7.23 (2H, m, -A rif  3 ' & 5 '), 7.13 (1H, d, J =  16.4 Hz, -C=C-H), 6.78 (2H, d, J  
=  2.4 Hz, -A r H 2 & 6 ), 6.43 (1H, t, J =  2.4 Hz, -A r H 4), 3.78 (6 H, s, -O C tf3).
13C-NM R (100 MHz, DMSO): 6  162.1 (d, -ArC 4 '), 161.0 (-ArC 3 & 5), 139.3 (-ArC 1),
133.8 (-ArC 1'), 128.7 (-C=C-H), 128.6 (d, -ArC 2 ' & 6 ') , 128.0 (-C=C-H), 115.9 (d, -ArC 3' 
& 5 '), 104.7 (-A rC 2 & 6 ), 100.2 (-ArC 4), 55.5 (-OCH3).
19F-NM R (376 MHz, DMSO): 6  -38.8 - -38.9 (IF , m).
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(E )-1-(4' -ethoxystyryl)-3,5-difluorobenzene 190
3.5-Difluorobenzoyl chloride (1.83 g, 6.7 mmol) and 4-ethoxystyrene (1.0 g, 6.7 mmol) were 
used. Recrystallisation from hexane/ethyl acetate 25:1 furnished 190 as yellow spherical 
crystals (0.32 g, 19%).
m.p. 82-84 °C.
Anal, calcd. for C i6H 140 iF2 : C, 73.83; H, 5.42.
Found C, 73.61; H, 5.85. -
IR  (KBr): u 2907, 2357, 1610, 1042, 844, 647 cm '1.
’H-NM R (400 MHz, DMSO): 6  7.52 (2H, d , J =  8 . 8  Hz, -A xH T S c  6 ') , 7.35 (1H, d, J =  16.4 
Hz, -C=C-H), 7.27-7.31 (2H, m, -ArH  2 & 6 ), 7.03-7.09 (2H, m, -A rtf 4 & -C=C -H), 6.94 
(2H, d , J =  8 . 8  Hz, -ArH 3 ' & 5 '), 4.03 (2H, q, J =  6 . 8  Hz, -OCH 2-), 1.32 (3H, t, J -  6 . 8  Hz, 
- O C H 2 C / / 3 ) .
13C -N M R (100 MHz, DMSO): 8  164.2 (d, -A rC 3), 161.8 (d, -A rC 5), 159.1 (-ArC 4 '), 141.9 
(t, -A rC 1), 131.4 (-C=C-H), 129.0 (-ArC 1'), 128.5 (-A rC 2 ' & 6 ') , 124.1 ( - C = C - H ) ,  115.0 (­
A rC  3 ' & 5 '), 109.2 (d, -ArC 2), 109.1 (d, -ArC 6 ), 102.4 (t, -ArC 4), 63.4 (-OCH2-, -VE 
DEPT), 14.9 ( - O C H 2 C H 3 ) .
19F-NM R (376 MHz, DMSO): 8  -35.0 (2F, t, / C F= 5.2 Hz). 
(£)-l-(4'-fluorostyryl)-3,5-diethoxybenzene 191
3.5-Diethoxybenzoyl chloride (1.87 g, 8.2 mmol) and 4-fluorostyrene (1.0 g, 8.2 mmol) were 
used. Recrystallisation from hexane/ethyl acetate 25:1 furnished 191 as yellow crystalline 
needles (0.68 g, 29%).
m.p. 58-60 °C.
Anal, calcd. for C i8H ,9 0 2Fi: C, 75.50; H, 6 .6 8 .
Found C, 75.60; H, 6.59.
IR (KBr): u 2974, 2351, 1591, 1505, 1382, 1184, 968, 832 cm '1.
’H -NM R (400 MHz, DMSO): 8  7.61-7.65 (2H, m, -A rtf  2 '&  6 '), 7.27 (1H, d, J =  16.0 Hz, - 
C=C-H), 7.20 (2H, t, J -  8 . 8  Hz, -A rH 3' & 5 '), 7.10 (1H, d, J =  16.4 Hz, -C=C-H), 6.14 (2H, 
d, J - 2.4 Hz, -A xH 2  & 6 ), 6.39 (1H, t, J =  2.4 Hz, -A ri/4 ) , 4.03 (4H, q, J =  1.2 Hz, -OCH 2- 
), 1.33 (6 H, t, 7 =  7.2 Hz, -OCHzCtfO-
13C-NM R (100 MHz, DMSO): 8  162.0 (d, -ArC 4 '), 160.2 (-ArC 3 & 5), 139.2 (-ArC 1), 
133.9 (d, -ArC 1'), 128.7 (-ArC 2 ' & 6 ') , 128.6 (-C=C-H), 127.9 (-C=C-H), 115.9 (d, -ArC 3' 
& 5 '), 105.1 (-ArC 2 & 6 ), 100.9 (-A rC 4), 63.3 (-OCH2-, -VE DEPT), 14.9 (-OCH 2 CH3). 
19F-NM R (376 MHz, DMSO): 8  -38.8 - -38.9 (IF , m).
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(E)-l-(4'-acetoxystyryl)-3,5-difliiorobenzene 192
3.5-Difluorobenzoyl chloride (4.38 g, 24.6 mmol) and 4-acetoxystyrene (4.0 g, 24.6 mmol) 
were used. Recrystallisation from hexane/ethyl acetate 12:1 furnished 192 as yellow planar 
crystals (3.94 g, 58%).
m.p. 142-144 °C.
Anal, calcd. for C ^ H ^ C ^ :  C, 70.07; H, 4.41.
Found C, 69.72; H, 4.46.
IR (KBr): u 2926, 2351, 1752, 1616, 1208, 968 c m 1.
!H-NM R (400 MHz, DMSO): 5 7.63 (2H, d, J =  8.4 Hz, -A r H 2 '&  6 '), 7.44 (1H, d, J =  16.4 
Hz, -C=C-H), 7.32-7.36 (2H, m, -A rH  2 & 6 ), 7.23 (1H, d, J =  16.4 Hz, -C=C-H), 7.17 (2H, 
d ,J =  8 . 8  Hz, -A rH  3 ' & 5 '), 7.08-7.14 (1H, m, -A rH 4), 2.29 (3H, s, -CH3).
13C-NM R (100 M Hz, DMSO): 5 169.5 (C =0), 164.2 (d, -ArC 3), 161.8 (d, -ArC 5), 150.7 (­
A rC  4 '), 141.4 (t, -ArC 1), 134.3 (-ArC 1'), 130.8 (-C=C-H), 128.1 (-ArC 2 ' & 6 ') , 126.6 (- 
C=C-H), 122.5 (-ArC 3 ' & 5 '), 109.6 (d, -ArC 2), 109.5 (d, -ArC 6 ), 102.7 (t, -ArC 4), 21.1 (- 
CH3).
19F-NM R (376 MHz, DMSO): 5 -34.8 (2F, t, J C‘F= 8 . 6  Hz). 
(£)-l-(4'-fluorostyryl)-3,5-diacetoxybenzene 193
3.5-Diacetoxybenzoyl chloride (1.03 g, 4.0 mmol) and 4-fluorostyrene (0.48 g, 4.0 mmol) 
were used. Recrystallisation from hexane/ethyl acetate 3:1 fam ished 193 as white crystalline 
needles (0.82 g, 65%).
m.p. 161-162 °C.
Anal, calcd. for C 18H 150 4 Fi: C, 68.78; H, 4.81.
Found C, 68.91; H, 4.65.
IR (KBr): u3 1 1 9 , 2929, 1774, 1655, 1509, 1401, 1197,912 cm '1.
!H-NM R (400 M Hz, CDCI3): 8  7.44-7.48 (2H, m, -A rH 2 '&  6 ') , 7.03-7.13 (5H, m, -A rH  2, 
6 , 3 ', 5 ' & -C=C-H ), 6.94 (1H, d, / =  16.0 Hz, -C=C-H), 6.84 (1H, t, 2.4 Hz, -A rH  4), 
2.32 (6 H, s, CH3).
13C-NM R (100 MHz, C D C I 3 ) :  5 169.4 (C^O), 162.9 (d, -ArC 4 '), 151.6 (-ArC 3 & 5), 139.9 
(-A rC 1), 133.2 (d, -ArC 1'), 129.8 (-C=C-H), 128.6 (d, -ArC 2' & 6 ') , 127.1 (d, -C=C-H),
117.2 (-ArC 2 & 6 ), 116.1 (d, -ArC 3' & 5 '), 114.2 (-ArC 4), 21.5 (-CH3).
,9F-NM R (376 MHz, CDC13): 5 -38.0 - -38.1 (IF , m).
(E )-1 -(4' -hydroxysty ryl)-3,5-difluorobenzene 194
Am m onium  acetate (4.5 g, 54.4 mmol) was added to a solution o f  (E)-l-(4 '-acetoxystyryl)-
3.5-difluorobenzene (2.0 g, 7.3 mmol) in aqueous methanol (4:1) and the solution was stirred 
at room temperature for 3 hrs. The title product was extracted w ith ethyl acetate and dried 
over MgSC>4 . The solvent was removed in vacuo to furnish 194 as an orange solid (1.03 g, 
81%).
m.p. 142-144 °C. Lit. 34 m.p. 141-142 °C.
Anal, calcd. for C i4H i0 OiF2: C, 72.40; H, 4.34.
Found C, 72.27; H, 4.61.
IR  (KBr): u 3364, 2926, 1592, 1246, 1104, 961 c m 1.
!H -NM R (400 MHz, DMSO): 5 8.04 (1H, s, -OH), 7.43 (2H, d, J  = 8.4 Hz, -A rH  2 '&  6 ') , 
7.24 - 7.31 (3H, m, -A xH 2 , 6  & -C=C-tf), 6.97-7.01 (2H, m, -A rtf  4 & -C=C -H), 6.81 (2H, 
d, J -  8 . 8  Hz, -A rH  3 ' & 5 ').
13C-NM R (100 MHz, DMSO): 6  164.2 (d, -A rC 3), 161.8 (d, -A rC 5), 158.3 (-A rC 4 ') , 142.0 
(t, -ArC 1), 131.8 (-C=C-H), 128.7 (-ArC 2 ' & 6 ') , 127.6 (-A rC 1'), 123.1 (d, -C=C-H),
116.0 (-ArC 3 ' & 5 '), 109.0 (d, -ArC 2), 108.9 (d, -ArC 6 ), 102.1 (t, -ArC 4).
19F-NM R (376 MHz, DMSO): 5 -35.0 (2F, t, J C'F= 8 . 6  Hz).
( i i ) - l -(4'-fluorostyryl)-3-acetoxy-5-hydro\y benzene 195
Am m onium  acetate (0.39 g, 5.09 mmol) was added to a solution o f  (E)-l-(4-fluorostyryl)-
3.5-diacetoxybenzene (0.1 g, 0.32 mmol) in aqueous methanol (4:1) and the solution was 
stirred at room temperature for 3 hrs. The title product was extracted w ith ethyl acetate and 
dried over M gS0 4 - The solvent was removed in vacuo to furnish 195 as a white pow der (1.05 
g, 76%).
m.p. 118-120 °C.
Anal, calcd. for CieHnOsF!: C, 70.58; H, 4.81.
Found C, 70.35; H, 5.00.
IR  (KBr): u 3336, 2364, 1770, 1586, 1509, 1206, 852 cm '1.
!H -NM R (400 MHz, CDC13): 5 7.40-7.43 (2H, m, - A iH 2 '& 6 '), 7.01-7.06 (2H, m, -A rH  3 '&  
5 ') , 6.97 (1H, d, 16.6 Hz, -C=C-H), 6.85 (1H, d, 16.6 Hz, -C=C-H), 6.78 (2H, d , J  =
8 . 8  Hz, -A r H 2 & 6 ), 6.49 (1H, t , J =  2.0 Hz, -A rH 4), 6.13 (1H, s, -OH), 2.33 (3H, s, CH3). 
13C-NM R (100 MHz, CDCI3): 5 170.6 (C =0), 162.9 (d, -ArC 4 '), 157.2 (-ArC 3), 151.9 (­
A rC  5), 140.1 (-ArC 1), 133.3 (d, -ArC 1'), 129.1 (-C=C-H), 128.5 (d, -ArC 2 ' & 6 ') , 127.6
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(-C=C-H), 116.0 (d, -ArC 3' & 5 '), 111.9 (-A rC 6 ), 111.6 (-ArC 2), 108.8 (-ArC 4), 21.6 (-
ch3).
19F-NM R (376 MHz, CDC13): 5 -39.3 - -39.4 (IF , m).
( Zs)-1-(4'-trichloroacety Is tyryl)-3,5-difluoro benzene 196
A  solution o f trichloroacetyl chloride (0.181 g, 1.0 mmol) in dichloromethane (3 mis) was 
added dropwise to a solution o f  (E)-l-(4-hydroxystyryl)-3,5-difluorobenzene (0.212 g, 1.0 
mm ol) and triethylamine (0.14 mis, 1.0 mmol) in dichloromethane (3 mis). The solution was 
stirred for 8  hrs then washed w ith 5% HC1 and water. The organic extract was then dried over 
MgSC>4 and the solvent was removed in vacuo. Recrysallisation from hexane/ethyl acetate 2:1 
furnished 196 as white crystalline needles (279 mg, 74%). 
m.p. 92-94 °C.
Anal, calcd. for C 16H 9O2F2CI3 : C, 50.89; H, 2.40.
Found C, 51.11; H, 2.63.
IR (K B r): u 3153, 2928, 1774, 1655, 1400, 1115 cm’1.
!H-NM R (400 MHz, C D C I 3 ) :  S 7.46 (2H, d, J =  7.2 Hz, -A rH 2 '&  6 ') , 7.14 (2H, d, J =  7.2 
Hz, -A rif  3 ' & 5 '), 6.99 (1H, d, J =  16.0 Hz, -C=C-H), 6.86-6.95 (3H, m, -A xH 2, 6  &-C=C-
H ), 6.60-6.65 (1H, m, -A rif  4).
13C-NM R (100 MHz, CDCI3): 5 164.9 (d, -ArC 3), 162.4 (d, -ArC 5), 160.8 (O O ) ,  150.6 (­
A rC  4 '), 140.7 (t, -ArC 1), 135.8 (-ArC 1'), 130.8 (-C=C-H), 128.4 (-ArC 2 ' & 6 ') , 128.0 (t, - 
C=C-H), 121.3 (-ArC 3 ' & 5 '), 109.6 (d, -ArC 2), 109.5 (d, -ArC 6 ), 103.4 (t, -A rC 4), 89.9 (- 
CCI3).
I9F-NM R (376 MHz, CDC13): 5 -34.6 (2F, t, J C'F= 7.8 Hz). 
(ls)-l-(4'-trifluoroacetylstyryl)-3,5-difluorobenzene 197
Trifluoroacetic anhydride (0.16 g, 0.76 mmol) was used. Recrystallisation from hexane/ethyl 
acetate 2:1 furnished 197 as white crystalline needles (152 mg, 61%). 
m.p. 139-141 °C.
Anal, calcd. for C i6H 9 0 2F5 : C, 58.54; H, 2.76.
Found C, 58.51; H, 2.75.
IR  (KBr): v 3140, 2928, 1655, 1591, 1400, 1117, 661 cm '1.
'H -N M R  (400 MHz, CDCI3): ô 7.32 (2H, d, J =  8 . 8  Hz, -A iH 2 '&  6 '), 6.95 (1H, d, J =  16.4 
Hz, -C=C-H), 6.88-6.92 (2H, m, -ArH  2 & 6 ), 6.75-6.79 (3H, m, -A rH  3 ', 5 ' & -C=C -H),
6.56-6.61 (1H, m, -A rH  4).
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13C-NM R (100 MHz, C D C I 3 ) :  5 164.9 (d, -ArC 3), 162.4 (d, -ArC 5), 156.3 (C = 0), 141.4 (t, - 
A rC  4 '), 131.1 (t, -ArC l), 130.7 (-ArC 1'), 129.6 (-C=C-H), 128.7 (-ArC 2 ' & 6 ') , 124.8 (t, - 
C=C-H), 116.1 (-ArC 3' & 5 '), 115.7 (-CF3), 109.2 (d, -ArC 2), 109.0 (d, -ArC 6 ), 102.7 (t, - 
A rC  4).
19F-NM R (376 MHz, CDC13): 5 -0.5 (3F), -35.1 (2F, t, J c'v= 7.8 Hz).
(£ )-!  -(4'-trim ethylacetylstyryl)-3,5-difluorobenzene 198
Trimethylacetyl chloride (0.091 g, 0.76 mmol) was used. Recrystallisation from hexane/ethyl 
acetate 2:1 furnished 198 as w hite crystalline needles (188 mg, 78%). 
m.p. 79-81 °C.
Anal, calcd. for C 19H 18O2F2 : C, 72.13; H, 5.73.
Found C, 72.01; H, 5.83.
IR (KBr): x> 2975, 2365, 1742, 1619, 1120, 670 cm '1.
•H-NMR (400 MHz, C D C I 3 ) :  5 7.38 (2H, d, J =  7.6 Hz, -A rH  2 '8c 6 ') , 6.92-6.98 (3H, m, - 
ArH  3 ', 5 ' & -C=C-H), 6.85-6.90 (2H, m, -A rif 2 & 6 ), 6.81 (1H, d, J =  16.4 Hz, -C=C -H),
6.57-6.60 (1H, m, -A rH  4), 1.27 (9H, s, -CH3).
13C-NM R (100 MHz, CDCI3): 5 177.4 ( (^ O ) , 164.9 (d, -ArC 3), 162.4 (d, -ArC 5), 151.5 (­
A rC  4 ') , 141.0 (t, -ArC 1), 134.2 (-ArC 1'), 130.6 (-C=C-H), 128.1 (-ArC 2 ' & 6 ') , 126.9 (t, - 
C=C-H), 122.3 (-A rC 3' & 5 '), 109.5 (d, -A rC 2), 109.3 (d, -ArC 6 ), 103.1 (t, -A rC 4), 39.5 (- 
C(CH3)3), 27.5 (-CH3).
19F-NM R (376 MHz, CDC13): 5 -34.9 (2F, t, / C‘F= 7.8 Hz). 
(2s)-4-(3,5-difluorostyryi)phenylmethanesulphonate 199
M ethanesulphonyl chloride (0.057 g, 0.50 mmol) was used. Recrystallisation from 
hexane/ethyl acetate 2:1 furnished 199 as white crystalline needles (110 mg, 71%). m.p. 85­
87 °C.
Anal, calcd. for C i5H i2 0 3 F2 S,: C, 58.05; H, 3.89.
Found C, 57.89; H, 4.09.
IR (KBr): u 3369, 2926, 1619, 1113 ,845 ,670  cm’1.
’H-NM R (400 MHz, CDCI3): 8  7.43 (2H, d, J =  8.4 Hz, -A rif 2 '&  6 '), 7.19 (2H, d, J =  8 . 8  
Hz, -A rH  3 ' & 5 '), 6.96 (1H, d, .7=16.4 Hz, -C=C-H), 6.84-6.92 (3H, m, -ArH  2, 6  & -C=C- 
H), 6.59-6.62 (1H, m, -A rH 4), 3.08 (3H, s, -CH3).
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13C-NM R (100 MHz, CDCIs): 5 164.8 (d, -ArC 3), 162.5 (d, -ArC 5), 149.2 (-ArC 4 '), 140.6 
(t, -A rC 1), 136.1 (-ArC 1'), 129.9 (-C=C-H), 128.6 (-ArC 2 ' & 6 ') , 128.1 (t, -C=C-H), 122.8 
(-A rC 3 ' & 5 '), 109.6 (d, -ArC 2), 109.5 (d, -ArC 6 ), 103.4 (t, -A rC 4), 37.8 (-CH3).
,9F-NM R (376 MHz, CDCI3): 5 -34.6 (2F, t, J C'F= 7.8 Hz).
(£)-4-(3,5-difluorostyryl)phenyl-4-fluorobenzenesulphonate 200
4-Fluorobenzenesulphonyl chloride (0.212 g, 1.0 mmol) was used. Recrystallisation from 
hexane/ethyl acetate 2:1 furnished 200 as white crystalline needles (195 mg, 50%). m.p. 71­
73 °C.
Anal, calcd. for C2 0 H 13O 3F3 S 1: C, 61.53; H, 3.35.
Found C, 61.45; H, 3.32.
IR (KBr): u 3118, 2365, 1592, 1400, 1200. 842 c m 1.
•H-NMR (400 MHz, CDCI3): 5 7.75-7.79 (2H, m, -Ar(S)H  2 & 6 ), 7.33 (2H, d, 8.4 Hz, - 
A rH 2 '&  6 ') , 7.09-7.14 (2H, m, -A r(S)tf 3 & 5), 6.93 (1H, d, .7=16.4 Hz, -C=C-H), 6.86-6.90 
(4H, m, -A rH  2, 6 , 3 '&  5 '), 6.83 (1H, d, .7=16.4 Hz, -C=C-H), 6.59-6.64 (1H, m, -A ri/4 ) . 
13C-NM R (100 MHz, CDCI3): 5 166.4 (d, -Ar(S)C 4), 164.8 (d, -ArC 3), 162.4 (d, -ArC 5), 
149.4 (-ArC 4 '), 140.6 (t, -ArC 1), 136.0 (-ArC 1'), 131.8 (d, -Ar(S)C 2 & 6 ), 130.5 (d, - 
A r(S)C  1), 129.9 (-C=C-H), 128.3 (-A rC 2 ' & 6 ') , 128.1 (t, -C=C-H), 123.1 (-ArC 3 ' & 5 '),
117.0 (d, -A r(S)C 3 & 5), 109.6 (d, -ArC 2), 109.5 (d, -ArC 6 ), 103.4 (t, -ArC 4).
19F-NM R (376 MHz, CDCI3): 5 -26.4 - -26.5 (IF , m), -34.6 (2F, t, J C'F= 7.8 Hz).
(£)-4-(3,5-difluorostyryl)phenyl-2-fluorobenzoate 201
2-Fluorobenzoyl chloride (0.158 g, 1.0 mmol) was used. Recrystallisation from hexane/ethyl 
acetate 2:1 furnished 201 as white crystalline needles (184 mg, 52%). m.p. 118-120 °C.
Anal, calcd. for C2 1H 13O 2F 3 : C, 71.18; H, 3.69.
Found C, 71.49; H, 3.41.
IR (KBr): u 3134, 2345, 1735, 1410, 1292, 847 cm '1.
'H -N M R  (400 MHz, CDCI3): 5 7.99-8.03 (1H, m, -A rH  6 a), 7.48-7.53 (1H, m, -A rH  4a), 
7.47 (2H, d, J =  8 . 8  Hz, - A r H 2 '& 6 ') , 7.09-7.20 ( 4H, m, -A r H 3 ',5 ',  3a & 5a), 7.00 (1H, d, J  
= 16.4 Hz, -C=C -H), 6.84-6.92 (3H, m, -A r H 2, 6  & -C=C - H) ,  6.58-6.62 (1H, m, -A ri/4 ) . 
13C-NM R (100 MHz, CDCI3): 5, 164.9 (d, -ArC 3), 163.0 (d, C = 0), 162.7 (d, -ArC 2a), 162.4 
(d, -A rC 5), 150.9 (-ArC 4 '), 140.9 (t, -ArC 1), 135.7 (d, -ArC 4), 134.7 (-ArC 1'), 132.9 (d, - 
A rC  6 a), 130.6 (-C=C-H), 128.2 (-A rC 2 ' & 6 '), 127.2 (t, -C=C-H), 124.5 (d, -ArC 5a), 122.4
234
(-ArC 3 ' & 5 '), 118.3 (d, -ArC la), 117.6 (d, -A rC 3a), 109.5 (d, -ArC 2), 109.3 (d, -ArC 6 ),
103.2 (t, -A rC 4).
19F-NM R (376 MHz, CDC13): 5 -32.7 - -32.8 (1F, m), -34.8 (2F, t, J C’F= 7.8 Hz).
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Appendix I 
Abbreviations
°c Degrees Celsius.
Â Angstrom.
Ac Acetyl
ACE Angiotensin converting enz)toie.
AIDS Acquired immunodeficienc> syndrome.
A la Alanine.
Arg Arginine.
Asp Aspartic acid.
ATP Adenosine triphosphate.
ß-Ala ß-alanine.
Boc Tert-butoxycarbonyl.
CaCl2 Calcium chloride.
CDCI3 Deuterated chloroform.
CH 2CI2 Dichlorom ethane.
CH 2N 2 Diazomethane.
cm ' 1 Per centimetre.
CNS Central nervous system.
a-CT a-Chymotrypsin.
COPD Chronic obstructure pulmonary disease.
Cyp Cytochrome P450.
Cys Cysteine.
DCC Dicyclohexylcarbodiimide.
DCU N, TV’-dicyclohexylurea.
DDQ 2,3-dichloro-5,6-dicyano-l,4-benzoquinone.
DEPT Distortionless enhancement through polarization transfer.
DFP Diisopropylfluorophosphate.
DMSO Dimethyl sulfoxide.
DTP Development therapeutic program.
EDC 1 -ethyl-3 -(3 -dimethylaminopropyl)carbodiimide.
ESIMS Electrospray ionisation mass spectroscopy.
Et3N Triethylamine.
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FDA Food and drug administration.
g Gram.
y-ABA y-aminobutyric acid.
Glu Glulamic acid.
Gly Glycine.
GST Glutathione 5-transferase.
HBr Hydrogen bromide.
His Histidine.
HIV Human immunodeficiency virus.
HMQC Heteronuclear multiple quantam coherence.
HOBt 1-hydroxybenzotriazole.
HONO Nitrous acid.
HRV Human rhinoviruses.
Hz Hertz.
IC 50 Concentration required to achieve 50% inhibition.
ICE Interleukin-1 converting enzyme,
lie Isoleucine
Iva Isovaline.
IR Infrared.
Kj Rate o f  inhibition.
Leu Leucine.
LDL Low density lipoprotein.
M Molar.
M DR Multidrug resistance,
m.p. M elting point.
M eOH Methanol,
ml Millilitre.
m m ol Millimole.
M MP Matrix metalloproteases.
MRP-1 Multidrug resistance protein 1.
NaBF4  Sodium tetrafluoroborale.
NaOH Sodium hydroxide.
NHM ec 7-amino-4-methylcoumarin.
NHNap 4-naphtylamine.
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nm Nanometre.
N M R Nuclear magnetic resonance.
NO Nitric oxide.
PgP P-glycoprotein.
Phe Phenylalanine.
Phegly Phenylglycine.
PM SF Phenylmethylsulphonyl fluoride.
Py.9HF Pyridinium polyhydrogen fluoride.
QSAR Quantitative structure activity relationship.
SAR Structure activity relationship.
Ser Serine.
SOCl2 Thionyl chloride.
Sta Statine.
THF Tetrahydrofuran.
TIMP Tissue inhibitors o f  metalloproteases.
TLCK Tosyl-L-lysine chloromethyl ketone.
TN F-a Tumor necrosis factor a.
TPCK Tosylamido-L-phenylethyl chloromethyl ketone.
Tris-HCl Tris(hydroxymethyl)aminomethane hydrochloride.
TsOH para- toi uenesulphonic acid.
Val Valine.
Z/CBz Benzyloxycarbonyl.
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